BRCA1	O 0
is	O 0
secreted	O 0
and	O 0
exhibits	O 0
properties	O 0
of	O 0
a	O 0
granin	O 0
.	O 0

Germline	O 0
mutations	O 0
in	O 0
BRCA1	O 0
are	O 0
responsible	O 0
for	O 0
most	O 0
cases	O 0
of	O 0
inherited	B-Disease 0
breast	I-Disease 0
and	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
.	O 0

However	O 0
,	O 0
the	O 0
function	O 0
of	O 0
the	O 0
BRCA1	O 0
protein	O 0
has	O 0
remained	O 0
elusive	O 0
.	O 0

We	O 0
now	O 0
show	O 0
that	O 0
BRCA1	O 0
encodes	O 0
a	O 0
190	O 0
-	O 0
kD	O 0
protein	O 0
with	O 0
sequence	O 0
homology	O 0
and	O 0
biochemical	O 0
analogy	O 0
to	O 0
the	O 0
granin	O 0
protein	O 0
family	O 0
.	O 0

Interestingly	O 0
,	O 0
BRCA2	O 0
also	O 0
includes	O 0
a	O 0
motif	O 0
similar	O 0
to	O 0
the	O 0
granin	O 0
consensus	O 0
at	O 0
the	O 0
C	O 0
terminus	O 0
of	O 0
the	O 0
protein	O 0
.	O 0

Both	O 0
BRCA1	O 0
and	O 0
the	O 0
granins	O 0
localize	O 0
to	O 0
secretory	O 0
vesicles	O 0
,	O 0
are	O 0
secreted	O 0
by	O 0
a	O 0
regulated	O 0
pathway	O 0
,	O 0
are	O 0
post	O 0
-	O 0
translationally	O 0
glycosylated	O 0
and	O 0
are	O 0
responsive	O 0
to	O 0
hormones	O 0
.	O 0

As	O 0
a	O 0
regulated	O 0
secretory	O 0
protein	O 0
,	O 0
BRCA1	O 0
appears	O 0
to	O 0
function	O 0
by	O 0
a	O 0
mechanism	O 0
not	O 0
previously	O 0
described	O 0
for	O 0
tumour	B-Disease 0
suppressor	O 0
gene	O 0
products	O 0
.	O 0
.	O 0

Ovarian	B-Disease 0
cancer	I-Disease 0
risk	O 0
in	O 0
BRCA1	O 0
carriers	O 0
is	O 0
modified	O 0
by	O 0
the	O 0
HRAS1	O 0
variable	O 0
number	O 0
of	O 0
tandem	O 0
repeat	O 0
(	O 0
VNTR	O 0
)	O 0
locus	O 0
.	O 0

Women	O 0
who	O 0
carry	O 0
a	O 0
mutation	O 0
in	O 0
the	O 0
BRCA1	O 0
gene	O 0
(	O 0
on	O 0
chromosome	O 0
17q21	O 0
)	O 0
,	O 0
have	O 0
an	O 0
80	O 0
%	O 0
risk	O 0
of	O 0
breast	B-Disease 0
cancer	I-Disease 0
and	O 0
a	O 0
40	O 0
%	O 0
risk	O 0
of	O 0
ovarian	B-Disease 0
cancer	I-Disease 0
by	O 0
the	O 0
age	O 0
of	O 0
70	O 0
(	O 0
ref	O 0
.	O 0
1	O 0
)	O 0
.	O 0

The	O 0
variable	O 0
penetrance	O 0
of	O 0
BRCA1	O 0
suggests	O 0
that	O 0
other	O 0
genetic	O 0
and	O 0
non	O 0
-	O 0
genetic	O 0
factors	O 0
play	O 0
a	O 0
role	O 0
in	O 0
tumourigenesis	O 0
in	O 0
these	O 0
individuals	O 0
.	O 0

The	O 0
HRAS1	O 0
variable	O 0
number	O 0
of	O 0
tandem	O 0
repeats	O 0
(	O 0
VNTR	O 0
)	O 0
polymorphism	O 0
,	O 0
located	O 0
1	O 0
kilobase	O 0
(	O 0
kb	O 0
)	O 0
downstream	O 0
of	O 0
the	O 0
HRAS1	O 0
proto	O 0
-	O 0
oncogene	O 0
(	O 0
chromosome	O 0
11p15	O 0
.	O 0
5	O 0
)	O 0
is	O 0
one	O 0
possible	O 0
genetic	O 0
modifier	O 0
of	O 0
cancer	B-Disease 0
penetrance	O 0
.	O 0

Individuals	O 0
who	O 0
have	O 0
rare	O 0
alleles	O 0
of	O 0
the	O 0
VNTR	O 0
have	O 0
an	O 0
increased	O 0
risk	O 0
of	O 0
certain	O 0
types	O 0
of	O 0
cancers	B-Disease 0
,	O 0
including	O 0
breast	B-Disease 0
cancer	I-Disease 0
(	O 0
2	O 0
-	O 0
4	O 0
)	O 0
.	O 0

To	O 0
investigate	O 0
whether	O 0
the	O 0
presence	O 0
of	O 0
rare	O 0
HRAS1	O 0
alleles	O 0
increases	O 0
susceptibility	O 0
to	O 0
hereditary	B-Disease 0
breast	I-Disease 0
and	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
,	O 0
we	O 0
have	O 0
typed	O 0
a	O 0
panel	O 0
of	O 0
307	O 0
female	O 0
BRCA1	O 0
carriers	O 0
at	O 0
this	O 0
locus	O 0
using	O 0
a	O 0
PCR	O 0
-	O 0
based	O 0
technique	O 0
.	O 0

The	O 0
risk	O 0
for	O 0
ovarian	B-Disease 0
cancer	I-Disease 0
was	O 0
2	O 0
.	O 0

11	O 0
times	O 0
greater	O 0
for	O 0
BRCA1	O 0
carriers	O 0
harbouring	O 0
one	O 0
or	O 0
two	O 0
rare	O 0
HRAS1	O 0
alleles	O 0
,	O 0
compared	O 0
to	O 0
carriers	O 0
with	O 0
only	O 0
common	O 0
alleles	O 0
(	O 0
P	O 0
=	O 0
0	O 0
.	O 0
015	O 0
)	O 0
.	O 0

The	O 0
magnitude	O 0
of	O 0
the	O 0
relative	O 0
risk	O 0
associated	O 0
with	O 0
a	O 0
rare	O 0
HRAS1	O 0
allele	O 0
was	O 0
not	O 0
altered	O 0
by	O 0
adjusting	O 0
for	O 0
the	O 0
other	O 0
known	O 0
risk	O 0
factors	O 0
for	O 0
hereditary	B-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
(	O 0
5	O 0
)	O 0
.	O 0

Susceptibility	O 0
to	O 0
breast	B-Disease 0
cancer	I-Disease 0
did	O 0
not	O 0
appear	O 0
to	O 0
be	O 0
affected	O 0
by	O 0
the	O 0
presence	O 0
of	O 0
rare	O 0
HRAS1	O 0
alleles	O 0
.	O 0

This	O 0
study	O 0
is	O 0
the	O 0
first	O 0
to	O 0
show	O 0
the	O 0
effect	O 0
of	O 0
a	O 0
modifying	O 0
gene	O 0
on	O 0
the	O 0
penetrance	O 0
of	O 0
an	O 0
inherited	B-Disease 0
cancer	I-Disease 0
syndrome	I-Disease 0

A	O 0
novel	O 0
homeodomain	O 0
-	O 0
encoding	O 0
gene	O 0
is	O 0
associated	O 0
with	O 0
a	O 0
large	O 0
CpG	O 0
island	O 0
interrupted	O 0
by	O 0
the	O 0
myotonic	B-Disease 0
dystrophy	I-Disease 0
unstable	O 0
(	O 0
CTG	O 0
)	O 0
n	O 0
repeat	O 0
.	O 0

Myotonic	B-Disease 0
dystrophy	I-Disease 0
(	O 0
DM	B-Disease 0
)	O 0
is	O 0
associated	O 0
with	O 0
a	O 0
(	O 0
CTG	O 0
)	O 0
n	O 0
trinucleotide	O 0
repeat	O 0
expansion	O 0
in	O 0
the	O 0
3	O 0
-	O 0
untranslated	O 0
region	O 0
of	O 0
a	O 0
protein	O 0
kinase	O 0
-	O 0
encoding	O 0
gene	O 0
,	O 0
DMPK	O 0
,	O 0
which	O 0
maps	O 0
to	O 0
chromosome	O 0
19q13	O 0
.	O 0

3	O 0
.	O 0

Characterisation	O 0
of	O 0
the	O 0
expression	O 0
of	O 0
this	O 0
gene	O 0
in	O 0
patient	O 0
tissues	O 0
has	O 0
thus	O 0
far	O 0
generated	O 0
conflicting	O 0
data	O 0
on	O 0
alterations	O 0
in	O 0
the	O 0
steady	O 0
state	O 0
levels	O 0
of	O 0
DMPK	O 0
mRNA	O 0
,	O 0
and	O 0
on	O 0
the	O 0
final	O 0
DMPK	O 0
protein	O 0
levels	O 0
in	O 0
the	O 0
presence	O 0
of	O 0
the	O 0
expansion	O 0
.	O 0

The	O 0
DM	B-Disease 0
region	O 0
of	O 0
chromosome	O 0
19	O 0
is	O 0
gene	O 0
rich	O 0
,	O 0
and	O 0
it	O 0
is	O 0
possible	O 0
that	O 0
the	O 0
repeat	O 0
expansion	O 0
may	O 0
lead	O 0
to	O 0
dysfunction	O 0
of	O 0
a	O 0
number	O 0
of	O 0
transcription	O 0
units	O 0
in	O 0
the	O 0
vicinity	O 0
,	O 0
perhaps	O 0
as	O 0
a	O 0
consequence	O 0
of	O 0
chromatin	O 0
disruption	O 0
.	O 0

We	O 0
have	O 0
searched	O 0
for	O 0
genes	O 0
associated	O 0
with	O 0
a	O 0
CpG	O 0
island	O 0
at	O 0
the	O 0
3	O 0
end	O 0
of	O 0
DMPK	O 0
.	O 0

Sequencing	O 0
of	O 0
this	O 0
region	O 0
shows	O 0
that	O 0
the	O 0
island	O 0
extends	O 0
over	O 0
3	O 0
.	O 0

5	O 0
kb	O 0
and	O 0
is	O 0
interrupted	O 0
by	O 0
the	O 0
(	O 0
CTG	O 0
)	O 0
n	O 0
repeat	O 0
.	O 0

Comparison	O 0
of	O 0
genomic	O 0
sequences	O 0
downstream	O 0
(	O 0
centromeric	O 0
)	O 0
of	O 0
the	O 0
repeat	O 0
in	O 0
human	O 0
and	O 0
mouse	O 0
identified	O 0
regions	O 0
of	O 0
significant	O 0
homology	O 0
.	O 0

These	O 0
correspond	O 0
to	O 0
exons	O 0
of	O 0
a	O 0
gene	O 0
predicted	O 0
to	O 0
encode	O 0
a	O 0
homeodomain	O 0
protein	O 0
.	O 0

RT	O 0
-	O 0
PCR	O 0
analysis	O 0
shows	O 0
that	O 0
this	O 0
gene	O 0
,	O 0
which	O 0
we	O 0
have	O 0
called	O 0
DM	B-Disease 0
locus	O 0
-	O 0
associated	O 0
homeodomain	O 0
protein	O 0
(	O 0
DMAHP	O 0
)	O 0
,	O 0
is	O 0
expressed	O 0
in	O 0
a	O 0
number	O 0
of	O 0
human	O 0
tissues	O 0
,	O 0
including	O 0
skeletal	O 0
muscle	O 0
,	O 0
heart	O 0
and	O 0
brain	O 0
.	O 0

Germline	O 0
mutations	O 0
in	O 0
the	O 0
RB1	O 0
gene	O 0
in	O 0
patients	O 0
with	O 0
hereditary	B-Disease 0
retinoblastoma	I-Disease 0
.	O 0

We	O 0
have	O 0
analyzed	O 0
the	O 0
27	O 0
exons	O 0
and	O 0
the	O 0
promoter	O 0
region	O 0
of	O 0
the	O 0
RB1	O 0
gene	O 0
in	O 0
familial	B-Disease 0
or	I-Disease 0
sporadic	I-Disease 0
bilateral	I-Disease 0
retinoblastoma	I-Disease 0
by	O 0
using	O 0
single	O 0
-	O 0
strand	O 0
conformation	O 0
polymorphism	O 0
analysis	O 0
.	O 0

For	O 0
improvement	O 0
over	O 0
previous	O 0
studies	O 0
,	O 0
a	O 0
new	O 0
set	O 0
of	O 0
primers	O 0
has	O 0
been	O 0
designed	O 0
,	O 0
which	O 0
allow	O 0
for	O 0
amplification	O 0
of	O 0
the	O 0
coding	O 0
and	O 0
splicing	O 0
sequences	O 0
only	O 0
.	O 0

The	O 0
positioning	O 0
of	O 0
the	O 0
polymerase	O 0
chain	O 0
reaction	O 0
(	O 0
PCR	O 0
)	O 0
primers	O 0
was	O 0
such	O 0
that	O 0
the	O 0
resulting	O 0
PCR	O 0
products	O 0
were	O 0
of	O 0
different	O 0
sizes	O 0
,	O 0
which	O 0
enabled	O 0
us	O 0
to	O 0
analyze	O 0
two	O 0
different	O 0
exons	O 0
simultaneously	O 0
and	O 0
still	O 0
distinguish	O 0
between	O 0
the	O 0
banding	O 0
profiles	O 0
for	O 0
both	O 0
(	O 0
biplex	O 0
analysis	O 0
)	O 0
.	O 0

By	O 0
using	O 0
this	O 0
approach	O 0
,	O 0
we	O 0
were	O 0
able	O 0
to	O 0
identify	O 0
mutation	O 0
in	O 0
22	O 0
new	O 0
patients	O 0
,	O 0
but	O 0
the	O 0
overall	O 0
efficiency	O 0
of	O 0
the	O 0
procedure	O 0
when	O 0
we	O 0
used	O 0
a	O 0
single	O 0
-	O 0
pass	O 0
regimen	O 0
was	O 0
only	O 0
48	O 0
%	O 0
.	O 0

The	O 0
mutations	O 0
were	O 0
small	O 0
insertions	O 0
and	O 0
deletions	O 0
and	O 0
point	O 0
mutations	O 0
in	O 0
roughly	O 0
equal	O 0
proportions	O 0
.	O 0
.	O 0

Type	B-Disease 0
II	I-Disease 0
human	I-Disease 0
complement	I-Disease 0
C2	I-Disease 0
deficiency	I-Disease 0
.	O 0

Allele	O 0
-	O 0
specific	O 0
amino	O 0
acid	O 0
substitutions	O 0
(	O 0
Ser189	O 0
-	O 0
-	O 0
>	O 0
Phe	O 0
;	O 0
Gly444	O 0
-	O 0
-	O 0
>	O 0
Arg	O 0
)	O 0
cause	O 0
impaired	O 0
C2	O 0
secretion	O 0
.	O 0

Type	B-Disease 0
II	I-Disease 0
complement	I-Disease 0
protein	I-Disease 0
C2	I-Disease 0
deficiency	I-Disease 0
is	O 0
characterized	O 0
by	O 0
a	O 0
selective	O 0
block	O 0
in	O 0
C2	O 0
secretion	O 0
.	O 0

The	O 0
Type	O 0
II	O 0
C2	O 0
null	O 0
allele	O 0
(	O 0
C2Q0	O 0
)	O 0
is	O 0
linked	O 0
to	O 0
two	O 0
major	O 0
histocompatibility	O 0
haplotypes	O 0
(	O 0
MHC	O 0
)	O 0
that	O 0
differ	O 0
from	O 0
the	O 0
MHC	O 0
of	O 0
the	O 0
more	O 0
common	O 0
Type	B-Disease 0
I	I-Disease 0
C2	I-Disease 0
deficiency	I-Disease 0
.	O 0

To	O 0
determine	O 0
the	O 0
molecular	O 0
basis	O 0
of	O 0
Type	B-Disease 0
II	I-Disease 0
deficiency	I-Disease 0
the	O 0
two	O 0
Type	O 0
II	O 0
C2Q0	O 0
genes	O 0
were	O 0
isolated	O 0
and	O 0
transfected	O 0
separately	O 0
into	O 0
L	O 0
-	O 0
cells	O 0
.	O 0

Subsequent	O 0
molecular	O 0
biology	O 0
,	O 0
biosynthetic	O 0
,	O 0
and	O 0
immunofluorescence	O 0
studies	O 0
demonstrated	O 0
that	O 0
C2	O 0
secretion	O 0
is	O 0
impaired	O 0
in	O 0
Type	B-Disease 0
II	I-Disease 0
C2	I-Disease 0
deficiency	I-Disease 0
because	O 0
of	O 0
different	O 0
missense	O 0
mutations	O 0
at	O 0
highly	O 0
conserved	O 0
residues	O 0
in	O 0
each	O 0
of	O 0
the	O 0
C2Q0	O 0
alleles	O 0
.	O 0

One	O 0
is	O 0
in	O 0
exon	O 0
5	O 0
(	O 0
nucleotide	O 0
C566	O 0
-	O 0
-	O 0
>	O 0
T	O 0
;	O 0
Ser189	O 0
-	O 0
-	O 0
>	O 0
Phe	O 0
)	O 0
of	O 0
the	O 0
C2Q0	O 0
gene	O 0
linked	O 0
to	O 0
the	O 0
MHC	O 0
haplotype	O 0
A11	O 0
,	O 0
B35	O 0
,	O 0
DRw1	O 0
,	O 0
BFS	O 0
,	O 0
C4A0B1	O 0
.	O 0

The	O 0
other	O 0
is	O 0
in	O 0
exon	O 0
11	O 0
(	O 0
G1930	O 0
-	O 0
-	O 0
>	O 0
A	O 0
;	O 0
Gly444	O 0
-	O 0
-	O 0
>	O 0
Arg	O 0
)	O 0
of	O 0
the	O 0
C2Q0	O 0
gene	O 0
linked	O 0
to	O 0
the	O 0
MHC	O 0
haplotype	O 0
A2	O 0
,	O 0
B5	O 0
,	O 0
DRw4	O 0
,	O 0
BFS	O 0
,	O 0
C4A3B1	O 0
.	O 0

Each	O 0
mutant	O 0
C2	O 0
gene	O 0
product	O 0
is	O 0
retained	O 0
early	O 0
in	O 0
the	O 0
secretory	O 0
pathway	O 0
.	O 0

These	O 0
mutants	O 0
provide	O 0
models	O 0
for	O 0
elucidating	O 0
the	O 0
C2	O 0
secretory	O 0
pathway	O 0
.	O 0
.	O 0

Defective	O 0
dimerization	O 0
of	O 0
von	B-Disease 0
Willebrand	I-Disease 0
factor	O 0
subunits	O 0
due	O 0
to	O 0
a	O 0
Cys	O 0
-	O 0
>	O 0
Arg	O 0
mutation	O 0
in	O 0
type	B-Disease 0
IID	I-Disease 0
von	I-Disease 0
Willebrand	I-Disease 0
disease	I-Disease 0
.	O 0

The	O 0
same	O 0
heterozygous	O 0
T	O 0
-	O 0
>	O 0
C	O 0
transition	O 0
at	O 0
nt	O 0
8567	O 0
of	O 0
the	O 0
von	B-Disease 0
Willebrand	I-Disease 0
factor	O 0
(	O 0
vWF	O 0
)	O 0
transcript	O 0
was	O 0
found	O 0
in	O 0
two	O 0
unrelated	O 0
patients	O 0
with	O 0
type	B-Disease 0
IID	I-Disease 0
von	I-Disease 0
Willebrand	I-Disease 0
disease	I-Disease 0
,	O 0
with	O 0
no	O 0
other	O 0
apparent	O 0
abnormality	O 0
.	O 0

In	O 0
one	O 0
family	O 0
,	O 0
both	O 0
alleles	O 0
were	O 0
normal	O 0
in	O 0
the	O 0
parents	O 0
and	O 0
one	O 0
sister	O 0
;	O 0
thus	O 0
,	O 0
the	O 0
mutation	O 0
originated	O 0
de	O 0
novo	O 0
in	O 0
the	O 0
proposita	O 0
.	O 0

The	O 0
second	O 0
patient	O 0
also	O 0
had	O 0
asymptomatic	O 0
parents	O 0
who	O 0
,	O 0
however	O 0
,	O 0
were	O 0
not	O 0
available	O 0
for	O 0
study	O 0
.	O 0

The	O 0
structural	O 0
consequences	O 0
of	O 0
the	O 0
identified	O 0
mutation	O 0
,	O 0
resulting	O 0
in	O 0
the	O 0
CyS2010	O 0
-	O 0
>	O 0
Arg	O 0
substitution	O 0
,	O 0
were	O 0
evaluated	O 0
by	O 0
expression	O 0
of	O 0
the	O 0
vWF	O 0
carboxyl	O 0
-	O 0
terminal	O 0
domain	O 0
containing	O 0
residues	O 0
1366	O 0
-	O 0
2050	O 0
.	O 0

Insect	O 0
cells	O 0
infected	O 0
with	O 0
recombinant	O 0
baculovirus	O 0
expressing	O 0
normal	O 0
vWF	O 0
sequence	O 0
secreted	O 0
a	O 0
disulfide	O 0
linked	O 0
dimeric	O 0
molecule	O 0
with	O 0
an	O 0
apparent	O 0
molecular	O 0
mass	O 0
of	O 0
150	O 0
kDa	O 0
before	O 0
reduction	O 0
,	O 0
yielding	O 0
a	O 0
single	O 0
band	O 0
of	O 0
80	O 0
kDa	O 0
after	O 0
disulfide	O 0
bond	O 0
reduction	O 0
.	O 0

In	O 0
contrast	O 0
,	O 0
cells	O 0
expressing	O 0
the	O 0
mutant	O 0
fragment	O 0
secreted	O 0
a	O 0
monomeric	O 0
molecule	O 0
of	O 0
apparent	O 0
molecular	O 0
mass	O 0
of	O 0
80	O 0
kDa	O 0
,	O 0
which	O 0
remained	O 0
unchanged	O 0
after	O 0
reduction	O 0
.	O 0

We	O 0
conclude	O 0
that	O 0
CyS2010	O 0
is	O 0
essential	O 0
for	O 0
normal	O 0
dimerization	O 0
of	O 0
vWF	O 0
subunits	O 0
through	O 0
disulfide	O 0
bonding	O 0
of	O 0
carboxyl	O 0
-	O 0
terminal	O 0
domains	O 0
and	O 0
that	O 0
a	O 0
heterozygous	O 0
mutation	O 0
in	O 0
the	O 0
corresponding	O 0
codon	O 0
is	O 0
responsible	O 0
for	O 0
defective	O 0
multimer	O 0
formation	O 0
in	O 0
type	B-Disease 0
IID	I-Disease 0
von	I-Disease 0
Willebrand	I-Disease 0
disease	I-Disease 0
.	O 0
.	O 0

Wiskott	B-Disease 0
-	I-Disease 0
Aldrich	I-Disease 0
syndrome	I-Disease 0
protein	O 0
,	O 0
a	O 0
novel	O 0
effector	O 0
for	O 0
the	O 0
GTPase	O 0
CDC42Hs	O 0
,	O 0
is	O 0
implicated	O 0
in	O 0
actin	O 0
polymerization	O 0
.	O 0

The	O 0
Rho	O 0
family	O 0
of	O 0
GTPases	O 0
control	O 0
diverse	O 0
biological	O 0
processes	O 0
,	O 0
including	O 0
cell	O 0
morphology	O 0
and	O 0
mitogenesis	O 0
.	O 0

We	O 0
have	O 0
identified	O 0
WASP	O 0
,	O 0
the	O 0
protein	O 0
that	O 0
is	O 0
defective	O 0
in	O 0
Wiskott	B-Disease 0
-	I-Disease 0
Aldrich	I-Disease 0
syndrome	I-Disease 0
(	O 0
WAS	B-Disease 0
)	O 0
,	O 0
as	O 0
a	O 0
novel	O 0
effector	O 0
for	O 0
CDC42Hs	O 0
,	O 0
but	O 0
not	O 0
for	O 0
the	O 0
other	O 0
Rho	O 0
family	O 0
members	O 0
,	O 0
Rac	O 0
and	O 0
Rho	O 0
.	O 0

This	O 0
interaction	O 0
is	O 0
dependent	O 0
on	O 0
the	O 0
presence	O 0
of	O 0
the	O 0
G	O 0
protein	O 0
-	O 0
binding	O 0
domain	O 0
.	O 0

Cellular	O 0
expression	O 0
of	O 0
epitope	O 0
-	O 0
tagged	O 0
WASP	O 0
produces	O 0
clusters	O 0
of	O 0
WASP	O 0
that	O 0
are	O 0
highly	O 0
enriched	O 0
in	O 0
polymerized	O 0
actin	O 0
.	O 0

This	O 0
clustering	O 0
is	O 0
not	O 0
observed	O 0
with	O 0
a	O 0
C	O 0
-	O 0
terminally	O 0
deleted	O 0
WASP	O 0
and	O 0
is	O 0
inhibited	O 0
by	O 0
coexpression	O 0
with	O 0
dominant	O 0
negative	O 0
CDC42Hs	O 0
-	O 0
N17	O 0
,	O 0
but	O 0
not	O 0
with	O 0
dominant	O 0
negative	O 0
forms	O 0
of	O 0
Rac	O 0
or	O 0
Rho	O 0
.	O 0

Thus	O 0
,	O 0
WASP	O 0
provides	O 0
a	O 0
novel	O 0
link	O 0
between	O 0
CDC42Hs	O 0
and	O 0
the	O 0
actin	O 0
cytoskeleton	O 0
,	O 0
which	O 0
suggests	O 0
a	O 0
molecular	O 0
mechanism	O 0
for	O 0
many	O 0
of	O 0
the	O 0
cellular	O 0
abnormalities	O 0
in	O 0
WAS	B-Disease 0
.	O 0

The	O 0
WASP	O 0
sequence	O 0
contains	O 0
two	O 0
novel	O 0
domains	O 0
that	O 0
are	O 0
homologous	O 0
to	O 0
other	O 0
proteins	O 0
involved	O 0
in	O 0
action	O 0
organization	O 0
.	O 0
.	O 0

X	B-Disease 0
-	I-Disease 0
linked	I-Disease 0
adrenoleukodystrophy	I-Disease 0
is	O 0
a	O 0
frequent	O 0
cause	O 0
of	O 0
idiopathic	O 0
Addison	B-Disease 0
'	I-Disease 0
s	I-Disease 0
disease	I-Disease 0
in	O 0
young	O 0
adult	O 0
male	O 0
patients	O 0
.	O 0

X	B-Disease 0
-	I-Disease 0
Linked	I-Disease 0
adrenoleukodystrophy	I-Disease 0
(	O 0
ALD	B-Disease 0
)	O 0
is	O 0
a	O 0
genetic	B-Disease 0
disease	I-Disease 0
associated	O 0
with	O 0
demyelination	B-Disease 0
of	I-Disease 0
the	I-Disease 0
central	I-Disease 0
nervous	I-Disease 0
system	I-Disease 0
,	O 0
adrenal	B-Disease 0
insufficiency	I-Disease 0
,	O 0
and	O 0
accumulation	O 0
of	O 0
very	O 0
long	O 0
chain	O 0
fatty	O 0
acids	O 0
in	O 0
tissue	O 0
and	O 0
body	O 0
fluids	O 0
.	O 0

ALD	B-Disease 0
is	O 0
due	O 0
to	O 0
mutation	O 0
of	O 0
a	O 0
gene	O 0
located	O 0
in	O 0
Xq28	O 0
that	O 0
encodes	O 0
a	O 0
peroxisomal	O 0
transporter	O 0
protein	O 0
of	O 0
unknown	O 0
function	O 0
.	O 0

The	O 0
most	O 0
common	O 0
phenotype	O 0
of	O 0
ALD	B-Disease 0
is	O 0
the	O 0
cerebral	O 0
form	O 0
(	O 0
45	O 0
%	O 0
)	O 0
that	O 0
develops	O 0
in	O 0
boys	O 0
between	O 0
5	O 0
-	O 0
12	O 0
yr	O 0
.	O 0

Adrenomyeloneuropathy	B-Disease 0
(	O 0
AMN	B-Disease 0
)	O 0
involves	O 0
the	O 0
spinal	O 0
cord	O 0
and	O 0
peripheral	O 0
nerves	O 0
in	O 0
young	O 0
adults	O 0
(	O 0
35	O 0
%	O 0
)	O 0
.	O 0

Adrenal	B-Disease 0
insufficiency	I-Disease 0
(	O 0
Addisons	B-Disease 0
disease	I-Disease 0
)	O 0
is	O 0
frequently	O 0
associated	O 0
with	O 0
AMN	B-Disease 0
or	O 0
cerebral	B-Disease 0
ALD	I-Disease 0
and	O 0
may	O 0
remain	O 0
the	O 0
only	O 0
clinical	O 0
expression	O 0
of	O 0
ALD	B-Disease 0
(	O 0
8	O 0
%	O 0
of	O 0
cases	O 0
)	O 0
.	O 0

The	O 0
prevalence	O 0
of	O 0
ALD	B-Disease 0
among	O 0
adults	O 0
with	O 0
Addisons	B-Disease 0
disease	I-Disease 0
remains	O 0
unknown	O 0
.	O 0

To	O 0
evaluate	O 0
this	O 0
prevalence	O 0
,	O 0
we	O 0
performed	O 0
biochemical	O 0
analysis	O 0
of	O 0
very	O 0
long	O 0
chain	O 0
fatty	O 0
acids	O 0
in	O 0
14	O 0
male	O 0
patients	O 0
(	O 0
age	O 0
ranging	O 0
from	O 0
12	O 0
-	O 0
45	O 0
yr	O 0
at	O 0
diagnosis	O 0
)	O 0
previously	O 0
diagnosed	O 0
as	O 0
having	O 0
primary	O 0
idiopathic	O 0
adrenocortical	B-Disease 0
insufficiency	I-Disease 0
.	O 0

In	O 0
5	O 0
of	O 0
14	O 0
patients	O 0
(	O 0
35	O 0
%	O 0
)	O 0
,	O 0
elevated	O 0
plasma	O 0
concentrations	O 0
of	O 0
very	O 0
long	O 0
chain	O 0
fatty	O 0
acids	O 0
were	O 0
detected	O 0
.	O 0

None	O 0
of	O 0
these	O 0
patients	O 0
had	O 0
adrenocortical	O 0
antibodies	O 0
.	O 0

By	O 0
electrophysiological	O 0
tests	O 0
and	O 0
magnetic	O 0
resonance	O 0
imaging	O 0
it	O 0
was	O 0
determined	O 0
that	O 0
two	O 0
patients	O 0
had	O 0
cerebral	B-Disease 0
ALD	I-Disease 0
,	O 0
one	O 0
had	O 0
adrenomyeloneuropathy	B-Disease 0
with	O 0
cerebral	O 0
involvement	O 0
,	O 0
and	O 0
two	O 0
had	O 0
preclinical	O 0
AMN	B-Disease 0
.	O 0

Our	O 0
data	O 0
support	O 0
the	O 0
hypothesis	O 0
that	O 0
ALD	B-Disease 0
is	O 0
a	O 0
frequent	O 0
cause	O 0
of	O 0
idiopathic	O 0
Addisons	B-Disease 0
disease	I-Disease 0
in	O 0
children	O 0
and	O 0
adults	O 0
.	O 0
.	O 0

Tumor	B-Disease 0
suppression	O 0
and	O 0
apoptosis	O 0
of	O 0
human	O 0
prostate	B-Disease 0
carcinoma	I-Disease 0
mediated	O 0
by	O 0
a	O 0
genetic	O 0
locus	O 0
within	O 0
human	O 0
chromosome	O 0
10pter	O 0
-	O 0
q11	O 0
.	O 0

Prostate	B-Disease 0
cancer	I-Disease 0
is	O 0
the	O 0
second	O 0
leading	O 0
cause	O 0
of	O 0
male	O 0
cancer	B-Disease 0
deaths	O 0
in	O 0
the	O 0
United	O 0
States	O 0
.	O 0

Yet	O 0
,	O 0
despite	O 0
a	O 0
large	O 0
international	O 0
effort	O 0
,	O 0
little	O 0
is	O 0
known	O 0
about	O 0
the	O 0
molecular	O 0
mechanisms	O 0
that	O 0
underlie	O 0
this	O 0
devastating	O 0
disease	O 0
.	O 0

Prostate	O 0
secretory	O 0
epithelial	O 0
cells	O 0
and	O 0
androgen	O 0
-	O 0
dependent	O 0
prostate	B-Disease 0
carcinomas	I-Disease 0
undergo	O 0
apoptosis	O 0
in	O 0
response	O 0
to	O 0
androgen	O 0
deprivation	O 0
and	O 0
,	O 0
furthermore	O 0
,	O 0
most	O 0
prostate	B-Disease 0
carcinomas	I-Disease 0
become	O 0
androgen	O 0
independent	O 0
and	O 0
refractory	O 0
to	O 0
further	O 0
therapeutic	O 0
manipulations	O 0
during	O 0
disease	O 0
progression	O 0
.	O 0

Definition	O 0
of	O 0
the	O 0
genetic	O 0
events	O 0
that	O 0
trigger	O 0
apoptosis	O 0
in	O 0
the	O 0
prostate	O 0
could	O 0
provide	O 0
important	O 0
insights	O 0
into	O 0
critical	O 0
pathways	O 0
in	O 0
normal	O 0
development	O 0
as	O 0
well	O 0
as	O 0
elucidate	O 0
the	O 0
perturbations	O 0
of	O 0
those	O 0
key	O 0
pathways	O 0
in	O 0
neoplastic	O 0
transformation	O 0
.	O 0

We	O 0
report	O 0
the	O 0
functional	O 0
definition	O 0
of	O 0
a	O 0
novel	O 0
genetic	O 0
locus	O 0
within	O 0
human	O 0
chromosome	O 0
10pter	O 0
-	O 0
q11	O 0
that	O 0
mediates	O 0
both	O 0
in	O 0
vivo	O 0
tumor	O 0
suppression	O 0
and	O 0
in	O 0
vitro	O 0
apoptosis	O 0
of	O 0
prostatic	B-Disease 0
adenocarcinoma	I-Disease 0
cells	O 0
.	O 0

A	O 0
defined	O 0
fragment	O 0
of	O 0
human	O 0
chromosome	O 0
10	O 0
was	O 0
transferred	O 0
via	O 0
microcell	O 0
fusion	O 0
into	O 0
a	O 0
prostate	B-Disease 0
adenocarcinoma	I-Disease 0
cell	O 0
line	O 0
.	O 0

Microcell	O 0
hybrids	O 0
containing	O 0
only	O 0
the	O 0
region	O 0
10pter	O 0
-	O 0
q11	O 0
were	O 0
suppressed	O 0
for	O 0
tumorigenicity	O 0
following	O 0
injection	O 0
of	O 0
microcell	O 0
hybrids	O 0
into	O 0
nude	O 0
mice	O 0
.	O 0

Furthermore	O 0
,	O 0
the	O 0
complemented	O 0
hybrids	O 0
undergo	O 0
programmed	O 0
cell	O 0
death	O 0
in	O 0
vitro	O 0
via	O 0
a	O 0
mechanism	O 0
that	O 0
does	O 0
not	O 0
require	O 0
nuclear	O 0
localization	O 0
of	O 0
p53	O 0
.	O 0

These	O 0
data	O 0
functionally	O 0
define	O 0
a	O 0
novel	O 0
genetic	O 0
locus	O 0
,	O 0
designated	O 0
PAC1	O 0
,	O 0
for	O 0
prostate	O 0
adenocarcinoma	O 0
1	O 0
,	O 0
involved	O 0
in	O 0
tumor	O 0
suppression	O 0
of	O 0
human	O 0
prostate	B-Disease 0
carcinoma	I-Disease 0
and	O 0
furthermore	O 0
strongly	O 0
suggest	O 0
that	O 0
the	O 0
cell	O 0
death	O 0
pathway	O 0
can	O 0
be	O 0
functionally	O 0
restored	O 0
in	O 0
prostatic	B-Disease 0
adenocarcinoma	I-Disease 0
.	O 0
.	O 0

Low	O 0
incidence	O 0
of	O 0
BRCA2	O 0
mutations	O 0
in	O 0
breast	B-Disease 0
carcinoma	I-Disease 0
and	O 0
other	O 0
cancers	B-Disease 0
.	O 0

Inherited	O 0
mutant	O 0
alleles	O 0
of	O 0
familial	O 0
tumour	B-Disease 0
suppressor	O 0
genes	O 0
predispose	O 0
individuals	O 0
to	O 0
particular	O 0
types	O 0
of	O 0
cancer	B-Disease 0
.	O 0

In	O 0
addition	O 0
to	O 0
an	O 0
involvement	O 0
in	O 0
inherited	O 0
susceptibility	O 0
to	O 0
cancer	B-Disease 0
,	O 0
these	O 0
tumour	B-Disease 0
suppressor	O 0
genes	O 0
are	O 0
targets	O 0
for	O 0
somatic	O 0
mutations	O 0
in	O 0
sporadic	B-Disease 0
cancers	I-Disease 0
of	O 0
the	O 0
same	O 0
type	O 0
found	O 0
in	O 0
the	O 0
familial	O 0
forms	O 0
.	O 0

An	O 0
exception	O 0
is	O 0
BRCA1	O 0
,	O 0
which	O 0
contributes	O 0
to	O 0
a	O 0
significant	O 0
fraction	O 0
of	O 0
familial	B-Disease 0
breast	I-Disease 0
and	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
,	O 0
but	O 0
undergoes	O 0
mutation	O 0
at	O 0
very	O 0
low	O 0
rates	O 0
in	O 0
sporadic	B-Disease 0
breast	I-Disease 0
and	I-Disease 0
ovarian	I-Disease 0
cancers	I-Disease 0
.	O 0

This	O 0
finding	O 0
suggests	O 0
that	O 0
other	O 0
genes	O 0
may	O 0
be	O 0
the	O 0
principal	O 0
targets	O 0
for	O 0
somatic	O 0
mutation	O 0
in	O 0
breast	B-Disease 0
carcinoma	I-Disease 0
.	O 0

A	O 0
second	O 0
,	O 0
recently	O 0
identified	O 0
familial	B-Disease 0
breast	I-Disease 0
cancer	I-Disease 0
gene	O 0
,	O 0
BRCA2	O 0
(	O 0
refs	O 0
5	O 0
-	O 0
8	O 0
)	O 0
,	O 0
accounts	O 0
for	O 0
a	O 0
proportion	O 0
of	O 0
breast	B-Disease 0
cancer	I-Disease 0
roughly	O 0
equal	O 0
to	O 0
BRCA1	O 0
.	O 0

Like	O 0
BRCA1	O 0
,	O 0
BRCA2	O 0
behaves	O 0
as	O 0
a	O 0
dominantly	O 0
inherited	O 0
tumour	B-Disease 0
suppressor	O 0
gene	O 0
.	O 0

Individuals	O 0
who	O 0
inherit	O 0
one	O 0
mutant	O 0
allele	O 0
are	O 0
at	O 0
increased	O 0
risk	O 0
for	O 0
breast	B-Disease 0
cancer	I-Disease 0
,	O 0
and	O 0
the	O 0
tumours	B-Disease 0
they	O 0
develop	O 0
lose	O 0
the	O 0
wild	O 0
-	O 0
type	O 0
allele	O 0
by	O 0
heterozygous	O 0
deletion	O 0
.	O 0

The	O 0
BRCA2	O 0
coding	O 0
sequence	O 0
is	O 0
huge	O 0
,	O 0
composed	O 0
of	O 0
26	O 0
exons	O 0
that	O 0
span	O 0
10	O 0
,	O 0
443	O 0
bp	O 0
.	O 0

Here	O 0
we	O 0
investigate	O 0
the	O 0
rate	O 0
of	O 0
BRCA2	O 0
mutation	O 0
in	O 0
sporadic	B-Disease 0
breast	I-Disease 0
cancers	I-Disease 0
and	O 0
in	O 0
a	O 0
set	O 0
of	O 0
cell	O 0
lines	O 0
that	O 0
represent	O 0
twelve	O 0
other	O 0
tumour	B-Disease 0
types	O 0
.	O 0

Surprisingly	O 0
,	O 0
mutations	O 0
in	O 0
BRCA2	O 0
are	O 0
infrequent	O 0
in	O 0
cancers	B-Disease 0
including	O 0
breast	B-Disease 0
carcinoma	I-Disease 0
.	O 0

However	O 0
,	O 0
a	O 0
probable	O 0
germline	O 0
mutation	O 0
in	O 0
a	O 0
pancreatic	B-Disease 0
tumour	I-Disease 0
cell	O 0
line	O 0
suggests	O 0
a	O 0
role	O 0
for	O 0
BRCA2	O 0
in	O 0
susceptibility	O 0
to	O 0
pancreatic	B-Disease 0
cancer	I-Disease 0
.	O 0
.	O 0

Founding	O 0
BRCA1	O 0
mutations	O 0
in	O 0
hereditary	B-Disease 0
breast	I-Disease 0
and	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
in	O 0
southern	O 0
Sweden	O 0
.	O 0

Nine	O 0
different	O 0
germ	O 0
-	O 0
line	O 0
mutations	O 0
in	O 0
the	O 0
BRCA1	O 0
breast	B-Disease 0
and	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
susceptibility	O 0
gene	O 0
were	O 0
identified	O 0
in	O 0
15	O 0
of	O 0
47	O 0
kindreds	O 0
from	O 0
southern	O 0
Sweden	O 0
,	O 0
by	O 0
use	O 0
of	O 0
SSCP	O 0
and	O 0
heteroduplex	O 0
analysis	O 0
of	O 0
all	O 0
exons	O 0
and	O 0
flanking	O 0
intron	O 0
region	O 0
and	O 0
by	O 0
a	O 0
protein	O 0
-	O 0
truncation	O 0
test	O 0
for	O 0
exon	O 0
11	O 0
,	O 0
followed	O 0
by	O 0
direct	O 0
sequencing	O 0
.	O 0

All	O 0
but	O 0
one	O 0
of	O 0
the	O 0
mutations	O 0
are	O 0
predicted	O 0
to	O 0
give	O 0
rise	O 0
to	O 0
premature	O 0
translation	O 0
termination	O 0
and	O 0
include	O 0
seven	O 0
frameshift	O 0
insertions	O 0
or	O 0
deletions	O 0
,	O 0
a	O 0
nonsense	O 0
mutation	O 0
,	O 0
and	O 0
a	O 0
splice	O 0
acceptor	O 0
site	O 0
mutation	O 0
.	O 0

The	O 0
remaining	O 0
mutation	O 0
is	O 0
a	O 0
missense	O 0
mutation	O 0
(	O 0
Cys61Gly	O 0
)	O 0
in	O 0
the	O 0
zinc	O 0
-	O 0
binding	O 0
motif	O 0
.	O 0

Four	O 0
novel	O 0
Swedish	O 0
founding	O 0
mutations	O 0
were	O 0
identified	O 0
the	O 0
nucleotide	O 0
2595	O 0
deletion	O 0
A	O 0
was	O 0
found	O 0
in	O 0
five	O 0
families	O 0
,	O 0
the	O 0
C	O 0
1806	O 0
T	O 0
nonsense	O 0
mutation	O 0
in	O 0
three	O 0
families	O 0
,	O 0
the	O 0
3166	O 0
insertion	O 0
TGAGA	O 0
in	O 0
three	O 0
families	O 0
,	O 0
and	O 0
the	O 0
nucleotide	O 0
1201	O 0
deletion	O 0
11	O 0
in	O 0
two	O 0
families	O 0
.	O 0

Analysis	O 0
of	O 0
the	O 0
intragenic	O 0
polymorphism	O 0
D17S855	O 0
supports	O 0
common	O 0
origins	O 0
of	O 0
the	O 0
mutations	O 0
.	O 0

Eleven	O 0
of	O 0
the	O 0
15	O 0
kindreds	O 0
manifesting	O 0
BRCA1	O 0
mutations	O 0
were	O 0
breast	B-Disease 0
-	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
families	O 0
,	O 0
several	O 0
of	O 0
them	O 0
with	O 0
a	O 0
predominant	O 0
ovarian	B-Disease 0
cancer	I-Disease 0
phenotype	O 0
.	O 0

The	O 0
set	O 0
of	O 0
32	O 0
families	O 0
in	O 0
which	O 0
no	O 0
BRCA1	O 0
alterations	O 0
were	O 0
detected	O 0
included	O 0
1	O 0
breast	B-Disease 0
-	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
kindred	O 0
manifesting	O 0
clear	O 0
linkage	O 0
to	O 0
the	O 0
BRCA1	O 0
region	O 0
and	O 0
loss	O 0
of	O 0
the	O 0
wild	O 0
-	O 0
type	O 0
chromosome	O 0
in	O 0
associated	O 0
tumors	B-Disease 0
.	O 0

Other	O 0
tumor	B-Disease 0
types	O 0
found	O 0
in	O 0
BRCA1	O 0
mutation	O 0
/	O 0
haplotype	O 0
carriers	O 0
included	O 0
prostatic	B-Disease 0
,	I-Disease 0
pancreas	I-Disease 0
,	I-Disease 0
skin	I-Disease 0
,	I-Disease 0
and	I-Disease 0
lung	I-Disease 0
cancer	I-Disease 0
,	O 0
a	O 0
malignant	B-Disease 0
melanoma	I-Disease 0
,	O 0
an	O 0
oligodendroglioma	B-Disease 0
,	O 0
and	O 0
a	O 0
carcinosarcoma	B-Disease 0
.	O 0

In	O 0
all	O 0
,	O 0
12	O 0
of	O 0
16	O 0
kindreds	O 0
manifesting	O 0
BRCA1	O 0
mutation	O 0
or	O 0
linkage	O 0
contained	O 0
ovarian	B-Disease 0
cancer	I-Disease 0
,	O 0
as	O 0
compared	O 0
with	O 0
only	O 0
6	O 0
of	O 0
the	O 0
remaining	O 0
31	O 0
families	O 0
(	O 0
P	O 0
<	O 0
.	O 0
001	O 0
)	O 0
.	O 0

The	O 0
present	O 0
study	O 0
confirms	O 0
the	O 0
involvement	O 0
of	O 0
BRCA1	O 0
in	O 0
disease	O 0
predisposition	O 0
for	O 0
a	O 0
subset	O 0
of	O 0
hereditary	B-Disease 0
breast	I-Disease 0
cancer	I-Disease 0
families	O 0
often	O 0
characterized	O 0
by	O 0
ovarian	B-Disease 0
cancers	I-Disease 0
.	O 0

Rapid	O 0
detection	O 0
of	O 0
regionally	O 0
clustered	O 0
germ	O 0
-	O 0
line	O 0
BRCA1	O 0
mutations	O 0
by	O 0
multiplex	O 0
heteroduplex	O 0
analysis	O 0
.	O 0

UKCCCR	O 0
Familial	O 0
Ovarian	B-Disease 0
Cancer	I-Disease 0
Study	O 0
Group	O 0
.	O 0

Germ	O 0
-	O 0
line	O 0
mutations	O 0
of	O 0
the	O 0
BRCA1	O 0
gene	O 0
are	O 0
responsible	O 0
for	O 0
a	O 0
substantial	O 0
proportion	O 0
of	O 0
families	O 0
with	O 0
multiple	O 0
cases	O 0
of	O 0
early	O 0
-	O 0
onset	O 0
breast	B-Disease 0
and	I-Disease 0
/	I-Disease 0
or	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
.	O 0

Since	O 0
the	O 0
isolation	O 0
of	O 0
BRCA1	O 0
last	O 0
year	O 0
,	O 0
>	O 0
65	O 0
distinct	O 0
mutations	O 0
scattered	O 0
throughout	O 0
the	O 0
coding	O 0
region	O 0
have	O 0
been	O 0
detected	O 0
,	O 0
making	O 0
analysis	O 0
of	O 0
the	O 0
gene	O 0
time	O 0
consuming	O 0
and	O 0
technically	O 0
challenging	O 0
.	O 0

We	O 0
have	O 0
developed	O 0
a	O 0
multiplex	O 0
heteroduplex	O 0
analysis	O 0
that	O 0
is	O 0
designed	O 0
to	O 0
analyze	O 0
one	O 0
-	O 0
quarter	O 0
of	O 0
the	O 0
coding	O 0
sequence	O 0
in	O 0
a	O 0
single	O 0
-	O 0
step	O 0
screening	O 0
procedure	O 0
and	O 0
that	O 0
will	O 0
detect	O 0
approximately	O 0
50	O 0
%	O 0
of	O 0
all	O 0
BRCA1	O 0
mutations	O 0
so	O 0
far	O 0
reported	O 0
in	O 0
breast	B-Disease 0
/	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
families	O 0
.	O 0

We	O 0
have	O 0
used	O 0
this	O 0
technique	O 0
to	O 0
analyze	O 0
BRCA1	O 0
in	O 0
162	O 0
families	O 0
with	O 0
a	O 0
history	O 0
of	O 0
breast	B-Disease 0
and	I-Disease 0
/	I-Disease 0
or	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
and	O 0
identified	O 0
12	O 0
distinct	O 0
mutations	O 0
in	O 0
35	O 0
families	O 0
.	O 0
.	O 0

A	O 0
previously	O 0
undescribed	O 0
mutation	O 0
within	O 0
the	O 0
tetramerisation	O 0
domain	O 0
of	O 0
TP53	O 0
in	O 0
a	O 0
family	O 0
with	O 0
Li	B-Disease 0
-	I-Disease 0
Fraumeni	I-Disease 0
syndrome	I-Disease 0
.	O 0

We	O 0
report	O 0
details	O 0
of	O 0
a	O 0
family	O 0
with	O 0
classic	O 0
Li	B-Disease 0
-	I-Disease 0
Fraumeni	I-Disease 0
syndrome	I-Disease 0
in	O 0
which	O 0
there	O 0
is	O 0
a	O 0
mutation	O 0
in	O 0
codon	O 0
344	O 0
of	O 0
the	O 0
tumour	B-Disease 0
suppressor	O 0
gene	O 0
TP53	O 0
.	O 0

Codon	O 0
344	O 0
is	O 0
a	O 0
key	O 0
residue	O 0
within	O 0
the	O 0
tetramerisation	O 0
domain	O 0
,	O 0
and	O 0
the	O 0
amino	O 0
acid	O 0
substitution	O 0
of	O 0
a	O 0
proline	O 0
for	O 0
a	O 0
leucine	O 0
is	O 0
predicted	O 0
to	O 0
have	O 0
profound	O 0
implications	O 0
for	O 0
tetramerisation	O 0
and	O 0
potentially	O 0
DNA	O 0
binding	O 0
.	O 0

This	O 0
is	O 0
the	O 0
first	O 0
report	O 0
of	O 0
a	O 0
mutation	O 0
at	O 0
this	O 0
residue	O 0
in	O 0
either	O 0
sporadic	B-Disease 0
tumours	I-Disease 0
or	O 0
in	O 0
the	O 0
germline	O 0
and	O 0
the	O 0
first	O 0
report	O 0
of	O 0
a	O 0
germline	O 0
mutation	O 0
within	O 0
the	O 0
tetramerisation	O 0
domain	O 0
.	O 0

The	O 0
family	O 0
does	O 0
not	O 0
appear	O 0
to	O 0
be	O 0
remarkable	O 0
in	O 0
the	O 0
spectrum	O 0
of	O 0
tumours	B-Disease 0
,	O 0
and	O 0
there	O 0
is	O 0
loss	O 0
of	O 0
the	O 0
wild	O 0
-	O 0
type	O 0
allele	O 0
in	O 0
a	O 0
leiomyosarcoma	B-Disease 0
from	O 0
the	O 0
proband	O 0
.	O 0

A	O 0
cell	O 0
line	O 0
has	O 0
been	O 0
established	O 0
from	O 0
the	O 0
tumour	B-Disease 0
of	O 0
the	O 0
proband	O 0
and	O 0
cytogenetic	O 0
and	O 0
molecular	O 0
studies	O 0
carried	O 0
out	O 0
,	O 0
providing	O 0
an	O 0
extensive	O 0
analysis	O 0
in	O 0
this	O 0
family	O 0
.	O 0
.	O 0

The	O 0
spectrum	O 0
of	O 0
RB1	O 0
germ	O 0
-	O 0
line	O 0
mutations	O 0
in	O 0
hereditary	B-Disease 0
retinoblastoma	I-Disease 0
.	O 0

We	O 0
have	O 0
searched	O 0
for	O 0
germ	O 0
-	O 0
line	O 0
RB1	O 0
mutations	O 0
in	O 0
119	O 0
patients	O 0
with	O 0
hereditary	B-Disease 0
retinoblastoma	I-Disease 0
.	O 0

Previous	O 0
investigations	O 0
by	O 0
Southern	O 0
blot	O 0
hybridization	O 0
and	O 0
PCR	O 0
fragment	O 0
-	O 0
length	O 0
analysis	O 0
had	O 0
revealed	O 0
mutations	O 0
in	O 0
48	O 0
patients	O 0
.	O 0

Here	O 0
we	O 0
report	O 0
on	O 0
the	O 0
analysis	O 0
of	O 0
the	O 0
remaining	O 0
71	O 0
patients	O 0
.	O 0

By	O 0
applying	O 0
heteroduplex	O 0
analysis	O 0
,	O 0
nonisotopic	O 0
SSCP	O 0
,	O 0
and	O 0
direct	O 0
sequencing	O 0
,	O 0
we	O 0
detected	O 0
germ	O 0
-	O 0
line	O 0
mutations	O 0
resulting	O 0
in	O 0
premature	O 0
termination	O 0
codons	O 0
or	O 0
disruption	O 0
of	O 0
splice	O 0
signals	O 0
in	O 0
51	O 0
(	O 0
72	O 0
%	O 0
)	O 0
of	O 0
the	O 0
71	O 0
patients	O 0
.	O 0

Four	O 0
patients	O 0
also	O 0
showed	O 0
rare	O 0
sequence	O 0
variants	O 0
.	O 0

No	O 0
region	O 0
of	O 0
the	O 0
RB1	O 0
gene	O 0
was	O 0
preferentially	O 0
involved	O 0
in	O 0
single	O 0
base	O 0
substitutions	O 0
.	O 0

Recurrent	O 0
transitions	O 0
were	O 0
observed	O 0
at	O 0
most	O 0
of	O 0
the	O 0
14	O 0
codons	O 0
within	O 0
the	O 0
RB1	O 0
.	O 0

No	O 0
mutation	O 0
was	O 0
observed	O 0
in	O 0
exons	O 0
25	O 0
-	O 0
27	O 0
,	O 0
although	O 0
this	O 0
region	O 0
contains	O 0
two	O 0
CGA	O 0
codons	O 0
.	O 0

This	O 0
suggests	O 0
that	O 0
mutations	O 0
within	O 0
the	O 0
3	O 0
-	O 0
terminal	O 0
region	O 0
of	O 0
the	O 0
RB1	O 0
gene	O 0
may	O 0
not	O 0
be	O 0
oncogenic	O 0
.	O 0

When	O 0
these	O 0
data	O 0
were	O 0
combined	O 0
with	O 0
the	O 0
results	O 0
of	O 0
our	O 0
previous	O 0
investigations	O 0
,	O 0
mutations	O 0
were	O 0
identified	O 0
in	O 0
a	O 0
total	O 0
of	O 0
99	O 0
(	O 0
83	O 0
%	O 0
)	O 0
of	O 0
119	O 0
patients	O 0
.	O 0

The	O 0
spectrum	O 0
comprises	O 0
15	O 0
%	O 0
large	O 0
deletions	O 0
,	O 0
26	O 0
%	O 0
small	O 0
length	O 0
alterations	O 0
,	O 0
and	O 0
42	O 0
%	O 0
base	O 0
substitutions	O 0
.	O 0

No	O 0
correlation	O 0
between	O 0
the	O 0
location	O 0
of	O 0
frameshift	O 0
or	O 0
nonsense	O 0
mutations	O 0
and	O 0
phenotypic	O 0
features	O 0
,	O 0
including	O 0
age	O 0
at	O 0
diagnosis	O 0
,	O 0
the	O 0
number	O 0
of	O 0
tumor	B-Disease 0
foci	O 0
,	O 0
and	O 0
manifestation	O 0
of	O 0
nonocular	B-Disease 0
tumors	I-Disease 0
was	O 0
observed	O 0
.	O 0
.	O 0

Phenotypic	O 0
characterization	O 0
of	O 0
individuals	O 0
with	O 0
30	O 0
-	O 0
40	O 0
CAG	O 0
repeats	O 0
in	O 0
the	O 0
Huntington	B-Disease 0
disease	I-Disease 0
(	O 0
HD	B-Disease 0
)	O 0
gene	O 0
reveals	O 0
HD	B-Disease 0
cases	O 0
with	O 0
36	O 0
repeats	O 0
and	O 0
apparently	O 0
normal	O 0
elderly	O 0
individuals	O 0
with	O 0
36	O 0
-	O 0
39	O 0
repeats	O 0
.	O 0

Abnormal	O 0
CAG	O 0
expansions	O 0
in	O 0
the	O 0
IT	O 0
-	O 0
15	O 0
gene	O 0
are	O 0
associated	O 0
with	O 0
Huntington	B-Disease 0
disease	I-Disease 0
(	O 0
HD	B-Disease 0
)	O 0
.	O 0

In	O 0
the	O 0
diagnostic	O 0
setting	O 0
it	O 0
is	O 0
necessary	O 0
to	O 0
define	O 0
the	O 0
limits	O 0
of	O 0
the	O 0
CAG	O 0
size	O 0
ranges	O 0
on	O 0
normal	O 0
and	O 0
HD	B-Disease 0
-	O 0
associated	O 0
chromosomes	O 0
.	O 0

Most	O 0
large	O 0
analyses	O 0
that	O 0
defined	O 0
the	O 0
limits	O 0
of	O 0
the	O 0
normal	O 0
and	O 0
pathological	O 0
size	O 0
ranges	O 0
employed	O 0
PCR	O 0
assays	O 0
,	O 0
which	O 0
included	O 0
the	O 0
CAG	O 0
repeats	O 0
and	O 0
a	O 0
CCG	O 0
repeat	O 0
tract	O 0
that	O 0
was	O 0
thought	O 0
to	O 0
be	O 0
invariant	O 0
.	O 0

Many	O 0
of	O 0
these	O 0
experiments	O 0
found	O 0
an	O 0
overlap	O 0
between	O 0
the	O 0
normal	O 0
and	O 0
disease	O 0
size	O 0
ranges	O 0
.	O 0

Subsequent	O 0
findings	O 0
that	O 0
the	O 0
CCG	O 0
repeats	O 0
vary	O 0
by	O 0
8	O 0
trinucleotide	O 0
lengths	O 0
suggested	O 0
that	O 0
the	O 0
limits	O 0
of	O 0
the	O 0
normal	O 0
and	O 0
disease	O 0
size	O 0
ranges	O 0
should	O 0
be	O 0
reevaluated	O 0
with	O 0
assays	O 0
that	O 0
exclude	O 0
the	O 0
CCG	O 0
polymorphism	O 0
.	O 0

Since	O 0
patients	O 0
with	O 0
between	O 0
30	O 0
and	O 0
40	O 0
repeats	O 0
are	O 0
rare	O 0
,	O 0
a	O 0
consortium	O 0
was	O 0
assembled	O 0
to	O 0
collect	O 0
such	O 0
individuals	O 0
.	O 0

All	O 0
178	O 0
samples	O 0
were	O 0
reanalyzed	O 0
in	O 0
Cambridge	O 0
by	O 0
using	O 0
assays	O 0
specific	O 0
for	O 0
the	O 0
CAG	O 0
repeats	O 0
.	O 0

We	O 0
have	O 0
optimized	O 0
methods	O 0
for	O 0
reliable	O 0
sizing	O 0
of	O 0
CAG	O 0
repeats	O 0
and	O 0
show	O 0
cases	O 0
that	O 0
demonstrate	O 0
the	O 0
dangers	O 0
of	O 0
using	O 0
PCR	O 0
assays	O 0
that	O 0
include	O 0
both	O 0
the	O 0
CAG	O 0
and	O 0
CCG	O 0
polymorphisms	O 0
.	O 0

Seven	O 0
HD	B-Disease 0
patients	O 0
had	O 0
36	O 0
repeats	O 0
,	O 0
which	O 0
confirms	O 0
that	O 0
this	O 0
allele	O 0
is	O 0
associated	O 0
with	O 0
disease	O 0
.	O 0

Individuals	O 0
without	O 0
apparent	O 0
symptoms	O 0
or	O 0
signs	O 0
of	O 0
HD	B-Disease 0
were	O 0
found	O 0
at	O 0
36	O 0
repeats	O 0
(	O 0
aged	O 0
74	O 0
,	O 0
78	O 0
,	O 0
79	O 0
,	O 0
and	O 0
87	O 0
years	O 0
)	O 0
,	O 0
37	O 0
repeats	O 0
(	O 0
aged	O 0
69	O 0
years	O 0
)	O 0
,	O 0
38	O 0
repeats	O 0
(	O 0
aged	O 0
69	O 0
and	O 0
90	O 0
years	O 0
)	O 0
,	O 0
and	O 0
39	O 0
repeats	O 0
(	O 0
aged	O 0
67	O 0
,	O 0
90	O 0
,	O 0
and	O 0
95	O 0
years	O 0
)	O 0
.	O 0

The	O 0
detailed	O 0
case	O 0
histories	O 0
of	O 0
an	O 0
exceptional	O 0
case	O 0
from	O 0
this	O 0
series	O 0
will	O 0
be	O 0
presented	O 0
a	O 0
95	O 0
-	O 0
year	O 0
-	O 0
old	O 0
man	O 0
with	O 0
39	O 0
repeats	O 0
who	O 0
did	O 0
not	O 0
have	O 0
classical	O 0
features	O 0
of	O 0
HD	B-Disease 0
.	O 0

The	O 0
apparently	O 0
healthy	O 0
survival	O 0
into	O 0
old	O 0
age	O 0
of	O 0
some	O 0
individuals	O 0
with	O 0
36	O 0
-	O 0
39	O 0
repeats	O 0
suggests	O 0
that	O 0
the	O 0
HD	B-Disease 0
mutation	O 0
may	O 0
not	O 0
always	O 0
be	O 0
fully	O 0
penetrant	O 0
.	O 0
.	O 0

Identification	O 0
and	O 0
expression	O 0
of	O 0
eight	O 0
novel	O 0
mutations	O 0
among	O 0
non	O 0
-	O 0
Jewish	O 0
patients	O 0
with	O 0
Canavan	B-Disease 0
disease	I-Disease 0
.	O 0

Canavan	B-Disease 0
disease	I-Disease 0
is	O 0
inherited	O 0
as	O 0
an	O 0
autosomal	O 0
recessive	O 0
trait	O 0
that	O 0
is	O 0
caused	O 0
by	O 0
the	O 0
deficiency	B-Disease 0
of	I-Disease 0
aspartoacylase	I-Disease 0
(	O 0
ASPA	O 0
)	O 0
.	O 0

The	O 0
majority	O 0
of	O 0
patients	O 0
with	O 0
Canavan	B-Disease 0
disease	I-Disease 0
are	O 0
from	O 0
an	O 0
Ashkenazi	O 0
Jewish	O 0
background	O 0
.	O 0

Mutations	O 0
in	O 0
ASPA	O 0
that	O 0
lead	O 0
to	O 0
loss	O 0
of	O 0
enzymatic	O 0
activity	O 0
have	O 0
been	O 0
identified	O 0
,	O 0
and	O 0
E285A	O 0
and	O 0
Y231X	O 0
are	O 0
the	O 0
two	O 0
predominant	O 0
mutations	O 0
that	O 0
account	O 0
for	O 0
97	O 0
%	O 0
of	O 0
the	O 0
mutant	O 0
chromosomes	O 0
in	O 0
Ashkenazi	O 0
Jewish	O 0
patients	O 0
.	O 0

The	O 0
current	O 0
study	O 0
was	O 0
aimed	O 0
at	O 0
finding	O 0
the	O 0
molecular	O 0
basis	O 0
of	O 0
Canavan	B-Disease 0
disease	I-Disease 0
in	O 0
25	O 0
independent	O 0
patients	O 0
of	O 0
non	O 0
-	O 0
Jewish	O 0
background	O 0
.	O 0

Eight	O 0
novel	O 0
and	O 0
three	O 0
previously	O 0
characterized	O 0
mutations	O 0
accounted	O 0
for	O 0
80	O 0
%	O 0
(	O 0
40	O 0
/	O 0
50	O 0
)	O 0
of	O 0
mutant	O 0
chromosomes	O 0
.	O 0

The	O 0
A305E	O 0
missense	O 0
mutation	O 0
accounted	O 0
for	O 0
48	O 0
%	O 0
(	O 0
24	O 0
/	O 0
50	O 0
)	O 0
of	O 0
mutant	O 0
chromosomes	O 0
in	O 0
patients	O 0
of	O 0
western	O 0
European	O 0
descent	O 0
,	O 0
while	O 0
the	O 0
two	O 0
predominant	O 0
Jewish	O 0
mutations	O 0
each	O 0
accounted	O 0
for	O 0
a	O 0
single	O 0
mutant	O 0
chromosome	O 0
.	O 0

The	O 0
eight	O 0
novel	O 0
mutations	O 0
identified	O 0
included	O 0
1	O 0
-	O 0
and	O 0
4	O 0
-	O 0
bp	O 0
deletions	O 0
(	O 0
32	O 0
deltaT	O 0
and	O 0
876	O 0
deltaAGAA	O 0
,	O 0
respectively	O 0
)	O 0
and	O 0
I16T	O 0
,	O 0
G27R	O 0
,	O 0
D114E	O 0
,	O 0
G123E	O 0
,	O 0
C152Y	O 0
,	O 0
and	O 0
R168C	O 0
missense	O 0
mutations	O 0
.	O 0

The	O 0
homozygous	O 0
32	O 0
deltaT	O 0
deletion	O 0
was	O 0
identified	O 0
in	O 0
the	O 0
only	O 0
known	O 0
patient	O 0
of	O 0
African	O 0
-	O 0
American	O 0
origin	O 0
with	O 0
Canavan	B-Disease 0
disease	I-Disease 0
.	O 0

The	O 0
heterozygosity	O 0
for	O 0
876	O 0
deltaAGAA	O 0
mutation	O 0
was	O 0
identified	O 0
in	O 0
three	O 0
independent	O 0
patients	O 0
from	O 0
England	O 0
.	O 0

Six	O 0
single	O 0
-	O 0
base	O 0
changes	O 0
leading	O 0
to	O 0
missense	O 0
mutations	O 0
were	O 0
identified	O 0
in	O 0
patients	O 0
from	O 0
Turkey	O 0
(	O 0
D114E	O 0
,	O 0
R168C	O 0
)	O 0
,	O 0
The	O 0
Netherlands	O 0
(	O 0
I16T	O 0
)	O 0
,	O 0
Germany	O 0
(	O 0
G27R	O 0
)	O 0
,	O 0
Ireland	O 0
(	O 0
C152Y	O 0
)	O 0
,	O 0
and	O 0
Canada	O 0
(	O 0
G123E	O 0
)	O 0
.	O 0

A	O 0
PCR	O 0
-	O 0
based	O 0
protocol	O 0
is	O 0
described	O 0
that	O 0
was	O 0
used	O 0
to	O 0
introduce	O 0
mutations	O 0
in	O 0
wild	O 0
-	O 0
type	O 0
cDNA	O 0
.	O 0

In	O 0
vitro	O 0
expression	O 0
of	O 0
mutant	O 0
cDNA	O 0
clones	O 0
demonstrated	O 0
that	O 0
all	O 0
of	O 0
these	O 0
mutations	O 0
led	O 0
to	O 0
a	O 0
deficiency	B-Disease 0
of	I-Disease 0
ASPA	I-Disease 0
and	O 0
should	O 0
therefore	O 0
result	O 0
in	O 0
Canavan	B-Disease 0
disease	I-Disease 0
.	O 0
.	O 0

Identification	O 0
and	O 0
chromosomal	O 0
localization	O 0
of	O 0
Atm	O 0
,	O 0
the	O 0
mouse	O 0
homolog	O 0
of	O 0
the	O 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
gene	O 0
.	O 0

Atm	O 0
,	O 0
the	O 0
mouse	O 0
homolog	O 0
of	O 0
the	O 0
human	O 0
ATM	O 0
gene	O 0
defective	O 0
in	O 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
(	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
)	O 0
,	O 0
has	O 0
been	O 0
identified	O 0
.	O 0

The	O 0
entire	O 0
coding	O 0
sequence	O 0
of	O 0
the	O 0
Atm	O 0
transcript	O 0
was	O 0
cloned	O 0
and	O 0
found	O 0
to	O 0
contain	O 0
an	O 0
open	O 0
reading	O 0
frame	O 0
encoding	O 0
a	O 0
protein	O 0
of	O 0
3066	O 0
amino	O 0
acids	O 0
with	O 0
84	O 0
%	O 0
overall	O 0
identity	O 0
and	O 0
91	O 0
%	O 0
similarity	O 0
to	O 0
the	O 0
human	O 0
ATM	O 0
protein	O 0
.	O 0

Variable	O 0
levels	O 0
of	O 0
expression	O 0
of	O 0
Atm	O 0
were	O 0
observed	O 0
in	O 0
different	O 0
tissues	O 0
.	O 0

Fluorescence	O 0
in	O 0
situ	O 0
hybridization	O 0
and	O 0
linkage	O 0
analysis	O 0
located	O 0
the	O 0
Atm	O 0
gene	O 0
on	O 0
mouse	O 0
chromosome	O 0
9	O 0
,	O 0
band	O 0
9C	O 0
,	O 0
in	O 0
a	O 0
region	O 0
homologous	O 0
to	O 0
the	O 0
ATM	O 0
region	O 0
on	O 0
human	O 0
chromosome	O 0
11q22	O 0
-	O 0
q23	O 0
.	O 0
.	O 0

The	O 0
mouse	O 0
homolog	O 0
of	O 0
the	O 0
Wiskott	B-Disease 0
-	I-Disease 0
Aldrich	I-Disease 0
syndrome	I-Disease 0
protein	O 0
(	O 0
WASP	O 0
)	O 0
gene	O 0
is	O 0
highly	O 0
conserved	O 0
and	O 0
maps	O 0
near	O 0
the	O 0
scurfy	O 0
(	O 0
sf	O 0
)	O 0
mutation	O 0
on	O 0
the	O 0
X	O 0
chromosome	O 0
.	O 0

The	O 0
mouse	O 0
WASP	O 0
gene	O 0
,	O 0
the	O 0
homolog	O 0
of	O 0
the	O 0
gene	O 0
mutated	O 0
in	O 0
Wiskott	B-Disease 0
-	I-Disease 0
Aldrich	I-Disease 0
syndrome	I-Disease 0
,	O 0
has	O 0
been	O 0
isolated	O 0
and	O 0
sequenced	O 0
.	O 0
the	O 0
predicted	O 0
amino	O 0
acid	O 0
sequence	O 0
is	O 0
86	O 0
%	O 0
identical	O 0
to	O 0
the	O 0
human	O 0
WASP	O 0
sequence	O 0
.	O 0

A	O 0
distinct	O 0
feature	O 0
of	O 0
the	O 0
mouse	O 0
gene	O 0
is	O 0
an	O 0
expanded	O 0
polymorphic	O 0
GGA	O 0
trinucleotide	O 0
repeat	O 0
that	O 0
codes	O 0
for	O 0
polyglycine	O 0
and	O 0
varies	O 0
from	O 0
15	O 0
to	O 0
17	O 0
triplets	O 0
in	O 0
different	O 0
Mus	O 0
musculus	O 0
strains	O 0
.	O 0

The	O 0
genomic	O 0
structure	O 0
of	O 0
the	O 0
mouse	O 0
WASP	O 0
gene	O 0
is	O 0
expressed	O 0
as	O 0
an	O 0
approximately	O 0
2	O 0
.	O 0

4	O 0
-	O 0
kb	O 0
mRNA	O 0
in	O 0
thymus	O 0
and	O 0
spleen	O 0
.	O 0

Chromosomal	O 0
mapping	O 0
in	O 0
an	O 0
interspecific	O 0
M	O 0
.	O 0

Musculus	O 0
/	O 0
M	O 0
.	O 0
spretus	O 0
backcross	O 0
placed	O 0
the	O 0
Wasp	O 0
locus	O 0
near	O 0
the	O 0
centromere	O 0
of	O 0
the	O 0
mouse	O 0
X	O 0
chromosome	O 0
,	O 0
inseparable	O 0
from	O 0
Gata1	O 0
,	O 0
Tcfe3	O 0
,	O 0
and	O 0
scurfy	O 0
(	O 0
sf	O 0
)	O 0
.	O 0

This	O 0
localization	O 0
makes	O 0
Wasp	O 0
a	O 0
candidate	O 0
for	O 0
involvement	O 0
in	O 0
scurfy	O 0
,	O 0
a	O 0
T	O 0
cell	O 0
-	O 0
mediated	O 0
fatal	B-Disease 0
lymphoreticular	I-Disease 0
disease	I-Disease 0
of	O 0
mice	O 0
that	O 0
has	O 0
previously	O 0
been	O 0
proposed	O 0
as	O 0
a	O 0
mouse	O 0
homolog	O 0
of	O 0
Wiskott	B-Disease 0
-	I-Disease 0
Aldrich	I-Disease 0
syndrome	I-Disease 0
.	O 0

Northern	O 0
analysis	O 0
of	O 0
sf	O 0
tissue	O 0
samples	O 0
indicated	O 0
the	O 0
presence	O 0
of	O 0
WASP	O 0
mRNA	O 0
in	O 0
liver	O 0
and	O 0
skin	O 0
,	O 0
presumably	O 0
as	O 0
a	O 0
consequence	O 0
of	O 0
lymphocytic	O 0
infiltration	O 0
,	O 0
but	O 0
non	O 0
abnormalities	O 0
in	O 0
the	O 0
amount	O 0
or	O 0
size	O 0
of	O 0
mRNA	O 0
present	O 0
.	O 0

Colchicine	O 0
in	O 0
breast	O 0
milk	O 0
of	O 0
patients	O 0
with	O 0
familial	B-Disease 0
Mediterranean	I-Disease 0
fever	I-Disease 0
.	O 0

OBJECTIVE	O 0
.	O 0

To	O 0
clarify	O 0
whether	O 0
colchicine	O 0
is	O 0
excreted	O 0
in	O 0
breast	O 0
milk	O 0
,	O 0
and	O 0
to	O 0
compare	O 0
its	O 0
concentrations	O 0
in	O 0
the	O 0
serum	O 0
and	O 0
breast	O 0
milk	O 0
of	O 0
lactating	O 0
women	O 0
who	O 0
have	O 0
familial	B-Disease 0
Mediterranean	I-Disease 0
fever	I-Disease 0
(	O 0
FMF	B-Disease 0
)	O 0
.	O 0

METHODS	O 0
.	O 0

Using	O 0
a	O 0
specific	O 0
radioimmunoassay	O 0
,	O 0
we	O 0
determined	O 0
colchicine	O 0
concentrations	O 0
in	O 0
the	O 0
serum	O 0
and	O 0
breast	O 0
milk	O 0
of	O 0
4	O 0
patients	O 0
at	O 0
various	O 0
time	O 0
points	O 0
,	O 0
following	O 0
oral	O 0
administration	O 0
of	O 0
the	O 0
drug	O 0
.	O 0

The	O 0
study	O 0
evaluated	O 0
4	O 0
patients	O 0
with	O 0
FMF	B-Disease 0
who	O 0
had	O 0
been	O 0
taking	O 0
colchicine	O 0
on	O 0
a	O 0
long	O 0
-	O 0
term	O 0
basis	O 0
.	O 0

RESULTS	O 0
.	O 0

Colchicine	O 0
was	O 0
found	O 0
to	O 0
be	O 0
excreted	O 0
in	O 0
breast	O 0
milk	O 0
.	O 0

Its	O 0
levels	O 0
ranged	O 0
between	O 0
1	O 0
.	O 0

9	O 0
and	O 0
8	O 0
.	O 0

6	O 0
ng	O 0
/	O 0
ml	O 0
,	O 0
which	O 0
were	O 0
similar	O 0
to	O 0
those	O 0
found	O 0
in	O 0
the	O 0
serum	O 0
(	O 0
parallel	O 0
concentration	O 0
time	O 0
curves	O 0
)	O 0
.	O 0

However	O 0
,	O 0
there	O 0
appeared	O 0
to	O 0
be	O 0
a	O 0
considerable	O 0
variation	O 0
in	O 0
colchicine	O 0
milk	O 0
concentration	O 0
among	O 0
the	O 0
different	O 0
patients	O 0
,	O 0
which	O 0
might	O 0
be	O 0
related	O 0
to	O 0
individual	O 0
breast	O 0
milk	O 0
composition	O 0
and	O 0
,	O 0
possibly	O 0
,	O 0
to	O 0
other	O 0
nutritional	O 0
or	O 0
metabolic	O 0
factors	O 0
.	O 0

CONCLUSION	O 0
.	O 0

The	O 0
extensive	O 0
peripheral	O 0
tissue	O 0
binding	O 0
and	O 0
relatively	O 0
low	O 0
concentration	O 0
of	O 0
colchicine	O 0
in	O 0
breast	O 0
milk	O 0
suggests	O 0
that	O 0
the	O 0
amount	O 0
ingested	O 0
by	O 0
the	O 0
infant	O 0
is	O 0
small	O 0
.	O 0

Furthermore	O 0
,	O 0
based	O 0
on	O 0
our	O 0
clinical	O 0
experience	O 0
,	O 0
nursing	O 0
appears	O 0
to	O 0
be	O 0
safe	O 0
for	O 0
lactating	O 0
women	O 0
with	O 0
FMF	B-Disease 0
who	O 0
continue	O 0
to	O 0
take	O 0
colchicine	O 0
.	O 0

Abnormal	O 0
myotonic	B-Disease 0
dystrophy	I-Disease 0
protein	O 0
kinase	O 0
levels	O 0
produce	O 0
only	O 0
mild	O 0
myopathy	B-Disease 0
in	O 0
mice	O 0
.	O 0

Myotonic	B-Disease 0
dystrophy	I-Disease 0
(	O 0
DM	B-Disease 0
)	O 0
is	O 0
commonly	O 0
associated	O 0
with	O 0
CTG	O 0
repeat	O 0
expansions	O 0
within	O 0
the	O 0
gene	O 0
for	O 0
DM	O 0
-	O 0
protein	O 0
kinase	O 0
(	O 0
DMPK	O 0
)	O 0
.	O 0

The	O 0
effect	O 0
of	O 0
altered	O 0
expression	O 0
levels	O 0
of	O 0
DMPK	O 0
,	O 0
which	O 0
is	O 0
ubiquitously	O 0
expressed	O 0
in	O 0
all	O 0
muscle	O 0
cell	O 0
lineages	O 0
during	O 0
development	O 0
,	O 0
was	O 0
examined	O 0
by	O 0
disrupting	O 0
the	O 0
endogenous	O 0
Dmpk	O 0
gene	O 0
and	O 0
overexpressing	O 0
a	O 0
normal	O 0
human	O 0
DMPK	O 0
transgene	O 0
in	O 0
mice	O 0
.	O 0

Nullizygous	O 0
(	O 0
-	O 0
/	O 0
-	O 0
)	O 0
mice	O 0
showed	O 0
only	O 0
inconsistent	O 0
and	O 0
minor	O 0
size	O 0
changes	O 0
in	O 0
head	O 0
and	O 0
neck	O 0
muscle	O 0
fibres	O 0
at	O 0
older	O 0
age	O 0
,	O 0
animals	O 0
with	O 0
the	O 0
highest	O 0
DMPK	O 0
transgene	O 0
expression	O 0
showed	O 0
hypertrophic	B-Disease 0
cardiomyopathy	I-Disease 0
and	O 0
enhanced	O 0
neonatal	O 0
mortality	O 0
.	O 0

However	O 0
,	O 0
both	O 0
models	O 0
lack	O 0
other	O 0
frequent	O 0
DM	B-Disease 0
symptoms	O 0
including	O 0
the	O 0
fibre	O 0
-	O 0
type	O 0
dependent	O 0
atrophy	B-Disease 0
,	O 0
myotonia	B-Disease 0
,	O 0
cataract	B-Disease 0
and	O 0
male	B-Disease 0
-	I-Disease 0
infertility	I-Disease 0
.	O 0

These	O 0
results	O 0
strengthen	O 0
the	O 0
contention	O 0
that	O 0
simple	O 0
loss	O 0
-	O 0
or	O 0
gain	O 0
-	O 0
of	O 0
-	O 0
expression	O 0
of	O 0
DMPK	O 0
is	O 0
not	O 0
the	O 0
only	O 0
crucial	O 0
requirement	O 0
for	O 0
development	O 0
of	O 0
the	O 0
disease	O 0
.	O 0
.	O 0

Mice	O 0
lacking	O 0
the	O 0
myotonic	B-Disease 0
dystrophy	I-Disease 0
protein	O 0
kinase	O 0
develop	O 0
a	O 0
late	O 0
onset	O 0
progressive	O 0
myopathy	B-Disease 0
.	O 0

Myotonic	B-Disease 0
dystrophy	I-Disease 0
(	O 0
DM	B-Disease 0
)	O 0
is	O 0
an	O 0
autosomal	B-Disease 0
dominant	I-Disease 0
disorder	I-Disease 0
resulting	O 0
from	O 0
the	O 0
expansion	O 0
of	O 0
a	O 0
CTG	O 0
repeat	O 0
in	O 0
the	O 0
3	O 0
untranslated	O 0
region	O 0
of	O 0
a	O 0
putative	O 0
protein	O 0
kinase	O 0
(	O 0
DMPK	O 0
)	O 0
.	O 0

To	O 0
elucidate	O 0
the	O 0
role	O 0
of	O 0
DMPK	O 0
in	O 0
DM	B-Disease 0
pathogenesis	O 0
we	O 0
have	O 0
developed	O 0
Dmpk	B-Disease 0
deficient	I-Disease 0
(	O 0
Dmpk	O 0
-	O 0
/	O 0
-	O 0
)	O 0
mice	O 0
.	O 0

Dmpk	O 0
-	O 0
/	O 0
-	O 0
mice	O 0
develop	O 0
a	O 0
late	O 0
-	O 0
onset	O 0
,	O 0
progressive	B-Disease 0
skeletal	I-Disease 0
myopathy	I-Disease 0
that	O 0
shares	O 0
some	O 0
pathological	O 0
features	O 0
with	O 0
DM	B-Disease 0
.	O 0

Muscles	O 0
from	O 0
mature	O 0
mice	O 0
show	O 0
variation	O 0
in	O 0
fibre	O 0
size	O 0
,	O 0
increased	O 0
fibre	B-Disease 0
degeneration	I-Disease 0
and	O 0
fibrosis	B-Disease 0
.	O 0

Adult	O 0
Dmpk	O 0
-	O 0
/	O 0
-	O 0
mice	O 0
show	O 0
ultrastructural	O 0
changes	O 0
in	O 0
muscle	O 0
and	O 0
a	O 0
50	O 0
%	O 0
decrease	O 0
in	O 0
force	O 0
generation	O 0
compared	O 0
to	O 0
young	O 0
mice	O 0
.	O 0

Our	O 0
results	O 0
indicate	O 0
that	O 0
DMPK	O 0
may	O 0
be	O 0
necessary	O 0
for	O 0
the	O 0
maintenance	O 0
of	O 0
skeletal	O 0
muscle	O 0
structure	O 0
and	O 0
function	O 0
and	O 0
suggest	O 0
that	O 0
a	O 0
decrease	O 0
in	O 0
DMPK	O 0
levels	O 0
may	O 0
contribute	O 0
to	O 0
DM	B-Disease 0
pathology	O 0
.	O 0
.	O 0

The	O 0
tumor	B-Disease 0
suppressor	O 0
gene	O 0
Brca1	O 0
is	O 0
required	O 0
for	O 0
embryonic	O 0
cellular	O 0
proliferation	O 0
in	O 0
the	O 0
mouse	O 0
.	O 0

Mutations	O 0
of	O 0
the	O 0
BRCA1	O 0
gone	O 0
in	O 0
humans	O 0
are	O 0
associated	O 0
with	O 0
predisposition	O 0
to	O 0
breast	B-Disease 0
and	I-Disease 0
ovarian	I-Disease 0
cancers	I-Disease 0
.	O 0

We	O 0
show	O 0
here	O 0
that	O 0
Brca1	O 0
+	O 0
/	O 0
-	O 0
mice	O 0
are	O 0
normal	O 0
and	O 0
fertile	O 0
and	O 0
lack	O 0
tumors	B-Disease 0
by	O 0
age	O 0
eleven	O 0
months	O 0
.	O 0

Homozygous	O 0
Brca1	O 0
(	O 0
5	O 0
-	O 0
6	O 0
)	O 0
mutant	O 0
mice	O 0
die	O 0
before	O 0
day	O 0
7	O 0
.	O 0

5	O 0
of	O 0
embryogenesis	O 0
.	O 0

Mutant	O 0
embryos	O 0
are	O 0
poorly	O 0
developed	O 0
,	O 0
with	O 0
no	O 0
evidence	O 0
of	O 0
mesoderm	O 0
formation	O 0
.	O 0

The	O 0
extraembryonic	O 0
region	O 0
is	O 0
abnormal	O 0
,	O 0
but	O 0
aggregation	O 0
with	O 0
wild	O 0
-	O 0
type	O 0
tetraploid	O 0
embryos	O 0
does	O 0
not	O 0
rescue	O 0
the	O 0
lethality	O 0
.	O 0

In	O 0
vivo	O 0
,	O 0
mutant	O 0
embryos	O 0
do	O 0
not	O 0
exhibit	O 0
increased	O 0
apoptosis	O 0
but	O 0
show	O 0
reduced	O 0
cell	O 0
proliferation	O 0
accompanied	O 0
by	O 0
decreased	O 0
expression	O 0
of	O 0
cyclin	O 0
E	O 0
and	O 0
mdm	O 0
-	O 0
2	O 0
,	O 0
a	O 0
regulator	O 0
of	O 0
p53	O 0
activity	O 0
.	O 0

The	O 0
expression	O 0
of	O 0
cyclin	O 0
-	O 0
dependent	O 0
kinase	O 0
inhibitor	O 0
p21	O 0
is	O 0
dramatically	O 0
increased	O 0
in	O 0
the	O 0
mutant	O 0
embryos	O 0
.	O 0

Buttressing	O 0
these	O 0
in	O 0
vivo	O 0
observations	O 0
is	O 0
the	O 0
fact	O 0
that	O 0
mutant	O 0
blastocyst	O 0
growth	O 0
is	O 0
grossly	O 0
impaired	O 0
in	O 0
vitro	O 0
.	O 0

Thus	O 0
,	O 0
the	O 0
death	O 0
of	O 0
Brca1	O 0
(	O 0
5	O 0
-	O 0
6	O 0
)	O 0
mutant	O 0
embryos	O 0
prior	O 0
to	O 0
gastrulation	O 0
may	O 0
be	O 0
due	O 0
to	O 0
a	O 0
failure	O 0
of	O 0
the	O 0
proliferative	O 0
burst	O 0
required	O 0
for	O 0
the	O 0
development	O 0
of	O 0
the	O 0
different	O 0
germ	O 0
layers	O 0
.	O 0

Increased	O 0
coronary	B-Disease 0
heart	I-Disease 0
disease	I-Disease 0
in	O 0
Japanese	O 0
-	O 0
American	O 0
men	O 0
with	O 0
mutation	O 0
in	O 0
the	O 0
cholesteryl	O 0
ester	O 0
transfer	O 0
protein	O 0
gene	O 0
despite	O 0
increased	O 0
HDL	O 0
levels	O 0
.	O 0

Plasma	O 0
high	O 0
density	O 0
lipoprotein	O 0
(	O 0
HDL	O 0
)	O 0
levels	O 0
are	O 0
strongly	O 0
genetically	O 0
determined	O 0
and	O 0
show	O 0
a	O 0
general	O 0
inverse	O 0
relationship	O 0
with	O 0
coronary	B-Disease 0
heart	I-Disease 0
disease	I-Disease 0
(	O 0
CHD	B-Disease 0
)	O 0
.	O 0

The	O 0
cholesteryl	O 0
ester	O 0
transfer	O 0
protein	O 0
(	O 0
CETP	O 0
)	O 0
mediates	O 0
the	O 0
transfer	O 0
of	O 0
cholesteryl	O 0
esters	O 0
from	O 0
HDL	O 0
to	O 0
other	O 0
lipoproteins	O 0
and	O 0
is	O 0
a	O 0
key	O 0
participant	O 0
in	O 0
the	O 0
reverse	O 0
transport	O 0
of	O 0
cholesterol	O 0
from	O 0
the	O 0
periphery	O 0
to	O 0
the	O 0
liver	O 0
.	O 0

A	O 0
high	O 0
prevalence	O 0
of	O 0
two	O 0
different	O 0
CETP	O 0
gene	O 0
mutations	O 0
(	O 0
D442G	O 0
,	O 0
5	O 0
.	O 0
1	O 0
%	O 0
;	O 0
intron	O 0
14G	O 0
A	O 0
,	O 0
0	O 0
.	O 0
5	O 0
%	O 0
)	O 0
,	O 0
was	O 0
found	O 0
in	O 0
3	O 0
,	O 0
469	O 0
men	O 0
of	O 0
Japanese	O 0
ancestry	O 0
in	O 0
the	O 0
Honolulu	O 0
Heart	O 0
Program	O 0
and	O 0
mutations	O 0
were	O 0
associated	O 0
with	O 0
decreased	O 0
CETP	O 0
(	O 0
-	O 0
35	O 0
%	O 0
)	O 0
and	O 0
increased	O 0
HDL	O 0
chol	O 0
levels	O 0
(	O 0
+	O 0
10	O 0
%	O 0
for	O 0
D442G	O 0
)	O 0
.	O 0

However	O 0
,	O 0
the	O 0
overall	O 0
prevalence	O 0
of	O 0
definite	O 0
CHD	B-Disease 0
was	O 0
21	O 0
%	O 0
in	O 0
men	O 0
with	O 0
mutations	O 0
and	O 0
16	O 0
%	O 0
in	O 0
men	O 0
without	O 0
mutations	O 0
.	O 0

The	O 0
relative	O 0
risk	O 0
(	O 0
RR	O 0
)	O 0
of	O 0
CHD	B-Disease 0
was	O 0
1	O 0
.	O 0

43	O 0
in	O 0
men	O 0
with	O 0
mutations	O 0
(	O 0
P	O 0
<	O 0
.	O 0
05	O 0
)	O 0
;	O 0
after	O 0
adjustment	O 0
for	O 0
CHD	B-Disease 0
risk	O 0
factors	O 0
,	O 0
the	O 0
RR	O 0
was	O 0
1	O 0
.	O 0

55	O 0
(	O 0
P	O 0
=	O 0
.	O 0
02	O 0
)	O 0
;	O 0
after	O 0
additional	O 0
adjustment	O 0
for	O 0
HDL	O 0
levels	O 0
,	O 0
the	O 0
RR	O 0
was	O 0
1	O 0
.	O 0

68	O 0
(	O 0
P	O 0
=	O 0
.	O 0
008	O 0
)	O 0
.	O 0

Similar	O 0
RR	O 0
values	O 0
were	O 0
obtained	O 0
for	O 0
the	O 0
D442G	O 0
mutation	O 0
alone	O 0
.	O 0

Increased	O 0
CHD	B-Disease 0
in	O 0
men	O 0
with	O 0
mutations	O 0
was	O 0
primarily	O 0
observed	O 0
for	O 0
HDL	O 0
chol	O 0
41	O 0
-	O 0
60	O 0
mg	O 0
/	O 0
dl	O 0
;	O 0
for	O 0
HDL	O 0
chol	O 0
>	O 0
60	O 0
mg	O 0
/	O 0
dl	O 0
men	O 0
with	O 0
and	O 0
without	O 0
mutations	O 0
had	O 0
low	O 0
CHD	B-Disease 0
prevalence	O 0
.	O 0

Thus	O 0
,	O 0
genetic	O 0
CETP	B-Disease 0
deficiency	I-Disease 0
appears	O 0
to	O 0
be	O 0
an	O 0
independent	O 0
risk	O 0
factor	O 0
for	O 0
CHD	B-Disease 0
,	O 0
primarily	O 0
due	O 0
to	O 0
increased	O 0
CHD	B-Disease 0
prevalence	O 0
in	O 0
men	O 0
with	O 0
the	O 0
D442G	O 0
mutation	O 0
and	O 0
HDL	O 0
cholesterol	O 0
between	O 0
41	O 0
and	O 0
60	O 0
mg	O 0
/	O 0
dl	O 0
.	O 0

The	O 0
findings	O 0
suggest	O 0
that	O 0
both	O 0
HDL	O 0
concentration	O 0
and	O 0
the	O 0
dynamics	O 0
of	O 0
cholesterol	O 0
transport	O 0
through	O 0
HDL	O 0
(	O 0
i	O 0
.	O 0
e	O 0
.	O 0
,	O 0
reverse	O 0
cholesterol	O 0
transport	O 0
)	O 0
determine	O 0
the	O 0
anti	O 0
-	O 0
atherogenicity	O 0
of	O 0
the	O 0
HDL	O 0
fraction	O 0
.	O 0

Mapping	O 0
the	O 0
homolog	O 0
of	O 0
the	O 0
human	O 0
Rb1	O 0
gene	O 0
to	O 0
chromosome	O 0
14	O 0
of	O 0
higher	O 0
primates	O 0
.	O 0

The	O 0
Rb1	O 0
gene	O 0
has	O 0
been	O 0
implicated	O 0
with	O 0
retinoblastoma	B-Disease 0
and	O 0
is	O 0
located	O 0
on	O 0
human	O 0
Chromosome	O 0
(	O 0
Chr	O 0
)	O 0
13q14	O 0
.	O 0

2	O 0
2	O 0
.	O 0

A	O 0
unique	O 0
sequence	O 0
human	O 0
Rb1	O 0
cosmid	O 0
DNA	O 0
probe	O 0
has	O 0
been	O 0
used	O 0
to	O 0
localize	O 0
this	O 0
region	O 0
on	O 0
apes	O 0
Chr	O 0
14	O 0
by	O 0
the	O 0
FISH	O 0
technique	O 0
.	O 0

The	O 0
conservation	O 0
of	O 0
the	O 0
Rb1	O 0
gene	O 0
in	O 0
higher	O 0
primates	O 0
at	O 0
the	O 0
corresponding	O 0
equivalent	O 0
chromosome	O 0
locus	O 0
(	O 0
14q14	O 0
)	O 0
of	O 0
the	O 0
human	O 0
may	O 0
serve	O 0
as	O 0
a	O 0
phylogenetic	O 0
marker	O 0
to	O 0
further	O 0
trace	O 0
the	O 0
evolutionary	O 0
pathway	O 0
of	O 0
human	O 0
descent	O 0
.	O 0

Wiskott	B-Disease 0
-	I-Disease 0
Aldrich	I-Disease 0
syndrome	I-Disease 0
:	O 0
no	O 0
strict	O 0
genotype	O 0
-	O 0
phenotype	O 0
correlations	O 0
but	O 0
clustering	O 0
of	O 0
missense	O 0
mutations	O 0
in	O 0
the	O 0
amino	O 0
-	O 0
terminal	O 0
part	O 0
of	O 0
the	O 0
WASP	O 0
gene	O 0
product	O 0
.	O 0

The	O 0
Wiskott	B-Disease 0
-	I-Disease 0
Aldrich	I-Disease 0
syndrome	I-Disease 0
protein	O 0
(	O 0
WASP	O 0
)	O 0
gene	O 0
was	O 0
found	O 0
to	O 0
be	O 0
mutated	O 0
in	O 0
patients	O 0
presenting	O 0
with	O 0
WAS	B-Disease 0
and	O 0
in	O 0
patients	O 0
showing	O 0
X	B-Disease 0
-	I-Disease 0
linked	I-Disease 0
thrombocytopenia	I-Disease 0
.	O 0

Mutation	O 0
analysis	O 0
in	O 0
19	O 0
families	O 0
of	O 0
German	O 0
,	O 0
Swiss	O 0
and	O 0
Turkish	O 0
descent	O 0
by	O 0
single	O 0
-	O 0
strand	O 0
conformation	O 0
polymorphism	O 0
and	O 0
sequencing	O 0
resulted	O 0
in	O 0
the	O 0
detection	O 0
of	O 0
seven	O 0
novel	O 0
and	O 0
10	O 0
known	O 0
mutations	O 0
.	O 0

A	O 0
striking	O 0
clustering	O 0
of	O 0
missense	O 0
mutations	O 0
in	O 0
the	O 0
first	O 0
four	O 0
exons	O 0
contrasted	O 0
with	O 0
a	O 0
random	O 0
distribution	O 0
of	O 0
nonsense	O 0
mutations	O 0
.	O 0

More	O 0
than	O 0
85	O 0
%	O 0
of	O 0
all	O 0
known	O 0
missense	O 0
mutations	O 0
were	O 0
localized	O 0
in	O 0
the	O 0
amino	O 0
-	O 0
terminal	O 0
stretch	O 0
of	O 0
the	O 0
WASP	O 0
gene	O 0
product	O 0
;	O 0
this	O 0
region	O 0
contained	O 0
a	O 0
mutational	O 0
hot	O 0
spot	O 0
at	O 0
codon	O 0
86	O 0
.	O 0

No	O 0
genotype	O 0
-	O 0
phenotype	O 0
correlation	O 0
emerged	O 0
after	O 0
a	O 0
comparison	O 0
of	O 0
the	O 0
identified	O 0
mutations	O 0
with	O 0
the	O 0
resulting	O 0
clinical	O 0
picture	O 0
for	O 0
a	O 0
classical	O 0
WAS	B-Disease 0
phenotype	O 0
.	O 0

A	O 0
substitution	O 0
at	O 0
codon	O 0
86	O 0
resulted	O 0
in	O 0
an	O 0
extremely	O 0
variable	O 0
expression	O 0
of	O 0
the	O 0
disease	O 0
in	O 0
a	O 0
large	O 0
Swiss	O 0
family	O 0
.	O 0

An	O 0
extended	O 0
homology	O 0
search	O 0
revealed	O 0
a	O 0
distant	O 0
relationship	O 0
of	O 0
this	O 0
stretch	O 0
to	O 0
the	O 0
vasodilator	O 0
-	O 0
stimulated	O 0
phosphoprotein	O 0
(	O 0
VASP	O 0
)	O 0
,	O 0
which	O 0
is	O 0
involved	O 0
in	O 0
the	O 0
maintenance	O 0
of	O 0
cyto	O 0
-	O 0
architecture	O 0
by	O 0
interacting	O 0
with	O 0
actin	O 0
-	O 0
like	O 0
filaments	O 0
.	O 0
.	O 0

Influence	O 0
of	O 0
PAX6	O 0
gene	O 0
dosage	O 0
on	O 0
development	O 0
:	O 0
overexpression	O 0
causes	O 0
severe	O 0
eye	B-Disease 0
abnormalities	I-Disease 0
.	O 0

Aniridia	B-Disease 0
in	O 0
man	O 0
and	O 0
Small	O 0
eye	O 0
in	O 0
mice	O 0
are	O 0
semidominant	B-Disease 0
developmental	I-Disease 0
disorders	I-Disease 0
caused	O 0
by	O 0
mutations	O 0
within	O 0
the	O 0
paired	O 0
box	O 0
gene	O 0
PAX6	O 0
.	O 0

Whereas	O 0
heterozygotes	O 0
suffer	O 0
from	O 0
iris	B-Disease 0
hypoplasia	I-Disease 0
,	O 0
homozygous	O 0
mice	O 0
lack	O 0
eyes	O 0
and	O 0
nasal	O 0
cavities	O 0
and	O 0
exhibit	O 0
brain	B-Disease 0
abnormalities	I-Disease 0
.	O 0

To	O 0
investigate	O 0
the	O 0
role	O 0
of	O 0
gene	O 0
dosage	O 0
in	O 0
more	O 0
detail	O 0
,	O 0
we	O 0
have	O 0
generated	O 0
yeast	O 0
artificial	O 0
chromosome	O 0
transgenic	O 0
mice	O 0
carrying	O 0
the	O 0
human	O 0
PAX6	O 0
locus	O 0
.	O 0

When	O 0
crossed	O 0
onto	O 0
the	O 0
Small	O 0
eye	O 0
background	O 0
,	O 0
the	O 0
transgene	O 0
rescues	O 0
the	O 0
mutant	O 0
phenotype	O 0
.	O 0

Strikingly	O 0
,	O 0
mice	O 0
carrying	O 0
multiple	O 0
copies	O 0
on	O 0
a	O 0
wild	O 0
-	O 0
type	O 0
background	O 0
show	O 0
specific	O 0
developmental	B-Disease 0
abnormalities	I-Disease 0
of	I-Disease 0
the	I-Disease 0
eye	I-Disease 0
,	O 0
but	O 0
not	O 0
of	O 0
other	O 0
tissues	O 0
expressing	O 0
the	O 0
gene	O 0
.	O 0

Thus	O 0
,	O 0
at	O 0
least	O 0
five	O 0
different	O 0
eye	O 0
phenotypes	O 0
are	O 0
associated	O 0
with	O 0
changes	O 0
in	O 0
PAX6	O 0
expression	O 0
.	O 0

We	O 0
provide	O 0
evidence	O 0
that	O 0
not	O 0
only	O 0
reduced	O 0
,	O 0
but	O 0
also	O 0
increased	O 0
levels	O 0
of	O 0
transcriptional	O 0
regulators	O 0
can	O 0
cause	O 0
developmental	B-Disease 0
defects	I-Disease 0
.	O 0
.	O 0

Heterodimer	O 0
formation	O 0
and	O 0
activity	O 0
in	O 0
the	O 0
human	O 0
enzyme	O 0
galactose	O 0
-	O 0
1	O 0
-	O 0
phosphate	O 0
uridylyltransferase	O 0
.	O 0

One	O 0
of	O 0
the	O 0
fundamental	O 0
questions	O 0
concerning	O 0
expression	O 0
and	O 0
function	O 0
of	O 0
dimeric	O 0
enzymes	O 0
involves	O 0
the	O 0
impact	O 0
of	O 0
naturally	O 0
occurring	O 0
mutations	O 0
on	O 0
subunit	O 0
assembly	O 0
and	O 0
heterodimer	O 0
activity	O 0
.	O 0

This	O 0
question	O 0
is	O 0
of	O 0
particular	O 0
interest	O 0
for	O 0
the	O 0
human	O 0
enzyme	O 0
galactose	O 0
-	O 0
l	O 0
-	O 0
phosphate	O 0
uridylyl	O 0
-	O 0
transferase	O 0
(	O 0
GALT	O 0
)	O 0
,	O 0
impairment	O 0
of	O 0
which	O 0
results	O 0
in	O 0
the	O 0
inherited	B-Disease 0
metabolic	I-Disease 0
disorder	I-Disease 0
galactosemia	B-Disease 0
,	O 0
because	O 0
many	O 0
if	O 0
not	O 0
most	O 0
patients	O 0
studied	O 0
to	O 0
date	O 0
are	O 0
compound	O 0
heterozygotes	O 0
rather	O 0
than	O 0
true	O 0
molecular	O 0
homozygotes	O 0
.	O 0

Furthermore	O 0
,	O 0
the	O 0
broad	O 0
range	O 0
of	O 0
phenotypic	O 0
severity	O 0
observed	O 0
in	O 0
these	O 0
patients	O 0
raises	O 0
the	O 0
possibility	O 0
that	O 0
allelic	O 0
combination	O 0
,	O 0
not	O 0
just	O 0
allelic	O 0
constitution	O 0
,	O 0
may	O 0
play	O 0
some	O 0
role	O 0
in	O 0
determining	O 0
outcome	O 0
.	O 0

In	O 0
the	O 0
work	O 0
described	O 0
herein	O 0
,	O 0
we	O 0
have	O 0
selected	O 0
two	O 0
distinct	O 0
naturally	O 0
occurring	O 0
null	O 0
mutations	O 0
of	O 0
GALT	O 0
,	O 0
Q188R	O 0
and	O 0
R333W	O 0
,	O 0
and	O 0
asked	O 0
the	O 0
questions	O 0
(	O 0
i	O 0
)	O 0
what	O 0
are	O 0
the	O 0
impacts	O 0
of	O 0
these	O 0
mutations	O 0
on	O 0
subunit	O 0
assembly	O 0
,	O 0
and	O 0
(	O 0
ii	O 0
)	O 0
if	O 0
heterodimers	O 0
do	O 0
form	O 0
,	O 0
are	O 0
they	O 0
active	O 0
?	O 0

To	O 0
answer	O 0
these	O 0
questions	O 0
,	O 0
we	O 0
have	O 0
established	O 0
a	O 0
yeast	O 0
system	O 0
for	O 0
the	O 0
coexpression	O 0
of	O 0
epitope	O 0
-	O 0
tagged	O 0
alleles	O 0
of	O 0
human	O 0
GALT	O 0
and	O 0
investigated	O 0
both	O 0
the	O 0
extent	O 0
of	O 0
specific	O 0
GALT	O 0
subunit	O 0
interactions	O 0
and	O 0
the	O 0
activity	O 0
of	O 0
defined	O 0
heterodimer	O 0
pools	O 0
.	O 0

We	O 0
have	O 0
found	O 0
that	O 0
both	O 0
homodimers	O 0
and	O 0
heterodimers	O 0
do	O 0
form	O 0
involving	O 0
each	O 0
of	O 0
the	O 0
mutant	O 0
subunits	O 0
tested	O 0
and	O 0
that	O 0
both	O 0
heterodimer	O 0
pools	O 0
retain	O 0
substantial	O 0
enzymatic	O 0
activity	O 0
.	O 0

These	O 0
results	O 0
are	O 0
significant	O 0
not	O 0
only	O 0
in	O 0
terms	O 0
of	O 0
their	O 0
implications	O 0
for	O 0
furthering	O 0
our	O 0
understanding	O 0
of	O 0
galactosemia	B-Disease 0
and	O 0
GALT	O 0
holoenzyme	O 0
structure	O 0
-	O 0
function	O 0
relationships	O 0
but	O 0
also	O 0
because	O 0
the	O 0
system	O 0
described	O 0
may	O 0
serve	O 0
as	O 0
a	O 0
model	O 0
for	O 0
similar	O 0
studies	O 0
of	O 0
other	O 0
complexes	O 0
composed	O 0
of	O 0
multiple	O 0
subunits	O 0
.	O 0
.	O 0

Cleavage	O 0
of	O 0
huntingtin	O 0
by	O 0
apopain	O 0
,	O 0
a	O 0
proapoptotic	O 0
cysteine	O 0
protease	O 0
,	O 0
is	O 0
modulated	O 0
by	O 0
the	O 0
polyglutamine	O 0
tract	O 0
.	O 0

Apoptosis	O 0
has	O 0
recently	O 0
been	O 0
recognized	O 0
as	O 0
a	O 0
mode	O 0
of	O 0
cell	O 0
death	O 0
in	O 0
Huntington	B-Disease 0
disease	I-Disease 0
(	O 0
HD	B-Disease 0
)	O 0
.	O 0

Apopain	O 0
,	O 0
a	O 0
human	O 0
counterpart	O 0
of	O 0
the	O 0
nematode	O 0
cysteine	O 0
protease	O 0
death	O 0
-	O 0
gene	O 0
product	O 0
,	O 0
CED	O 0
-	O 0
3	O 0
,	O 0
has	O 0
a	O 0
key	O 0
role	O 0
in	O 0
proteolytic	O 0
events	O 0
leading	O 0
to	O 0
apoptosis	O 0
.	O 0

Here	O 0
we	O 0
show	O 0
that	O 0
apoptotic	O 0
extracts	O 0
and	O 0
apopain	O 0
itself	O 0
specifically	O 0
cleave	O 0
the	O 0
HD	B-Disease 0
gene	O 0
product	O 0
,	O 0
huntingtin	O 0
.	O 0

The	O 0
rate	O 0
of	O 0
cleavage	O 0
increases	O 0
with	O 0
the	O 0
length	O 0
of	O 0
the	O 0
huntingtin	O 0
polyglutamine	O 0
tract	O 0
,	O 0
providing	O 0
an	O 0
explanation	O 0
for	O 0
the	O 0
gain	O 0
-	O 0
of	O 0
-	O 0
function	O 0
associated	O 0
with	O 0
CAG	O 0
expansion	O 0
.	O 0

Our	O 0
results	O 0
show	O 0
that	O 0
huntingtin	O 0
is	O 0
cleaved	O 0
by	O 0
cysteine	O 0
proteases	O 0
and	O 0
suggest	O 0
that	O 0
HD	B-Disease 0
might	O 0
be	O 0
a	O 0
disorder	B-Disease 0
of	I-Disease 0
inappropriate	I-Disease 0
apoptosis	I-Disease 0
.	O 0
.	O 0

The	O 0
5	O 0
'	O 0
end	O 0
of	O 0
the	O 0
BRCA1	O 0
gene	O 0
lies	O 0
within	O 0
a	O 0
duplicated	O 0
region	O 0
of	O 0
human	O 0
chromosome	O 0
17q21	O 0
.	O 0

To	O 0
begin	O 0
to	O 0
address	O 0
the	O 0
hypothesis	O 0
that	O 0
abnormal	O 0
regulation	O 0
of	O 0
the	O 0
breast	B-Disease 0
/	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
susceptibility	O 0
gene	O 0
BRCA1	O 0
is	O 0
a	O 0
critical	O 0
step	O 0
in	O 0
sporadic	O 0
breast	O 0
/	O 0
ovarian	O 0
tumorigenesis	O 0
,	O 0
we	O 0
have	O 0
determined	O 0
the	O 0
detailed	O 0
structure	O 0
of	O 0
the	O 0
BRCA1	O 0
genomic	O 0
region	O 0
.	O 0

We	O 0
show	O 0
that	O 0
this	O 0
region	O 0
of	O 0
the	O 0
genome	O 0
contains	O 0
a	O 0
tandem	O 0
duplication	O 0
of	O 0
approximately	O 0
30	O 0
kilobases	O 0
,	O 0
which	O 0
results	O 0
in	O 0
two	O 0
copies	O 0
of	O 0
BRCA1	O 0
exons	O 0
1	O 0
and	O 0
2	O 0
,	O 0
of	O 0
exons	O 0
1	O 0
and	O 0
3	O 0
of	O 0
the	O 0
adjacent	O 0
1A1	O 0
-	O 0
3B	O 0
gene	O 0
and	O 0
of	O 0
the	O 0
previously	O 0
reported	O 0
295	O 0
base	O 0
pair	O 0
intergenic	O 0
region	O 0
.	O 0

Sequence	O 0
analysis	O 0
of	O 0
the	O 0
duplicated	O 0
exons	O 0
of	O 0
BRCA1	O 0
and	O 0
1A1	O 0
-	O 0
3B	O 0
and	O 0
flanking	O 0
genomic	O 0
DNA	O 0
reveals	O 0
maintenance	O 0
of	O 0
the	O 0
intron	O 0
-	O 0
exon	O 0
structure	O 0
and	O 0
a	O 0
high	O 0
degree	O 0
of	O 0
nucleotide	O 0
sequence	O 0
identity	O 0
,	O 0
suggesting	O 0
that	O 0
these	O 0
are	O 0
non	O 0
-	O 0
processed	O 0
pseudogenes	O 0
and	O 0
that	O 0
the	O 0
duplication	O 0
is	O 0
a	O 0
recent	O 0
event	O 0
in	O 0
evolutionary	O 0
terms	O 0
.	O 0

We	O 0
also	O 0
show	O 0
that	O 0
a	O 0
processed	O 0
pseudogene	O 0
of	O 0
the	O 0
acidic	O 0
ribosomal	O 0
phosphoprotein	O 0
P1	O 0
(	O 0
ARPP1	O 0
)	O 0
is	O 0
inserted	O 0
directly	O 0
upstream	O 0
of	O 0
pseudo	O 0
-	O 0
BRCA1	O 0
exon	O 0
1A	O 0
.	O 0

We	O 0
believe	O 0
that	O 0
these	O 0
findings	O 0
could	O 0
not	O 0
only	O 0
confound	O 0
BRCA1	O 0
mutation	O 0
analysis	O 0
,	O 0
but	O 0
could	O 0
have	O 0
implications	O 0
for	O 0
the	O 0
normal	O 0
and	O 0
abnormal	O 0
regulation	O 0
of	O 0
BRCA1	O 0
transcription	O 0
,	O 0
translation	O 0
and	O 0
function	O 0
.	O 0
.	O 0

Deletion	O 0
of	O 0
small	O 0
nuclear	O 0
ribonucleoprotein	O 0
polypeptide	O 0
N	O 0
(	O 0
SNRPN	O 0
)	O 0
in	O 0
Prader	B-Disease 0
-	I-Disease 0
Willi	I-Disease 0
syndrome	I-Disease 0
detected	O 0
by	O 0
fluorescence	O 0
in	O 0
situ	O 0
hybridization	O 0
:	O 0
two	O 0
sibs	O 0
with	O 0
the	O 0
typical	O 0
phenotype	O 0
without	O 0
a	O 0
cytogenetic	O 0
deletion	O 0
in	O 0
chromosome	O 0
15q	O 0
.	O 0

The	O 0
small	O 0
nuclear	O 0
ribonucleoprotein	O 0
polypeptide	O 0
N	O 0
(	O 0
SNRPN	O 0
)	O 0
gene	O 0
is	O 0
regarded	O 0
as	O 0
one	O 0
of	O 0
the	O 0
candidates	O 0
for	O 0
Prader	B-Disease 0
-	I-Disease 0
Willi	I-Disease 0
syndrome	I-Disease 0
(	O 0
PWS	B-Disease 0
)	O 0
.	O 0

We	O 0
describe	O 0
two	O 0
sibs	O 0
with	O 0
typical	O 0
PWS	B-Disease 0
presenting	O 0
deletion	O 0
of	O 0
SNRPN	O 0
detected	O 0
by	O 0
fluorescence	O 0
in	O 0
situ	O 0
hybridization	O 0
(	O 0
FISH	O 0
)	O 0
.	O 0

Neither	O 0
a	O 0
cytogenetically	O 0
detectable	O 0
15q12	O 0
deletion	O 0
nor	O 0
a	O 0
deletion	O 0
for	O 0
the	O 0
D15S11	O 0
,	O 0
D15S10	O 0
,	O 0
and	O 0
GABRB3	O 0
cosmid	O 0
probes	O 0
were	O 0
found	O 0
in	O 0
either	O 0
patient	O 0
.	O 0

This	O 0
implies	O 0
a	O 0
smaller	O 0
deletion	O 0
limited	O 0
to	O 0
the	O 0
PWS	B-Disease 0
critical	O 0
region	O 0
.	O 0

FISH	O 0
with	O 0
a	O 0
SNRPN	O 0
probe	O 0
will	O 0
permit	O 0
analysis	O 0
of	O 0
PWS	B-Disease 0
patients	O 0
with	O 0
limited	O 0
deletions	O 0
not	O 0
detectable	O 0
with	O 0
other	O 0
probes	O 0
.	O 0
.	O 0

Expression	O 0
of	O 0
the	O 0
von	B-Disease 0
Hippel	I-Disease 0
-	I-Disease 0
Lindau	I-Disease 0
disease	I-Disease 0
tumour	I-Disease 0
suppressor	O 0
gene	O 0
during	O 0
human	O 0
embryogenesis	O 0
.	O 0

The	O 0
von	B-Disease 0
Hippel	I-Disease 0
-	I-Disease 0
Lindau	I-Disease 0
(	I-Disease 0
VHL	I-Disease 0
)	I-Disease 0
disease	I-Disease 0
product	O 0
is	O 0
thought	O 0
to	O 0
down	O 0
-	O 0
regulate	O 0
transcription	O 0
by	O 0
antagonizing	O 0
elongin	O 0
-	O 0
enhanced	O 0
transcriptional	O 0
elongation	O 0
.	O 0

Germline	O 0
VHL	B-Disease 0
gene	O 0
mutations	O 0
predispose	O 0
to	O 0
the	O 0
development	O 0
of	O 0
retinal	B-Disease 0
,	I-Disease 0
cerebellar	I-Disease 0
and	I-Disease 0
spinal	I-Disease 0
haemangioblastomas	I-Disease 0
,	O 0
renal	B-Disease 0
cell	I-Disease 0
carcinoma	I-Disease 0
and	O 0
phaeochromocytoma	B-Disease 0
.	O 0

In	O 0
addition	O 0
,	O 0
somatic	O 0
Inactivation	O 0
of	O 0
the	O 0
VHL	B-Disease 0
gene	O 0
is	O 0
frequent	O 0
in	O 0
sporadic	B-Disease 0
renal	I-Disease 0
cell	I-Disease 0
carcinoma	I-Disease 0
and	O 0
haemangioblastoma	B-Disease 0
.	O 0

Regulation	O 0
of	O 0
transcript	O 0
elongation	O 0
is	O 0
an	O 0
important	O 0
control	O 0
mechanism	O 0
for	O 0
gene	O 0
expression	O 0
and	O 0
the	O 0
VHL	B-Disease 0
gene	O 0
might	O 0
modify	O 0
the	O 0
expression	O 0
of	O 0
proto	O 0
-	O 0
oncogenes	O 0
and	O 0
growth	O 0
suppressor	O 0
genes	O 0
during	O 0
embryogenesis	O 0
.	O 0

We	O 0
therefore	O 0
investigated	O 0
the	O 0
expression	O 0
of	O 0
VHL	B-Disease 0
mRNA	O 0
during	O 0
human	O 0
embryogenesis	O 0
by	O 0
in	O 0
situ	O 0
hybridization	O 0
studies	O 0
at	O 0
4	O 0
,	O 0
6	O 0
and	O 0
10	O 0
weeks	O 0
post	O 0
conception	O 0
.	O 0

Although	O 0
VHL	B-Disease 0
mRNA	O 0
was	O 0
expressed	O 0
in	O 0
all	O 0
three	O 0
germ	O 0
layers	O 0
,	O 0
strong	O 0
expression	O 0
was	O 0
noted	O 0
in	O 0
the	O 0
central	O 0
nervous	O 0
system	O 0
,	O 0
kidneys	O 0
,	O 0
testis	O 0
and	O 0
lung	O 0
.	O 0

Within	O 0
the	O 0
kidney	O 0
,	O 0
VHL	B-Disease 0
mRNA	O 0
was	O 0
differentially	O 0
expressed	O 0
within	O 0
renal	O 0
tubules	O 0
suggesting	O 0
that	O 0
the	O 0
VHL	B-Disease 0
gene	O 0
product	O 0
may	O 0
have	O 0
a	O 0
specific	O 0
role	O 0
in	O 0
kidney	O 0
development	O 0
.	O 0

Two	O 0
alternatively	O 0
spliced	O 0
VHL	B-Disease 0
mRNAs	O 0
characterized	O 0
by	O 0
inclusion	O 0
(	O 0
isoform	O 0
I	O 0
)	O 0
or	O 0
exclusion	O 0
(	O 0
isoform	O 0
II	O 0
)	O 0
of	O 0
exon	O 0
2	O 0
are	O 0
transcribed	O 0
in	O 0
adult	O 0
tissues	O 0
.	O 0

To	O 0
investigate	O 0
if	O 0
the	O 0
two	O 0
isoforms	O 0
are	O 0
differentially	O 0
expressed	O 0
during	O 0
embryogenesis	O 0
,	O 0
VHL	B-Disease 0
mRNA	O 0
was	O 0
reverse	O 0
transcribed	O 0
from	O 0
13	O 0
fetal	O 0
tissues	O 0
(	O 0
8	O 0
-	O 0
10	O 0
weeks	O 0
gestation	O 0
)	O 0
.	O 0

The	O 0
quantitative	O 0
distribution	O 0
of	O 0
VHL	B-Disease 0
mRNA	O 0
within	O 0
fetal	O 0
tissues	O 0
reflected	O 0
that	O 0
seen	O 0
by	O 0
in	O 0
situ	O 0
hybridization	O 0
and	O 0
the	O 0
ratio	O 0
of	O 0
the	O 0
two	O 0
VHL	B-Disease 0
isoforms	O 0
was	O 0
similar	O 0
between	O 0
tissues	O 0
.	O 0

Although	O 0
the	O 0
genes	O 0
regulated	O 0
by	O 0
the	O 0
VHL	B-Disease 0
gene	O 0
product	O 0
have	O 0
not	O 0
yet	O 0
been	O 0
identified	O 0
,	O 0
our	O 0
findings	O 0
are	O 0
compatible	O 0
with	O 0
the	O 0
hypothesis	O 0
that	O 0
VHL	B-Disease 0
-	O 0
mediated	O 0
control	O 0
of	O 0
transcriptional	O 0
elongation	O 0
may	O 0
have	O 0
a	O 0
role	O 0
in	O 0
normal	O 0
human	O 0
development	O 0
.	O 0
.	O 0

Genetic	O 0
heterogeneity	O 0
in	O 0
hereditary	B-Disease 0
breast	I-Disease 0
cancer	I-Disease 0
:	O 0
role	O 0
of	O 0
BRCA1	O 0
and	O 0
BRCA2	O 0
.	O 0

The	O 0
common	O 0
hereditary	O 0
forms	O 0
of	O 0
breast	B-Disease 0
cancer	I-Disease 0
have	O 0
been	O 0
largely	O 0
attributed	O 0
to	O 0
the	O 0
inheritance	O 0
of	O 0
mutations	O 0
in	O 0
the	O 0
BRCA1	O 0
or	O 0
BRCA2	O 0
genes	O 0
.	O 0

However	O 0
,	O 0
it	O 0
is	O 0
not	O 0
yet	O 0
clear	O 0
what	O 0
proportion	O 0
of	O 0
hereditary	B-Disease 0
breast	I-Disease 0
cancer	I-Disease 0
is	O 0
explained	O 0
by	O 0
BRCA1	O 0
and	O 0
BRCA2	O 0
or	O 0
by	O 0
some	O 0
other	O 0
unidentified	O 0
susceptibility	O 0
gene	O 0
(	O 0
s	O 0
)	O 0
.	O 0

We	O 0
describe	O 0
the	O 0
proportion	O 0
of	O 0
hereditary	B-Disease 0
breast	I-Disease 0
cancer	I-Disease 0
explained	O 0
by	O 0
BRCA1	O 0
or	O 0
BRCA2	O 0
in	O 0
a	O 0
sample	O 0
of	O 0
North	O 0
American	O 0
hereditary	B-Disease 0
breast	I-Disease 0
cancers	I-Disease 0
and	O 0
assess	O 0
the	O 0
evidence	O 0
for	O 0
additional	O 0
susceptibility	O 0
genes	O 0
that	O 0
may	O 0
confer	O 0
hereditary	B-Disease 0
breast	I-Disease 0
or	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
risk	O 0
.	O 0

Twenty	O 0
-	O 0
three	O 0
families	O 0
were	O 0
identified	O 0
through	O 0
two	O 0
high	O 0
-	O 0
risk	O 0
breast	B-Disease 0
cancer	I-Disease 0
research	O 0
programs	O 0
.	O 0

Genetic	O 0
analysis	O 0
was	O 0
undertaken	O 0
to	O 0
establish	O 0
linkage	O 0
between	O 0
the	O 0
breast	B-Disease 0
or	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
cases	O 0
and	O 0
markers	O 0
on	O 0
chromosomes	O 0
17q	O 0
(	O 0
BRCA1	O 0
)	O 0
and	O 0
13q	O 0
(	O 0
BRCA2	O 0
)	O 0
.	O 0

Mutation	O 0
analysis	O 0
in	O 0
the	O 0
BRCA1	O 0
and	O 0
BRCA2	O 0
genes	O 0
was	O 0
also	O 0
undertaken	O 0
in	O 0
all	O 0
families	O 0
.	O 0

The	O 0
pattern	O 0
of	O 0
hereditary	B-Disease 0
cancer	I-Disease 0
in	O 0
14	O 0
(	O 0
61	O 0
%	O 0
)	O 0
of	O 0
the	O 0
23	O 0
families	O 0
studied	O 0
was	O 0
attributed	O 0
to	O 0
BRCA1	O 0
by	O 0
a	O 0
combination	O 0
of	O 0
linkage	O 0
and	O 0
mutation	O 0
analyses	O 0
.	O 0

No	O 0
families	O 0
were	O 0
attributed	O 0
to	O 0
BRCA2	O 0
.	O 0

Five	O 0
families	O 0
(	O 0
22	O 0
%	O 0
)	O 0
provided	O 0
evidence	O 0
against	O 0
linkage	O 0
to	O 0
both	O 0
BRCA1	O 0
and	O 0
BRCA2	O 0
.	O 0

No	O 0
BRCA1	O 0
or	O 0
BRCA2	O 0
mutations	O 0
were	O 0
detected	O 0
in	O 0
these	O 0
five	O 0
families	O 0
.	O 0

The	O 0
BRCA1	O 0
or	O 0
BRCA2	O 0
status	O 0
of	O 0
four	O 0
families	O 0
(	O 0
17	O 0
%	O 0
)	O 0
could	O 0
not	O 0
be	O 0
determined	O 0
.	O 0

BRCA1	O 0
and	O 0
BRCA2	O 0
probably	O 0
explain	O 0
the	O 0
majority	O 0
of	O 0
hereditary	B-Disease 0
breast	I-Disease 0
cancer	I-Disease 0
that	O 0
exists	O 0
in	O 0
the	O 0
North	O 0
American	O 0
population	O 0
.	O 0

However	O 0
,	O 0
one	O 0
or	O 0
more	O 0
additional	O 0
genes	O 0
may	O 0
yet	O 0
be	O 0
found	O 0
that	O 0
explain	O 0
some	O 0
proportion	O 0
of	O 0
hereditary	B-Disease 0
breast	I-Disease 0
cancer	I-Disease 0
.	O 0
.	O 0

An	O 0
intronic	O 0
mutation	O 0
in	O 0
a	O 0
lariat	O 0
branchpoint	O 0
sequence	O 0
is	O 0
a	O 0
direct	O 0
cause	O 0
of	O 0
an	O 0
inherited	B-Disease 0
human	I-Disease 0
disorder	I-Disease 0
(	O 0
fish	B-Disease 0
-	I-Disease 0
eye	I-Disease 0
disease	I-Disease 0
)	O 0
.	O 0

The	O 0
first	O 0
step	O 0
in	O 0
the	O 0
splicing	O 0
of	O 0
an	O 0
intron	O 0
from	O 0
nuclear	O 0
precursors	O 0
of	O 0
mRNA	O 0
results	O 0
in	O 0
the	O 0
formation	O 0
of	O 0
a	O 0
lariat	O 0
structure	O 0
.	O 0

A	O 0
distinct	O 0
intronic	O 0
nucleotide	O 0
sequence	O 0
,	O 0
known	O 0
as	O 0
the	O 0
branchpoint	O 0
region	O 0
,	O 0
plays	O 0
a	O 0
central	O 0
role	O 0
in	O 0
this	O 0
process	O 0
.	O 0

We	O 0
here	O 0
describe	O 0
a	O 0
point	O 0
mutation	O 0
in	O 0
such	O 0
a	O 0
sequence	O 0
.	O 0

Three	O 0
sisters	O 0
were	O 0
shown	O 0
to	O 0
suffer	O 0
from	O 0
fish	B-Disease 0
-	I-Disease 0
eye	I-Disease 0
disease	I-Disease 0
(	O 0
FED	B-Disease 0
)	O 0
,	O 0
a	O 0
disorder	O 0
which	O 0
is	O 0
caused	O 0
by	O 0
mutations	O 0
in	O 0
the	O 0
gene	O 0
coding	O 0
for	O 0
lecithin	O 0
cholesterol	O 0
acyltransferase	O 0
(	O 0
LCAT	O 0
)	O 0
.	O 0

Sequencing	O 0
of	O 0
the	O 0
LCAT	O 0
gene	O 0
of	O 0
all	O 0
three	O 0
probands	O 0
revealed	O 0
compound	O 0
heterozygosity	O 0
for	O 0
a	O 0
missense	O 0
mutation	O 0
in	O 0
exon	O 0
4	O 0
which	O 0
is	O 0
reported	O 0
to	O 0
underlie	O 0
the	O 0
FED	B-Disease 0
phenotype	O 0
,	O 0
and	O 0
a	O 0
point	O 0
mutation	O 0
located	O 0
in	O 0
intron	O 0
4	O 0
(	O 0
IVS4	O 0
T	O 0
-	O 0
22C	O 0
)	O 0
.	O 0

By	O 0
performing	O 0
in	O 0
vitro	O 0
expression	O 0
of	O 0
LCAT	O 0
minigenes	O 0
and	O 0
reverse	O 0
transcriptase	O 0
PCR	O 0
on	O 0
mRNA	O 0
isolated	O 0
from	O 0
leukocytes	O 0
of	O 0
the	O 0
patient	O 0
,	O 0
this	O 0
gene	O 0
defect	O 0
was	O 0
shown	O 0
to	O 0
cause	O 0
a	O 0
null	O 0
allele	O 0
as	O 0
the	O 0
result	O 0
of	O 0
complete	O 0
intron	O 0
retention	O 0
.	O 0

In	O 0
conclusion	O 0
,	O 0
we	O 0
demonstrated	O 0
that	O 0
a	O 0
point	O 0
mutation	O 0
in	O 0
a	O 0
lariat	O 0
branchpoint	O 0
consensus	O 0
sequence	O 0
causes	O 0
a	O 0
null	O 0
allele	O 0
in	O 0
a	O 0
patient	O 0
with	O 0
FED	B-Disease 0
.	O 0

In	O 0
addition	O 0
,	O 0
our	O 0
finding	O 0
illustrates	O 0
the	O 0
importance	O 0
of	O 0
this	O 0
sequence	O 0
for	O 0
normal	O 0
human	O 0
mRNA	O 0
processing	O 0
.	O 0

Finally	O 0
,	O 0
this	O 0
report	O 0
provides	O 0
a	O 0
widely	O 0
applicable	O 0
strategy	O 0
which	O 0
ensures	O 0
fast	O 0
and	O 0
effective	O 0
screening	O 0
for	O 0
intronic	O 0
defects	O 0
that	O 0
underlie	O 0
differential	O 0
gene	O 0
expression	O 0
.	O 0
.	O 0

Mutations	O 0
associated	O 0
with	O 0
variant	O 0
phenotypes	O 0
in	O 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
.	O 0

We	O 0
have	O 0
identified	O 0
14	O 0
families	O 0
with	O 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
(	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
)	O 0
in	O 0
which	O 0
mutation	O 0
of	O 0
the	O 0
ATM	O 0
gene	O 0
is	O 0
associated	O 0
with	O 0
a	O 0
less	O 0
severe	O 0
clinical	O 0
and	O 0
cellular	O 0
phenotype	O 0
(	O 0
approximately	O 0
10	O 0
%	O 0
-	O 0
15	O 0
%	O 0
of	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
families	O 0
identified	O 0
in	O 0
the	O 0
United	O 0
Kingdom	O 0
)	O 0
.	O 0

In	O 0
10	O 0
of	O 0
these	O 0
families	O 0
,	O 0
all	O 0
the	O 0
homozygotes	O 0
have	O 0
a	O 0
137	O 0
-	O 0
bp	O 0
insertion	O 0
in	O 0
their	O 0
cDNA	O 0
caused	O 0
by	O 0
a	O 0
point	O 0
mutation	O 0
in	O 0
a	O 0
sequence	O 0
resembling	O 0
a	O 0
splice	O 0
-	O 0
donor	O 0
site	O 0
.	O 0

The	O 0
second	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
allele	O 0
has	O 0
a	O 0
different	O 0
mutation	O 0
in	O 0
each	O 0
patient	O 0
.	O 0

We	O 0
show	O 0
that	O 0
the	O 0
less	O 0
severe	O 0
phenotype	O 0
in	O 0
these	O 0
patients	O 0
is	O 0
caused	O 0
by	O 0
some	O 0
degree	O 0
of	O 0
normal	O 0
splicing	O 0
,	O 0
which	O 0
occurs	O 0
as	O 0
an	O 0
alternative	O 0
product	O 0
from	O 0
the	O 0
insertion	O 0
-	O 0
containing	O 0
allele	O 0
.	O 0

The	O 0
level	O 0
of	O 0
the	O 0
137	O 0
-	O 0
bp	O 0
PCR	O 0
product	O 0
containing	O 0
the	O 0
insertion	O 0
was	O 0
lowest	O 0
in	O 0
two	O 0
patients	O 0
who	O 0
showed	O 0
a	O 0
later	O 0
onset	O 0
of	O 0
cerebellar	B-Disease 0
ataxia	I-Disease 0
.	O 0

A	O 0
further	O 0
four	O 0
families	O 0
who	O 0
do	O 0
not	O 0
have	O 0
this	O 0
insertion	O 0
have	O 0
been	O 0
identified	O 0
.	O 0

Mutations	O 0
detected	O 0
in	O 0
two	O 0
of	O 0
four	O 0
of	O 0
these	O 0
are	O 0
missense	O 0
mutations	O 0
,	O 0
normally	O 0
rare	O 0
in	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
patients	O 0
.	O 0

The	O 0
demonstration	O 0
of	O 0
mutations	O 0
giving	O 0
rise	O 0
to	O 0
a	O 0
slightly	O 0
milder	O 0
phenotype	O 0
in	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
raises	O 0
the	O 0
interesting	O 0
question	O 0
of	O 0
what	O 0
range	O 0
of	O 0
phenotypes	O 0
might	O 0
occur	O 0
in	O 0
individuals	O 0
in	O 0
whom	O 0
both	O 0
mutations	O 0
are	O 0
milder	O 0
.	O 0

One	O 0
possibility	O 0
might	O 0
be	O 0
that	O 0
individuals	O 0
who	O 0
are	O 0
compound	O 0
heterozygotes	O 0
for	O 0
ATM	O 0
mutations	O 0
are	O 0
more	O 0
common	O 0
than	O 0
we	O 0
realize	O 0
.	O 0
.	O 0

Mutation	O 0
of	O 0
the	O 0
VHL	O 0
gene	O 0
is	O 0
associated	O 0
exclusively	O 0
with	O 0
the	O 0
development	O 0
of	O 0
non	B-Disease 0
-	I-Disease 0
papillary	I-Disease 0
renal	I-Disease 0
cell	I-Disease 0
carcinomas	I-Disease 0
.	O 0

To	O 0
define	O 0
the	O 0
possible	O 0
role	O 0
of	O 0
the	O 0
VHL	B-Disease 0
gene	O 0
in	O 0
the	O 0
development	O 0
of	O 0
sporadic	B-Disease 0
renal	I-Disease 0
cell	I-Disease 0
carcinomas	I-Disease 0
,	O 0
91	O 0
different	O 0
parenchymal	B-Disease 0
tumours	I-Disease 0
of	I-Disease 0
the	I-Disease 0
kidney	I-Disease 0
have	O 0
been	O 0
investigated	O 0
for	O 0
mutation	O 0
of	O 0
the	O 0
VHL	B-Disease 0
gene	O 0
by	O 0
single	O 0
strand	O 0
conformation	O 0
polymorphism	O 0
(	O 0
SSCP	O 0
)	O 0
and	O 0
/	O 0
or	O 0
heteroduplex	O 0
(	O 0
HD	O 0
)	O 0
techniques	O 0
.	O 0

Chromosome	O 0
3p	O 0
deletion	O 0
was	O 0
detected	O 0
in	O 0
98	O 0
per	O 0
cent	O 0
of	O 0
non	B-Disease 0
-	I-Disease 0
papillary	I-Disease 0
renal	I-Disease 0
cell	I-Disease 0
carcinomas	I-Disease 0
and	O 0
in	O 0
25	O 0
per	O 0
cent	O 0
of	O 0
chromophobe	O 0
renal	B-Disease 0
cell	I-Disease 0
carcinomas	I-Disease 0
.	O 0

In	O 0
22	O 0
of	O 0
the	O 0
43	O 0
non	B-Disease 0
-	I-Disease 0
papillary	I-Disease 0
renal	I-Disease 0
cell	I-Disease 0
carcinomas	I-Disease 0
,	O 0
abnormally	O 0
migrating	O 0
DNA	O 0
bands	O 0
were	O 0
detected	O 0
by	O 0
SSCP	O 0
and	O 0
/	O 0
or	O 0
HD	O 0
analysis	O 0
.	O 0

No	O 0
mobility	O 0
shift	O 0
was	O 0
seen	O 0
in	O 0
any	O 0
of	O 0
the	O 0
23	O 0
chromophobe	O 0
renal	B-Disease 0
cell	I-Disease 0
carcinomas	I-Disease 0
.	O 0

In	O 0
addition	O 0
,	O 0
15	O 0
papillary	B-Disease 0
renal	I-Disease 0
cell	I-Disease 0
tumours	I-Disease 0
and	O 0
ten	O 0
renal	B-Disease 0
oncocytomas	I-Disease 0
,	O 0
which	O 0
are	O 0
characterized	O 0
by	O 0
genetic	O 0
changes	O 0
other	O 0
than	O 0
loss	O 0
of	O 0
chromosome	O 0
3p	O 0
sequences	O 0
,	O 0
were	O 0
analysed	O 0
for	O 0
mutation	O 0
of	O 0
the	O 0
VHL	B-Disease 0
gene	O 0
.	O 0

None	O 0
of	O 0
these	O 0
tumours	B-Disease 0
showed	O 0
abnormal	O 0
migration	O 0
patterns	O 0
.	O 0

The	O 0
results	O 0
indicate	O 0
that	O 0
mutation	O 0
of	O 0
the	O 0
VHL	B-Disease 0
gene	O 0
is	O 0
associated	O 0
exclusively	O 0
with	O 0
the	O 0
development	O 0
of	O 0
non	B-Disease 0
-	I-Disease 0
papillary	I-Disease 0
renal	I-Disease 0
cell	I-Disease 0
carcinoma	I-Disease 0
.	O 0
.	O 0

The	O 0
Emery	B-Disease 0
-	I-Disease 0
Dreifuss	I-Disease 0
muscular	I-Disease 0
dystrophy	I-Disease 0
protein	O 0
,	O 0
emerin	O 0
,	O 0
is	O 0
a	O 0
nuclear	O 0
membrane	O 0
protein	O 0
.	O 0

A	O 0
large	O 0
fragment	O 0
of	O 0
emerin	O 0
cDNA	O 0
was	O 0
prepared	O 0
by	O 0
PCR	O 0
and	O 0
expressed	O 0
as	O 0
a	O 0
recombinant	O 0
protein	O 0
in	O 0
Escherichia	O 0
coli	O 0
.	O 0

Using	O 0
this	O 0
as	O 0
immunogen	O 0
,	O 0
we	O 0
prepared	O 0
a	O 0
panel	O 0
of	O 0
12	O 0
monoclonal	O 0
antibodies	O 0
which	O 0
recognise	O 0
at	O 0
least	O 0
four	O 0
different	O 0
epitopes	O 0
on	O 0
emerin	O 0
in	O 0
order	O 0
to	O 0
ensure	O 0
that	O 0
emerin	O 0
can	O 0
be	O 0
distinguished	O 0
from	O 0
non	O 0
-	O 0
specific	O 0
cross	O 0
-	O 0
reacting	O 0
proteins	O 0
.	O 0

All	O 0
the	O 0
mAbs	O 0
recognised	O 0
a	O 0
34	O 0
kDa	O 0
protein	O 0
in	O 0
all	O 0
tissues	O 0
tested	O 0
,	O 0
though	O 0
minor	O 0
emerin	O 0
-	O 0
related	O 0
bands	O 0
were	O 0
also	O 0
detected	O 0
in	O 0
some	O 0
tissues	O 0
.	O 0

Immunofluorescence	O 0
microscopy	O 0
showed	O 0
that	O 0
emerin	O 0
is	O 0
located	O 0
at	O 0
the	O 0
nuclear	O 0
rim	O 0
in	O 0
all	O 0
tissues	O 0
examined	O 0
.	O 0

A	O 0
muscle	O 0
biopsy	O 0
from	O 0
an	O 0
Emery	B-Disease 0
-	I-Disease 0
Dreifuss	I-Disease 0
muscular	I-Disease 0
dystrophy	I-Disease 0
(	O 0
EMDM	B-Disease 0
)	O 0
patient	O 0
showed	O 0
complete	O 0
absence	O 0
of	O 0
emerin	O 0
by	O 0
both	O 0
Western	O 0
blotting	O 0
and	O 0
immunohistochemistry	O 0
,	O 0
suggesting	O 0
a	O 0
simple	O 0
diagnostic	O 0
antibody	O 0
test	O 0
for	O 0
EDMD	B-Disease 0
families	O 0
.	O 0

Biochemical	O 0
fractionation	O 0
of	O 0
brain	O 0
and	O 0
liver	O 0
tissues	O 0
showed	O 0
that	O 0
emerin	O 0
was	O 0
present	O 0
in	O 0
nuclei	O 0
purified	O 0
by	O 0
centrifugation	O 0
through	O 0
65	O 0
%	O 0
sucrose	O 0
and	O 0
was	O 0
absent	O 0
from	O 0
soluble	O 0
fractions	O 0
(	O 0
post	O 0
-	O 0
100	O 0
,	O 0
000	O 0
g	O 0
)	O 0
.	O 0

From	O 0
these	O 0
results	O 0
,	O 0
together	O 0
with	O 0
sequence	O 0
and	O 0
structural	O 0
homologies	O 0
between	O 0
emerin	O 0
,	O 0
thymopoietins	O 0
and	O 0
the	O 0
nuclear	O 0
lamina	O 0
-	O 0
associated	O 0
protein	O 0
,	O 0
LAP2	O 0
,	O 0
we	O 0
suggest	O 0
that	O 0
emerin	O 0
will	O 0
prove	O 0
to	O 0
be	O 0
one	O 0
member	O 0
of	O 0
a	O 0
family	O 0
of	O 0
inner	O 0
nuclear	O 0
membrane	O 0
proteins	O 0
.	O 0
.	O 0

Mutation	O 0
of	O 0
MSH3	O 0
in	O 0
endometrial	B-Disease 0
cancer	I-Disease 0
and	O 0
evidence	O 0
for	O 0
its	O 0
functional	O 0
role	O 0
in	O 0
heteroduplex	O 0
repair	O 0
.	O 0

Many	O 0
human	O 0
tumours	B-Disease 0
have	O 0
length	O 0
alterations	O 0
in	O 0
repetitive	O 0
sequence	O 0
elements	O 0
.	O 0

Although	O 0
this	O 0
microsatellite	B-Disease 0
instability	I-Disease 0
has	O 0
been	O 0
attributed	O 0
to	O 0
mutations	O 0
in	O 0
four	O 0
DNA	O 0
mismatch	O 0
repair	O 0
genes	O 0
in	O 0
hereditary	B-Disease 0
nonpolyposis	I-Disease 0
colorectal	I-Disease 0
cancer	I-Disease 0
(	O 0
HNPCC	B-Disease 0
)	O 0
kindreds	O 0
,	O 0
many	O 0
sporadic	B-Disease 0
tumours	I-Disease 0
exhibit	O 0
instability	O 0
but	O 0
no	O 0
detectable	O 0
mutations	O 0
in	O 0
these	O 0
genes	O 0
.	O 0

It	O 0
is	O 0
therefore	O 0
of	O 0
interest	O 0
to	O 0
identify	O 0
other	O 0
genes	O 0
that	O 0
contribute	O 0
to	O 0
this	O 0
instability	O 0
.	O 0

In	O 0
yeast	O 0
,	O 0
mutations	O 0
in	O 0
several	O 0
genes	O 0
,	O 0
including	O 0
RTH	O 0
and	O 0
MSH3	O 0
,	O 0
cause	O 0
microsatellite	O 0
instability	O 0
.	O 0

Thus	O 0
,	O 0
we	O 0
screened	O 0
16	O 0
endometrial	B-Disease 0
carcinomas	I-Disease 0
with	O 0
microsatellite	O 0
instability	O 0
for	O 0
alterations	O 0
in	O 0
FEN1	O 0
(	O 0
the	O 0
human	O 0
homolog	O 0
of	O 0
RTH	O 0
)	O 0
and	O 0
in	O 0
MSH3	O 0
(	O 0
refs	O 0
12	O 0
-	O 0
14	O 0
)	O 0
.	O 0

Although	O 0
we	O 0
found	O 0
no	O 0
FEN1	O 0
mutations	O 0
,	O 0
a	O 0
frameshift	O 0
mutation	O 0
in	O 0
MSH3	O 0
was	O 0
observed	O 0
in	O 0
an	O 0
endometrial	B-Disease 0
carcinoma	I-Disease 0
and	O 0
in	O 0
an	O 0
endometrial	B-Disease 0
carcinoma	I-Disease 0
cell	O 0
line	O 0
.	O 0

Extracts	O 0
of	O 0
the	O 0
cell	O 0
line	O 0
were	O 0
deficient	O 0
in	O 0
repair	O 0
of	O 0
DNA	O 0
substrates	O 0
containing	O 0
mismatches	O 0
or	O 0
extra	O 0
nucleotides	O 0
.	O 0

Introducing	O 0
chromosome	O 0
5	O 0
,	O 0
encoding	O 0
the	O 0
MSH3	O 0
gene	O 0
,	O 0
into	O 0
the	O 0
mutant	O 0
cell	O 0
line	O 0
increased	O 0
the	O 0
stability	O 0
of	O 0
some	O 0
but	O 0
not	O 0
all	O 0
microsatellites	O 0
.	O 0

Extracts	O 0
of	O 0
these	O 0
cells	O 0
repaired	O 0
certain	O 0
substrates	O 0
containing	O 0
extra	O 0
nucleotides	O 0
,	O 0
but	O 0
were	O 0
deficient	O 0
in	O 0
repair	O 0
of	O 0
those	O 0
containing	O 0
mismatches	O 0
or	O 0
other	O 0
extra	O 0
nucleotides	O 0
.	O 0

A	O 0
subsequent	O 0
search	O 0
revealed	O 0
a	O 0
second	O 0
gene	O 0
mutation	O 0
in	O 0
HHUA	O 0
cells	O 0
,	O 0
a	O 0
missense	O 0
mutation	O 0
in	O 0
the	O 0
MSH6	O 0
gene	O 0
.	O 0

Together	O 0
the	O 0
data	O 0
suggest	O 0
that	O 0
the	O 0
MSH3	O 0
gene	O 0
encodes	O 0
a	O 0
product	O 0
that	O 0
functions	O 0
in	O 0
repair	O 0
of	O 0
some	O 0
but	O 0
not	O 0
all	O 0
pre	O 0
-	O 0
mutational	O 0
intermediates	O 0
,	O 0
its	O 0
mutation	O 0
in	O 0
tumours	B-Disease 0
can	O 0
result	O 0
in	O 0
genomic	O 0
instability	O 0
and	O 0
,	O 0
as	O 0
in	O 0
yeast	O 0
,	O 0
MSH3	O 0
and	O 0
MSH6	O 0
are	O 0
partially	O 0
redundant	O 0
for	O 0
mismatch	O 0
repair	O 0
.	O 0
.	O 0

Comparative	O 0
genome	O 0
mapping	O 0
of	O 0
the	O 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
region	O 0
in	O 0
mouse	O 0
,	O 0
rat	O 0
,	O 0
and	O 0
Syrian	O 0
hamster	O 0
.	O 0

Chromosomal	O 0
locations	O 0
of	O 0
the	O 0
Atm	O 0
(	O 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
(	O 0
AT	B-Disease 0
)	O 0
-	O 0
mutated	O 0
)	O 0
and	O 0
Acat1	O 0
(	O 0
mitochondrial	O 0
acetoacetyl	O 0
-	O 0
CoA	O 0
thiolase	O 0
)	O 0
genes	O 0
in	O 0
mouse	O 0
,	O 0
rat	O 0
,	O 0
and	O 0
Syrian	O 0
hamster	O 0
were	O 0
determined	O 0
by	O 0
direct	O 0
R	O 0
-	O 0
banding	O 0
FISH	O 0
.	O 0

Both	O 0
genes	O 0
were	O 0
colocalized	O 0
to	O 0
the	O 0
C	O 0
-	O 0
D	O 0
band	O 0
of	O 0
mouse	O 0
chromosome	O 0
9	O 0
,	O 0
the	O 0
proximal	O 0
end	O 0
of	O 0
q24	O 0
.	O 0

1	O 0
of	O 0
rat	O 0
chromosome	O 0
8	O 0
,	O 0
and	O 0
qa4	O 0
-	O 0
qa5	O 0
of	O 0
Syrian	O 0
hamster	O 0
chromosome	O 0
12	O 0
.	O 0

The	O 0
regions	O 0
in	O 0
the	O 0
mouse	O 0
and	O 0
rat	O 0
were	O 0
homologous	O 0
to	O 0
human	O 0
chromosome	O 0
11q	O 0
.	O 0

Fine	O 0
genetic	O 0
linkage	O 0
mapping	O 0
of	O 0
the	O 0
mouse	O 0
AT	B-Disease 0
region	O 0
was	O 0
performed	O 0
using	O 0
the	O 0
interspecific	O 0
backcross	O 0
mice	O 0
.	O 0

Atm	O 0
,	O 0
Acat1	O 0
,	O 0
and	O 0
Npat	O 0
,	O 0
which	O 0
is	O 0
a	O 0
new	O 0
gene	O 0
isolated	O 0
from	O 0
the	O 0
AT	O 0
region	O 0
,	O 0
and	O 0
12	O 0
flanking	O 0
microsatellite	O 0
DNA	O 0
markers	O 0
were	O 0
examined	O 0
.	O 0

No	O 0
recombinations	O 0
were	O 0
found	O 0
among	O 0
the	O 0
Atm	O 0
,	O 0
Npat	O 0
,	O 0
Acat1	O 0
,	O 0
and	O 0
D9Mit6	O 0
loci	O 0
,	O 0
and	O 0
these	O 0
loci	O 0
were	O 0
mapped	O 0
2	O 0
.	O 0

0	O 0
cM	O 0
distal	O 0
to	O 0
D9Mit99	O 0
and	O 0
1	O 0
.	O 0

3	O 0
cM	O 0
proximal	O 0
to	O 0
D9Mit102	O 0
.	O 0

Comparison	O 0
of	O 0
the	O 0
linkage	O 0
map	O 0
of	O 0
mouse	O 0
chromosome	O 0
9	O 0
(	O 0
MMU9	O 0
)	O 0
and	O 0
that	O 0
of	O 0
human	O 0
chromosome	O 0
11	O 0
(	O 0
HSA11	O 0
)	O 0
indicates	O 0
that	O 0
there	O 0
is	O 0
a	O 0
chromosomal	O 0
rearrangement	O 0
due	O 0
to	O 0
an	O 0
inversion	O 0
between	O 0
Ets1	O 0
and	O 0
Atm	O 0
-	O 0
Npat	O 0
-	O 0
Acat1	O 0
and	O 0
that	O 0
the	O 0
inversion	O 0
of	O 0
MMU9	O 0
originated	O 0
from	O 0
the	O 0
chromosomal	O 0
breakage	O 0
at	O 0
the	O 0
boundary	O 0
between	O 0
Gria4	O 0
and	O 0
Atm	O 0
-	O 0
Npat	O 0
-	O 0
Acat1	O 0
on	O 0
HSA11	O 0
.	O 0

This	O 0
type	O 0
of	O 0
inversion	O 0
appeared	O 0
to	O 0
be	O 0
conserved	O 0
in	O 0
the	O 0
three	O 0
rodent	O 0
species	O 0
,	O 0
mouse	O 0
,	O 0
rat	O 0
,	O 0
and	O 0
Syrian	O 0
hamster	O 0
,	O 0
using	O 0
additional	O 0
comparative	O 0
mapping	O 0
data	O 0
with	O 0
the	O 0
Rck	O 0
gene	O 0

An	O 0
animal	O 0
model	O 0
for	O 0
Norrie	B-Disease 0
disease	I-Disease 0
(	O 0
ND	B-Disease 0
)	O 0
:	O 0
gene	O 0
targeting	O 0
of	O 0
the	O 0
mouse	O 0
ND	B-Disease 0
gene	O 0
.	O 0

In	O 0
order	O 0
to	O 0
elucidate	O 0
the	O 0
cellular	O 0
and	O 0
molecular	O 0
processes	O 0
which	O 0
are	O 0
involved	O 0
in	O 0
Norrie	B-Disease 0
disease	I-Disease 0
(	O 0
ND	B-Disease 0
)	O 0
,	O 0
we	O 0
have	O 0
used	O 0
gene	O 0
targeting	O 0
technology	O 0
to	O 0
generate	O 0
ND	B-Disease 0
mutant	O 0
mice	O 0
.	O 0

The	O 0
murine	O 0
homologue	O 0
of	O 0
the	O 0
ND	B-Disease 0
gene	O 0
was	O 0
cloned	O 0
and	O 0
shown	O 0
to	O 0
encode	O 0
a	O 0
polypeptide	O 0
that	O 0
shares	O 0
94	O 0
%	O 0
of	O 0
the	O 0
amino	O 0
acid	O 0
sequence	O 0
with	O 0
its	O 0
human	O 0
counterpart	O 0
.	O 0

RNA	O 0
in	O 0
situ	O 0
hybridization	O 0
revealed	O 0
expression	O 0
in	O 0
retina	O 0
,	O 0
brain	O 0
and	O 0
the	O 0
olfactory	O 0
bulb	O 0
and	O 0
epithelium	O 0
of	O 0
2	O 0
week	O 0
old	O 0
mice	O 0
.	O 0

Hemizygous	O 0
mice	O 0
carrying	O 0
a	O 0
replacement	O 0
mutation	O 0
in	O 0
exon	O 0
2	O 0
of	O 0
the	O 0
ND	B-Disease 0
gene	O 0
developed	O 0
retrolental	O 0
structures	O 0
in	O 0
the	O 0
vitreous	O 0
body	O 0
and	O 0
showed	O 0
an	O 0
overall	O 0
disorganization	O 0
of	O 0
the	O 0
retinal	O 0
ganglion	O 0
cell	O 0
layer	O 0
.	O 0

The	O 0
outer	O 0
plexiform	O 0
layer	O 0
disappears	O 0
occasionally	O 0
,	O 0
resulting	O 0
in	O 0
a	O 0
juxtaposed	O 0
inner	O 0
and	O 0
outer	O 0
nuclear	O 0
layer	O 0
.	O 0

At	O 0
the	O 0
same	O 0
regions	O 0
,	O 0
the	O 0
outer	O 0
segments	O 0
of	O 0
the	O 0
photoreceptor	O 0
cell	O 0
layer	O 0
are	O 0
no	O 0
longer	O 0
present	O 0
.	O 0

These	O 0
ocular	O 0
findings	O 0
are	O 0
consistent	O 0
with	O 0
observations	O 0
in	O 0
ND	B-Disease 0
patients	O 0
and	O 0
the	O 0
generated	O 0
mouse	O 0
line	O 0
provides	O 0
a	O 0
faithful	O 0
model	O 0
for	O 0
study	O 0
of	O 0
early	O 0
pathogenic	O 0
events	O 0
in	O 0
this	O 0
severe	O 0
X	B-Disease 0
-	I-Disease 0
linked	I-Disease 0
recessive	I-Disease 0
neurological	I-Disease 0
disorder	I-Disease 0
.	O 0
.	O 0

The	O 0
hybrid	O 0
PAX3	O 0
-	O 0
FKHR	O 0
fusion	O 0
protein	O 0
of	O 0
alveolar	B-Disease 0
rhabdomyosarcoma	I-Disease 0
transforms	O 0
fibroblasts	O 0
in	O 0
culture	O 0
.	O 0

Pediatric	B-Disease 0
alveolar	I-Disease 0
rhabdomyosarcoma	I-Disease 0
is	O 0
characterized	O 0
by	O 0
a	O 0
chromosomal	O 0
translocation	O 0
that	O 0
fuses	O 0
parts	O 0
of	O 0
the	O 0
PAX3	O 0
and	O 0
FKHR	O 0
genes	O 0
.	O 0

PAX3	O 0
codes	O 0
for	O 0
a	O 0
transcriptional	O 0
regulator	O 0
that	O 0
controls	O 0
developmental	O 0
programs	O 0
,	O 0
and	O 0
FKHR	O 0
codes	O 0
for	O 0
a	O 0
forkhead	O 0
-	O 0
winged	O 0
helix	O 0
protein	O 0
,	O 0
also	O 0
a	O 0
likely	O 0
transcription	O 0
factor	O 0
.	O 0

The	O 0
PAX3	O 0
-	O 0
FKHR	O 0
fusion	O 0
product	O 0
retains	O 0
the	O 0
DNA	O 0
binding	O 0
domains	O 0
of	O 0
the	O 0
PAX3	O 0
protein	O 0
and	O 0
the	O 0
putative	O 0
activator	O 0
domain	O 0
of	O 0
the	O 0
FKHR	O 0
protein	O 0
.	O 0

The	O 0
PAX3	O 0
-	O 0
FKHR	O 0
protein	O 0
has	O 0
been	O 0
shown	O 0
to	O 0
function	O 0
as	O 0
a	O 0
transcriptional	O 0
activator	O 0
.	O 0

Using	O 0
the	O 0
RCAS	O 0
retroviral	O 0
vector	O 0
,	O 0
we	O 0
have	O 0
introduced	O 0
the	O 0
PAX3	O 0
-	O 0
FKHR	O 0
gene	O 0
into	O 0
chicken	O 0
embryo	O 0
fibroblasts	O 0
.	O 0

Expression	O 0
of	O 0
the	O 0
PAX3	O 0
-	O 0
FKHR	O 0
protein	O 0
in	O 0
these	O 0
cells	O 0
leads	O 0
to	O 0
transformation	O 0
the	O 0
cells	O 0
become	O 0
enlarged	O 0
,	O 0
grow	O 0
tightly	O 0
packed	O 0
and	O 0
in	O 0
multiple	O 0
layers	O 0
,	O 0
and	O 0
acquire	O 0
the	O 0
ability	O 0
for	O 0
anchorage	O 0
-	O 0
independent	O 0
growth	O 0
.	O 0

This	O 0
cellular	O 0
transformation	O 0
in	O 0
vitro	O 0
will	O 0
facilitate	O 0
studies	O 0
on	O 0
the	O 0
mechanism	O 0
of	O 0
PAX3	O 0
-	O 0
FKHR	O 0
-	O 0
induced	O 0
oncogenesis	O 0
.	O 0
.	O 0

Somatic	O 0
-	O 0
cell	O 0
selection	O 0
is	O 0
a	O 0
major	O 0
determinant	O 0
of	O 0
the	O 0
blood	O 0
-	O 0
cell	O 0
phenotype	O 0
in	O 0
heterozygotes	O 0
for	O 0
glucose	O 0
-	O 0
6	O 0
-	O 0
phosphate	O 0
dehydrogenase	O 0
mutations	O 0
causing	O 0
severe	O 0
enzyme	B-Disease 0
deficiency	I-Disease 0
.	O 0

X	O 0
-	O 0
chromosome	O 0
inactivation	O 0
in	O 0
mammals	O 0
is	O 0
regarded	O 0
as	O 0
an	O 0
essentially	O 0
random	O 0
process	O 0
,	O 0
but	O 0
the	O 0
resulting	O 0
somatic	O 0
-	O 0
cell	O 0
mosaicism	O 0
creates	O 0
the	O 0
opportunity	O 0
for	O 0
cell	O 0
selection	O 0
.	O 0

In	O 0
most	O 0
people	O 0
with	O 0
red	O 0
-	O 0
blood	O 0
-	O 0
cell	O 0
glucose	B-Disease 0
-	I-Disease 0
6	I-Disease 0
-	I-Disease 0
phosphate	I-Disease 0
dehydrogenase	I-Disease 0
(	I-Disease 0
G6PD	I-Disease 0
)	I-Disease 0
deficiency	I-Disease 0
,	O 0
the	O 0
enzyme	O 0
-	O 0
deficient	O 0
phenotype	O 0
is	O 0
only	O 0
moderately	O 0
expressed	O 0
in	O 0
nucleated	O 0
cells	O 0
.	O 0

However	O 0
,	O 0
in	O 0
a	O 0
small	O 0
subset	O 0
of	O 0
hemizygous	O 0
males	O 0
who	O 0
suffer	O 0
from	O 0
chronic	B-Disease 0
nonspherocytic	I-Disease 0
hemolytic	I-Disease 0
anemia	I-Disease 0
,	O 0
the	O 0
underlying	O 0
mutations	O 0
(	O 0
designated	O 0
class	O 0
I	O 0
)	O 0
cause	O 0
more	O 0
-	O 0
severe	O 0
G6PD	B-Disease 0
deficiency	I-Disease 0
,	O 0
and	O 0
this	O 0
might	O 0
provide	O 0
an	O 0
opportunity	O 0
for	O 0
selection	O 0
in	O 0
heterozygous	O 0
females	O 0
during	O 0
development	O 0
.	O 0

In	O 0
order	O 0
to	O 0
test	O 0
this	O 0
possibility	O 0
we	O 0
have	O 0
analyzed	O 0
four	O 0
heterozygotes	O 0
for	O 0
class	O 0
I	O 0
G6PD	O 0
mutations	O 0
two	O 0
with	O 0
G6PD	O 0
Portici	O 0
(	O 0
1178G	O 0
-	O 0
-	O 0
>	O 0
A	O 0
)	O 0
and	O 0
two	O 0
with	O 0
G6PD	O 0
Bari	O 0
(	O 0
1187C	O 0
-	O 0
-	O 0
>	O 0
T	O 0
)	O 0
.	O 0

We	O 0
found	O 0
that	O 0
in	O 0
fractionated	O 0
blood	O 0
cell	O 0
types	O 0
(	O 0
including	O 0
erythroid	O 0
,	O 0
myeloid	O 0
,	O 0
and	O 0
lymphoid	O 0
cell	O 0
lineages	O 0
)	O 0
there	O 0
was	O 0
a	O 0
significant	O 0
excess	O 0
of	O 0
G6PD	O 0
-	O 0
normal	O 0
cells	O 0
.	O 0

The	O 0
significant	O 0
concordance	O 0
that	O 0
we	O 0
have	O 0
observed	O 0
in	O 0
the	O 0
degree	O 0
of	O 0
imbalance	O 0
in	O 0
the	O 0
different	O 0
blood	O 0
-	O 0
cell	O 0
lineages	O 0
indicates	O 0
that	O 0
a	O 0
selective	O 0
mechanism	O 0
is	O 0
likely	O 0
to	O 0
operate	O 0
at	O 0
the	O 0
level	O 0
of	O 0
pluripotent	O 0
blood	O 0
stem	O 0
cells	O 0
.	O 0

Thus	O 0
,	O 0
it	O 0
appears	O 0
that	O 0
severe	O 0
G6PD	B-Disease 0
deficiency	I-Disease 0
affects	O 0
adversely	O 0
the	O 0
proliferation	O 0
or	O 0
the	O 0
survival	O 0
of	O 0
nucleated	O 0
blood	O 0
cells	O 0
and	O 0
that	O 0
this	O 0
phenotypic	O 0
characteristic	O 0
is	O 0
critical	O 0
during	O 0
hematopoiesis	O 0
.	O 0
.	O 0

Analysis	O 0
of	O 0
meiotic	O 0
segregation	O 0
,	O 0
using	O 0
single	O 0
-	O 0
sperm	O 0
typing	O 0
:	O 0
meiotic	O 0
drive	O 0
at	O 0
the	O 0
myotonic	B-Disease 0
dystrophy	I-Disease 0
locus	O 0
.	O 0

Meiotic	O 0
drive	O 0
at	O 0
the	O 0
myotonic	B-Disease 0
dystrophy	I-Disease 0
(	O 0
DM	B-Disease 0
)	O 0
locus	O 0
has	O 0
recently	O 0
been	O 0
suggested	O 0
as	O 0
being	O 0
responsible	O 0
for	O 0
maintaining	O 0
the	O 0
frequency	O 0
,	O 0
in	O 0
the	O 0
human	O 0
population	O 0
,	O 0
of	O 0
DM	B-Disease 0
chromosomes	O 0
capable	O 0
of	O 0
expansion	O 0
to	O 0
the	O 0
disease	O 0
state	O 0
.	O 0

In	O 0
order	O 0
to	O 0
test	O 0
this	O 0
hypothesis	O 0
,	O 0
we	O 0
have	O 0
studied	O 0
samples	O 0
of	O 0
single	O 0
sperm	O 0
from	O 0
three	O 0
individuals	O 0
heterozygous	O 0
at	O 0
the	O 0
DM	B-Disease 0
locus	O 0
,	O 0
each	O 0
with	O 0
one	O 0
allele	O 0
larger	O 0
and	O 0
one	O 0
allele	O 0
smaller	O 0
than	O 0
19	O 0
CTG	O 0
repeats	O 0
.	O 0

To	O 0
guard	O 0
against	O 0
the	O 0
possible	O 0
problem	O 0
of	O 0
differential	O 0
PCR	O 0
amplification	O 0
rates	O 0
based	O 0
on	O 0
the	O 0
lengths	O 0
of	O 0
the	O 0
alleles	O 0
,	O 0
the	O 0
sperm	O 0
were	O 0
also	O 0
typed	O 0
at	O 0
another	O 0
closely	O 0
linked	O 0
marker	O 0
whose	O 0
allele	O 0
size	O 0
was	O 0
unrelated	O 0
to	O 0
the	O 0
allele	O 0
size	O 0
at	O 0
the	O 0
DM	B-Disease 0
locus	O 0
.	O 0

Using	O 0
statistical	O 0
models	O 0
specifically	O 0
designed	O 0
to	O 0
study	O 0
single	O 0
-	O 0
sperm	O 0
segregation	O 0
data	O 0
,	O 0
we	O 0
find	O 0
no	O 0
evidence	O 0
of	O 0
meiotic	O 0
segregation	O 0
distortion	O 0
.	O 0

The	O 0
upper	O 0
limit	O 0
of	O 0
the	O 0
two	O 0
-	O 0
sided	O 0
95	O 0
%	O 0
confidence	O 0
interval	O 0
for	O 0
the	O 0
estimate	O 0
of	O 0
the	O 0
common	O 0
segregation	O 0
probability	O 0
for	O 0
the	O 0
three	O 0
donors	O 0
is	O 0
at	O 0
or	O 0
below	O 0
.	O 0

515	O 0
for	O 0
all	O 0
models	O 0
considered	O 0
,	O 0
and	O 0
no	O 0
statistically	O 0
significant	O 0
difference	O 0
from	O 0
.	O 0

5	O 0
is	O 0
detected	O 0
in	O 0
any	O 0
of	O 0
the	O 0
models	O 0
.	O 0

This	O 0
suggests	O 0
that	O 0
any	O 0
greater	O 0
amount	O 0
of	O 0
segregation	O 0
distortion	O 0
at	O 0
the	O 0
myotonic	B-Disease 0
dystrophy	I-Disease 0
locus	O 0
must	O 0
result	O 0
from	O 0
events	O 0
following	O 0
sperm	O 0
ejaculation	O 0
.	O 0

LPP	O 0
,	O 0
the	O 0
preferred	O 0
fusion	O 0
partner	O 0
gene	O 0
of	O 0
HMGIC	O 0
in	O 0
lipomas	B-Disease 0
,	O 0
is	O 0
a	O 0
novel	O 0
member	O 0
of	O 0
the	O 0
LIM	O 0
protein	O 0
gene	O 0
family	O 0
.	O 0

A	O 0
major	O 0
cytogenetic	O 0
subgroup	O 0
of	O 0
lipomas	B-Disease 0
is	O 0
characterized	O 0
by	O 0
recurrent	O 0
chromosome	O 0
aberrations	O 0
,	O 0
mainly	O 0
translocations	O 0
,	O 0
that	O 0
involve	O 0
chromosome	O 0
segment	O 0
12q13	O 0
-	O 0
q15	O 0
.	O 0

Multiple	O 0
chromosomes	O 0
have	O 0
been	O 0
found	O 0
as	O 0
the	O 0
translocation	O 0
partners	O 0
of	O 0
chromosome	O 0
12	O 0
but	O 0
3q27	O 0
-	O 0
q28	O 0
is	O 0
preferentially	O 0
involved	O 0
.	O 0

In	O 0
previous	O 0
studies	O 0
,	O 0
it	O 0
has	O 0
been	O 0
shown	O 0
that	O 0
the	O 0
high	O 0
mobility	O 0
group	O 0
(	O 0
HMG	O 0
)	O 0
protein	O 0
gene	O 0
HMGIC	O 0
at	O 0
12q15	O 0
is	O 0
consistently	O 0
rearranged	O 0
as	O 0
a	O 0
consequence	O 0
of	O 0
these	O 0
translocations	O 0
.	O 0

Here	O 0
,	O 0
we	O 0
report	O 0
the	O 0
identification	O 0
and	O 0
characterization	O 0
of	O 0
the	O 0
chromosome	O 0
3	O 0
-	O 0
derived	O 0
translocation	O 0
partner	O 0
gene	O 0
,	O 0
which	O 0
we	O 0
have	O 0
designated	O 0
LPP	O 0
(	O 0
lipoma	B-Disease 0
preferred	O 0
partner	O 0
gene	O 0
)	O 0
.	O 0

Using	O 0
3	O 0
-	O 0
RACE	O 0
analysis	O 0
of	O 0
HMGIC	O 0
fusion	O 0
transcripts	O 0
in	O 0
lipoma	B-Disease 0
cell	O 0
line	O 0
Li	O 0
-	O 0
501	O 0
/	O 0
SV40	O 0
,	O 0
ectopic	O 0
genetic	O 0
sequences	O 0
were	O 0
obtained	O 0
,	O 0
which	O 0
by	O 0
CASH	O 0
(	O 0
chromosome	O 0
assignment	O 0
using	O 0
somatic	O 0
cell	O 0
hybrids	O 0
)	O 0
and	O 0
FISH	O 0
(	O 0
fluorescence	O 0
in	O 0
situ	O 0
hybridization	O 0
)	O 0
analysis	O 0
were	O 0
found	O 0
to	O 0
originate	O 0
from	O 0
chromosome	O 0
segment	O 0
3q27	O 0
-	O 0
q28	O 0
.	O 0

In	O 0
Northern	O 0
blot	O 0
analysis	O 0
,	O 0
an	O 0
mRNA	O 0
of	O 0
over	O 0
10	O 0
kb	O 0
was	O 0
detected	O 0
by	O 0
these	O 0
ectopic	O 0
sequences	O 0
in	O 0
a	O 0
variety	O 0
of	O 0
human	O 0
tissues	O 0
but	O 0
not	O 0
in	O 0
brain	O 0
and	O 0
peripheral	O 0
blood	O 0
leukocytes	O 0
.	O 0

Upon	O 0
partial	O 0
cDNA	O 0
cloning	O 0
,	O 0
features	O 0
of	O 0
the	O 0
genetic	O 0
organization	O 0
of	O 0
LPP	O 0
were	O 0
established	O 0
.	O 0

The	O 0
gene	O 0
was	O 0
found	O 0
to	O 0
span	O 0
a	O 0
genomic	O 0
region	O 0
of	O 0
over	O 0
400	O 0
kb	O 0
.	O 0

Nucleotide	O 0
sequence	O 0
analysis	O 0
of	O 0
a	O 0
composite	O 0
cDNA	O 0
of	O 0
LPP	O 0
revealed	O 0
an	O 0
open	O 0
reading	O 0
frame	O 0
of	O 0
1836	O 0
nucleotides	O 0
encoding	O 0
a	O 0
proline	O 0
-	O 0
rich	O 0
protein	O 0
containing	O 0
a	O 0
leucine	O 0
-	O 0
zipper	O 0
motif	O 0
in	O 0
its	O 0
amino	O 0
-	O 0
terminal	O 0
region	O 0
and	O 0
three	O 0
LIM	O 0
domains	O 0
in	O 0
its	O 0
carboxy	O 0
-	O 0
terminal	O 0
region	O 0
.	O 0

The	O 0
LPP	O 0
-	O 0
encoded	O 0
protein	O 0
should	O 0
be	O 0
classified	O 0
as	O 0
a	O 0
novel	O 0
member	O 0
of	O 0
the	O 0
group	O 0
3	O 0
proteins	O 0
of	O 0
the	O 0
LIM	O 0
protein	O 0
gene	O 0
family	O 0
.	O 0

Using	O 0
reverse	O 0
transcriptase	O 0
combined	O 0
with	O 0
polymerase	O 0
chain	O 0
reactions	O 0
in	O 0
the	O 0
analysis	O 0
of	O 0
a	O 0
number	O 0
of	O 0
lipoma	B-Disease 0
cell	O 0
lines	O 0
and	O 0
primary	B-Disease 0
lipomas	I-Disease 0
,	O 0
it	O 0
appeared	O 0
that	O 0
LPP	O 0
is	O 0
frequently	O 0
rearranged	O 0
also	O 0
in	O 0
cases	O 0
without	O 0
a	O 0
cytogenetically	O 0
detectable	O 0
involvement	O 0
of	O 0
3q27	O 0
-	O 0
q28	O 0
.	O 0

Two	O 0
alternative	O 0
HMGIC	O 0
/	O 0
LPP	O 0
hybrid	O 0
transcripts	O 0
have	O 0
been	O 0
detected	O 0
;	O 0
the	O 0
difference	O 0
between	O 0
them	O 0
is	O 0
mainly	O 0
the	O 0
presence	O 0
of	O 0
either	O 0
two	O 0
or	O 0
three	O 0
LIM	O 0
domains	O 0
in	O 0
the	O 0
predicted	O 0
HMGI	O 0
-	O 0
C	O 0
/	O 0
LPP	O 0
fusion	O 0
proteins	O 0
.	O 0
.	O 0

Absence	O 0
of	O 0
disease	O 0
phenotype	O 0
and	O 0
intergenerational	O 0
stability	O 0
of	O 0
the	O 0
CAG	O 0
repeat	O 0
in	O 0
transgenic	O 0
mice	O 0
expressing	O 0
the	O 0
human	O 0
Huntington	B-Disease 0
disease	I-Disease 0
transcript	O 0
.	O 0

The	O 0
mutation	O 0
underlying	O 0
Huntington	B-Disease 0
disease	I-Disease 0
(	O 0
HD	B-Disease 0
)	O 0
is	O 0
CAG	O 0
expansion	O 0
in	O 0
the	O 0
first	O 0
exon	O 0
of	O 0
the	O 0
HD	B-Disease 0
gene	O 0
.	O 0

In	O 0
order	O 0
to	O 0
investigate	O 0
the	O 0
role	O 0
of	O 0
CAG	O 0
expansion	O 0
in	O 0
the	O 0
pathogenesis	O 0
of	O 0
HD	B-Disease 0
,	O 0
we	O 0
have	O 0
produced	O 0
transgenic	O 0
mice	O 0
containing	O 0
the	O 0
full	O 0
length	O 0
human	O 0
HD	B-Disease 0
cDNA	O 0
with	O 0
44	O 0
CAG	O 0
repeats	O 0
.	O 0

By	O 0
1	O 0
year	O 0
,	O 0
these	O 0
mice	O 0
have	O 0
no	O 0
behavioral	B-Disease 0
abnormalities	I-Disease 0
and	O 0
morphometric	O 0
analysis	O 0
at	O 0
6	O 0
(	O 0
one	O 0
animal	O 0
)	O 0
and	O 0
9	O 0
(	O 0
two	O 0
animals	O 0
)	O 0
months	O 0
age	O 0
revealed	O 0
no	O 0
changes	O 0
.	O 0

Despite	O 0
high	O 0
levels	O 0
of	O 0
mRNA	O 0
expression	O 0
,	O 0
there	O 0
was	O 0
no	O 0
evidence	O 0
of	O 0
the	O 0
HD	B-Disease 0
gene	O 0
product	O 0
in	O 0
any	O 0
of	O 0
these	O 0
transgenic	O 0
mice	O 0
.	O 0

In	O 0
vitro	O 0
transfection	O 0
studies	O 0
indicated	O 0
that	O 0
the	O 0
inclusion	O 0
of	O 0
120	O 0
bp	O 0
of	O 0
the	O 0
5	O 0
UTR	O 0
in	O 0
the	O 0
cDNA	O 0
construct	O 0
and	O 0
the	O 0
presence	O 0
of	O 0
a	O 0
frameshift	O 0
mutation	O 0
at	O 0
nucleotide	O 0
2349	O 0
prevented	O 0
expression	O 0
of	O 0
the	O 0
HD	B-Disease 0
cDNA	O 0
.	O 0

These	O 0
findings	O 0
suggest	O 0
that	O 0
the	O 0
pathogenesis	O 0
of	O 0
HD	B-Disease 0
is	O 0
not	O 0
mediated	O 0
through	O 0
DNA	O 0
-	O 0
protein	O 0
interaction	O 0
and	O 0
that	O 0
presence	O 0
of	O 0
the	O 0
RNA	O 0
transcript	O 0
with	O 0
an	O 0
expanded	O 0
CAG	O 0
repeat	O 0
is	O 0
insufficient	O 0
to	O 0
cause	O 0
the	O 0
disease	O 0
.	O 0

Rather	O 0
,	O 0
translation	O 0
of	O 0
the	O 0
CAG	O 0
is	O 0
crucial	O 0
for	O 0
the	O 0
pathogenesis	O 0
of	O 0
HD	B-Disease 0
.	O 0

In	O 0
contrast	O 0
to	O 0
that	O 0
seen	O 0
in	O 0
humans	O 0
,	O 0
the	O 0
CAG	O 0
repeat	O 0
in	O 0
these	O 0
mice	O 0
was	O 0
remarkably	O 0
stable	O 0
in	O 0
97	O 0
meioses	O 0
.	O 0

This	O 0
suggests	O 0
that	O 0
genomic	O 0
sequences	O 0
may	O 0
play	O 0
a	O 0
critical	O 0
role	O 0
in	O 0
influencing	O 0
repeat	O 0
instability	O 0
.	O 0
.	O 0

FISH	O 0
studies	O 0
in	O 0
a	O 0
patient	O 0
with	O 0
sporadic	B-Disease 0
aniridia	I-Disease 0
and	O 0
t	O 0
(	O 0
7	O 0
;	O 0
11	O 0
)	O 0
(	O 0
q31	O 0
.	O 0
2	O 0
;	O 0
p13	O 0
)	O 0
.	O 0

A	O 0
2	O 0
year	O 0
old	O 0
female	O 0
presenting	O 0
with	O 0
bilateral	B-Disease 0
sporadic	I-Disease 0
aniridia	I-Disease 0
was	O 0
found	O 0
to	O 0
have	O 0
an	O 0
apparently	O 0
balanced	O 0
reciprocal	O 0
translocation	O 0
with	O 0
a	O 0
chromosome	O 0
11	O 0
breakpoint	O 0
within	O 0
band	O 0
p13	O 0
.	O 0

Fluorescence	O 0
in	O 0
situ	O 0
hybridisation	O 0
(	O 0
FISH	O 0
)	O 0
studies	O 0
with	O 0
distal	O 0
11p13	O 0
specific	O 0
cosmids	O 0
showed	O 0
that	O 0
the	O 0
chromosome	O 0
11	O 0
breakpoint	O 0
lay	O 0
between	O 0
the	O 0
aniridia	B-Disease 0
(	O 0
PAX6	O 0
)	O 0
locus	O 0
and	O 0
a	O 0
region	O 0
approximately	O 0
100	O 0
kb	O 0
distal	O 0
to	O 0
PAX6	O 0
defined	O 0
by	O 0
the	O 0
cosmid	O 0
FO2121	O 0
.	O 0

Although	O 0
this	O 0
patient	O 0
did	O 0
not	O 0
have	O 0
a	O 0
detectable	O 0
deletion	O 0
within	O 0
PAX6	O 0
,	O 0
her	O 0
aniridia	B-Disease 0
may	O 0
have	O 0
resulted	O 0
from	O 0
a	O 0
disruption	O 0
of	O 0
the	O 0
distal	O 0
chromatin	O 0
domain	O 0
containing	O 0
either	O 0
enhancers	O 0
or	O 0
regulators	O 0
for	O 0
PAX6	O 0
.	O 0

This	O 0
case	O 0
may	O 0
therefore	O 0
be	O 0
another	O 0
example	O 0
of	O 0
aniridia	B-Disease 0
caused	O 0
by	O 0
a	O 0
position	O 0
effect	O 0
as	O 0
recently	O 0
described	O 0
in	O 0
two	O 0
familial	B-Disease 0
aniridia	I-Disease 0
patients	O 0
in	O 0
which	O 0
the	O 0
phenotype	O 0
cosegregated	O 0
with	O 0
chromosome	B-Disease 0
abnormalities	I-Disease 0
with	O 0
11p13	O 0
breakpoints	O 0
.	O 0
.	O 0

Muscle	O 0
expression	O 0
of	O 0
glucose	B-Disease 0
-	I-Disease 0
6	I-Disease 0
-	I-Disease 0
phosphate	I-Disease 0
dehydrogenase	I-Disease 0
deficiency	I-Disease 0
in	O 0
different	O 0
variants	O 0
.	O 0

Muscle	O 0
expression	O 0
of	O 0
G6PD	B-Disease 0
deficiency	I-Disease 0
has	O 0
been	O 0
investigated	O 0
in	O 0
Mediterranean	O 0
,	O 0
Seattle	O 0
-	O 0
like	O 0
and	O 0
A	O 0
-	O 0
variants	O 0
.	O 0

G6PD	O 0
activity	O 0
was	O 0
detected	O 0
in	O 0
samples	O 0
obtained	O 0
from	O 0
biopsies	O 0
on	O 0
the	O 0
quadriceps	O 0
muscle	O 0
of	O 0
seven	O 0
males	O 0
and	O 0
one	O 0
female	O 0
.	O 0

The	O 0
type	O 0
of	O 0
genetic	O 0
variant	O 0
was	O 0
determined	O 0
by	O 0
molecular	O 0
analysis	O 0
of	O 0
DNA	O 0
,	O 0
extracted	O 0
from	O 0
blood	O 0
samples	O 0
.	O 0

All	O 0
variants	O 0
showed	O 0
the	O 0
enzyme	O 0
defect	O 0
in	O 0
muscle	O 0
.	O 0

A	O 0
statistically	O 0
significant	O 0
relationship	O 0
was	O 0
found	O 0
in	O 0
the	O 0
activity	O 0
of	O 0
G6PD	O 0
between	O 0
erythrocytes	O 0
and	O 0
muscle	O 0
of	O 0
the	O 0
male	O 0
subjects	O 0
(	O 0
r	O 0
=	O 0
0	O 0
.	O 0
968	O 0
;	O 0
p	O 0
=	O 0
0	O 0
.	O 0
00008	O 0
)	O 0
.	O 0

The	O 0
equation	O 0
for	O 0
the	O 0
best	O 0
fit	O 0
line	O 0
was	O 0
Y	O 0
=	O 0
0	O 0
.	O 0

390X	O 0
+	O 0
0	O 0
.	O 0

198	O 0
198	O 0
.	O 0

The	O 0
results	O 0
suggest	O 0
that	O 0
,	O 0
for	O 0
a	O 0
given	O 0
variant	O 0
,	O 0
the	O 0
extent	O 0
of	O 0
the	O 0
enzyme	O 0
defect	O 0
in	O 0
muscle	O 0
may	O 0
be	O 0
determined	O 0
,	O 0
using	O 0
this	O 0
equation	O 0
,	O 0
from	O 0
the	O 0
G6PD	O 0
activity	O 0
of	O 0
erythrocytes	O 0

Gene	O 0
therapy	O 0
for	O 0
phenylketonuria	B-Disease 0
.	O 0

Classical	O 0
phenylketonuria	B-Disease 0
(	O 0
PKU	B-Disease 0
)	O 0
is	O 0
an	O 0
autosomal	B-Disease 0
recessive	I-Disease 0
disorder	I-Disease 0
caused	O 0
by	O 0
a	O 0
deficiency	B-Disease 0
of	I-Disease 0
hepatic	I-Disease 0
phenylalanine	I-Disease 0
hydroxylase	I-Disease 0
(	O 0
PAH	O 0
)	O 0
.	O 0

Limitations	O 0
of	O 0
the	O 0
current	O 0
dietary	O 0
treatment	O 0
for	O 0
PKU	B-Disease 0
have	O 0
led	O 0
to	O 0
the	O 0
development	O 0
of	O 0
potential	O 0
treatments	O 0
based	O 0
on	O 0
somatic	O 0
gene	O 0
transfer	O 0
.	O 0

Three	O 0
different	O 0
vector	O 0
systems	O 0
have	O 0
been	O 0
examined	O 0
.	O 0

Vectors	O 0
derived	O 0
from	O 0
a	O 0
recombinant	O 0
retrovirus	O 0
or	O 0
a	O 0
DNA	O 0
/	O 0
protein	O 0
complex	O 0
can	O 0
efficiently	O 0
transduce	O 0
the	O 0
PAH	O 0
cDNA	O 0
into	O 0
PAH	B-Disease 0
-	I-Disease 0
deficient	I-Disease 0
hepatocytes	O 0
in	O 0
vitro	O 0
,	O 0
but	O 0
the	O 0
application	O 0
of	O 0
these	O 0
vector	O 0
systems	O 0
is	O 0
presently	O 0
limited	O 0
by	O 0
their	O 0
low	O 0
transduction	O 0
efficiency	O 0
in	O 0
vivo	O 0
.	O 0

In	O 0
contrast	O 0
,	O 0
a	O 0
vector	O 0
derived	O 0
from	O 0
a	O 0
recombinant	O 0
adenovirus	O 0
can	O 0
restore	O 0
10	O 0
%	O 0
-	O 0
80	O 0
%	O 0
of	O 0
normal	O 0
hepatic	O 0
PAH	O 0
activity	O 0
into	O 0
PAH	B-Disease 0
-	I-Disease 0
deficient	I-Disease 0
mice	O 0
,	O 0
which	O 0
completely	O 0
normalizes	O 0
serum	O 0
phenylalanine	O 0
levels	O 0
.	O 0

This	O 0
treatment	O 0
is	O 0
transient	O 0
and	O 0
cannot	O 0
be	O 0
effectively	O 0
re	O 0
-	O 0
administered	O 0
due	O 0
to	O 0
the	O 0
presence	O 0
of	O 0
neutralizing	O 0
antibodies	O 0
directed	O 0
against	O 0
the	O 0
recombinant	O 0
adenoviral	O 0
vector	O 0
.	O 0

However	O 0
,	O 0
these	O 0
findings	O 0
suggest	O 0
that	O 0
PKU	B-Disease 0
can	O 0
be	O 0
completely	O 0
corrected	O 0
by	O 0
somatic	O 0
gene	O 0
therapy	O 0
,	O 0
and	O 0
provide	O 0
some	O 0
direction	O 0
for	O 0
the	O 0
future	O 0
development	O 0
of	O 0
adenoviral	O 0
vectors	O 0
.	O 0
.	O 0

Exon	O 0
-	O 0
intron	O 0
structure	O 0
of	O 0
the	O 0
human	O 0
neuronal	O 0
nicotinic	O 0
acetylcholine	O 0
receptor	O 0
alpha	O 0
4	O 0
subunit	O 0
(	O 0
CHRNA4	O 0
)	O 0
.	O 0

The	O 0
human	O 0
neuronal	O 0
nicotinic	O 0
acetylcholine	O 0
receptor	O 0
alpha	O 0
4	O 0
subunit	O 0
gene	O 0
(	O 0
CHRNA4	O 0
)	O 0
is	O 0
located	O 0
in	O 0
the	O 0
candidate	O 0
region	O 0
for	O 0
three	O 0
different	O 0
phenotypes	O 0
benign	B-Disease 0
familial	I-Disease 0
neonatal	I-Disease 0
convulsions	I-Disease 0
,	O 0
autosomal	B-Disease 0
dominant	I-Disease 0
nocturnal	I-Disease 0
frontal	I-Disease 0
lobe	I-Disease 0
epilepsy	I-Disease 0
,	O 0
and	O 0
low	O 0
-	O 0
voltage	O 0
EEG	O 0
.	O 0

Recently	O 0
,	O 0
a	O 0
missense	O 0
mutation	O 0
in	O 0
transmembrane	O 0
domain	O 0
2	O 0
of	O 0
CHRNA4	O 0
was	O 0
found	O 0
to	O 0
be	O 0
associated	O 0
with	O 0
autosomal	B-Disease 0
dominant	I-Disease 0
nocturnal	I-Disease 0
frontal	I-Disease 0
lobe	I-Disease 0
epilepsy	I-Disease 0
in	O 0
one	O 0
extended	O 0
pedigree	O 0
.	O 0

We	O 0
have	O 0
determined	O 0
the	O 0
genomic	O 0
organization	O 0
of	O 0
CHRNA4	O 0
,	O 0
which	O 0
consists	O 0
of	O 0
six	O 0
exons	O 0
distributed	O 0
over	O 0
approximately	O 0
17	O 0
kb	O 0
of	O 0
genomic	O 0
DNA	O 0
.	O 0

The	O 0
nucleotide	O 0
sequence	O 0
obtained	O 0
from	O 0
the	O 0
genomic	O 0
regions	O 0
adjacent	O 0
to	O 0
the	O 0
exon	O 0
boundaries	O 0
enabled	O 0
us	O 0
to	O 0
develop	O 0
a	O 0
set	O 0
of	O 0
primer	O 0
pairs	O 0
for	O 0
PCR	O 0
amplification	O 0
of	O 0
the	O 0
complete	O 0
coding	O 0
region	O 0
.	O 0

The	O 0
sequence	O 0
analysis	O 0
provides	O 0
the	O 0
basis	O 0
for	O 0
a	O 0
comprehensive	O 0
mutation	O 0
screening	O 0
of	O 0
CHRNA4	O 0
in	O 0
the	O 0
above	O 0
-	O 0
mentioned	O 0
phenotypes	O 0
and	O 0
possibly	O 0
in	O 0
other	O 0
types	O 0
of	O 0
idiopathic	B-Disease 0
epilepsies	I-Disease 0
.	O 0
.	O 0

Ashkenazi	O 0
Jewish	O 0
population	O 0
frequencies	O 0
for	O 0
common	O 0
mutations	O 0
in	O 0
BRCA1	O 0
and	O 0
BRCA2	O 0
.	O 0

BRCA1	O 0
and	O 0
BRCA2	O 0
are	O 0
the	O 0
two	O 0
major	O 0
identified	O 0
causes	O 0
of	O 0
inherited	B-Disease 0
breast	I-Disease 0
cancer	I-Disease 0
,	O 0
with	O 0
mutations	O 0
in	O 0
either	O 0
gene	O 0
conferring	O 0
up	O 0
to	O 0
80	O 0
-	O 0
90	O 0
%	O 0
lifetime	O 0
risk	O 0
of	O 0
breast	B-Disease 0
cancer	I-Disease 0
in	O 0
carrier	O 0
females	O 0
.	O 0

Mutations	O 0
in	O 0
BRCA1	O 0
account	O 0
for	O 0
approximately	O 0
45	O 0
%	O 0
of	O 0
familial	B-Disease 0
breast	I-Disease 0
cancer	I-Disease 0
and	O 0
90	O 0
%	O 0
of	O 0
inherited	B-Disease 0
breast	I-Disease 0
/	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
,	O 0
whereas	O 0
mutations	O 0
in	O 0
BRCA2	O 0
account	O 0
for	O 0
a	O 0
comparable	O 0
percentage	O 0
of	O 0
inherited	B-Disease 0
breast	I-Disease 0
cancer	I-Disease 0
cases	O 0
.	O 0

Over	O 0
85	O 0
distinct	O 0
BRCA1	O 0
mutations	O 0
and	O 0
a	O 0
growing	O 0
list	O 0
of	O 0
BRCA2	O 0
mutations	O 0
have	O 0
been	O 0
identified	O 0
,	O 0
with	O 0
the	O 0
majority	O 0
resulting	O 0
in	O 0
protein	O 0
truncation	O 0
.	O 0

A	O 0
specific	O 0
BRCA1	O 0
mutation	O 0
,	O 0
185delAG	O 0
,	O 0
has	O 0
a	O 0
reported	O 0
increased	O 0
carrier	O 0
frequency	O 0
of	O 0
approximately	O 0
0	O 0
.	O 0

9	O 0
%	O 0
in	O 0
the	O 0
Ashkenazi	O 0
Jewish	O 0
population	O 0
,	O 0
but	O 0
is	O 0
also	O 0
found	O 0
in	O 0
rare	O 0
non	O 0
-	O 0
Jewish	O 0
patients	O 0
with	O 0
a	O 0
different	O 0
haplotype	O 0
.	O 0

The	O 0
6174delT	O 0
mutation	O 0
in	O 0
BRCA2	O 0
was	O 0
recently	O 0
identified	O 0
as	O 0
a	O 0
frequent	O 0
mutation	O 0
in	O 0
8	O 0
out	O 0
of	O 0
107	O 0
Ashkenazi	O 0
Jewish	O 0
women	O 0
diagnosed	O 0
with	O 0
breast	B-Disease 0
cancer	I-Disease 0
by	O 0
age	O 0
50	O 0
(	O 0
ref	O 0
.	O 0
8	O 0
)	O 0
,	O 0
as	O 0
well	O 0
as	O 0
in	O 0
three	O 0
Ashkenazi	O 0
male	B-Disease 0
breast	I-Disease 0
cancer	I-Disease 0
patients	O 0
.	O 0

We	O 0
have	O 0
conducted	O 0
a	O 0
large	O 0
-	O 0
scale	O 0
population	O 0
study	O 0
to	O 0
investigate	O 0
the	O 0
prevalence	O 0
of	O 0
specific	O 0
BRCA1	O 0
and	O 0
BRCA2	O 0
mutations	O 0
in	O 0
Ashkenazi	O 0
Jewish	O 0
individuals	O 0
who	O 0
were	O 0
unselected	O 0
for	O 0
breast	B-Disease 0
cancer	I-Disease 0
.	O 0

BRCA1	O 0
mutation	O 0
screening	O 0
on	O 0
approximately	O 0
3	O 0
,	O 0
000	O 0
Ashkenazi	O 0
Jewish	O 0
samples	O 0
determined	O 0
a	O 0
carrier	O 0
frequency	O 0
of	O 0
1	O 0
.	O 0

09	O 0
%	O 0
for	O 0
the	O 0
185delAG	O 0
mutation	O 0
and	O 0
0	O 0
.	O 0

13	O 0
%	O 0
for	O 0
the	O 0
5382insC	O 0
mutation	O 0
.	O 0

BRCA2	O 0
analysis	O 0
on	O 0
3	O 0
,	O 0
085	O 0
individuals	O 0
from	O 0
the	O 0
same	O 0
population	O 0
showed	O 0
a	O 0
carrier	O 0
frequency	O 0
of	O 0
1	O 0
.	O 0

52	O 0
%	O 0
for	O 0
the	O 0
6174delT	O 0
mutation	O 0
.	O 0

This	O 0
expanded	O 0
population	O 0
-	O 0
based	O 0
study	O 0
confirms	O 0
that	O 0
the	O 0
BRCA1	O 0
185delAG	O 0
mutation	O 0
and	O 0
the	O 0
BRCA2	O 0
6174delT	O 0
mutation	O 0
constitute	O 0
the	O 0
two	O 0
most	O 0
frequent	O 0
mutation	O 0
alleles	O 0
predisposing	O 0
to	O 0
hereditary	B-Disease 0
breast	I-Disease 0
cancer	I-Disease 0
among	O 0
the	O 0
Ashkenazim	O 0
,	O 0
and	O 0
suggests	O 0
a	O 0
relatively	O 0
lower	O 0
penetrance	O 0
for	O 0
the	O 0
6174delT	O 0
mutation	O 0
in	O 0
BRCA2	O 0

Dual	O 0
roles	O 0
of	O 0
ATM	O 0
in	O 0
the	O 0
cellular	O 0
response	O 0
to	O 0
radiation	O 0
and	O 0
in	O 0
cell	O 0
growth	O 0
control	O 0
.	O 0

The	O 0
gene	O 0
mutated	O 0
in	O 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
(	O 0
AT	B-Disease 0
)	O 0
patients	O 0
,	O 0
denoted	O 0
ATM	O 0
,	O 0
encodes	O 0
a	O 0
putative	O 0
protein	O 0
or	O 0
lipid	O 0
kinase	O 0
.	O 0

To	O 0
elucidate	O 0
the	O 0
functions	O 0
of	O 0
ATM	O 0
,	O 0
we	O 0
disrupted	O 0
the	O 0
mouse	O 0
ATM	O 0
gene	O 0
through	O 0
homologous	O 0
recombination	O 0
in	O 0
mice	O 0
.	O 0

Consistent	O 0
with	O 0
cellular	O 0
defects	O 0
of	O 0
AT	B-Disease 0
patients	O 0
,	O 0
the	O 0
ATM	O 0
-	O 0
/	O 0
-	O 0
cells	O 0
are	O 0
hypersensitive	O 0
to	O 0
gamma	O 0
-	O 0
irradiation	O 0
and	O 0
defective	O 0
in	O 0
cell	O 0
-	O 0
cycle	O 0
arrest	O 0
following	O 0
radiation	O 0
,	O 0
correlating	O 0
with	O 0
a	O 0
defective	O 0
up	O 0
-	O 0
regulation	O 0
of	O 0
p53	O 0
.	O 0

In	O 0
addition	O 0
,	O 0
ATM	O 0
-	O 0
/	O 0
-	O 0
mouse	O 0
thymocytes	O 0
are	O 0
more	O 0
resistant	O 0
to	O 0
apoptosis	O 0
induced	O 0
by	O 0
gamma	O 0
-	O 0
irradiation	O 0
than	O 0
normal	O 0
thymocytes	O 0
.	O 0

ATM	O 0
-	O 0
/	O 0
-	O 0
fibroblasts	O 0
are	O 0
inefficient	O 0
in	O 0
G1	O 0
to	O 0
S	O 0
-	O 0
phase	O 0
progression	O 0
following	O 0
serum	O 0
stimulation	O 0
and	O 0
senesce	O 0
after	O 0
only	O 0
a	O 0
few	O 0
passages	O 0
in	O 0
culture	O 0
.	O 0

They	O 0
have	O 0
an	O 0
increased	O 0
constitutive	O 0
level	O 0
of	O 0
p21CP1	O 0
/	O 0
WAF1	O 0
.	O 0

The	O 0
ATM	O 0
protein	O 0
is	O 0
therefore	O 0
critical	O 0
both	O 0
for	O 0
cellular	O 0
responses	O 0
to	O 0
ionizing	O 0
radiation	O 0
and	O 0
for	O 0
normal	O 0
cell	O 0
-	O 0
cycle	O 0
progression	O 0
.	O 0

ATM	O 0
+	O 0
/	O 0
-	O 0
fibroblasts	O 0
and	O 0
thymocytes	O 0
showed	O 0
intermediately	O 0
defective	O 0
responses	O 0
to	O 0
irradiation	O 0
but	O 0
no	O 0
growth	O 0
defect	O 0
,	O 0
suggesting	O 0
that	O 0
the	O 0
increased	O 0
cancer	B-Disease 0
risk	O 0
of	O 0
AT	B-Disease 0
heterozygotes	O 0
could	O 0
be	O 0
attributable	O 0
to	O 0
poor	O 0
checkpoint	O 0
function	O 0
.	O 0
.	O 0

Targeted	O 0
disruption	O 0
of	O 0
ATM	O 0
leads	O 0
to	O 0
growth	B-Disease 0
retardation	I-Disease 0
,	O 0
chromosomal	B-Disease 0
fragmentation	I-Disease 0
during	I-Disease 0
meiosis	I-Disease 0
,	O 0
immune	B-Disease 0
defects	I-Disease 0
,	O 0
and	O 0
thymic	B-Disease 0
lymphoma	I-Disease 0
.	O 0

ATM	O 0
,	O 0
the	O 0
gene	O 0
mutated	O 0
in	O 0
the	O 0
inherited	B-Disease 0
human	I-Disease 0
disease	I-Disease 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
,	O 0
is	O 0
a	O 0
member	O 0
of	O 0
a	O 0
family	O 0
of	O 0
kinases	O 0
involved	O 0
in	O 0
DNA	O 0
metabolism	O 0
and	O 0
cell	O 0
-	O 0
cycle	O 0
checkpoint	O 0
control	O 0
.	O 0

To	O 0
help	O 0
clarify	O 0
the	O 0
physiological	O 0
roles	O 0
of	O 0
the	O 0
ATM	O 0
protein	O 0
,	O 0
we	O 0
disrupted	O 0
the	O 0
ATM	O 0
gene	O 0
in	O 0
mice	O 0
through	O 0
homologous	O 0
recombination	O 0
.	O 0

Initial	O 0
evaluation	O 0
of	O 0
the	O 0
ATM	O 0
knockout	O 0
animals	O 0
indicates	O 0
that	O 0
inactivation	O 0
of	O 0
the	O 0
mouse	O 0
ATM	O 0
gene	O 0
recreates	O 0
much	O 0
of	O 0
the	O 0
phenotype	O 0
of	O 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
.	O 0

The	O 0
homozygous	O 0
mutant	O 0
(	O 0
ATM	O 0
-	O 0
/	O 0
-	O 0
)	O 0
mice	O 0
are	O 0
viable	O 0
,	O 0
growth	O 0
-	O 0
retarded	O 0
,	O 0
and	O 0
infertile	O 0
.	O 0

The	O 0
infertility	B-Disease 0
of	O 0
ATM	O 0
-	O 0
/	O 0
-	O 0
mice	O 0
results	O 0
from	O 0
meiotic	O 0
failure	O 0
.	O 0

Meiosis	O 0
is	O 0
arrested	O 0
at	O 0
the	O 0
zygotene	O 0
/	O 0
pachytene	O 0
stage	O 0
of	O 0
prophase	O 0
I	O 0
as	O 0
a	O 0
result	O 0
of	O 0
abnormal	O 0
chromosomal	O 0
synapsis	O 0
and	O 0
subsequent	O 0
chromosome	O 0
fragmentation	O 0
.	O 0

Immune	B-Disease 0
defects	I-Disease 0
also	O 0
are	O 0
evident	O 0
in	O 0
ATM	O 0
-	O 0
/	O 0
-	O 0
mice	O 0
,	O 0
including	O 0
reduced	O 0
numbers	O 0
of	O 0
B220	O 0
+	O 0
CD43	O 0
-	O 0
pre	O 0
-	O 0
B	O 0
cells	O 0
,	O 0
thymocytes	O 0
,	O 0
and	O 0
peripheral	O 0
T	O 0
cells	O 0
,	O 0
as	O 0
well	O 0
as	O 0
functional	O 0
impairment	O 0
of	O 0
T	O 0
-	O 0
cell	O 0
-	O 0
dependent	O 0
immune	O 0
responses	O 0
.	O 0

The	O 0
cerebella	O 0
of	O 0
ATM	O 0
-	O 0
/	O 0
-	O 0
mice	O 0
appear	O 0
normal	O 0
by	O 0
histologic	O 0
examination	O 0
at	O 0
3	O 0
to	O 0
4	O 0
months	O 0
and	O 0
the	O 0
mice	O 0
have	O 0
no	O 0
gross	O 0
behavioral	B-Disease 0
abnormalities	I-Disease 0
.	O 0

The	O 0
majority	O 0
of	O 0
mutant	O 0
mice	O 0
rapidly	O 0
develop	O 0
thymic	B-Disease 0
lymphomas	I-Disease 0
and	O 0
die	O 0
before	O 0
4	O 0
months	O 0
of	O 0
age	O 0
.	O 0

These	O 0
findings	O 0
indicate	O 0
that	O 0
the	O 0
ATM	O 0
gene	O 0
product	O 0
plays	O 0
an	O 0
essential	O 0
role	O 0
in	O 0
a	O 0
diverse	O 0
group	O 0
of	O 0
cellular	O 0
processes	O 0
,	O 0
including	O 0
meiosis	O 0
,	O 0
the	O 0
normal	O 0
growth	O 0
of	O 0
somatic	O 0
tissues	O 0
,	O 0
immune	O 0
development	O 0
,	O 0
and	O 0
tumor	B-Disease 0
suppression	O 0
.	O 0
.	O 0

Cloning	O 0
and	O 0
characterization	O 0
of	O 0
human	O 0
very	O 0
-	O 0
long	O 0
-	O 0
chain	O 0
acyl	O 0
-	O 0
CoA	O 0
dehydrogenase	O 0
cDNA	O 0
,	O 0
chromosomal	O 0
assignment	O 0
of	O 0
the	O 0
gene	O 0
and	O 0
identification	O 0
in	O 0
four	O 0
patients	O 0
of	O 0
nine	O 0
different	O 0
mutations	O 0
within	O 0
the	O 0
VLCAD	O 0
gene	O 0
.	O 0

Very	O 0
-	O 0
long	O 0
-	O 0
chain	O 0
acyl	O 0
-	O 0
CoA	O 0
dehydrogenase	O 0
(	O 0
VLCAD	O 0
)	O 0
is	O 0
one	O 0
of	O 0
four	O 0
straight	O 0
-	O 0
chain	O 0
acyl	O 0
-	O 0
CoA	O 0
dehydrogenase	O 0
(	O 0
ACD	O 0
)	O 0
enzymes	O 0
,	O 0
which	O 0
are	O 0
all	O 0
nuclear	O 0
encoded	O 0
mitochondrial	O 0
flavoproteins	O 0
catalyzing	O 0
the	O 0
initial	O 0
step	O 0
in	O 0
fatty	O 0
acid	O 0
beta	O 0
-	O 0
oxidation	O 0
.	O 0

We	O 0
have	O 0
used	O 0
the	O 0
very	O 0
fast	O 0
,	O 0
Rapid	O 0
Amplification	O 0
of	O 0
cDNA	O 0
Ends	O 0
(	O 0
RACE	O 0
)	O 0
based	O 0
strategy	O 0
to	O 0
obtain	O 0
the	O 0
sequence	O 0
of	O 0
cDNAs	O 0
encoding	O 0
human	O 0
VLCAD	O 0
from	O 0
placenta	O 0
and	O 0
fibroblasts	O 0
.	O 0

Alignment	O 0
of	O 0
the	O 0
predicted	O 0
amino	O 0
acid	O 0
sequence	O 0
of	O 0
human	O 0
VLCAD	O 0
with	O 0
those	O 0
of	O 0
the	O 0
other	O 0
human	O 0
ACD	O 0
enzymes	O 0
revealed	O 0
extensive	O 0
sequence	O 0
homology	O 0
.	O 0

Moreover	O 0
,	O 0
human	O 0
VLCAD	O 0
and	O 0
human	O 0
acyl	O 0
-	O 0
CoA	O 0
oxidase	O 0
showed	O 0
extensive	O 0
sequence	O 0
homology	O 0
corroborating	O 0
the	O 0
notion	O 0
that	O 0
these	O 0
genes	O 0
are	O 0
evolutionarily	O 0
related	O 0
.	O 0

Southern	O 0
blot	O 0
analysis	O 0
of	O 0
genomic	O 0
DNA	O 0
from	O 0
hybrid	O 0
cell	O 0
lines	O 0
was	O 0
used	O 0
to	O 0
localize	O 0
the	O 0
VLCAD	O 0
gene	O 0
to	O 0
human	O 0
chromosome	O 0
17p11	O 0
.	O 0

2	O 0
-	O 0
p11	O 0
.	O 0

13105	O 0
.	O 0

Using	O 0
Northern	O 0
and	O 0
Western	O 0
blot	O 0
analysis	O 0
to	O 0
investigate	O 0
the	O 0
tissue	O 0
specific	O 0
distribution	O 0
of	O 0
VLCAD	O 0
mRNA	O 0
and	O 0
protein	O 0
in	O 0
several	O 0
human	O 0
tissues	O 0
we	O 0
showed	O 0
that	O 0
VLCAD	O 0
is	O 0
most	O 0
abundant	O 0
in	O 0
heart	O 0
and	O 0
skeletal	O 0
muscle	O 0
.	O 0

This	O 0
agrees	O 0
well	O 0
with	O 0
the	O 0
fact	O 0
that	O 0
cardiac	O 0
and	O 0
muscle	O 0
symptoms	O 0
are	O 0
characteristic	O 0
for	O 0
patients	O 0
with	O 0
VLCAD	B-Disease 0
deficiency	I-Disease 0
.	O 0

Northern	O 0
blot	O 0
analysis	O 0
and	O 0
sequencing	O 0
of	O 0
cloned	O 0
PCR	O 0
amplified	O 0
VLCAD	O 0
cDNA	O 0
from	O 0
four	O 0
unrelated	O 0
patients	O 0
with	O 0
VLCAD	B-Disease 0
deficiency	I-Disease 0
showed	O 0
that	O 0
VLCAD	O 0
mRNA	O 0
was	O 0
undetectable	O 0
in	O 0
one	O 0
patient	O 0
and	O 0
that	O 0
the	O 0
other	O 0
three	O 0
have	O 0
mutations	O 0
in	O 0
both	O 0
VLCAD	O 0
alleles	O 0
.	O 0

Western	O 0
blot	O 0
analysis	O 0
of	O 0
patient	O 0
fibroblasts	O 0
showed	O 0
that	O 0
the	O 0
identified	O 0
mutations	O 0
result	O 0
in	O 0
severely	O 0
reduced	O 0
amounts	O 0
of	O 0
VLCAD	O 0
protein	O 0
.	O 0

Molecular	O 0
bases	O 0
of	O 0
combined	B-Disease 0
subtotal	I-Disease 0
deficiencies	I-Disease 0
of	I-Disease 0
C6	I-Disease 0
and	I-Disease 0
C7	I-Disease 0
:	O 0
their	O 0
effects	O 0
in	O 0
combination	O 0
with	O 0
other	O 0
C6	B-Disease 0
and	I-Disease 0
C7	I-Disease 0
deficiencies	I-Disease 0
.	O 0

Combined	B-Disease 0
subtotal	I-Disease 0
deficiency	I-Disease 0
of	I-Disease 0
C6	I-Disease 0
and	I-Disease 0
C7	I-Disease 0
,	O 0
in	O 0
which	O 0
both	O 0
proteins	O 0
are	O 0
expressed	O 0
at	O 0
very	O 0
low	O 0
levels	O 0
,	O 0
has	O 0
been	O 0
observed	O 0
in	O 0
homozygous	O 0
form	O 0
in	O 0
two	O 0
families	O 0
.	O 0

A	O 0
defect	O 0
at	O 0
the	O 0
5	O 0
splice	O 0
donor	O 0
site	O 0
of	O 0
intron	O 0
15	O 0
of	O 0
the	O 0
C6	O 0
gene	O 0
explains	O 0
the	O 0
low	O 0
molecular	O 0
weight	O 0
of	O 0
the	O 0
C6	O 0
protein	O 0
and	O 0
is	O 0
probably	O 0
responsible	O 0
for	O 0
its	O 0
low	O 0
expressed	O 0
concentration	O 0
.	O 0

The	O 0
C7	O 0
defect	O 0
is	O 0
more	O 0
enigmatic	O 0
the	O 0
protein	O 0
is	O 0
of	O 0
normal	O 0
molecular	O 0
weight	O 0
,	O 0
low	O 0
circulating	O 0
concentration	O 0
,	O 0
and	O 0
altered	O 0
isoelectric	O 0
point	O 0
.	O 0

An	O 0
Arg	O 0
>	O 0
Ser	O 0
codon	O 0
substitution	O 0
in	O 0
exon	O 0
11	O 0
is	O 0
the	O 0
only	O 0
molecular	O 0
alteration	O 0
within	O 0
the	O 0
mature	O 0
C7	O 0
protein	O 0
.	O 0

These	O 0
defects	O 0
are	O 0
associated	O 0
with	O 0
a	O 0
characteristic	O 0
set	O 0
of	O 0
polymorphic	O 0
DNA	O 0
markers	O 0
in	O 0
the	O 0
C6	O 0
/	O 0
C7	O 0
region	O 0
,	O 0
forming	O 0
a	O 0
distinct	O 0
haplotype	O 0
.	O 0

The	O 0
haplotype	O 0
has	O 0
been	O 0
found	O 0
in	O 0
combination	O 0
with	O 0
a	O 0
number	O 0
of	O 0
other	O 0
haplotypes	O 0
containing	O 0
defective	O 0
genes	O 0
that	O 0
lead	O 0
either	O 0
to	O 0
C6	B-Disease 0
or	I-Disease 0
C7	I-Disease 0
deficiency	I-Disease 0
,	O 0
but	O 0
with	O 0
different	O 0
consequences	O 0
.	O 0

Where	O 0
it	O 0
is	O 0
combined	O 0
with	O 0
a	O 0
C6	B-Disease 0
-	I-Disease 0
deficient	I-Disease 0
gene	O 0
,	O 0
the	O 0
serum	O 0
C7	O 0
levels	O 0
can	O 0
be	O 0
surprisingly	O 0
high	O 0
,	O 0
possibly	O 0
because	O 0
there	O 0
is	O 0
no	O 0
C6	O 0
generating	O 0
C56	O 0
to	O 0
consume	O 0
the	O 0
C7	O 0
.	O 0

In	O 0
contrast	O 0
,	O 0
where	O 0
the	O 0
C7	O 0
genes	O 0
are	O 0
both	O 0
defective	O 0
(	O 0
but	O 0
still	O 0
partially	O 0
functional	O 0
)	O 0
,	O 0
there	O 0
may	O 0
be	O 0
a	O 0
profound	O 0
deficit	O 0
of	O 0
circulating	O 0
C7	O 0
because	O 0
there	O 0
is	O 0
ample	O 0
C6	O 0
to	O 0
produce	O 0
C56	O 0
and	O 0
consume	O 0
the	O 0
already	O 0
small	O 0
amount	O 0
of	O 0
C7	O 0
.	O 0

Each	O 0
molecular	O 0
defect	O 0
has	O 0
also	O 0
been	O 0
found	O 0
in	O 0
isolation	O 0
and	O 0
has	O 0
the	O 0
expected	O 0
effect	O 0
.	O 0
.	O 0

Genetic	O 0
bases	O 0
of	O 0
human	O 0
complement	B-Disease 0
C7	I-Disease 0
deficiency	I-Disease 0
.	O 0

Complement	B-Disease 0
C7	I-Disease 0
deficiency	I-Disease 0
(	O 0
C7D	B-Disease 0
)	O 0
is	O 0
associated	O 0
frequently	O 0
with	O 0
recurrent	O 0
bacterial	B-Disease 0
infections	I-Disease 0
,	O 0
especially	O 0
meningitis	B-Disease 0
caused	O 0
by	O 0
Neisseria	B-Disease 0
meningitidis	I-Disease 0
.	O 0

We	O 0
report	O 0
in	O 0
this	O 0
work	O 0
the	O 0
molecular	O 0
bases	O 0
of	O 0
C7D	B-Disease 0
in	O 0
two	O 0
unrelated	O 0
Japanese	O 0
males	O 0
.	O 0

We	O 0
used	O 0
exon	O 0
-	O 0
specific	O 0
PCR	O 0
/	O 0
single	O 0
-	O 0
strand	O 0
conformation	O 0
polymorphism	O 0
analysis	O 0
as	O 0
a	O 0
screening	O 0
step	O 0
for	O 0
mutations	O 0
.	O 0

Subsequent	O 0
direct	O 0
sequencing	O 0
of	O 0
the	O 0
target	O 0
exons	O 0
identified	O 0
homozygous	O 0
mutations	O 0
in	O 0
exon	O 0
16	O 0
of	O 0
case	O 0
1	O 0
and	O 0
in	O 0
exon	O 0
15	O 0
of	O 0
case	O 0
2	O 0
.	O 0

The	O 0
mutation	O 0
of	O 0
case	O 0
1	O 0
was	O 0
a	O 0
homozygous	O 0
T	O 0
to	O 0
A	O 0
transversion	O 0
at	O 0
nucleotide	O 0
2250	O 0
,	O 0
the	O 0
third	O 0
nucleotide	O 0
of	O 0
the	O 0
codon	O 0
TGT	O 0
for	O 0
Cys728	O 0
,	O 0
leading	O 0
to	O 0
a	O 0
stop	O 0
codon	O 0
TGA	O 0
(	O 0
C728X	O 0
)	O 0
.	O 0

In	O 0
case	O 0
2	O 0
,	O 0
a	O 0
homozygous	O 0
2	O 0
-	O 0
bp	O 0
deletion	O 0
(	O 0
2137delTG	O 0
/	O 0
2138delGT	O 0
/	O 0
2139delTG	O 0
)	O 0
caused	O 0
a	O 0
frameshift	O 0
,	O 0
generating	O 0
a	O 0
premature	O 0
termination	O 0
codon	O 0
4	O 0
to	O 0
6	O 0
nucleotides	O 0
downstream	O 0
.	O 0

Family	O 0
study	O 0
in	O 0
case	O 0
1	O 0
confirmed	O 0
the	O 0
genetic	O 0
nature	O 0
of	O 0
the	O 0
defect	O 0
.	O 0

Moreover	O 0
,	O 0
we	O 0
detected	O 0
a	O 0
novel	O 0
polymorphism	O 0
in	O 0
intron	O 0
11	O 0
that	O 0
presumably	O 0
is	O 0
linked	O 0
to	O 0
the	O 0
mutation	O 0
responsible	O 0
for	O 0
C7D	B-Disease 0
in	O 0
case	O 0
1	O 0
.	O 0

Our	O 0
results	O 0
indicate	O 0
that	O 0
the	O 0
pathogenesis	O 0
of	O 0
C7D	B-Disease 0
is	O 0
heterogeneous	O 0
like	O 0
most	O 0
of	O 0
the	O 0
other	O 0
deficiencies	B-Disease 0
of	I-Disease 0
complement	I-Disease 0
components	I-Disease 0
.	O 0
.	O 0

HPRT	B-Disease 0
-	I-Disease 0
APRT	I-Disease 0
-	I-Disease 0
deficient	I-Disease 0
mice	O 0
are	O 0
not	O 0
a	O 0
model	O 0
for	O 0
lesch	B-Disease 0
-	I-Disease 0
nyhan	I-Disease 0
syndrome	I-Disease 0
.	O 0

Complete	B-Disease 0
hypoxanthine	I-Disease 0
-	I-Disease 0
guanine	I-Disease 0
phosphoribosyl	I-Disease 0
-	I-Disease 0
transferase	I-Disease 0
(	I-Disease 0
HPRT	I-Disease 0
)	I-Disease 0
deficiency	I-Disease 0
in	O 0
humans	O 0
results	O 0
in	O 0
the	O 0
Lesch	B-Disease 0
-	I-Disease 0
Nyhan	I-Disease 0
syndrome	I-Disease 0
which	O 0
is	O 0
characterized	O 0
,	O 0
among	O 0
other	O 0
features	O 0
,	O 0
by	O 0
compulsive	O 0
self	O 0
-	O 0
injurious	O 0
behavior	O 0
.	O 0

HPRT	B-Disease 0
-	I-Disease 0
deficient	I-Disease 0
mice	O 0
generated	O 0
using	O 0
mouse	O 0
embryonic	O 0
stem	O 0
cells	O 0
exhibit	O 0
none	O 0
of	O 0
the	O 0
behavioral	O 0
symptoms	O 0
associated	O 0
with	O 0
the	O 0
Lesch	B-Disease 0
-	I-Disease 0
Nyhan	I-Disease 0
syndrome	I-Disease 0
.	O 0

Administration	O 0
of	O 0
drugs	O 0
that	O 0
inhibit	O 0
adenine	O 0
phosphoribosyltransferase	O 0
(	O 0
APRT	O 0
)	O 0
in	O 0
HPRT	B-Disease 0
-	I-Disease 0
deficient	I-Disease 0
mice	O 0
has	O 0
produced	O 0
the	O 0
suggestion	O 0
that	O 0
deficiency	B-Disease 0
of	I-Disease 0
APRT	I-Disease 0
in	O 0
combination	O 0
with	O 0
HPRT	B-Disease 0
-	I-Disease 0
deficiency	I-Disease 0
in	O 0
mice	O 0
may	O 0
lead	O 0
to	O 0
self	O 0
-	O 0
mutilation	O 0
behavior	O 0
[	O 0
C	O 0
.	O 0
L	O 0
.	O 0
Wu	O 0
and	O 0
D	O 0
.	O 0
W	O 0
.	O 0
Melton	O 0
(	O 0
1993	O 0
)	O 0
Nature	O 0
Genet	O 0
.	O 0
3	O 0
,	O 0
235	O 0
-	O 0
240	O 0
]	O 0
.	O 0

To	O 0
test	O 0
this	O 0
proposition	O 0
,	O 0
we	O 0
bred	O 0
HPRT	B-Disease 0
-	I-Disease 0
APRT	I-Disease 0
-	I-Disease 0
deficient	I-Disease 0
mice	O 0
.	O 0

Although	O 0
the	O 0
doubly	O 0
-	O 0
deficient	O 0
mice	O 0
excrete	O 0
adenine	O 0
and	O 0
its	O 0
highly	O 0
insoluble	O 0
derivative	O 0
,	O 0
2	O 0
,	O 0
8	O 0
-	O 0
dihydroxyadenine	O 0
,	O 0
which	O 0
are	O 0
also	O 0
associated	O 0
with	O 0
human	O 0
APRT	B-Disease 0
deficiency	I-Disease 0
,	O 0
additional	O 0
abnormalities	O 0
or	O 0
any	O 0
self	O 0
-	O 0
injurious	O 0
behavior	O 0
were	O 0
not	O 0
detected	O 0
.	O 0

Thus	O 0
,	O 0
APRT	B-Disease 0
-	I-Disease 0
HPRT	I-Disease 0
-	I-Disease 0
deficient	I-Disease 0
mice	O 0
,	O 0
which	O 0
are	O 0
devoid	O 0
of	O 0
any	O 0
purine	O 0
salvage	O 0
pathways	O 0
,	O 0
show	O 0
no	O 0
novel	O 0
phenotype	O 0
and	O 0
are	O 0
not	O 0
a	O 0
model	O 0
for	O 0
the	O 0
behavioral	B-Disease 0
abnormalities	I-Disease 0
associated	O 0
with	O 0
the	O 0
Lesch	B-Disease 0
-	I-Disease 0
Nyhan	I-Disease 0
syndrome	I-Disease 0
as	O 0
previously	O 0
suggested	O 0

Somatic	O 0
alterations	O 0
of	O 0
the	O 0
DPC4	O 0
gene	O 0
in	O 0
human	O 0
colorectal	B-Disease 0
cancers	I-Disease 0
in	O 0
vivo	O 0
.	O 0

BACKGROUND	O 0
&	O 0
AIMS	O 0
The	O 0
chromosome	O 0
region	O 0
18q21	O 0
has	O 0
been	O 0
shown	O 0
to	O 0
be	O 0
frequently	O 0
deleted	O 0
in	O 0
colorectal	B-Disease 0
cancers	I-Disease 0
,	O 0
and	O 0
such	O 0
frequent	O 0
allelic	O 0
loss	O 0
is	O 0
a	O 0
hallmark	O 0
of	O 0
the	O 0
presence	O 0
of	O 0
a	O 0
tumor	O 0
-	O 0
suppressor	O 0
gene	O 0
.	O 0

The	O 0
DPC4	O 0
gene	O 0
,	O 0
which	O 0
is	O 0
located	O 0
at	O 0
18q21	O 0
,	O 0
has	O 0
been	O 0
identified	O 0
as	O 0
a	O 0
tumor	O 0
-	O 0
suppressor	O 0
gene	O 0
from	O 0
examination	O 0
of	O 0
pancreatic	B-Disease 0
cancers	I-Disease 0
.	O 0

The	O 0
aim	O 0
of	O 0
the	O 0
present	O 0
study	O 0
was	O 0
to	O 0
determine	O 0
if	O 0
it	O 0
might	O 0
also	O 0
be	O 0
altered	O 0
in	O 0
colorectal	B-Disease 0
cancers	I-Disease 0
.	O 0

METHODS	O 0
Mutation	O 0
analyses	O 0
of	O 0
the	O 0
DPC4	O 0
gene	O 0
were	O 0
performed	O 0
on	O 0
complementary	O 0
DNA	O 0
samples	O 0
from	O 0
31	O 0
primary	O 0
colorectal	B-Disease 0
cancer	I-Disease 0
specimens	O 0
using	O 0
a	O 0
combination	O 0
of	O 0
polymerase	O 0
chain	O 0
reaction	O 0
,	O 0
single	O 0
-	O 0
strand	O 0
conformation	O 0
polymorphism	O 0
,	O 0
and	O 0
DNA	O 0
sequencing	O 0
.	O 0

RESULTS	O 0
Four	O 0
missense	O 0
mutations	O 0
producing	O 0
amino	O 0
acid	O 0
substitutions	O 0
and	O 0
a	O 0
somatic	O 0
12	O 0
-	O 0
base	O 0
pair	O 0
deletion	O 0
in	O 0
the	O 0
coding	O 0
region	O 0
of	O 0
the	O 0
DPC4	O 0
gene	O 0
were	O 0
detected	O 0
in	O 0
the	O 0
31	O 0
cancers	B-Disease 0
(	O 0
16	O 0
%	O 0
;	O 0
5	O 0
of	O 0
31	O 0
)	O 0
.	O 0

CONCLUSIONS	O 0
The	O 0
DPC4	O 0
gene	O 0
may	O 0
play	O 0
a	O 0
role	O 0
as	O 0
a	O 0
tumor	O 0
-	O 0
suppressor	O 0
gene	O 0
in	O 0
a	O 0
fraction	O 0
of	O 0
colorectal	B-Disease 0
cancers	I-Disease 0
;	O 0
however	O 0
,	O 0
while	O 0
allelic	O 0
loss	O 0
at	O 0
18q21	O 0
is	O 0
very	O 0
often	O 0
seen	O 0
in	O 0
colorectal	B-Disease 0
cancers	I-Disease 0
,	O 0
only	O 0
a	O 0
minority	O 0
show	O 0
DPC4	O 0
mutations	O 0
,	O 0
suggesting	O 0
that	O 0
there	O 0
might	O 0
be	O 0
another	O 0
tumor	O 0
-	O 0
suppressor	O 0
gene	O 0
in	O 0
this	O 0
chromosome	O 0
region	O 0
.	O 0
.	O 0

Pleiotropic	O 0
defects	O 0
in	O 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
protein	O 0
-	O 0
deficient	O 0
mice	O 0
.	O 0

We	O 0
have	O 0
generated	O 0
a	O 0
mouse	O 0
model	O 0
for	O 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
by	O 0
using	O 0
gene	O 0
targeting	O 0
to	O 0
generate	O 0
mice	O 0
that	O 0
do	O 0
not	O 0
express	O 0
the	O 0
Atm	O 0
protein	O 0
.	O 0

Atm	O 0
-	O 0
deficient	O 0
mice	O 0
are	O 0
retarded	O 0
in	O 0
growth	O 0
,	O 0
do	O 0
not	O 0
produce	O 0
mature	O 0
sperm	O 0
,	O 0
and	O 0
exhibit	O 0
severe	O 0
defects	O 0
in	O 0
T	O 0
cell	O 0
maturation	O 0
while	O 0
going	O 0
on	O 0
to	O 0
develop	O 0
thymomas	B-Disease 0
.	O 0

Atm	O 0
-	O 0
deficient	O 0
fibroblasts	O 0
grow	O 0
poorly	O 0
in	O 0
culture	O 0
and	O 0
display	O 0
a	O 0
high	O 0
level	O 0
of	O 0
double	O 0
-	O 0
stranded	O 0
chromosome	O 0
breaks	O 0
.	O 0

Atm	O 0
-	O 0
deficient	O 0
thymocytes	O 0
undergo	O 0
spontaneous	O 0
apoptosis	O 0
in	O 0
vitro	O 0
significantly	O 0
more	O 0
than	O 0
controls	O 0
.	O 0

Atm	O 0
-	O 0
deficient	O 0
mice	O 0
then	O 0
exhibit	O 0
many	O 0
of	O 0
the	O 0
same	O 0
symptoms	O 0
found	O 0
in	O 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
patients	O 0
and	O 0
in	O 0
cells	O 0
derived	O 0
from	O 0
them	O 0
.	O 0

Furthermore	O 0
,	O 0
we	O 0
demonstrate	O 0
that	O 0
the	O 0
Atm	O 0
protein	O 0
exists	O 0
as	O 0
two	O 0
discrete	O 0
molecular	O 0
species	O 0
,	O 0
and	O 0
that	O 0
loss	O 0
of	O 0
one	O 0
or	O 0
of	O 0
both	O 0
of	O 0
these	O 0
can	O 0
lead	O 0
to	O 0
the	O 0
development	O 0
of	O 0
the	O 0
disease	O 0
.	O 0
.	O 0

The	O 0
DCC	O 0
protein	O 0
and	O 0
prognosis	O 0
in	O 0
colorectal	B-Disease 0
cancer	I-Disease 0
.	O 0

BACKGROUND	O 0
Allelic	O 0
loss	O 0
of	O 0
chromosome	O 0
18q	O 0
predicts	O 0
a	O 0
poor	O 0
outcome	O 0
in	O 0
patients	O 0
with	O 0
stage	B-Disease 0
II	I-Disease 0
colorectal	I-Disease 0
cancer	I-Disease 0
.	O 0

Although	O 0
the	O 0
specific	O 0
gene	O 0
inactivated	O 0
by	O 0
this	O 0
allelic	O 0
loss	O 0
has	O 0
not	O 0
been	O 0
elucidated	O 0
,	O 0
the	O 0
DCC	O 0
(	O 0
deleted	O 0
in	O 0
colorectal	B-Disease 0
cancer	I-Disease 0
)	O 0
gene	O 0
is	O 0
a	O 0
candidate	O 0
.	O 0

We	O 0
investigated	O 0
whether	O 0
the	O 0
expression	O 0
of	O 0
the	O 0
DCC	O 0
protein	O 0
in	O 0
tumor	B-Disease 0
cells	O 0
is	O 0
a	O 0
prognostic	O 0
marker	O 0
in	O 0
colorectal	B-Disease 0
carcinoma	I-Disease 0
.	O 0

METHODS	O 0
The	O 0
expression	O 0
of	O 0
DCC	O 0
was	O 0
evaluated	O 0
immunohistochemically	O 0
in	O 0
132	O 0
paraffin	O 0
-	O 0
embedded	O 0
samples	O 0
from	O 0
patients	O 0
with	O 0
curatively	O 0
resected	O 0
stage	B-Disease 0
II	I-Disease 0
and	I-Disease 0
III	I-Disease 0
colorectal	I-Disease 0
carcinomas	I-Disease 0
.	O 0

The	O 0
Cox	O 0
proportional	O 0
-	O 0
hazards	O 0
model	O 0
was	O 0
used	O 0
to	O 0
adjust	O 0
for	O 0
covariates	O 0
including	O 0
age	O 0
,	O 0
sex	O 0
,	O 0
tumor	B-Disease 0
site	O 0
,	O 0
degree	O 0
of	O 0
tumor	B-Disease 0
differentiation	O 0
,	O 0
and	O 0
use	O 0
of	O 0
adjuvant	O 0
therapy	O 0
.	O 0

RESULTS	O 0
The	O 0
expression	O 0
of	O 0
DCC	O 0
was	O 0
a	O 0
strong	O 0
positive	O 0
predictive	O 0
factor	O 0
for	O 0
survival	O 0
in	O 0
both	O 0
stage	B-Disease 0
II	I-Disease 0
and	I-Disease 0
stage	I-Disease 0
III	I-Disease 0
colorectal	I-Disease 0
carcinomas	I-Disease 0
.	O 0

In	O 0
patients	O 0
with	O 0
stage	O 0
II	O 0
disease	O 0
whose	O 0
tumors	B-Disease 0
expressed	O 0
DCC	O 0
,	O 0
the	O 0
five	O 0
-	O 0
year	O 0
survival	O 0
rate	O 0
was	O 0
94	O 0
.	O 0

3	O 0
percent	O 0
,	O 0
whereas	O 0
in	O 0
patients	O 0
with	O 0
DCC	B-Disease 0
-	I-Disease 0
negative	I-Disease 0
tumors	I-Disease 0
,	O 0
the	O 0
survival	O 0
rate	O 0
was	O 0
61	O 0
.	O 0

6	O 0
percent	O 0
(	O 0
P	O 0
<	O 0
0	O 0
.	O 0
001	O 0
)	O 0
.	O 0

In	O 0
patients	O 0
with	O 0
stage	B-Disease 0
III	I-Disease 0
disease	I-Disease 0
,	O 0
the	O 0
respective	O 0
survival	O 0
rates	O 0
were	O 0
59	O 0
.	O 0

3	O 0
percent	O 0
and	O 0
33	O 0
.	O 0

2	O 0
percent	O 0
(	O 0
P	O 0
=	O 0
0	O 0
.	O 0
03	O 0
)	O 0
.	O 0

CONCLUSIONS	O 0
DCC	O 0
is	O 0
a	O 0
prognostic	O 0
marker	O 0
in	O 0
patients	O 0
with	O 0
stage	B-Disease 0
II	I-Disease 0
or	I-Disease 0
stage	I-Disease 0
III	I-Disease 0
colorectal	I-Disease 0
cancer	I-Disease 0
.	O 0

In	O 0
stage	B-Disease 0
II	I-Disease 0
colorectal	I-Disease 0
carcinomas	I-Disease 0
,	O 0
the	O 0
absence	O 0
of	O 0
DCC	O 0
identifies	O 0
a	O 0
subgroup	O 0
of	O 0
patients	O 0
with	O 0
lesions	O 0
that	O 0
behave	O 0
like	O 0
stage	B-Disease 0
III	I-Disease 0
cancers	I-Disease 0
.	O 0

These	O 0
findings	O 0
may	O 0
thus	O 0
have	O 0
therapeutic	O 0
implications	O 0
in	O 0
this	O 0
group	O 0
of	O 0
patients	O 0

Association	O 0
of	O 0
anxiety	B-Disease 0
-	I-Disease 0
related	I-Disease 0
traits	I-Disease 0
with	O 0
a	O 0
polymorphism	O 0
in	O 0
the	O 0
serotonin	O 0
transporter	O 0
gene	O 0
regulatory	O 0
region	O 0
.	O 0

Transporter	O 0
-	O 0
facilitated	O 0
uptake	O 0
of	O 0
serotonin	O 0
(	O 0
5	O 0
-	O 0
hydroxytryptamine	O 0
or	O 0
5	O 0
-	O 0
HT	O 0
)	O 0
has	O 0
been	O 0
implicated	O 0
in	O 0
anxiety	B-Disease 0
in	O 0
humans	O 0
and	O 0
animal	O 0
models	O 0
and	O 0
is	O 0
the	O 0
site	O 0
of	O 0
action	O 0
of	O 0
widely	O 0
used	O 0
uptake	O 0
-	O 0
inhibiting	O 0
antidepressant	O 0
and	O 0
antianxiety	O 0
drugs	O 0
.	O 0

Human	O 0
5	O 0
-	O 0
HT	O 0
transporter	O 0
(	O 0
5	O 0
-	O 0
HTT	O 0
)	O 0
gene	O 0
transcription	O 0
is	O 0
modulated	O 0
by	O 0
a	O 0
common	O 0
polymorphism	O 0
in	O 0
its	O 0
upstream	O 0
regulatory	O 0
region	O 0
.	O 0

The	O 0
short	O 0
variant	O 0
of	O 0
the	O 0
polymorphism	O 0
reduces	O 0
the	O 0
transcriptional	O 0
efficiency	O 0
of	O 0
the	O 0
5	O 0
-	O 0
HTT	O 0
gene	O 0
promoter	O 0
,	O 0
resulting	O 0
in	O 0
decreased	O 0
5	O 0
-	O 0
HTT	O 0
expression	O 0
and	O 0
5	O 0
-	O 0
HT	O 0
uptake	O 0
in	O 0
lymphoblasts	O 0
.	O 0

Association	O 0
studies	O 0
in	O 0
two	O 0
independent	O 0
samples	O 0
totaling	O 0
505	O 0
individuals	O 0
revealed	O 0
that	O 0
the	O 0
5	O 0
-	O 0
HTT	O 0
polymorphism	O 0
accounts	O 0
for	O 0
3	O 0
to	O 0
4	O 0
percent	O 0
of	O 0
total	O 0
variation	O 0
and	O 0
7	O 0
to	O 0
9	O 0
percent	O 0
of	O 0
inherited	O 0
variance	O 0
in	O 0
anxiety	B-Disease 0
-	I-Disease 0
related	I-Disease 0
personality	I-Disease 0
traits	I-Disease 0
in	O 0
individuals	O 0
as	O 0
well	O 0
as	O 0
sibships	O 0
.	O 0
.	O 0

Phenotypic	O 0
and	O 0
genotypic	O 0
overlap	O 0
between	O 0
atelosteogenesis	B-Disease 0
type	I-Disease 0
2	I-Disease 0
and	O 0
diastrophic	B-Disease 0
dysplasia	I-Disease 0
.	O 0

Mutations	O 0
in	O 0
the	O 0
diastrophic	B-Disease 0
dysplasia	I-Disease 0
sulfate	O 0
transporter	O 0
gene	O 0
DTDST	O 0
have	O 0
been	O 0
associated	O 0
with	O 0
a	O 0
family	O 0
of	O 0
chondrodysplasias	B-Disease 0
that	O 0
comprises	O 0
,	O 0
in	O 0
order	O 0
of	O 0
increasing	O 0
severity	O 0
,	O 0
diastrophic	B-Disease 0
dysplasia	I-Disease 0
(	O 0
DTD	B-Disease 0
)	O 0
,	O 0
atelosteogenesis	B-Disease 0
type	I-Disease 0
2	I-Disease 0
(	O 0
AO2	B-Disease 0
)	O 0
,	O 0
and	O 0
achondrogenesis	B-Disease 0
type	I-Disease 0
1B	I-Disease 0
(	O 0
ACG1B	B-Disease 0
)	O 0
.	O 0

To	O 0
learn	O 0
more	O 0
about	O 0
the	O 0
molecular	O 0
basis	O 0
of	O 0
DTDST	B-Disease 0
chondrodysplasias	I-Disease 0
and	O 0
about	O 0
genotype	O 0
-	O 0
phenotype	O 0
correlations	O 0
,	O 0
we	O 0
studied	O 0
fibroblast	O 0
cultures	O 0
of	O 0
three	O 0
new	O 0
patients	O 0
one	O 0
with	O 0
AO	B-Disease 0
-	I-Disease 0
2	I-Disease 0
,	O 0
one	O 0
with	O 0
DTD	B-Disease 0
,	O 0
and	O 0
one	O 0
with	O 0
an	O 0
intermediate	O 0
phenotype	O 0
(	O 0
AO2	B-Disease 0
/	O 0
DTD	B-Disease 0
)	O 0
.	O 0

Reduced	O 0
incorporation	O 0
of	O 0
inorganic	O 0
sulfate	O 0
into	O 0
macromolecules	O 0
was	O 0
found	O 0
in	O 0
all	O 0
three	O 0
.	O 0

Each	O 0
of	O 0
the	O 0
three	O 0
patients	O 0
was	O 0
found	O 0
to	O 0
be	O 0
heterozygous	O 0
for	O 0
a	O 0
c862t	O 0
transition	O 0
predicting	O 0
a	O 0
R279W	O 0
substitution	O 0
in	O 0
the	O 0
third	O 0
extracellular	O 0
loop	O 0
of	O 0
DTDST	O 0
.	O 0

In	O 0
two	O 0
patients	O 0
(	O 0
DTD	B-Disease 0
and	O 0
AO2	B-Disease 0
/	O 0
DTD	B-Disease 0
)	O 0
,	O 0
no	O 0
other	O 0
structural	O 0
mutation	O 0
was	O 0
found	O 0
,	O 0
but	O 0
polymerase	O 0
chain	O 0
reaction	O 0
amplification	O 0
and	O 0
single	O 0
-	O 0
strand	O 0
conformation	O 0
polymorphism	O 0
analysis	O 0
of	O 0
fibroblast	O 0
cDNA	O 0
showed	O 0
reduced	O 0
mRNA	O 0
levels	O 0
of	O 0
the	O 0
wild	O 0
-	O 0
type	O 0
DTDST	O 0
allele	O 0
these	O 0
two	O 0
patients	O 0
may	O 0
be	O 0
compound	O 0
heterozygotes	O 0
for	O 0
the	O 0
"	O 0
Finnish	O 0
"	O 0
mutation	O 0
(	O 0
as	O 0
yet	O 0
uncharacterized	O 0
at	O 0
the	O 0
DNA	O 0
level	O 0
)	O 0
,	O 0
which	O 0
causes	O 0
reduced	O 0
expression	O 0
of	O 0
DTDST	O 0
.	O 0

The	O 0
third	O 0
patient	O 0
(	O 0
with	O 0
AO2	B-Disease 0
)	O 0
had	O 0
the	O 0
R279W	O 0
mutation	O 0
compounded	O 0
with	O 0
a	O 0
novel	O 0
mutation	O 0
,	O 0
the	O 0
deletion	O 0
of	O 0
cytosine	O 0
418	O 0
(	O 0
delta	O 0
c418	O 0
)	O 0
,	O 0
predicting	O 0
a	O 0
frameshift	O 0
with	O 0
premature	O 0
termination	O 0
.	O 0

Also	O 0
the	O 0
delta	O 0
c418	O 0
allele	O 0
was	O 0
underrepresented	O 0
in	O 0
the	O 0
cDNA	O 0
,	O 0
in	O 0
accordance	O 0
with	O 0
previous	O 0
observations	O 0
that	O 0
premature	O 0
stop	O 0
codons	O 0
reduce	O 0
mRNA	O 0
levels	O 0
.	O 0

The	O 0
presence	O 0
of	O 0
the	O 0
DTDST	O 0
R279W	O 0
mutation	O 0
in	O 0
a	O 0
total	O 0
of	O 0
11	O 0
patients	O 0
with	O 0
AO2	B-Disease 0
or	O 0
DTD	B-Disease 0
emphasizes	O 0
the	O 0
overlap	O 0
between	O 0
these	O 0
conditions	O 0
.	O 0

This	O 0
mutation	O 0
has	O 0
not	O 0
been	O 0
found	O 0
so	O 0
far	O 0
in	O 0
8	O 0
analyzed	O 0
ACG1B	B-Disease 0
patients	O 0
,	O 0
suggesting	O 0
that	O 0
it	O 0
allows	O 0
some	O 0
residual	O 0
activity	O 0
of	O 0
the	O 0
sulfate	O 0
transporter	O 0
.	O 0
.	O 0

Identification	O 0
of	O 0
WASP	O 0
mutations	O 0
,	O 0
mutation	O 0
hotspots	O 0
and	O 0
genotype	O 0
-	O 0
phenotype	O 0
disparities	O 0
in	O 0
24	O 0
patients	O 0
with	O 0
the	O 0
Wiskott	B-Disease 0
-	I-Disease 0
Aldrich	I-Disease 0
syndrome	I-Disease 0
.	O 0

The	O 0
Wiskott	B-Disease 0
-	I-Disease 0
Aldrich	I-Disease 0
syndrome	I-Disease 0
(	O 0
WAS	B-Disease 0
)	O 0
,	O 0
an	O 0
X	B-Disease 0
-	I-Disease 0
linked	I-Disease 0
immunodeficiency	I-Disease 0
disease	I-Disease 0
caused	O 0
by	O 0
mutation	O 0
in	O 0
the	O 0
recently	O 0
isolated	O 0
gene	O 0
encoding	O 0
WAS	B-Disease 0
protein	O 0
(	O 0
WASP	O 0
)	O 0
,	O 0
is	O 0
known	O 0
to	O 0
be	O 0
associated	O 0
with	O 0
extensive	O 0
clinical	O 0
heterogeneity	O 0
.	O 0

Cumulative	O 0
mutation	O 0
data	O 0
have	O 0
revealed	O 0
that	O 0
WASP	O 0
genotypes	O 0
are	O 0
also	O 0
highly	O 0
variable	O 0
among	O 0
WAS	B-Disease 0
patients	O 0
,	O 0
but	O 0
the	O 0
relationship	O 0
of	O 0
phenotype	O 0
with	O 0
genotype	O 0
in	O 0
this	O 0
disease	O 0
remains	O 0
unclear	O 0
.	O 0

To	O 0
address	O 0
this	O 0
issue	O 0
we	O 0
characterized	O 0
WASP	O 0
mutations	O 0
in	O 0
24	O 0
unrelated	O 0
WAS	B-Disease 0
patients	O 0
,	O 0
including	O 0
18	O 0
boys	O 0
with	O 0
severe	O 0
classical	O 0
WAS	B-Disease 0
and	O 0
6	O 0
boys	O 0
expressing	O 0
mild	O 0
forms	O 0
of	O 0
the	O 0
disease	O 0
,	O 0
and	O 0
then	O 0
examined	O 0
the	O 0
degree	O 0
of	O 0
correlation	O 0
of	O 0
these	O 0
as	O 0
well	O 0
as	O 0
all	O 0
previously	O 0
published	O 0
WASP	O 0
mutations	O 0
with	O 0
disease	O 0
severity	O 0
.	O 0

By	O 0
analysis	O 0
of	O 0
these	O 0
compiled	O 0
mutation	O 0
data	O 0
,	O 0
we	O 0
demonstrated	O 0
clustering	O 0
of	O 0
WASP	O 0
mutations	O 0
within	O 0
the	O 0
four	O 0
most	O 0
N	O 0
-	O 0
terminal	O 0
exons	O 0
of	O 0
the	O 0
gene	O 0
and	O 0
also	O 0
identified	O 0
several	O 0
sites	O 0
within	O 0
this	O 0
region	O 0
as	O 0
hotspots	O 0
for	O 0
WASP	O 0
mutation	O 0
.	O 0

These	O 0
characteristics	O 0
were	O 0
observed	O 0
,	O 0
however	O 0
,	O 0
in	O 0
both	O 0
severe	O 0
and	O 0
mild	O 0
cases	O 0
of	O 0
the	O 0
disease	O 0
.	O 0

Similarly	O 0
,	O 0
while	O 0
the	O 0
cumulative	O 0
data	O 0
revealed	O 0
a	O 0
predominance	O 0
of	O 0
missense	O 0
mutations	O 0
among	O 0
the	O 0
WASP	O 0
gene	O 0
lesions	O 0
observed	O 0
in	O 0
boys	O 0
with	O 0
isolated	B-Disease 0
thrombocytopenia	I-Disease 0
,	O 0
missense	O 0
mutations	O 0
were	O 0
not	O 0
exclusively	O 0
associated	O 0
with	O 0
milder	O 0
WAS	B-Disease 0
phenotypes	O 0
,	O 0
but	O 0
also	O 0
comprised	O 0
a	O 0
substantial	O 0
portion	O 0
(	O 0
38	O 0
%	O 0
)	O 0
of	O 0
the	O 0
WASP	O 0
gene	O 0
defects	O 0
found	O 0
in	O 0
patients	O 0
with	O 0
severe	O 0
disease	O 0
.	O 0

These	O 0
findings	O 0
,	O 0
as	O 0
well	O 0
as	O 0
the	O 0
detection	O 0
of	O 0
identical	O 0
WASP	O 0
mutations	O 0
in	O 0
patients	O 0
with	O 0
disparate	O 0
phenotypes	O 0
,	O 0
reveal	O 0
a	O 0
lack	O 0
of	O 0
phenotype	O 0
concordance	O 0
with	O 0
genotype	O 0
in	O 0
WAS	B-Disease 0
and	O 0
thus	O 0
imply	O 0
that	O 0
phenotypic	O 0
outcome	O 0
in	O 0
this	O 0
disease	O 0
cannot	O 0
be	O 0
reliably	O 0
predicted	O 0
solely	O 0
on	O 0
the	O 0
basis	O 0
of	O 0
WASP	O 0
genotypes	O 0
.	O 0
.	O 0

Germline	O 0
mutations	O 0
in	O 0
the	O 0
3	O 0
'	O 0
part	O 0
of	O 0
APC	B-Disease 0
exon	O 0
15	O 0
do	O 0
not	O 0
result	O 0
in	O 0
truncated	O 0
proteins	O 0
and	O 0
are	O 0
associated	O 0
with	O 0
attenuated	O 0
adenomatous	B-Disease 0
polyposis	I-Disease 0
coli	I-Disease 0
.	O 0

Familial	B-Disease 0
adenomatous	I-Disease 0
polyposis	I-Disease 0
(	O 0
FAP	B-Disease 0
)	O 0
is	O 0
an	O 0
inherited	O 0
predisposition	O 0
to	O 0
colorectal	B-Disease 0
cancer	I-Disease 0
characterized	O 0
by	O 0
the	O 0
development	O 0
of	O 0
numerous	O 0
adenomatous	B-Disease 0
polyps	I-Disease 0
predominantly	O 0
in	O 0
the	O 0
colorectal	O 0
region	O 0
.	O 0

Germline	O 0
mutations	O 0
in	O 0
the	O 0
adenomatous	B-Disease 0
polyposis	I-Disease 0
coli	I-Disease 0
(	O 0
APC	B-Disease 0
)	O 0
gene	O 0
are	O 0
responsible	O 0
for	O 0
most	O 0
cases	O 0
of	O 0
FAP	B-Disease 0
.	O 0

Mutations	O 0
at	O 0
the	O 0
5	O 0
end	O 0
of	O 0
APC	B-Disease 0
are	O 0
known	O 0
to	O 0
be	O 0
associated	O 0
with	O 0
a	O 0
relatively	O 0
mild	O 0
form	O 0
of	O 0
the	O 0
disease	O 0
,	O 0
called	O 0
attenuated	B-Disease 0
adenomatous	I-Disease 0
polyposis	I-Disease 0
coli	I-Disease 0
(	O 0
AAPC	B-Disease 0
)	O 0
.	O 0

We	O 0
identified	O 0
a	O 0
frameshift	O 0
mutation	O 0
in	O 0
the	O 0
3	O 0
part	O 0
of	O 0
exon	O 0
15	O 0
,	O 0
resulting	O 0
in	O 0
a	O 0
stop	O 0
codon	O 0
at	O 0
1862	O 0
,	O 0
in	O 0
a	O 0
large	O 0
Dutch	O 0
kindred	O 0
with	O 0
AAPC	B-Disease 0
.	O 0

Western	O 0
blot	O 0
analysis	O 0
of	O 0
lymphoblastoid	O 0
cell	O 0
lines	O 0
derived	O 0
from	O 0
affected	O 0
family	O 0
members	O 0
from	O 0
this	O 0
kindred	O 0
,	O 0
as	O 0
well	O 0
as	O 0
from	O 0
a	O 0
previously	O 0
reported	O 0
Swiss	O 0
family	O 0
carrying	O 0
a	O 0
frameshift	O 0
mutation	O 0
at	O 0
codon	O 0
1987	O 0
and	O 0
displaying	O 0
a	O 0
similar	O 0
attenuated	O 0
phenotype	O 0
,	O 0
showed	O 0
only	O 0
the	O 0
wild	O 0
-	O 0
type	O 0
APC	B-Disease 0
protein	O 0
.	O 0

Our	O 0
study	O 0
indicates	O 0
that	O 0
chain	O 0
-	O 0
terminating	O 0
mutations	O 0
located	O 0
in	O 0
the	O 0
3	O 0
part	O 0
of	O 0
APC	B-Disease 0
do	O 0
not	O 0
result	O 0
in	O 0
detectable	O 0
truncated	O 0
polypeptides	O 0
and	O 0
we	O 0
hypothesize	O 0
that	O 0
this	O 0
is	O 0
likely	O 0
to	O 0
be	O 0
the	O 0
basis	O 0
for	O 0
the	O 0
observed	O 0
AAPC	B-Disease 0
phenotype	O 0
.	O 0
.	O 0

Complete	O 0
genomic	O 0
sequence	O 0
and	O 0
analysis	O 0
of	O 0
117	O 0
kb	O 0
of	O 0
human	O 0
DNA	O 0
containing	O 0
the	O 0
gene	O 0
BRCA1	O 0
.	O 0

Over	O 0
100	O 0
distinct	O 0
disease	O 0
-	O 0
associated	O 0
mutations	O 0
have	O 0
been	O 0
identified	O 0
in	O 0
the	O 0
breast	B-Disease 0
-	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
susceptibility	O 0
gene	O 0
BRCA1	O 0
.	O 0

Loss	O 0
of	O 0
the	O 0
wild	O 0
-	O 0
type	O 0
allele	O 0
in	O 0
>	O 0
90	O 0
%	O 0
of	O 0
tumors	B-Disease 0
from	O 0
patients	O 0
with	O 0
inherited	O 0
BRCA1	O 0
mutations	O 0
indicates	O 0
tumor	B-Disease 0
suppressive	O 0
function	O 0
.	O 0

The	O 0
low	O 0
incidence	O 0
of	O 0
somatic	O 0
mutations	O 0
suggests	O 0
that	O 0
BRCA1	O 0
inactivation	O 0
in	O 0
sporadic	O 0
tumors	B-Disease 0
occurs	O 0
by	O 0
alternative	O 0
mechanisms	O 0
,	O 0
such	O 0
as	O 0
interstitial	O 0
chromosomal	O 0
deletion	O 0
or	O 0
reduced	O 0
transcription	O 0
.	O 0

To	O 0
identify	O 0
possible	O 0
features	O 0
of	O 0
the	O 0
BRCA1	O 0
genomic	O 0
region	O 0
that	O 0
may	O 0
contribute	O 0
to	O 0
chromosomal	O 0
instability	O 0
as	O 0
well	O 0
as	O 0
potential	O 0
transcriptional	O 0
regulatory	O 0
elements	O 0
,	O 0
a	O 0
117	O 0
,	O 0
143	O 0
-	O 0
bp	O 0
DNA	O 0
sequence	O 0
encompassing	O 0
BRCA1	O 0
was	O 0
obtained	O 0
by	O 0
random	O 0
sequencing	O 0
of	O 0
four	O 0
cosmids	O 0
identified	O 0
from	O 0
a	O 0
human	O 0
chromosome	O 0
17	O 0
specific	O 0
library	O 0
.	O 0

The	O 0
24	O 0
exons	O 0
of	O 0
BRCA1	O 0
span	O 0
an	O 0
81	O 0
-	O 0
kb	O 0
region	O 0
that	O 0
has	O 0
an	O 0
unusually	O 0
high	O 0
density	O 0
of	O 0
Alu	O 0
repetitive	O 0
DNA	O 0
(	O 0
41	O 0
.	O 0
5	O 0
%	O 0
)	O 0
,	O 0
but	O 0
relatively	O 0
low	O 0
density	O 0
(	O 0
4	O 0
.	O 0
8	O 0
%	O 0
)	O 0
of	O 0
other	O 0
repetitive	O 0
sequences	O 0
.	O 0

BRCA1	O 0
intron	O 0
lengths	O 0
range	O 0
in	O 0
size	O 0
from	O 0
403	O 0
bp	O 0
to	O 0
9	O 0
.	O 0

2	O 0
kb	O 0
and	O 0
contain	O 0
the	O 0
intragenic	O 0
microsatellite	O 0
markers	O 0
D17S1323	O 0
,	O 0
D17S1322	O 0
,	O 0
and	O 0
D17S855	O 0
,	O 0
which	O 0
localize	O 0
to	O 0
introns	O 0
12	O 0
,	O 0
19	O 0
,	O 0
and	O 0
20	O 0
,	O 0
respectively	O 0
.	O 0

In	O 0
addition	O 0
to	O 0
BRCA1	O 0
,	O 0
the	O 0
contig	O 0
contains	O 0
two	O 0
complete	O 0
genes	O 0
Rho7	O 0
,	O 0
a	O 0
member	O 0
of	O 0
the	O 0
rho	O 0
family	O 0
of	O 0
GTP	O 0
binding	O 0
proteins	O 0
,	O 0
and	O 0
VAT1	O 0
,	O 0
an	O 0
abundant	O 0
membrane	O 0
protein	O 0
of	O 0
cholinergic	O 0
synaptic	O 0
vesicles	O 0
.	O 0

Partial	O 0
sequences	O 0
of	O 0
the	O 0
1A1	O 0
-	O 0
3B	O 0
B	O 0
-	O 0
box	O 0
protein	O 0
pseudogene	O 0
and	O 0
IFP	O 0
35	O 0
,	O 0
an	O 0
interferon	O 0
induced	O 0
leucine	O 0
zipper	O 0
protein	O 0
,	O 0
reside	O 0
within	O 0
the	O 0
contig	O 0
.	O 0

An	O 0
L21	O 0
ribosomal	O 0
protein	O 0
pseudogene	O 0
is	O 0
embedded	O 0
in	O 0
BRCA1	O 0
intron	O 0
13	O 0
.	O 0

The	O 0
order	O 0
of	O 0
genes	O 0
on	O 0
the	O 0
chromosome	O 0
is	O 0
centromere	O 0
-	O 0
1FP	O 0
35	O 0
-	O 0
VAT1	O 0
-	O 0
Rho7	O 0
-	O 0
BRCA1	O 0
-	O 0
1A1	O 0
-	O 0
3B	O 0
-	O 0
telomere	O 0

Identification	O 0
of	O 0
a	O 0
RING	O 0
protein	O 0
that	O 0
can	O 0
interact	O 0
in	O 0
vivo	O 0
with	O 0
the	O 0
BRCA1	O 0
gene	O 0
product	O 0
.	O 0

The	O 0
hereditary	B-Disease 0
breast	I-Disease 0
and	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
gene	O 0
,	O 0
BRCA1	O 0
,	O 0
encodes	O 0
a	O 0
large	O 0
polypeptide	O 0
that	O 0
contains	O 0
the	O 0
cysteine	O 0
-	O 0
rich	O 0
RING	O 0
motif	O 0
,	O 0
a	O 0
zinc	O 0
-	O 0
binding	O 0
domain	O 0
found	O 0
in	O 0
a	O 0
variety	O 0
of	O 0
regulatory	O 0
proteins	O 0
.	O 0

Here	O 0
we	O 0
describe	O 0
a	O 0
novel	O 0
protein	O 0
that	O 0
interacts	O 0
in	O 0
vivo	O 0
with	O 0
the	O 0
N	O 0
-	O 0
terminal	O 0
region	O 0
of	O 0
BRCA1	O 0
.	O 0

This	O 0
BRCA1	O 0
-	O 0
associated	O 0
RING	O 0
domain	O 0
(	O 0
BARD1	O 0
)	O 0
protein	O 0
contains	O 0
an	O 0
N	O 0
-	O 0
terminal	O 0
RING	O 0
motif	O 0
,	O 0
three	O 0
tandem	O 0
ankyrin	O 0
repeats	O 0
,	O 0
and	O 0
a	O 0
C	O 0
-	O 0
terminal	O 0
sequence	O 0
with	O 0
significant	O 0
homology	O 0
to	O 0
the	O 0
phylogenetically	O 0
conserved	O 0
BRCT	O 0
domains	O 0
that	O 0
lie	O 0
near	O 0
the	O 0
C	O 0
terminus	O 0
of	O 0
BRCA1	O 0
.	O 0

The	O 0
BARD1	O 0
/	O 0
BRCA1	O 0
interaction	O 0
is	O 0
disrupted	O 0
by	O 0
BRCA1	O 0
missense	O 0
mutations	O 0
that	O 0
segregate	O 0
with	O 0
breast	B-Disease 0
cancer	I-Disease 0
susceptibility	O 0
,	O 0
indicating	O 0
that	O 0
BARD1	O 0
may	O 0
be	O 0
involved	O 0
in	O 0
mediating	O 0
tumour	B-Disease 0
suppression	O 0
by	O 0
BRCA1	O 0
.	O 0
.	O 0

Detection	O 0
of	O 0
heterozygous	O 0
mutations	O 0
in	O 0
BRCA1	O 0
using	O 0
high	O 0
density	O 0
oligonucleotide	O 0
arrays	O 0
and	O 0
two	O 0
-	O 0
colour	O 0
fluorescence	O 0
analysis	O 0
.	O 0

The	O 0
ability	O 0
to	O 0
scan	O 0
a	O 0
large	O 0
gene	O 0
rapidly	O 0
and	O 0
accurately	O 0
for	O 0
all	O 0
possible	O 0
heterozygous	O 0
mutations	O 0
in	O 0
large	O 0
numbers	O 0
of	O 0
patient	O 0
samples	O 0
will	O 0
be	O 0
critical	O 0
for	O 0
the	O 0
future	O 0
of	O 0
medicine	O 0
.	O 0

We	O 0
have	O 0
designed	O 0
high	O 0
-	O 0
density	O 0
arrays	O 0
consisting	O 0
of	O 0
over	O 0
96	O 0
,	O 0
600	O 0
oligonucleotides	O 0
20	O 0
-	O 0
nucleotides	O 0
(	O 0
nt	O 0
)	O 0
in	O 0
length	O 0
to	O 0
screen	O 0
for	O 0
a	O 0
wide	O 0
range	O 0
of	O 0
heterozygous	O 0
mutations	O 0
in	O 0
the	O 0
3	O 0
.	O 0

45	O 0
-	O 0
kilobases	O 0
(	O 0
kb	O 0
)	O 0
exon	O 0
11	O 0
of	O 0
the	O 0
hereditary	B-Disease 0
breast	I-Disease 0
and	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
gene	O 0
BRCA1	O 0
.	O 0

Reference	O 0
and	O 0
test	O 0
samples	O 0
were	O 0
co	O 0
-	O 0
hybridized	O 0
to	O 0
these	O 0
arrays	O 0
and	O 0
differences	O 0
in	O 0
hybridization	O 0
patterns	O 0
quantitated	O 0
by	O 0
two	O 0
-	O 0
colour	O 0
analysis	O 0
.	O 0

Fourteen	O 0
of	O 0
fifteen	O 0
patient	O 0
samples	O 0
with	O 0
known	O 0
mutations	O 0
were	O 0
accurately	O 0
diagnosed	O 0
,	O 0
and	O 0
no	O 0
false	O 0
positive	O 0
mutations	O 0
were	O 0
identified	O 0
in	O 0
20	O 0
control	O 0
samples	O 0
.	O 0

Eight	O 0
single	O 0
nucleotide	O 0
polymorphisms	O 0
were	O 0
also	O 0
readily	O 0
detected	O 0
.	O 0

DNA	O 0
chip	O 0
-	O 0
based	O 0
assays	O 0
may	O 0
provide	O 0
a	O 0
valuable	O 0
new	O 0
technology	O 0
for	O 0
high	O 0
-	O 0
throughput	O 0
cost	O 0
-	O 0
efficient	O 0
detection	O 0
of	O 0
genetic	O 0
alterations	O 0
.	O 0

Autosomal	O 0
dominant	O 0
primary	O 0
hyperparathyroidism	B-Disease 0
and	I-Disease 0
jaw	I-Disease 0
tumor	I-Disease 0
syndrome	I-Disease 0
associated	O 0
with	O 0
renal	B-Disease 0
hamartomas	I-Disease 0
and	O 0
cystic	B-Disease 0
kidney	I-Disease 0
disease	I-Disease 0
:	O 0
linkage	O 0
to	O 0
1q21	O 0
-	O 0
q32	O 0
and	O 0
loss	O 0
of	O 0
the	O 0
wild	O 0
type	O 0
allele	O 0
in	O 0
renal	B-Disease 0
hamartomas	I-Disease 0
.	O 0

Hereditary	B-Disease 0
hyperparathyroidism	I-Disease 0
-	I-Disease 0
jaw	I-Disease 0
tumor	I-Disease 0
syndrome	I-Disease 0
(	O 0
HPT	B-Disease 0
-	I-Disease 0
JT	I-Disease 0
)	O 0
is	O 0
an	O 0
autosomal	B-Disease 0
dominant	I-Disease 0
disease	I-Disease 0
(	O 0
OMIM	O 0
145001	O 0
)	O 0
that	O 0
has	O 0
recently	O 0
been	O 0
mapped	O 0
to	O 0
chromosomal	O 0
region	O 0
1q21	O 0
-	O 0
q32	O 0
(	O 0
HRPT2	O 0
)	O 0
.	O 0

Here	O 0
we	O 0
report	O 0
two	O 0
families	O 0
with	O 0
HPT	B-Disease 0
-	I-Disease 0
JT	I-Disease 0
syndrome	I-Disease 0
in	O 0
which	O 0
adult	B-Disease 0
renal	I-Disease 0
hamartomas	I-Disease 0
or	O 0
cystic	B-Disease 0
kidney	I-Disease 0
disease	I-Disease 0
were	O 0
prominent	O 0
associated	O 0
features	O 0
,	O 0
possibly	O 0
representing	O 0
a	O 0
new	O 0
phenotypic	O 0
variant	O 0
of	O 0
the	O 0
HPT	B-Disease 0
-	I-Disease 0
JT	I-Disease 0
syndrome	I-Disease 0
.	O 0

In	O 0
the	O 0
first	O 0
family	O 0
,	O 0
renal	B-Disease 0
lesions	I-Disease 0
were	O 0
present	O 0
in	O 0
five	O 0
out	O 0
of	O 0
six	O 0
affected	O 0
individuals	O 0
,	O 0
whereas	O 0
HPT	B-Disease 0
and	O 0
JT	B-Disease 0
were	O 0
seen	O 0
in	O 0
four	O 0
and	O 0
two	O 0
cases	O 0
,	O 0
respectively	O 0
.	O 0

In	O 0
the	O 0
second	O 0
family	O 0
,	O 0
JT	B-Disease 0
was	O 0
found	O 0
in	O 0
three	O 0
of	O 0
the	O 0
five	O 0
affected	O 0
individuals	O 0
and	O 0
two	O 0
affected	O 0
members	O 0
also	O 0
exhibited	O 0
polycystic	B-Disease 0
kidney	I-Disease 0
disease	I-Disease 0
.	O 0

The	O 0
possibility	O 0
of	O 0
the	O 0
latter	O 0
cosegregating	O 0
as	O 0
a	O 0
separate	O 0
autosomal	O 0
dominant	O 0
gene	O 0
can	O 0
not	O 0
be	O 0
ruled	O 0
out	O 0
.	O 0

A	O 0
sex	O 0
-	O 0
dependent	O 0
penetrance	O 0
of	O 0
primary	B-Disease 0
HPT	I-Disease 0
,	O 0
resulting	O 0
in	O 0
predominantly	O 0
male	O 0
-	O 0
affected	O 0
cases	O 0
was	O 0
evident	O 0
in	O 0
the	O 0
two	O 0
families	O 0
.	O 0

Twenty	O 0
microsatellite	O 0
markers	O 0
in	O 0
the	O 0
HRPT2	O 0
region	O 0
were	O 0
typed	O 0
,	O 0
in	O 0
addition	O 0
to	O 0
markers	O 0
in	O 0
the	O 0
multiple	B-Disease 0
endocrine	I-Disease 0
neoplasia	I-Disease 0
(	I-Disease 0
MEN	I-Disease 0
)	I-Disease 0
types	I-Disease 0
1	I-Disease 0
and	I-Disease 0
2	I-Disease 0
regions	O 0
at	O 0
11q13	O 0
and	O 0
10q11	O 0
.	O 0

The	O 0
disease	O 0
in	O 0
these	O 0
two	O 0
kindreds	O 0
was	O 0
linked	O 0
to	O 0
five	O 0
markers	O 0
in	O 0
the	O 0
1q21	O 0
-	O 0
q32	O 0
region	O 0
(	O 0
logarithm	O 0
-	O 0
of	O 0
-	O 0
odds	O 0
scores	O 0
3	O 0
.	O 0
2	O 0
-	O 0
4	O 0
2	O 0
-	O 0
4	O 0
.	O 0
2	O 0
)	O 0
,	O 0
whereas	O 0
linkage	O 0
to	O 0
the	O 0
MEN1	B-Disease 0
and	O 0
MEN2	B-Disease 0
regions	O 0
was	O 0
excluded	O 0
.	O 0

Meiotic	O 0
recombinations	O 0
detected	O 0
in	O 0
affected	O 0
individuals	O 0
placed	O 0
the	O 0
locus	O 0
telomeric	O 0
of	O 0
D1S215	O 0
,	O 0
thus	O 0
narrowing	O 0
the	O 0
HRPT2	O 0
region	O 0
from	O 0
>	O 0
60	O 0
to	O 0
approximately	O 0
34	O 0
centimorgans	O 0
.	O 0

Loss	O 0
of	O 0
heterozygosity	O 0
was	O 0
studied	O 0
in	O 0
seven	O 0
renal	B-Disease 0
hamartomas	I-Disease 0
from	O 0
two	O 0
affected	O 0
individuals	O 0
in	O 0
the	O 0
first	O 0
family	O 0
,	O 0
as	O 0
well	O 0
as	O 0
in	O 0
a	O 0
jaw	B-Disease 0
tumor	I-Disease 0
and	O 0
a	O 0
parathyroid	B-Disease 0
tumor	I-Disease 0
from	O 0
the	O 0
second	O 0
family	O 0
.	O 0

All	O 0
renal	B-Disease 0
hamartomas	I-Disease 0
showed	O 0
loss	O 0
of	O 0
heterozygosity	O 0
at	O 0
the	O 0
1q21	O 0
-	O 0
q32	O 0
region	O 0
.	O 0

The	O 0
losses	O 0
invariably	O 0
involved	O 0
the	O 0
wild	O 0
type	O 0
allele	O 0
derived	O 0
from	O 0
the	O 0
unaffected	O 0
parent	O 0
,	O 0
suggesting	O 0
the	O 0
inactivation	O 0
of	O 0
a	O 0
tumor	B-Disease 0
suppressor	O 0
gene	O 0
in	O 0
this	O 0
region	O 0

Independent	O 0
origin	O 0
of	O 0
single	O 0
and	O 0
double	O 0
mutations	O 0
in	O 0
the	O 0
human	O 0
glucose	O 0
6	O 0
-	O 0
phosphate	O 0
dehydrogenase	O 0
gene	O 0
.	O 0

The	O 0
vast	O 0
majority	O 0
of	O 0
both	O 0
polymorphic	O 0
and	O 0
sporadic	O 0
G6PD	O 0
variants	O 0
are	O 0
due	O 0
to	O 0
single	O 0
missense	O 0
mutations	O 0
.	O 0

In	O 0
the	O 0
four	O 0
polymorphic	O 0
variants	O 0
that	O 0
have	O 0
two	O 0
point	O 0
mutations	O 0
,	O 0
one	O 0
of	O 0
the	O 0
mutations	O 0
is	O 0
always	O 0
376	O 0
A	O 0
-	O 0
-	O 0
>	O 0
G	O 0
(	O 0
126	O 0
Asn	O 0
-	O 0
-	O 0
>	O 0
Asp	O 0
)	O 0
,	O 0
which	O 0
on	O 0
its	O 0
own	O 0
gives	O 0
rise	O 0
to	O 0
the	O 0
nondeficient	O 0
polymorphic	O 0
variant	O 0
,	O 0
G6PD	O 0
A	O 0
.	O 0

In	O 0
a	O 0
study	O 0
of	O 0
G6PD	B-Disease 0
deficient	I-Disease 0
patients	O 0
who	O 0
presented	O 0
with	O 0
clinical	O 0
favism	B-Disease 0
in	O 0
Spain	O 0
,	O 0
we	O 0
have	O 0
found	O 0
a	O 0
new	O 0
polymorphic	O 0
variant	O 0
that	O 0
we	O 0
have	O 0
called	O 0
G6PD	O 0
Malaga	O 0
,	O 0
whose	O 0
only	O 0
abnormality	O 0
is	O 0
a	O 0
542	O 0
A	O 0
-	O 0
-	O 0
>	O 0
T	O 0
(	O 0
181	O 0
Asp	O 0
-	O 0
-	O 0
>	O 0
Val	O 0
)	O 0
mutation	O 0
.	O 0

This	O 0
is	O 0
the	O 0
same	O 0
mutation	O 0
as	O 0
previously	O 0
found	O 0
in	O 0
association	O 0
with	O 0
the	O 0
mutation	O 0
of	O 0
G6PD	O 0
A	O 0
in	O 0
the	O 0
double	O 0
mutant	O 0
,	O 0
G6PD	O 0
Santamaria	O 0
.	O 0

G6PD	O 0
Malaga	O 0
is	O 0
associated	O 0
with	O 0
enzyme	B-Disease 0
deficiency	I-Disease 0
(	O 0
class	O 0
III	O 0
)	O 0
,	O 0
and	O 0
the	O 0
enzymic	O 0
properties	O 0
of	O 0
G6PD	O 0
Malaga	O 0
and	O 0
G6PD	O 0
Santamaria	O 0
are	O 0
quite	O 0
similar	O 0
,	O 0
indicating	O 0
that	O 0
in	O 0
this	O 0
case	O 0
the	O 0
effects	O 0
of	O 0
the	O 0
two	O 0
mutations	O 0
are	O 0
additive	O 0
rather	O 0
than	O 0
synergistic	O 0
.	O 0

G6PD	O 0
Santamaria	O 0
might	O 0
have	O 0
been	O 0
produced	O 0
by	O 0
recombination	O 0
between	O 0
G6PD	O 0
A	O 0
and	O 0
G6PD	O 0
Malaga	O 0
;	O 0
however	O 0
haplotype	O 0
analysis	O 0
,	O 0
including	O 0
the	O 0
use	O 0
of	O 0
a	O 0
new	O 0
silent	O 0
polymorphism	O 0
,	O 0
suggests	O 0
that	O 0
the	O 0
same	O 0
542	O 0
A	O 0
-	O 0
-	O 0
>	O 0
T	O 0
mutation	O 0
has	O 0
taken	O 0
place	O 0
independently	O 0
in	O 0
a	O 0
G6PD	O 0
B	O 0
gene	O 0
to	O 0
give	O 0
G6PD	O 0
Malaga	O 0
and	O 0
in	O 0
a	O 0
G6PD	O 0
A	O 0
gene	O 0
to	O 0
give	O 0
G6PD	O 0
Santamaria	O 0
.	O 0

These	O 0
findings	O 0
help	O 0
to	O 0
outline	O 0
the	O 0
relationship	O 0
and	O 0
evolution	O 0
of	O 0
mutations	O 0
in	O 0
the	O 0
human	O 0
G6PD	O 0
locus	O 0
.	O 0
.	O 0

BRCA1	O 0
R841W	O 0
:	O 0
a	O 0
strong	O 0
candidate	O 0
for	O 0
a	O 0
common	O 0
mutation	O 0
with	O 0
moderate	O 0
phenotype	O 0
.	O 0

BRCA1	O 0
mutations	O 0
cause	O 0
increased	O 0
risk	O 0
for	O 0
breast	B-Disease 0
and	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
,	O 0
frequently	O 0
of	O 0
early	O 0
onset	O 0
.	O 0

Many	O 0
different	O 0
mutations	O 0
occur	O 0
in	O 0
BRCA1	O 0
,	O 0
including	O 0
several	O 0
examples	O 0
of	O 0
recurrent	O 0
mutations	O 0
,	O 0
each	O 0
of	O 0
which	O 0
accounts	O 0
for	O 0
a	O 0
significant	O 0
number	O 0
of	O 0
families	O 0
with	O 0
heritable	O 0
cancer	B-Disease 0
predisposition	O 0
.	O 0

These	O 0
common	O 0
mutations	O 0
have	O 0
an	O 0
etiological	O 0
role	O 0
in	O 0
many	O 0
breast	B-Disease 0
and	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
cases	O 0
and	O 0
provide	O 0
the	O 0
opportunity	O 0
to	O 0
examine	O 0
genotype	O 0
-	O 0
phenotype	O 0
correlations	O 0
and	O 0
genotype	O 0
-	O 0
environment	O 0
interactions	O 0
in	O 0
individuals	O 0
with	O 0
the	O 0
identical	O 0
BRCA1	O 0
lesion	O 0
.	O 0

We	O 0
report	O 0
a	O 0
novel	O 0
missense	O 0
change	O 0
in	O 0
BRCA1	O 0
,	O 0
2640	O 0
C	O 0
-	O 0
-	O 0
>	O 0
T	O 0
(	O 0
R841W	O 0
)	O 0
,	O 0
found	O 0
in	O 0
3	O 0
cases	O 0
from	O 0
a	O 0
subject	O 0
group	O 0
of	O 0
305	O 0
breast	B-Disease 0
and	I-Disease 0
79	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
cases	O 0
from	O 0
Orange	O 0
County	O 0
,	O 0
CA	O 0
.	O 0

These	O 0
are	O 0
consecutive	O 0
,	O 0
population	O 0
-	O 0
based	O 0
cases	O 0
not	O 0
selected	O 0
for	O 0
age	O 0
or	O 0
family	O 0
history	O 0
.	O 0

In	O 0
all	O 0
three	O 0
cases	O 0
,	O 0
there	O 0
is	O 0
a	O 0
strong	O 0
family	O 0
history	O 0
of	O 0
breast	B-Disease 0
,	I-Disease 0
ovarian	I-Disease 0
,	I-Disease 0
or	I-Disease 0
other	I-Disease 0
cancers	I-Disease 0
possibly	O 0
related	O 0
to	O 0
a	O 0
BRCA1	O 0
defect	O 0
and	O 0
family	O 0
members	O 0
showed	O 0
a	O 0
high	O 0
concordance	O 0
of	O 0
cancer	B-Disease 0
incidence	O 0
with	O 0
the	O 0
presence	O 0
of	O 0
R841W	O 0
.	O 0

The	O 0
age	O 0
of	O 0
cancer	B-Disease 0
onset	O 0
was	O 0
not	O 0
always	O 0
distinct	O 0
from	O 0
typical	O 0
sporadic	O 0
cases	O 0
.	O 0

Testing	O 0
of	O 0
a	O 0
sample	O 0
of	O 0
413	O 0
unrelated	O 0
individuals	O 0
to	O 0
examine	O 0
the	O 0
hypothesis	O 0
that	O 0
R841W	O 0
might	O 0
be	O 0
a	O 0
rare	O 0
polymorphism	O 0
detected	O 0
one	O 0
additional	O 0
instance	O 0
in	O 0
a	O 0
woman	O 0
with	O 0
breast	B-Disease 0
cancer	I-Disease 0
diagnosed	O 0
at	O 0
age	O 0
77	O 0
years	O 0
,	O 0
and	O 0
cancer	B-Disease 0
in	O 0
one	O 0
parent	O 0
.	O 0

R841W	O 0
is	O 0
likely	O 0
to	O 0
be	O 0
an	O 0
etiologically	O 0
significant	O 0
lesion	O 0
with	O 0
involvement	O 0
in	O 0
close	O 0
to	O 0
1	O 0
%	O 0
(	O 0
95	O 0
%	O 0
confidence	O 0
interval	O 0
of	O 0
0	O 0
-	O 0
1	O 0
.	O 0
7	O 0
%	O 0
)	O 0
of	O 0
all	O 0
breast	B-Disease 0
and	I-Disease 0
ovarian	I-Disease 0
cancers	I-Disease 0
in	O 0
this	O 0
population	O 0
.	O 0

Ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
:	O 0
founder	O 0
effect	O 0
among	O 0
north	O 0
African	O 0
Jews	O 0
.	O 0

The	O 0
ATM	O 0
gene	O 0
is	O 0
responsible	O 0
for	O 0
the	O 0
autosomal	B-Disease 0
recessive	I-Disease 0
disorder	I-Disease 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
(	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
)	O 0
,	O 0
characterized	O 0
by	O 0
cerebellar	B-Disease 0
degeneration	I-Disease 0
,	O 0
immunodeficiency	B-Disease 0
and	O 0
cancer	B-Disease 0
predisposition	I-Disease 0
.	O 0

A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
carriers	O 0
were	O 0
reported	O 0
to	O 0
be	O 0
moderately	O 0
cancer	B-Disease 0
-	I-Disease 0
prone	I-Disease 0
.	O 0

A	O 0
wide	O 0
variety	O 0
of	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
mutations	O 0
,	O 0
most	O 0
of	O 0
which	O 0
are	O 0
unique	O 0
to	O 0
single	O 0
families	O 0
,	O 0
were	O 0
identified	O 0
in	O 0
various	O 0
ethnic	O 0
groups	O 0
,	O 0
precluding	O 0
carrier	O 0
screening	O 0
with	O 0
mutation	O 0
-	O 0
specific	O 0
assays	O 0
.	O 0

However	O 0
,	O 0
a	O 0
single	O 0
mutation	O 0
was	O 0
observed	O 0
in	O 0
32	O 0
/	O 0
33	O 0
defective	O 0
ATM	O 0
alleles	O 0
in	O 0
Jewish	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
families	O 0
of	O 0
North	O 0
African	O 0
origin	O 0
,	O 0
coming	O 0
from	O 0
various	O 0
regions	O 0
of	O 0
Morocco	O 0
and	O 0
Tunisia	O 0
.	O 0

This	O 0
mutation	O 0
,	O 0
103C	O 0
-	O 0
-	O 0
>	O 0
T	O 0
,	O 0
results	O 0
in	O 0
a	O 0
stop	O 0
codon	O 0
at	O 0
position	O 0
35	O 0
of	O 0
the	O 0
ATM	O 0
protein	O 0
.	O 0

In	O 0
keeping	O 0
with	O 0
the	O 0
nature	O 0
of	O 0
this	O 0
mutation	O 0
,	O 0
various	O 0
antibodies	O 0
directed	O 0
against	O 0
the	O 0
ATM	O 0
protein	O 0
failed	O 0
to	O 0
defect	O 0
this	O 0
protein	O 0
in	O 0
patient	O 0
cells	O 0
.	O 0

A	O 0
rapid	O 0
carrier	O 0
detection	O 0
assay	O 0
detected	O 0
this	O 0
mutation	O 0
in	O 0
three	O 0
out	O 0
of	O 0
488	O 0
ATM	O 0
alleles	O 0
of	O 0
Jewish	O 0
Moroccan	O 0
or	O 0
Tunisian	O 0
origin	O 0
.	O 0

This	O 0
founder	O 0
effect	O 0
provides	O 0
a	O 0
unique	O 0
opportunity	O 0
for	O 0
population	O 0
-	O 0
based	O 0
screening	O 0
for	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
carriers	O 0
in	O 0
a	O 0
large	O 0
Jewish	O 0
community	O 0
.	O 0
.	O 0

Mutation	O 0
analysis	O 0
of	O 0
BRCA1	O 0
and	O 0
BRCA2	O 0
in	O 0
a	O 0
male	B-Disease 0
breast	I-Disease 0
cancer	I-Disease 0
population	O 0
.	O 0

A	O 0
population	O 0
-	O 0
based	O 0
series	O 0
of	O 0
54	O 0
male	B-Disease 0
breast	I-Disease 0
cancer	I-Disease 0
cases	O 0
from	O 0
Southern	O 0
California	O 0
were	O 0
analyzed	O 0
for	O 0
germ	O 0
-	O 0
line	O 0
mutations	O 0
in	O 0
the	O 0
inherited	B-Disease 0
breast	I-Disease 0
/	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
genes	O 0
,	O 0
BRCA1	O 0
and	O 0
BRCA2	O 0
.	O 0

Nine	O 0
(	O 0
17	O 0
%	O 0
)	O 0
of	O 0
the	O 0
patients	O 0
had	O 0
a	O 0
family	O 0
history	O 0
of	O 0
breast	B-Disease 0
and	I-Disease 0
/	I-Disease 0
or	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
in	O 0
at	O 0
least	O 0
one	O 0
first	O 0
-	O 0
degree	O 0
relative	O 0
.	O 0

A	O 0
further	O 0
seven	O 0
(	O 0
13	O 0
%	O 0
)	O 0
of	O 0
the	O 0
patients	O 0
reported	O 0
breast	B-Disease 0
/	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
in	O 0
at	O 0
least	O 0
one	O 0
second	O 0
-	O 0
degree	O 0
relative	O 0
and	O 0
in	O 0
no	O 0
first	O 0
-	O 0
degree	O 0
relatives	O 0
.	O 0

No	O 0
germ	O 0
-	O 0
line	O 0
BRCA1	O 0
mutations	O 0
were	O 0
found	O 0
.	O 0

Two	O 0
male	B-Disease 0
breast	I-Disease 0
cancer	I-Disease 0
patients	O 0
(	O 0
4	O 0
%	O 0
of	O 0
the	O 0
total	O 0
)	O 0
were	O 0
found	O 0
to	O 0
carry	O 0
novel	O 0
truncating	O 0
mutations	O 0
in	O 0
the	O 0
BRCA2	O 0
gene	O 0
.	O 0

Only	O 0
one	O 0
of	O 0
the	O 0
two	O 0
male	B-Disease 0
breast	I-Disease 0
cancer	I-Disease 0
patients	O 0
carrying	O 0
a	O 0
BRCA2	O 0
mutation	O 0
had	O 0
a	O 0
family	O 0
history	O 0
of	O 0
cancer	B-Disease 0
,	O 0
with	O 0
one	O 0
case	O 0
of	O 0
ovarian	B-Disease 0
cancer	I-Disease 0
in	O 0
a	O 0
first	O 0
-	O 0
degree	O 0
relative	O 0
.	O 0

The	O 0
remaining	O 0
eight	O 0
cases	O 0
(	O 0
89	O 0
%	O 0
)	O 0
of	O 0
male	B-Disease 0
breast	I-Disease 0
cancer	I-Disease 0
with	O 0
a	O 0
family	O 0
history	O 0
of	O 0
breast	B-Disease 0
/	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
in	O 0
first	O 0
-	O 0
degree	O 0
relatives	O 0
remain	O 0
unaccounted	O 0
for	O 0
by	O 0
mutations	O 0
in	O 0
either	O 0
the	O 0
BRCA1	O 0
gene	O 0
or	O 0
the	O 0
BRCA2	O 0
gene	O 0
.	O 0
.	O 0

Molecular	O 0
basis	O 0
for	O 0
Duarte	B-Disease 0
and	I-Disease 0
Los	I-Disease 0
Angeles	I-Disease 0
variant	I-Disease 0
galactosemia	I-Disease 0
.	O 0

Human	O 0
orythrocytes	O 0
that	O 0
are	O 0
homozygous	O 0
for	O 0
the	O 0
Duarte	B-Disease 0
enzyme	I-Disease 0
variant	I-Disease 0
of	I-Disease 0
galactosemia	I-Disease 0
(	O 0
D	O 0
/	O 0
D	O 0
)	O 0
have	O 0
a	O 0
characteristic	O 0
isoform	O 0
on	O 0
isoelectric	O 0
focusing	O 0
and	O 0
50	O 0
%	O 0
reduction	O 0
in	O 0
galactose	O 0
-	O 0
1	O 0
-	O 0
phosphate	O 0
uridyltransferase	O 0
(	O 0
GALT	O 0
)	O 0
enzyme	O 0
activity	O 0
.	O 0

The	O 0
Duarte	O 0
biochemical	O 0
phenotype	O 0
has	O 0
a	O 0
molecular	O 0
genotype	O 0
of	O 0
N314D	O 0
/	O 0
N314D	O 0
.	O 0

The	O 0
characteristic	O 0
Duarte	O 0
isoform	O 0
is	O 0
also	O 0
associated	O 0
with	O 0
a	O 0
variant	O 0
called	O 0
the	O 0
"	O 0
Los	O 0
Angeles	O 0
(	O 0
LA	O 0
)	O 0
phenotype	O 0
,	O 0
"	O 0
which	O 0
has	O 0
increased	O 0
GALT	O 0
enzyme	O 0
activity	O 0
.	O 0

We	O 0
evaluated	O 0
GALT	O 0
enzyme	O 0
activity	O 0
and	O 0
screened	O 0
the	O 0
GALT	O 0
genes	O 0
of	O 0
145	O 0
patients	O 0
with	O 0
one	O 0
or	O 0
more	O 0
N314D	O 0
-	O 0
containing	O 0
alleles	O 0
.	O 0

We	O 0
found	O 0
seven	O 0
with	O 0
the	O 0
LA	O 0
biochemical	O 0
phenotype	O 0
,	O 0
and	O 0
all	O 0
had	O 0
a	O 0
1721C	O 0
-	O 0
-	O 0
>	O 0
T	O 0
transition	O 0
in	O 0
exon	O 0
7	O 0
in	O 0
cis	O 0
with	O 0
the	O 0
N314D	O 0
missense	O 0
mutation	O 0
.	O 0

The	O 0
1721C	O 0
-	O 0
-	O 0
>	O 0
T	O 0
transition	O 0
is	O 0
a	O 0
neutral	O 0
polymorphism	O 0
for	O 0
leucine	O 0
at	O 0
amino	O 0
acid	O 0
218	O 0
(	O 0
L218L	O 0
)	O 0
.	O 0

In	O 0
pedigree	O 0
analyses	O 0
,	O 0
this	O 0
1721C	O 0
-	O 0
-	O 0
>	O 0
T	O 0
transition	O 0
segregated	O 0
with	O 0
the	O 0
LA	O 0
phenotype	O 0
of	O 0
increased	O 0
GALT	O 0
activity	O 0
in	O 0
three	O 0
different	O 0
biochemical	O 0
phenotypes	O 0
(	O 0
LA	O 0
/	O 0
N	O 0
,	O 0
LA	O 0
/	O 0
G	O 0
,	O 0
and	O 0
LA	O 0
/	O 0
D	O 0
)	O 0
.	O 0

To	O 0
determine	O 0
the	O 0
mechanism	O 0
for	O 0
increased	O 0
activity	O 0
of	O 0
the	O 0
LA	O 0
variant	O 0
,	O 0
we	O 0
compared	O 0
GALT	O 0
mRNA	O 0
,	O 0
protein	O 0
abundance	O 0
,	O 0
and	O 0
enzyme	O 0
thermal	O 0
stability	O 0
in	O 0
lymphoblast	O 0
cell	O 0
lines	O 0
of	O 0
D	O 0
and	O 0
LA	O 0
phenotypes	O 0
with	O 0
comparable	O 0
genotypes	O 0
.	O 0

GALT	O 0
protein	O 0
abundance	O 0
was	O 0
increased	O 0
in	O 0
LA	O 0
compared	O 0
to	O 0
D	O 0
alleles	O 0
,	O 0
but	O 0
mRNA	O 0
was	O 0
similar	O 0
among	O 0
all	O 0
genotypes	O 0
.	O 0

When	O 0
LA	O 0
/	O 0
D	O 0
and	O 0
D	O 0
/	O 0
D	O 0
GALT	O 0
biochemical	O 0
phenotypes	O 0
were	O 0
compared	O 0
to	O 0
N	O 0
/	O 0
N	O 0
GALT	O 0
phenotypes	O 0
,	O 0
both	O 0
had	O 0
50	O 0
%	O 0
,	O 0
as	O 0
compared	O 0
to	O 0
21	O 0
%	O 0
,	O 0
reduction	O 0
in	O 0
GALT	O 0
activity	O 0
in	O 0
the	O 0
wild	O 0
type	O 0
(	O 0
N	O 0
/	O 0
N	O 0
)	O 0
after	O 0
exposure	O 0
at	O 0
identical	O 0
initial	O 0
enzyme	O 0
activity	O 0
to	O 0
50	O 0
degrees	O 0
C	O 0
for	O 0
15	O 0
min	O 0
.	O 0

We	O 0
conclude	O 0
that	O 0
the	O 0
codon	O 0
change	O 0
N314D	O 0
in	O 0
cis	O 0
with	O 0
the	O 0
base	O 0
-	O 0
pair	O 0
transition	O 0
1721C	O 0
-	O 0
-	O 0
>	O 0
T	O 0
produces	O 0
the	O 0
LA	B-Disease 0
variant	I-Disease 0
of	I-Disease 0
galactosemia	I-Disease 0
and	O 0
that	O 0
this	O 0
nucleotide	O 0
change	O 0
increases	O 0
GALT	O 0
activity	O 0
by	O 0
increasing	O 0
GALT	O 0
protein	O 0
abundance	O 0
without	O 0
increasing	O 0
transcription	O 0
or	O 0
decreasing	O 0
thermal	O 0
lability	O 0
.	O 0

A	O 0
favorable	O 0
codon	O 0
bias	O 0
for	O 0
the	O 0
mutated	O 0
codon	O 0
with	O 0
consequently	O 0
increased	O 0
translation	O 0
rates	O 0
is	O 0
postulated	O 0
as	O 0
the	O 0
mechanism	O 0
.	O 0
.	O 0

The	O 0
TSG101	O 0
tumor	B-Disease 0
susceptibility	O 0
gene	O 0
is	O 0
located	O 0
in	O 0
chromosome	O 0
11	O 0
band	O 0
p15	O 0
and	O 0
is	O 0
mutated	O 0
in	O 0
human	O 0
breast	B-Disease 0
cancer	I-Disease 0
.	O 0

Recent	O 0
work	O 0
has	O 0
identified	O 0
a	O 0
mouse	O 0
gene	O 0
(	O 0
tsg101	O 0
)	O 0
whose	O 0
inactivation	O 0
in	O 0
fibroblasts	O 0
results	O 0
in	O 0
cellular	O 0
transformation	O 0
and	O 0
the	O 0
ability	O 0
to	O 0
produce	O 0
metastatic	B-Disease 0
tumors	I-Disease 0
in	O 0
nude	O 0
mice	O 0
.	O 0

Here	O 0
,	O 0
we	O 0
report	O 0
that	O 0
the	O 0
human	O 0
homolog	O 0
,	O 0
TSG101	O 0
,	O 0
which	O 0
we	O 0
isolated	O 0
and	O 0
mapped	O 0
to	O 0
chromosome	O 0
11	O 0
,	O 0
bands	O 0
15	O 0
.	O 0

1	O 0
-	O 0
15	O 0
1	O 0
-	O 0
15	O 0
.	O 0

2	O 0
,	O 0
a	O 0
region	O 0
proposed	O 0
to	O 0
contain	O 0
tumor	B-Disease 0
suppressor	O 0
gene	O 0
(	O 0
s	O 0
)	O 0
,	O 0
is	O 0
mutated	O 0
at	O 0
high	O 0
frequency	O 0
in	O 0
human	O 0
breast	B-Disease 0
cancer	I-Disease 0
.	O 0

In	O 0
7	O 0
of	O 0
15	O 0
uncultured	O 0
primary	O 0
human	O 0
breast	B-Disease 0
carcinomas	I-Disease 0
,	O 0
intragenic	O 0
deletions	O 0
were	O 0
shown	O 0
in	O 0
TSG101	O 0
genomic	O 0
DNA	O 0
and	O 0
transcripts	O 0
by	O 0
gel	O 0
and	O 0
sequence	O 0
analysis	O 0
,	O 0
and	O 0
mutations	O 0
affecting	O 0
two	O 0
TSG101	O 0
alleles	O 0
were	O 0
identified	O 0
in	O 0
four	O 0
of	O 0
these	O 0
cancers	B-Disease 0
.	O 0

No	O 0
TSG101	O 0
defects	O 0
were	O 0
found	O 0
in	O 0
matched	O 0
normal	O 0
breast	O 0
tissue	O 0
from	O 0
the	O 0
breast	B-Disease 0
cancer	I-Disease 0
patients	O 0
.	O 0

These	O 0
findings	O 0
strongly	O 0
implicate	O 0
TSG101	O 0
mutations	O 0
in	O 0
human	O 0
breast	B-Disease 0
cancer	I-Disease 0

Moderate	O 0
intergenerational	O 0
and	O 0
somatic	O 0
instability	O 0
of	O 0
a	O 0
55	O 0
-	O 0
CTG	O 0
repeat	O 0
in	O 0
transgenic	O 0
mice	O 0
.	O 0

Myotonic	B-Disease 0
dystrophy	I-Disease 0
(	O 0
DM	B-Disease 0
)	O 0
is	O 0
associated	O 0
with	O 0
the	O 0
expansion	O 0
of	O 0
a	O 0
(	O 0
CTG	O 0
)	O 0
n	O 0
trinucleotide	O 0
repeat	O 0
in	O 0
the	O 0
3	O 0
untranslated	O 0
region	O 0
(	O 0
UTR	O 0
)	O 0
of	O 0
the	O 0
DM	B-Disease 0
protein	O 0
kinase	O 0
gene	O 0
(	O 0
DMPK	O 0
)	O 0
.	O 0

The	O 0
(	O 0
CTG	O 0
)	O 0
n	O 0
repeat	O 0
is	O 0
polymorphic	O 0
and	O 0
varies	O 0
in	O 0
size	O 0
between	O 0
5	O 0
and	O 0
37	O 0
repeats	O 0
in	O 0
unaffected	O 0
individuals	O 0
whereas	O 0
in	O 0
affected	O 0
patients	O 0
there	O 0
are	O 0
between	O 0
50	O 0
and	O 0
4	O 0
,	O 0
000	O 0
CTGs	O 0
.	O 0

The	O 0
size	O 0
of	O 0
the	O 0
(	O 0
CTG	O 0
)	O 0
n	O 0
repeat	O 0
,	O 0
which	O 0
increases	O 0
through	O 0
generations	O 0
,	O 0
generally	O 0
correlates	O 0
with	O 0
clinical	O 0
severity	O 0
and	O 0
age	O 0
of	O 0
onset	O 0
.	O 0

The	O 0
instability	O 0
of	O 0
the	O 0
CTG	O 0
repeat	O 0
appears	O 0
to	O 0
depend	O 0
on	O 0
its	O 0
size	O 0
as	O 0
well	O 0
as	O 0
on	O 0
the	O 0
sex	O 0
of	O 0
the	O 0
transmitting	O 0
parent	O 0
.	O 0

Moreover	O 0
,	O 0
mitotic	O 0
instability	O 0
analysis	O 0
of	O 0
different	O 0
human	O 0
DM	B-Disease 0
tissues	O 0
shows	O 0
length	O 0
mosaicism	O 0
between	O 0
different	O 0
cell	O 0
lineages	O 0
.	O 0

The	O 0
molecular	O 0
mechanisms	O 0
of	O 0
triplet	O 0
instability	O 0
remain	O 0
elusive	O 0
.	O 0

To	O 0
investigate	O 0
the	O 0
role	O 0
of	O 0
genomic	O 0
sequences	O 0
in	O 0
instability	O 0
,	O 0
we	O 0
produced	O 0
transgenic	O 0
mice	O 0
containing	O 0
a	O 0
45	O 0
-	O 0
kb	O 0
genomic	O 0
segment	O 0
with	O 0
a	O 0
55	O 0
-	O 0
CTG	O 0
repeat	O 0
cloned	O 0
from	O 0
a	O 0
mildly	O 0
affected	O 0
patient	O 0
.	O 0

In	O 0
contrast	O 0
to	O 0
other	O 0
mouse	O 0
models	O 0
containing	O 0
CAG	O 0
repeats	O 0
within	O 0
cDNAs	O 0
,	O 0
these	O 0
mice	O 0
showed	O 0
both	O 0
intergenerational	O 0
and	O 0
somatic	O 0
repeat	O 0
instability	O 0
.	O 0
.	O 0

Missense	O 0
mutations	O 0
in	O 0
the	O 0
Fas	O 0
gene	O 0
resulting	O 0
in	O 0
autoimmune	B-Disease 0
lymphoproliferative	I-Disease 0
syndrome	I-Disease 0
:	O 0
a	O 0
molecular	O 0
and	O 0
immunological	O 0
analysis	O 0
.	O 0

Programmed	O 0
cell	O 0
death	O 0
(	O 0
or	O 0
apoptosis	O 0
)	O 0
is	O 0
a	O 0
physiological	O 0
process	O 0
essential	O 0
to	O 0
the	O 0
normal	O 0
development	O 0
and	O 0
homeostatic	O 0
maintenance	O 0
of	O 0
the	O 0
immune	O 0
system	O 0
.	O 0

The	O 0
Fas	O 0
/	O 0
Apo	O 0
-	O 0
1	O 0
receptor	O 0
plays	O 0
a	O 0
crucial	O 0
role	O 0
in	O 0
the	O 0
regulation	O 0
of	O 0
apoptosis	O 0
,	O 0
as	O 0
demonstrated	O 0
by	O 0
lymphoproliferation	O 0
in	O 0
MRL	O 0
-	O 0
lpr	O 0
/	O 0
lpr	O 0
mice	O 0
and	O 0
by	O 0
the	O 0
recently	O 0
described	O 0
autoimmune	B-Disease 0
lymphoproliferative	I-Disease 0
syndrome	I-Disease 0
(	O 0
ALPS	B-Disease 0
)	O 0
in	O 0
humans	O 0
,	O 0
both	O 0
of	O 0
which	O 0
are	O 0
due	O 0
to	O 0
mutations	O 0
in	O 0
the	O 0
Fas	O 0
gene	O 0
.	O 0

We	O 0
describe	O 0
a	O 0
novel	O 0
family	O 0
with	O 0
ALPS	B-Disease 0
in	O 0
which	O 0
three	O 0
affected	O 0
siblings	O 0
carry	O 0
two	O 0
distinct	O 0
missense	O 0
mutations	O 0
on	O 0
both	O 0
the	O 0
Fas	O 0
gene	O 0
alleles	O 0
and	O 0
show	O 0
lack	O 0
of	O 0
Fas	O 0
-	O 0
induced	O 0
apoptosis	O 0
.	O 0

The	O 0
children	O 0
share	O 0
common	O 0
clinical	O 0
features	O 0
including	O 0
splenomegaly	B-Disease 0
and	O 0
lymphadenopathy	B-Disease 0
,	O 0
but	O 0
only	O 0
one	O 0
developed	O 0
severe	O 0
autoimmune	B-Disease 0
manifestations	I-Disease 0
.	O 0

In	O 0
all	O 0
three	O 0
siblings	O 0
,	O 0
we	O 0
demonstrated	O 0
the	O 0
presence	O 0
of	O 0
anergic	O 0
CD3	O 0
+	O 0
CD4	O 0
-	O 0
CD8	O 0
-	O 0
(	O 0
double	O 0
negative	O 0
,	O 0
[	O 0
DN	O 0
]	O 0
)	O 0
T	O 0
cells	O 0
;	O 0
moreover	O 0
,	O 0
a	O 0
chronic	O 0
lymphocyte	O 0
activation	O 0
was	O 0
found	O 0
,	O 0
as	O 0
demonstrated	O 0
by	O 0
the	O 0
presence	O 0
of	O 0
high	O 0
levels	O 0
of	O 0
HLA	O 0
-	O 0
DR	O 0
expression	O 0
on	O 0
peripheral	O 0
CD3	O 0
+	O 0
cells	O 0
and	O 0
by	O 0
the	O 0
presence	O 0
of	O 0
high	O 0
levels	O 0
of	O 0
serum	O 0
activation	O 0
markers	O 0
such	O 0
as	O 0
soluble	O 0
interleukin	O 0
-	O 0
2	O 0
receptor	O 0
(	O 0
slL	O 0
-	O 0
2R	O 0
)	O 0
and	O 0
soluble	O 0
CD30	O 0
(	O 0
sCD30	O 0
)	O 0
.	O 0
.	O 0

The	O 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
gene	O 0
product	O 0
,	O 0
a	O 0
constitutively	O 0
expressed	O 0
nuclear	O 0
protein	O 0
that	O 0
is	O 0
not	O 0
up	O 0
-	O 0
regulated	O 0
following	O 0
genome	O 0
damage	O 0
.	O 0

The	O 0
product	O 0
of	O 0
the	O 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
gene	O 0
(	O 0
ATM	O 0
)	O 0
was	O 0
identified	O 0
by	O 0
using	O 0
an	O 0
antiserum	O 0
developed	O 0
to	O 0
a	O 0
peptide	O 0
corresponding	O 0
to	O 0
the	O 0
deduced	O 0
amino	O 0
acid	O 0
sequence	O 0
.	O 0

The	O 0
ATM	O 0
protein	O 0
is	O 0
a	O 0
single	O 0
,	O 0
high	O 0
-	O 0
molecular	O 0
weight	O 0
protein	O 0
predominantly	O 0
confined	O 0
to	O 0
the	O 0
nucleus	O 0
of	O 0
human	O 0
fibroblasts	O 0
,	O 0
but	O 0
is	O 0
present	O 0
in	O 0
both	O 0
nuclear	O 0
and	O 0
microsomal	O 0
fractions	O 0
from	O 0
human	O 0
lymphoblast	O 0
cells	O 0
and	O 0
peripheral	O 0
blood	O 0
lymphocytes	O 0
.	O 0

ATM	O 0
protein	O 0
levels	O 0
and	O 0
localization	O 0
remain	O 0
constant	O 0
throughout	O 0
all	O 0
stages	O 0
of	O 0
the	O 0
cell	O 0
cycle	O 0
.	O 0

Truncated	O 0
ATM	O 0
protein	O 0
was	O 0
not	O 0
detected	O 0
in	O 0
lymphoblasts	O 0
from	O 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
patients	O 0
homozygous	O 0
for	O 0
mutations	O 0
leading	O 0
to	O 0
premature	O 0
protein	O 0
termination	O 0
.	O 0

Exposure	O 0
of	O 0
normal	O 0
human	O 0
cells	O 0
to	O 0
gamma	O 0
-	O 0
irradiation	O 0
and	O 0
the	O 0
radiomimetic	O 0
drug	O 0
neocarzinostatin	O 0
had	O 0
no	O 0
effect	O 0
on	O 0
ATM	O 0
protein	O 0
levels	O 0
,	O 0
in	O 0
contrast	O 0
to	O 0
a	O 0
noted	O 0
rise	O 0
in	O 0
p53	O 0
levels	O 0
over	O 0
the	O 0
same	O 0
time	O 0
interval	O 0
.	O 0

These	O 0
findings	O 0
are	O 0
consistent	O 0
with	O 0
a	O 0
role	O 0
for	O 0
the	O 0
ATM	O 0
protein	O 0
in	O 0
ensuring	O 0
the	O 0
fidelity	O 0
of	O 0
DNA	O 0
repair	O 0
and	O 0
cell	O 0
cycle	O 0
regulation	O 0
following	O 0
genome	O 0
damage	O 0
.	O 0
.	O 0

Type	O 0
III	O 0
collagen	O 0
is	O 0
crucial	O 0
for	O 0
collagen	O 0
I	O 0
fibrillogenesis	O 0
and	O 0
for	O 0
normal	O 0
cardiovascular	O 0
development	O 0
.	O 0

Type	O 0
III	O 0
collagen	O 0
is	O 0
a	O 0
fibrillar	O 0
forming	O 0
collagen	O 0
comprising	O 0
three	O 0
alpha1	O 0
(	O 0
III	O 0
)	O 0
chains	O 0
and	O 0
is	O 0
expressed	O 0
in	O 0
early	O 0
embryos	O 0
and	O 0
throughout	O 0
embryogenesis	O 0
.	O 0

In	O 0
the	O 0
adult	O 0
,	O 0
type	O 0
III	O 0
collagen	O 0
is	O 0
a	O 0
major	O 0
component	O 0
of	O 0
the	O 0
extracellular	O 0
matrix	O 0
in	O 0
a	O 0
variety	O 0
of	O 0
internal	O 0
organs	O 0
and	O 0
skin	O 0
.	O 0

Mutations	O 0
in	O 0
the	O 0
COL3A1	O 0
gene	O 0
have	O 0
been	O 0
implicated	O 0
as	O 0
a	O 0
cause	O 0
of	O 0
type	B-Disease 0
IV	I-Disease 0
Ehlers	I-Disease 0
-	I-Disease 0
Danlos	I-Disease 0
syndrome	I-Disease 0
,	O 0
a	O 0
disease	O 0
leading	O 0
to	O 0
aortic	B-Disease 0
rupture	I-Disease 0
in	O 0
early	O 0
adult	O 0
life	O 0
.	O 0

To	O 0
directly	O 0
study	O 0
the	O 0
role	O 0
of	O 0
Col3a1	O 0
in	O 0
development	O 0
and	O 0
disease	O 0
,	O 0
we	O 0
have	O 0
inactivated	O 0
the	O 0
Col3a1	O 0
gene	O 0
in	O 0
embryonic	O 0
stem	O 0
cells	O 0
by	O 0
homologous	O 0
recombination	O 0
.	O 0

The	O 0
mutated	O 0
allele	O 0
was	O 0
transmitted	O 0
through	O 0
the	O 0
mouse	O 0
germ	O 0
line	O 0
and	O 0
homozygous	O 0
mutant	O 0
animals	O 0
were	O 0
derived	O 0
from	O 0
heterozygous	O 0
intercrosses	O 0
.	O 0

About	O 0
10	O 0
%	O 0
of	O 0
the	O 0
homozygous	O 0
mutant	O 0
animals	O 0
survived	O 0
to	O 0
adulthood	O 0
but	O 0
have	O 0
a	O 0
much	O 0
shorter	O 0
life	O 0
span	O 0
compared	O 0
with	O 0
wild	O 0
-	O 0
type	O 0
mice	O 0
.	O 0

The	O 0
major	O 0
cause	O 0
of	O 0
death	O 0
of	O 0
mutant	O 0
mice	O 0
was	O 0
rupture	O 0
of	O 0
the	O 0
major	O 0
blood	O 0
vessels	O 0
,	O 0
similar	O 0
to	O 0
patients	O 0
with	O 0
type	B-Disease 0
IV	I-Disease 0
Ehlers	I-Disease 0
-	I-Disease 0
Danlos	I-Disease 0
syndrome	I-Disease 0
.	O 0

Ultrastructural	O 0
analysis	O 0
of	O 0
tissues	O 0
from	O 0
mutant	O 0
mice	O 0
revealed	O 0
that	O 0
type	O 0
III	O 0
collagen	O 0
is	O 0
essential	O 0
for	O 0
normal	O 0
collagen	O 0
I	O 0
fibrillogenesis	O 0
in	O 0
the	O 0
cardiovascular	O 0
system	O 0
and	O 0
other	O 0
organs	O 0
.	O 0
.	O 0

Nonsense	O 0
mutation	O 0
in	O 0
exon	O 0
3	O 0
of	O 0
the	O 0
proteolipid	O 0
protein	O 0
gene	O 0
(	O 0
PLP	O 0
)	O 0
in	O 0
a	O 0
family	O 0
with	O 0
an	O 0
unusual	O 0
form	O 0
of	O 0
Pelizaeus	B-Disease 0
-	I-Disease 0
Merzbacher	I-Disease 0
disease	I-Disease 0
.	O 0

We	O 0
report	O 0
a	O 0
G	O 0
-	O 0
-	O 0
>	O 0
A	O 0
transition	O 0
at	O 0
nucleotide	O 0
431	O 0
of	O 0
the	O 0
proteolipid	O 0
protein	O 0
gene	O 0
(	O 0
PLP	O 0
)	O 0
results	O 0
in	O 0
a	O 0
nonsense	O 0
codon	O 0
in	O 0
a	O 0
family	O 0
with	O 0
an	O 0
unusual	O 0
form	O 0
of	O 0
Pelizaeus	B-Disease 0
-	I-Disease 0
Merzbacher	I-Disease 0
disease	I-Disease 0
(	O 0
PMD	B-Disease 0
)	O 0
.	O 0

The	O 0
mutation	O 0
,	O 0
which	O 0
creates	O 0
a	O 0
second	O 0
AluI	O 0
restriction	O 0
site	O 0
,	O 0
results	O 0
in	O 0
a	O 0
nonsense	O 0
mutation	O 0
in	O 0
PLP	O 0
.	O 0

The	O 0
clinical	O 0
picture	O 0
resembles	O 0
somewhat	O 0
that	O 0
of	O 0
X	B-Disease 0
-	I-Disease 0
linked	I-Disease 0
spastic	I-Disease 0
paraplegia	I-Disease 0
(	O 0
SPG	B-Disease 0
)	O 0
.	O 0

It	O 0
differs	O 0
from	O 0
this	O 0
and	O 0
both	O 0
the	O 0
classical	O 0
and	O 0
connatal	O 0
forms	O 0
of	O 0
PMD	B-Disease 0
in	O 0
that	O 0
it	O 0
is	O 0
relatively	O 0
mild	O 0
in	O 0
form	O 0
,	O 0
onset	O 0
is	O 0
delayed	O 0
beyond	O 0
age	O 0
2	O 0
years	O 0
,	O 0
nystagmus	B-Disease 0
is	O 0
absent	O 0
,	O 0
tremors	B-Disease 0
are	O 0
prominent	O 0
,	O 0
mental	B-Disease 0
retardation	I-Disease 0
is	O 0
not	O 0
severe	O 0
,	O 0
some	O 0
patients	O 0
show	O 0
dementia	B-Disease 0
or	O 0
personality	B-Disease 0
disorders	I-Disease 0
,	O 0
the	O 0
disease	O 0
is	O 0
progressive	O 0
rather	O 0
than	O 0
static	O 0
in	O 0
some	O 0
,	O 0
and	O 0
several	O 0
females	O 0
show	O 0
signs	O 0
of	O 0
disease	O 0
.	O 0

The	O 0
nonsense	O 0
mutation	O 0
,	O 0
which	O 0
is	O 0
in	O 0
exon	O 0
3B	O 0
,	O 0
should	O 0
block	O 0
the	O 0
synthesis	O 0
of	O 0
normal	O 0
PLP	O 0
but	O 0
spare	O 0
DM20	O 0
,	O 0
the	O 0
isoform	O 0
whose	O 0
persistence	O 0
has	O 0
been	O 0
associated	O 0
with	O 0
mild	O 0
forms	O 0
of	O 0
PLP	B-Disease 0
-	I-Disease 0
associated	I-Disease 0
disease	I-Disease 0
in	O 0
both	O 0
humans	O 0
and	O 0
mice	O 0
.	O 0
.	O 0

Common	O 0
BRCA1	O 0
variants	O 0
and	O 0
susceptibility	O 0
to	O 0
breast	B-Disease 0
and	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
in	O 0
the	O 0
general	O 0
population	O 0
.	O 0

Most	O 0
multiple	O 0
case	O 0
families	O 0
of	O 0
young	O 0
onset	O 0
breast	B-Disease 0
cancer	I-Disease 0
and	O 0
ovarian	B-Disease 0
cancer	I-Disease 0
are	O 0
thought	O 0
to	O 0
be	O 0
due	O 0
to	O 0
highly	O 0
penetrant	O 0
mutations	O 0
in	O 0
the	O 0
predisposing	O 0
genes	O 0
BRCA1	O 0
and	O 0
BRCA2	O 0
.	O 0

However	O 0
,	O 0
these	O 0
mutations	O 0
are	O 0
uncommon	O 0
in	O 0
the	O 0
population	O 0
and	O 0
they	O 0
probably	O 0
account	O 0
for	O 0
only	O 0
a	O 0
few	O 0
percent	O 0
of	O 0
all	O 0
breast	B-Disease 0
cancer	I-Disease 0
incidence	O 0
.	O 0

A	O 0
much	O 0
larger	O 0
fraction	O 0
of	O 0
breast	B-Disease 0
cancer	I-Disease 0
might	O 0
,	O 0
in	O 0
principle	O 0
,	O 0
be	O 0
due	O 0
to	O 0
common	O 0
variants	O 0
which	O 0
confer	O 0
more	O 0
modest	O 0
individual	O 0
risks	O 0
.	O 0

There	O 0
are	O 0
several	O 0
common	O 0
polymorphisms	O 0
in	O 0
the	O 0
BRCA1	O 0
gene	O 0
which	O 0
generate	O 0
amino	O 0
acid	O 0
substitutions	O 0
.	O 0

We	O 0
have	O 0
examined	O 0
the	O 0
frequency	O 0
of	O 0
four	O 0
of	O 0
these	O 0
polymorphisms	O 0
Gln356Arg	O 0
,	O 0
Pro871Leu	O 0
,	O 0
Glu1038Gly	O 0
and	O 0
Ser1613Gly	O 0
in	O 0
large	O 0
series	O 0
of	O 0
breast	B-Disease 0
and	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
cases	O 0
and	O 0
matched	O 0
controls	O 0
.	O 0

Due	O 0
to	O 0
strong	O 0
linkage	O 0
disequilibrium	O 0
,	O 0
these	O 0
four	O 0
sites	O 0
generate	O 0
only	O 0
three	O 0
haplotypes	O 0
with	O 0
a	O 0
frequency	O 0
>	O 0
1	O 0
.	O 0

3	O 0
%	O 0
.	O 0

The	O 0
most	O 0
common	O 0
haplotypes	O 0
,	O 0
defined	O 0
by	O 0
the	O 0
alleles	O 0
Gln356Pro871Glu1038Ser1613	O 0
and	O 0
Gln356Leu871Gly1038Gly1613	O 0
,	O 0
have	O 0
frequencies	O 0
of	O 0
0	O 0
.	O 0

57	O 0
and	O 0
0	O 0
.	O 0

32	O 0
respectively	O 0
,	O 0
and	O 0
these	O 0
frequencies	O 0
do	O 0
not	O 0
differ	O 0
significantly	O 0
between	O 0
patient	O 0
and	O 0
control	O 0
groups	O 0
.	O 0

Thus	O 0
the	O 0
most	O 0
common	O 0
polymorphisms	O 0
of	O 0
the	O 0
BRCA1	O 0
gene	O 0
do	O 0
not	O 0
make	O 0
a	O 0
significant	O 0
contribution	O 0
to	O 0
breast	B-Disease 0
or	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
risk	O 0
.	O 0

However	O 0
,	O 0
our	O 0
data	O 0
suggest	O 0
that	O 0
the	O 0
Arg356	O 0
allele	O 0
may	O 0
have	O 0
a	O 0
different	O 0
genotype	O 0
distribution	O 0
in	O 0
breast	B-Disease 0
cancer	I-Disease 0
patients	O 0
from	O 0
that	O 0
in	O 0
controls	O 0
(	O 0
Arg356	O 0
homozygotes	O 0
are	O 0
more	O 0
frequent	O 0
in	O 0
the	O 0
control	O 0
groups	O 0
,	O 0
P	O 0
=	O 0
0	O 0
.	O 0
01	O 0
)	O 0
,	O 0
indicating	O 0
that	O 0
it	O 0
may	O 0
be	O 0
protective	O 0
against	O 0
breast	B-Disease 0
cancer	I-Disease 0
.	O 0

If	O 0
this	O 0
finding	O 0
can	O 0
be	O 0
confirmed	O 0
,	O 0
it	O 0
may	O 0
provide	O 0
an	O 0
insight	O 0
into	O 0
the	O 0
structural	O 0
features	O 0
of	O 0
the	O 0
BRCA1	O 0
protein	O 0
that	O 0
are	O 0
important	O 0
for	O 0
its	O 0
function	O 0
.	O 0

Kniest	B-Disease 0
dysplasia	I-Disease 0
:	O 0
Dr	O 0
.	O 0
W	O 0
.	O 0

Kniest	O 0
,	O 0
his	O 0
patient	O 0
,	O 0
the	O 0
molecular	O 0
defect	O 0
.	O 0

Kniest	B-Disease 0
dysplasia	I-Disease 0
is	O 0
a	O 0
severe	O 0
chondrodysplasia	B-Disease 0
caused	O 0
by	O 0
the	O 0
defective	B-Disease 0
formation	I-Disease 0
of	I-Disease 0
type	I-Disease 0
II	I-Disease 0
collagen	I-Disease 0
.	O 0

We	O 0
report	O 0
about	O 0
Dr	O 0
.	O 0
Kniest	O 0
,	O 0
who	O 0
first	O 0
described	O 0
the	O 0
condition	O 0
in	O 0
1952	O 0
,	O 0
and	O 0
his	O 0
patient	O 0
,	O 0
who	O 0
,	O 0
at	O 0
the	O 0
age	O 0
of	O 0
50	O 0
years	O 0
is	O 0
severely	B-Disease 0
handicapped	I-Disease 0
with	O 0
short	B-Disease 0
stature	I-Disease 0
,	O 0
restricted	B-Disease 0
joint	I-Disease 0
mobility	I-Disease 0
,	O 0
and	O 0
blindness	B-Disease 0
but	O 0
is	O 0
mentally	O 0
alert	O 0
and	O 0
leads	O 0
an	O 0
active	O 0
life	O 0
.	O 0

Molecular	O 0
analysis	O 0
of	O 0
the	O 0
patients	O 0
DNA	O 0
showed	O 0
a	O 0
single	O 0
base	O 0
(	O 0
G	O 0
)	O 0
deletion	O 0
involving	O 0
the	O 0
GT	O 0
dinucleotide	O 0
at	O 0
the	O 0
start	O 0
of	O 0
intron	O 0
18	O 0
destroying	O 0
a	O 0
splice	O 0
site	O 0
of	O 0
the	O 0
COL2A1	O 0
gene	O 0
.	O 0

This	O 0
is	O 0
in	O 0
accordance	O 0
with	O 0
molecular	O 0
findings	O 0
in	O 0
other	O 0
patients	O 0
with	O 0
Kniest	B-Disease 0
dysplasia	I-Disease 0
and	O 0
confirms	O 0
,	O 0
in	O 0
the	O 0
original	O 0
patient	O 0
,	O 0
that	O 0
the	O 0
disorder	O 0
is	O 0
caused	O 0
by	O 0
small	O 0
inframe	O 0
deletions	O 0
often	O 0
due	O 0
to	O 0
exon	O 0
skipping	O 0
as	O 0
a	O 0
result	O 0
of	O 0
COL2A1	O 0
splice	O 0
site	O 0
mutations	O 0
.	O 0
.	O 0

Cloning	O 0
of	O 0
the	O 0
homogentisate	O 0
1	O 0
,	O 0
2	O 0
-	O 0
dioxygenase	O 0
gene	O 0
,	O 0
the	O 0
key	O 0
enzyme	O 0
of	O 0
alkaptonuria	B-Disease 0
in	O 0
mouse	O 0
.	O 0

We	O 0
determined	O 0
48	O 0
amino	O 0
acid	O 0
residues	O 0
from	O 0
five	O 0
peptides	O 0
from	O 0
the	O 0
homogeneous	O 0
monomer	O 0
of	O 0
homogentisate	O 0
1	O 0
,	O 0
2	O 0
-	O 0
dioxygenase	O 0
(	O 0
HGO	O 0
;	O 0
E	O 0
.	O 0
C	O 0
.	O 0
1	O 0
.	O 0
13	O 0
.	O 0
11	O 0
.	O 0
15	O 0
)	O 0
of	O 0
mouse	O 0
liver	O 0
.	O 0

After	O 0
digestion	O 0
with	O 0
trypsin	O 0
,	O 0
peptides	O 0
were	O 0
separated	O 0
by	O 0
reversed	O 0
phase	O 0
chromatography	O 0
and	O 0
amino	O 0
acid	O 0
sequenced	O 0
.	O 0

The	O 0
deduced	O 0
codon	O 0
sequence	O 0
of	O 0
three	O 0
peptides	O 0
was	O 0
used	O 0
to	O 0
derive	O 0
degenerated	O 0
oligomeres	O 0
.	O 0

By	O 0
combining	O 0
these	O 0
oligos	O 0
,	O 0
we	O 0
were	O 0
able	O 0
to	O 0
amplify	O 0
fragments	O 0
from	O 0
100	O 0
to	O 0
300	O 0
bases	O 0
(	O 0
b	O 0
)	O 0
from	O 0
mouse	O 0
liver	O 0
cDNA	O 0
by	O 0
polymerase	O 0
chain	O 0
reaction	O 0
after	O 0
reverse	O 0
transcription	O 0
(	O 0
RT	O 0
-	O 0
PCR	O 0
)	O 0
.	O 0

A	O 0
fragment	O 0
of	O 0
200	O 0
b	O 0
was	O 0
cloned	O 0
and	O 0
used	O 0
as	O 0
a	O 0
probe	O 0
to	O 0
screen	O 0
a	O 0
mouse	O 0
liver	O 0
cDNA	O 0
library	O 0
.	O 0

One	O 0
clone	O 0
from	O 0
this	O 0
library	O 0
contained	O 0
the	O 0
complete	O 0
cDNA	O 0
-	O 0
insert	O 0
for	O 0
HGO	O 0
as	O 0
determined	O 0
by	O 0
sequencing	O 0
.	O 0

The	O 0
cDNA	O 0
encodes	O 0
for	O 0
a	O 0
protein	O 0
of	O 0
50	O 0
kDa	O 0
,	O 0
as	O 0
predicted	O 0
.	O 0

The	O 0
cDNA	O 0
of	O 0
mouse	O 0
HGO	O 0
has	O 0
an	O 0
overall	O 0
identity	O 0
of	O 0
41	O 0
%	O 0
to	O 0
the	O 0
corresponding	O 0
gene	O 0
hmgA	O 0
from	O 0
Aspergillus	O 0
.	O 0

Sequence	O 0
similarities	O 0
to	O 0
human	O 0
expressed	O 0
sequence	O 0
tags	O 0
(	O 0
EST	O 0
)	O 0
clones	O 0
ranged	O 0
from	O 0
70	O 0
%	O 0
to	O 0
20	O 0
%	O 0
.	O 0

The	O 0
positions	O 0
of	O 0
122	O 0
conserved	O 0
amino	O 0
acids	O 0
could	O 0
be	O 0
determined	O 0
by	O 0
multiple	O 0
sequence	O 0
alignment	O 0
.	O 0

We	O 0
identified	O 0
one	O 0
first	O 0
intron	O 0
of	O 0
928	O 0
b	O 0
in	O 0
the	O 0
mouse	O 0
gene	O 0
.	O 0

The	O 0
gene	O 0
for	O 0
HGO	O 0
seems	O 0
to	O 0
be	O 0
expressed	O 0
in	O 0
various	O 0
tissues	O 0
,	O 0
as	O 0
shown	O 0
by	O 0
RT	O 0
-	O 0
PCR	O 0
on	O 0
different	O 0
cDNAs	O 0
.	O 0

FISH	O 0
experiments	O 0
with	O 0
the	O 0
whole	O 0
murine	O 0
cDNA	O 0
as	O 0
probe	O 0
clearly	O 0
revealed	O 0
signals	O 0
at	O 0
the	O 0
human	O 0
chromosomal	O 0
band	O 0
3q13	O 0
.	O 0

3	O 0
-	O 0
q21	O 0
.	O 0

This	O 0
corresponds	O 0
well	O 0
to	O 0
the	O 0
previous	O 0
assignment	O 0
of	O 0
the	O 0
locus	O 0
for	O 0
the	O 0
human	O 0
alkaptonuria	B-Disease 0
gene	O 0
(	O 0
AKU	O 0
)	O 0
to	O 0
the	O 0
same	O 0
chromosomal	O 0
region	O 0
by	O 0
multipoint	O 0
linkage	O 0
analysis	O 0
.	O 0

We	O 0
therefore	O 0
conclude	O 0
that	O 0
the	O 0
HGO	O 0
cDNA	O 0
encodes	O 0
the	O 0
gene	O 0
responsible	O 0
for	O 0
alkaptonuria	B-Disease 0
.	O 0

PTEN	O 0
,	O 0
a	O 0
putative	O 0
protein	O 0
tyrosine	O 0
phosphatase	O 0
gene	O 0
mutated	O 0
in	O 0
human	O 0
brain	B-Disease 0
,	I-Disease 0
breast	I-Disease 0
,	I-Disease 0
and	I-Disease 0
prostate	I-Disease 0
cancer	I-Disease 0
.	O 0

Mapping	O 0
of	O 0
homozygous	O 0
deletions	O 0
on	O 0
human	O 0
chromosome	O 0
10q23	O 0
has	O 0
led	O 0
to	O 0
the	O 0
isolation	O 0
of	O 0
a	O 0
candidate	O 0
tumor	B-Disease 0
suppressor	O 0
gene	O 0
,	O 0
PTEN	O 0
,	O 0
that	O 0
appears	O 0
to	O 0
be	O 0
mutated	O 0
at	O 0
considerable	O 0
frequency	O 0
in	O 0
human	O 0
cancers	B-Disease 0
.	O 0

In	O 0
preliminary	O 0
screens	O 0
,	O 0
mutations	O 0
of	O 0
PTEN	O 0
were	O 0
detected	O 0
in	O 0
31	O 0
%	O 0
(	O 0
13	O 0
/	O 0
42	O 0
)	O 0
of	O 0
glioblastoma	B-Disease 0
cell	O 0
lines	O 0
and	O 0
xenografts	O 0
,	O 0
100	O 0
%	O 0
(	O 0
4	O 0
/	O 0
4	O 0
)	O 0
of	O 0
prostate	B-Disease 0
cancer	I-Disease 0
cell	O 0
lines	O 0
,	O 0
6	O 0
%	O 0
(	O 0
4	O 0
/	O 0
65	O 0
)	O 0
of	O 0
breast	B-Disease 0
cancer	I-Disease 0
cell	O 0
lines	O 0
and	O 0
xenografts	O 0
,	O 0
and	O 0
17	O 0
%	O 0
(	O 0
3	O 0
/	O 0
18	O 0
)	O 0
of	O 0
primary	B-Disease 0
glioblastomas	I-Disease 0
.	O 0

The	O 0
predicted	O 0
PTEN	O 0
product	O 0
has	O 0
a	O 0
protein	O 0
tyrosine	O 0
phosphatase	O 0
domain	O 0
and	O 0
extensive	O 0
homology	O 0
to	O 0
tensin	O 0
,	O 0
a	O 0
protein	O 0
that	O 0
interacts	O 0
with	O 0
actin	O 0
filaments	O 0
at	O 0
focal	O 0
adhesions	O 0
.	O 0

These	O 0
homologies	O 0
suggest	O 0
that	O 0
PTEN	O 0
may	O 0
suppress	O 0
tumor	B-Disease 0
cell	O 0
growth	O 0
by	O 0
antagonizing	O 0
protein	O 0
tyrosine	O 0
kinases	O 0
and	O 0
may	O 0
regulate	O 0
tumor	B-Disease 0
cell	O 0
invasion	O 0
and	O 0
metastasis	B-Disease 0
through	O 0
interactions	O 0
at	O 0
focal	O 0
adhesions	O 0
.	O 0
.	O 0

Heterogeneity	O 0
in	O 0
Schwartz	B-Disease 0
-	I-Disease 0
Jampel	I-Disease 0
chondrodystrophic	I-Disease 0
myotonia	I-Disease 0
.	O 0

The	O 0
Schwartz	B-Disease 0
-	I-Disease 0
Jampel	I-Disease 0
syndrome	I-Disease 0
(	O 0
SJS	B-Disease 0
;	O 0
chondrodystrophic	B-Disease 0
myotonia	I-Disease 0
;	O 0
McK	O 0
255	O 0
,	O 0
800	O 0
)	O 0
is	O 0
a	O 0
recessively	B-Disease 0
inherited	I-Disease 0
condition	I-Disease 0
defined	O 0
by	O 0
myotonia	B-Disease 0
,	O 0
short	B-Disease 0
stature	I-Disease 0
,	O 0
and	O 0
bone	B-Disease 0
dysplasia	I-Disease 0
.	O 0

Genetic	O 0
linkage	O 0
between	O 0
SJS	B-Disease 0
and	O 0
chromosomal	O 0
region	O 0
1q36	O 0
-	O 0
34	O 0
has	O 0
been	O 0
observed	O 0
in	O 0
several	O 0
families	O 0
,	O 0
but	O 0
the	O 0
gene	O 0
has	O 0
not	O 0
yet	O 0
been	O 0
identified	O 0
.	O 0

We	O 0
studied	O 0
the	O 0
clinical	O 0
and	O 0
radiological	O 0
features	O 0
in	O 0
81	O 0
patients	O 0
from	O 0
the	O 0
literature	O 0
and	O 0
5	O 0
own	O 0
patients	O 0
trying	O 0
to	O 0
identify	O 0
distinct	O 0
subgroups	O 0
.	O 0

In	O 0
addition	O 0
,	O 0
we	O 0
tested	O 0
genetic	O 0
linkage	O 0
to	O 0
the	O 0
SJS	B-Disease 0
locus	O 0
on	O 0
chromosome	O 0
1	O 0
in	O 0
one	O 0
family	O 0
with	O 0
two	O 0
affected	O 0
sibs	O 0
.	O 0

We	O 0
found	O 0
that	O 0
a	O 0
group	O 0
of	O 0
patients	O 0
have	O 0
mild	O 0
skeletal	O 0
changes	O 0
which	O 0
may	O 0
be	O 0
secondary	O 0
consequences	O 0
of	O 0
myotonia	B-Disease 0
,	O 0
while	O 0
another	O 0
group	O 0
of	O 0
patients	O 0
appear	O 0
to	O 0
have	O 0
primary	O 0
bone	B-Disease 0
dysplasia	I-Disease 0
with	O 0
myotonia	B-Disease 0
.	O 0

Within	O 0
this	O 0
latter	O 0
group	O 0
,	O 0
there	O 0
are	O 0
differences	O 0
in	O 0
age	O 0
of	O 0
manifestation	O 0
,	O 0
clinical	O 0
course	O 0
and	O 0
pattern	O 0
of	O 0
bone	O 0
changes	O 0
.	O 0

We	O 0
tentatively	O 0
isolate	O 0
three	O 0
different	O 0
types	O 0
of	O 0
SJS	B-Disease 0
type	I-Disease 0
1A	I-Disease 0
,	O 0
usually	O 0
recognized	O 0
in	O 0
childhood	O 0
,	O 0
with	O 0
moderate	O 0
bone	B-Disease 0
dysplasia	I-Disease 0
,	O 0
corresponding	O 0
to	O 0
the	O 0
original	O 0
descriptions	O 0
of	O 0
Schwartz	O 0
,	O 0
Jampel	O 0
and	O 0
Aberfeld	O 0
;	O 0
type	O 0
1B	O 0
,	O 0
similar	O 0
to	O 0
type	O 0
1A	O 0
but	O 0
recognizable	O 0
at	O 0
birth	O 0
,	O 0
with	O 0
more	O 0
pronounced	O 0
bone	B-Disease 0
dysplasia	I-Disease 0
resembling	O 0
Kniest	B-Disease 0
dysplasia	I-Disease 0
;	O 0
and	O 0
type	O 0
2	O 0
,	O 0
manifest	O 0
at	O 0
birth	O 0
,	O 0
with	O 0
increased	O 0
mortality	O 0
and	O 0
bone	B-Disease 0
dysplasia	I-Disease 0
resembling	O 0
Pyle	B-Disease 0
disease	I-Disease 0
.	O 0

Genetic	O 0
analysis	O 0
of	O 0
the	O 0
family	O 0
with	O 0
two	O 0
sibs	O 0
affected	O 0
by	O 0
SJS	B-Disease 0
type	I-Disease 0
2	I-Disease 0
showed	O 0
evidence	O 0
against	O 0
linkage	O 0
to	O 0
chromosome	O 0
1p36	O 0
-	O 0
34	O 0
.	O 0

CONCLUSIONS	O 0
SJS	B-Disease 0
is	O 0
clinically	O 0
and	O 0
radiologically	O 0
heterogeneous	O 0
.	O 0

The	O 0
causes	O 0
of	O 0
heterogeneity	O 0
are	O 0
not	O 0
known	O 0
yet	O 0
but	O 0
are	O 0
likely	O 0
to	O 0
include	O 0
both	O 0
different	O 0
mutations	O 0
at	O 0
the	O 0
SJS	B-Disease 0
locus	O 0
on	O 0
chromosome	O 0
1	O 0
and	O 0
the	O 0
presence	O 0
of	O 0
a	O 0
second	O 0
SJS	B-Disease 0
locus	O 0
.	O 0

A	O 0
tentative	O 0
clinico	O 0
-	O 0
radiological	O 0
classification	O 0
can	O 0
be	O 0
useful	O 0
for	O 0
the	O 0
characterization	O 0
of	O 0
patients	O 0
and	O 0
the	O 0
development	O 0
of	O 0
genotype	O 0
-	O 0
phenotype	O 0
correlations	O 0
.	O 0
.	O 0

A	O 0
clinical	O 0
overview	O 0
of	O 0
WT1	O 0
gene	O 0
mutations	O 0
.	O 0

Mutations	O 0
in	O 0
the	O 0
WT1	O 0
gene	O 0
were	O 0
anticipated	O 0
to	O 0
explain	O 0
the	O 0
genetic	O 0
basis	O 0
of	O 0
the	O 0
childhood	O 0
kidney	B-Disease 0
cancer	I-Disease 0
,	O 0
Wilms	B-Disease 0
tumour	I-Disease 0
(	O 0
WT	B-Disease 0
)	O 0
.	O 0

Six	O 0
years	O 0
on	O 0
,	O 0
we	O 0
review	O 0
100	O 0
reports	O 0
of	O 0
intragenic	O 0
WT1	O 0
mutations	O 0
and	O 0
examine	O 0
the	O 0
accompanying	O 0
clinical	O 0
phenotypes	O 0
.	O 0

While	O 0
only	O 0
5	O 0
%	O 0
of	O 0
sporadic	B-Disease 0
Wilms	I-Disease 0
tumours	I-Disease 0
have	O 0
intragenic	O 0
WT1	O 0
mutations	O 0
,	O 0
>	O 0
90	O 0
%	O 0
of	O 0
patients	O 0
with	O 0
the	O 0
Denys	B-Disease 0
-	I-Disease 0
Drash	I-Disease 0
syndrome	I-Disease 0
(	O 0
renal	B-Disease 0
nephropathy	I-Disease 0
,	O 0
gonadal	B-Disease 0
anomaly	I-Disease 0
,	O 0
predisposition	B-Disease 0
to	I-Disease 0
WT	I-Disease 0
)	O 0
carry	O 0
constitutional	O 0
intragenic	O 0
WT1	O 0
mutations	O 0
.	O 0

WT1	O 0
mutations	O 0
have	O 0
also	O 0
been	O 0
reported	O 0
in	O 0
juvenile	B-Disease 0
granulosa	I-Disease 0
cell	I-Disease 0
tumour	I-Disease 0
,	O 0
non	B-Disease 0
-	I-Disease 0
asbestos	I-Disease 0
related	I-Disease 0
mesothelioma	I-Disease 0
,	O 0
desmoplastic	B-Disease 0
small	I-Disease 0
round	I-Disease 0
cell	I-Disease 0
tumour	I-Disease 0
and	O 0
,	O 0
most	O 0
recently	O 0
,	O 0
acute	B-Disease 0
myeloid	I-Disease 0
leukemia	I-Disease 0
.	O 0
.	O 0

A	O 0
mutation	O 0
in	O 0
autosomal	B-Disease 0
dominant	I-Disease 0
myotonia	I-Disease 0
congenita	I-Disease 0
affects	O 0
pore	O 0
properties	O 0
of	O 0
the	O 0
muscle	O 0
chloride	O 0
channel	O 0
.	O 0

Autosomal	B-Disease 0
dominant	I-Disease 0
myotonia	I-Disease 0
congenita	I-Disease 0
is	O 0
an	O 0
inherited	B-Disease 0
disorder	I-Disease 0
of	I-Disease 0
skeletal	I-Disease 0
muscle	I-Disease 0
caused	O 0
by	O 0
mutations	O 0
in	O 0
a	O 0
voltage	O 0
-	O 0
gated	O 0
Cl	O 0
-	O 0
channel	O 0
gene	O 0
(	O 0
CLCN1	O 0
,	O 0
7q35	O 0
)	O 0
.	O 0

Here	O 0
,	O 0
we	O 0
report	O 0
that	O 0
a	O 0
mutation	O 0
predicting	O 0
the	O 0
substitution	O 0
of	O 0
Gly	O 0
230	O 0
by	O 0
glutamic	O 0
acid	O 0
(	O 0
G230E	O 0
)	O 0
between	O 0
segments	O 0
D3	O 0
and	O 0
D4	O 0
dramatically	O 0
alters	O 0
the	O 0
pore	O 0
properties	O 0
of	O 0
a	O 0
recombinant	O 0
human	O 0
muscle	O 0
Cl	O 0
-	O 0
channel	O 0
(	O 0
hCIC	O 0
-	O 0
1	O 0
)	O 0
expressed	O 0
in	O 0
a	O 0
mammalian	O 0
cell	O 0
line	O 0
(	O 0
tsA201	O 0
)	O 0
.	O 0

The	O 0
G230E	O 0
mutation	O 0
causes	O 0
substantial	O 0
changes	O 0
in	O 0
anion	O 0
and	O 0
cation	O 0
selectivity	O 0
as	O 0
well	O 0
as	O 0
a	O 0
fundamental	O 0
change	O 0
in	O 0
rectification	O 0
of	O 0
the	O 0
current	O 0
-	O 0
voltage	O 0
relationship	O 0
.	O 0

Whereas	O 0
wild	O 0
-	O 0
type	O 0
channels	O 0
are	O 0
characterized	O 0
by	O 0
pronounced	O 0
inward	O 0
rectification	O 0
and	O 0
a	O 0
Cl	O 0
>	O 0
thiocyanate	O 0
>	O 0
Br	O 0
>	O 0
NO	O 0
(	O 0
3	O 0
)	O 0
>	O 0
I	O 0
>	O 0
CH	O 0
(	O 0
3	O 0
)	O 0
SO	O 0
(	O 0
3	O 0
)	O 0
selectivity	O 0
,	O 0
G230E	O 0
exhibits	O 0
outward	O 0
rectification	O 0
at	O 0
positive	O 0
potentials	O 0
and	O 0
a	O 0
thiocyanate	O 0
>	O 0
NO	O 0
(	O 0
3	O 0
)	O 0
>	O 0
I	O 0
>	O 0
Br	O 0
>	O 0
Cl	O 0
>	O 0
CH	O 0
(	O 0
3	O 0
)	O 0
SO	O 0
(	O 0
3	O 0
)	O 0
selectivity	O 0
.	O 0

Furthermore	O 0
,	O 0
the	O 0
cation	O 0
-	O 0
to	O 0
-	O 0
anion	O 0
permeability	O 0
ratio	O 0
of	O 0
the	O 0
mutant	O 0
is	O 0
much	O 0
greater	O 0
than	O 0
that	O 0
of	O 0
the	O 0
wild	O 0
-	O 0
type	O 0
channel	O 0
.	O 0

Voltage	O 0
-	O 0
dependent	O 0
blocks	O 0
by	O 0
intracellular	O 0
and	O 0
extracellular	O 0
iodide	O 0
help	O 0
to	O 0
distinguish	O 0
two	O 0
distinct	O 0
ion	O 0
binding	O 0
sites	O 0
within	O 0
the	O 0
hClC	O 0
-	O 0
1	O 0
conduction	O 0
pathway	O 0
.	O 0

Both	O 0
binding	O 0
sites	O 0
are	O 0
preserved	O 0
in	O 0
the	O 0
mutant	O 0
but	O 0
have	O 0
decreased	O 0
affinities	O 0
for	O 0
iodide	O 0
.	O 0

These	O 0
findings	O 0
suggest	O 0
that	O 0
Gly	O 0
230	O 0
is	O 0
critical	O 0
for	O 0
normal	O 0
ion	O 0
conductance	O 0
in	O 0
hClC	O 0
-	O 0
1	O 0
and	O 0
that	O 0
this	O 0
residue	O 0
resides	O 0
within	O 0
the	O 0
channel	O 0
pore	O 0
.	O 0
.	O 0

The	O 0
incidence	O 0
of	O 0
PAX6	O 0
mutation	O 0
in	O 0
patients	O 0
with	O 0
simple	O 0
aniridia	B-Disease 0
:	O 0
an	O 0
evaluation	O 0
of	O 0
mutation	O 0
detection	O 0
in	O 0
12	O 0
cases	O 0
.	O 0

Twelve	O 0
aniridia	B-Disease 0
patients	O 0
,	O 0
five	O 0
with	O 0
a	O 0
family	O 0
history	O 0
and	O 0
seven	O 0
presumed	O 0
to	O 0
be	O 0
sporadic	O 0
,	O 0
were	O 0
exhaustively	O 0
screened	O 0
in	O 0
order	O 0
to	O 0
test	O 0
what	O 0
proportion	O 0
of	O 0
people	O 0
with	O 0
aniridia	B-Disease 0
,	O 0
uncomplicated	O 0
by	O 0
associated	O 0
anomalies	O 0
,	O 0
carry	O 0
mutations	O 0
in	O 0
the	O 0
human	O 0
PAX6	O 0
gene	O 0
.	O 0

Mutations	O 0
were	O 0
detected	O 0
in	O 0
90	O 0
%	O 0
of	O 0
the	O 0
cases	O 0
.	O 0

Three	O 0
mutation	O 0
detection	O 0
techniques	O 0
were	O 0
used	O 0
to	O 0
determine	O 0
if	O 0
one	O 0
method	O 0
was	O 0
superior	O 0
for	O 0
this	O 0
gene	O 0
.	O 0

The	O 0
protein	O 0
truncation	O 0
test	O 0
(	O 0
PTT	O 0
)	O 0
was	O 0
used	O 0
on	O 0
RT	O 0
-	O 0
PCR	O 0
products	O 0
,	O 0
SSCP	O 0
on	O 0
genomic	O 0
PCR	O 0
amplifications	O 0
,	O 0
and	O 0
chemical	O 0
cleavage	O 0
of	O 0
mismatch	O 0
on	O 0
both	O 0
RT	O 0
-	O 0
PCR	O 0
and	O 0
genomic	O 0
amplifications	O 0
.	O 0

For	O 0
RT	O 0
-	O 0
PCR	O 0
products	O 0
,	O 0
only	O 0
the	O 0
translated	O 0
portion	O 0
of	O 0
the	O 0
gene	O 0
was	O 0
screened	O 0
.	O 0

On	O 0
genomic	O 0
products	O 0
exons	O 0
1	O 0
to	O 0
13	O 0
(	O 0
including	O 0
740	O 0
bp	O 0
of	O 0
the	O 0
3	O 0
untranslated	O 0
sequence	O 0
and	O 0
all	O 0
intron	O 0
/	O 0
exon	O 0
boundaries	O 0
)	O 0
were	O 0
screened	O 0
,	O 0
as	O 0
was	O 0
a	O 0
neuroretina	O 0
specific	O 0
enhancer	O 0
in	O 0
intron	O 0
4	O 0
.	O 0

Ten	O 0
of	O 0
the	O 0
possible	O 0
12	O 0
mutations	O 0
in	O 0
the	O 0
five	O 0
familial	O 0
cases	O 0
and	O 0
five	O 0
of	O 0
the	O 0
sporadic	O 0
patients	O 0
were	O 0
found	O 0
,	O 0
all	O 0
of	O 0
which	O 0
conformed	O 0
to	O 0
a	O 0
functional	O 0
outcome	O 0
of	O 0
haploinsufficiency	O 0
.	O 0

Five	O 0
were	O 0
splice	O 0
site	O 0
mutations	O 0
(	O 0
one	O 0
in	O 0
the	O 0
donor	O 0
site	O 0
of	O 0
intron	O 0
4	O 0
,	O 0
two	O 0
in	O 0
the	O 0
donor	O 0
site	O 0
of	O 0
intron	O 0
6	O 0
,	O 0
one	O 0
in	O 0
each	O 0
of	O 0
the	O 0
acceptor	O 0
sites	O 0
of	O 0
introns	O 0
8	O 0
and	O 0
9	O 0
)	O 0
and	O 0
five	O 0
were	O 0
nonsense	O 0
mutations	O 0
in	O 0
exons	O 0
8	O 0
,	O 0
9	O 0
,	O 0
10	O 0
,	O 0
11	O 0
,	O 0
and	O 0
12	O 0
.	O 0

SSCP	O 0
analysis	O 0
of	O 0
individually	O 0
amplified	O 0
exons	O 0
,	O 0
with	O 0
which	O 0
nine	O 0
of	O 0
the	O 0
10	O 0
mutations	O 0
were	O 0
seen	O 0
,	O 0
was	O 0
the	O 0
most	O 0
useful	O 0
detection	O 0
method	O 0
for	O 0
PAX6	O 0
.	O 0
.	O 0

Insulin	O 0
gene	O 0
region	O 0
contributes	O 0
to	O 0
genetic	O 0
susceptibility	O 0
to	O 0
,	O 0
but	O 0
may	O 0
not	O 0
to	O 0
low	O 0
incidence	O 0
of	O 0
,	O 0
insulin	B-Disease 0
-	I-Disease 0
dependent	I-Disease 0
diabetes	I-Disease 0
mellitus	I-Disease 0
in	O 0
Japanese	O 0
.	O 0

In	O 0
the	O 0
Caucasian	O 0
population	O 0
,	O 0
it	O 0
has	O 0
been	O 0
demonstrated	O 0
that	O 0
the	O 0
insulin	O 0
gene	O 0
(	O 0
INS	O 0
)	O 0
region	O 0
contains	O 0
the	O 0
insulin	B-Disease 0
-	I-Disease 0
dependent	I-Disease 0
diabetes	I-Disease 0
mellitus	I-Disease 0
locus	O 0
(	O 0
IDDM2	O 0
)	O 0
.	O 0

In	O 0
the	O 0
Japanese	O 0
population	O 0
,	O 0
however	O 0
,	O 0
there	O 0
has	O 0
been	O 0
no	O 0
report	O 0
demonstrating	O 0
the	O 0
contribution	O 0
of	O 0
IDDM2	O 0
to	O 0
the	O 0
pathogenesis	O 0
of	O 0
IDDM	B-Disease 0
.	O 0

We	O 0
conducted	O 0
an	O 0
association	O 0
study	O 0
of	O 0
IDDM	B-Disease 0
in	O 0
a	O 0
large	O 0
number	O 0
of	O 0
Japanese	O 0
subjects	O 0
with	O 0
multiple	O 0
polymorphisms	O 0
in	O 0
INS	O 0
region	O 0
.	O 0

We	O 0
found	O 0
a	O 0
significant	O 0
association	O 0
of	O 0
the	O 0
INS	O 0
region	O 0
with	O 0
IDDM	B-Disease 0
.	O 0

Alleles	O 0
positively	O 0
associated	O 0
with	O 0
IDDM	B-Disease 0
in	O 0
INS	O 0
region	O 0
were	O 0
the	O 0
same	O 0
as	O 0
those	O 0
positively	O 0
-	O 0
associated	O 0
with	O 0
IDDM	B-Disease 0
in	O 0
Caucasian	O 0
population	O 0
,	O 0
although	O 0
positively	O 0
-	O 0
associated	O 0
alleles	O 0
are	O 0
very	O 0
common	O 0
(	O 0
allele	O 0
frequencies	O 0
>	O 0
0	O 0
.	O 0
9	O 0
)	O 0
in	O 0
the	O 0
Japanese	O 0
general	O 0
population	O 0
.	O 0

These	O 0
data	O 0
suggest	O 0
that	O 0
IDDM2	O 0
is	O 0
involved	O 0
in	O 0
the	O 0
genetic	O 0
susceptibility	O 0
to	O 0
IDDM	B-Disease 0
in	O 0
Japanese	O 0
.	O 0

The	O 0
high	O 0
frequencies	O 0
of	O 0
disease	O 0
-	O 0
associated	O 0
alleles	O 0
in	O 0
the	O 0
general	O 0
population	O 0
suggest	O 0
that	O 0
IDDM2	O 0
locus	O 0
is	O 0
not	O 0
responsible	O 0
for	O 0
the	O 0
low	O 0
incidence	O 0
of	O 0
IDDM	B-Disease 0
in	O 0
Japanese	O 0
.	O 0

The	O 0
human	O 0
complement	O 0
C9	O 0
gene	O 0
:	O 0
identification	O 0
of	O 0
two	O 0
mutations	O 0
causing	O 0
deficiency	O 0
and	O 0
revision	O 0
of	O 0
the	O 0
gene	O 0
structure	O 0
.	O 0

The	O 0
ninth	O 0
component	O 0
of	O 0
human	O 0
complement	O 0
(	O 0
C9	O 0
)	O 0
is	O 0
the	O 0
last	O 0
of	O 0
the	O 0
terminal	O 0
complement	O 0
components	O 0
creating	O 0
the	O 0
membrane	O 0
attack	O 0
complex	O 0
.	O 0

C9	O 0
is	O 0
a	O 0
single	O 0
-	O 0
chain	O 0
serum	O 0
protein	O 0
that	O 0
is	O 0
encoded	O 0
by	O 0
a	O 0
gene	O 0
located	O 0
on	O 0
chromosome	O 0
5p	O 0
.	O 0

Deficiency	B-Disease 0
of	I-Disease 0
terminal	I-Disease 0
complement	I-Disease 0
components	I-Disease 0
is	O 0
generally	O 0
associated	O 0
with	O 0
recurrent	O 0
neisseria	B-Disease 0
infections	I-Disease 0
.	O 0

We	O 0
studied	O 0
a	O 0
previously	O 0
described	O 0
Swiss	O 0
family	O 0
with	O 0
inherited	B-Disease 0
C9	I-Disease 0
deficiency	I-Disease 0
.	O 0

To	O 0
identify	O 0
the	O 0
genetic	O 0
basis	O 0
of	O 0
C9	B-Disease 0
deficiency	I-Disease 0
,	O 0
we	O 0
developed	O 0
an	O 0
approach	O 0
using	O 0
exon	O 0
-	O 0
specific	O 0
PCR	O 0
and	O 0
direct	O 0
DNA	O 0
sequencing	O 0
.	O 0

As	O 0
a	O 0
cause	O 0
of	O 0
C9	B-Disease 0
deficiency	I-Disease 0
,	O 0
we	O 0
found	O 0
two	O 0
different	O 0
point	O 0
mutations	O 0
,	O 0
both	O 0
generating	O 0
TGA	O 0
stop	O 0
codons	O 0
in	O 0
the	O 0
coding	O 0
sequence	O 0
.	O 0

One	O 0
mutation	O 0
,	O 0
a	O 0
C	O 0
to	O 0
A	O 0
exchange	O 0
,	O 0
was	O 0
detected	O 0
in	O 0
exon	O 0
2	O 0
at	O 0
cDNA	O 0
position	O 0
166	O 0
,	O 0
the	O 0
other	O 0
,	O 0
a	O 0
C	O 0
to	O 0
T	O 0
exchange	O 0
,	O 0
was	O 0
located	O 0
in	O 0
exon	O 0
4	O 0
(	O 0
cDNA	O 0
position	O 0
464	O 0
)	O 0
.	O 0

In	O 0
family	O 0
studies	O 0
of	O 0
three	O 0
first	O 0
-	O 0
degree	O 0
relatives	O 0
with	O 0
heterozygous	O 0
C9	B-Disease 0
deficiency	I-Disease 0
,	O 0
we	O 0
demonstrated	O 0
that	O 0
the	O 0
two	O 0
mutations	O 0
are	O 0
segregating	O 0
independently	O 0
.	O 0

Therefore	O 0
,	O 0
these	O 0
mutations	O 0
are	O 0
sufficient	O 0
to	O 0
explain	O 0
the	O 0
complete	O 0
deficiency	O 0
of	O 0
both	O 0
the	O 0
probands	O 0
studied	O 0
.	O 0

DNA	O 0
sequencing	O 0
of	O 0
the	O 0
exon	O 0
-	O 0
intron	O 0
junctions	O 0
revealed	O 0
a	O 0
number	O 0
of	O 0
revisions	O 0
regarding	O 0
the	O 0
boundaries	O 0
between	O 0
exons	O 0
4	O 0
,	O 0
5	O 0
,	O 0
and	O 0
6	O 0
as	O 0
well	O 0
as	O 0
between	O 0
exons	O 0
10	O 0
and	O 0
11	O 0
.	O 0

No	O 0
additional	O 0
introns	O 0
were	O 0
detected	O 0
in	O 0
exons	O 0
6	O 0
and	O 0
10	O 0
.	O 0

Furthermore	O 0
,	O 0
DNA	O 0
marker	O 0
studies	O 0
were	O 0
conducted	O 0
using	O 0
known	O 0
polymorphisms	O 0
of	O 0
the	O 0
C6	O 0
,	O 0
C7	O 0
,	O 0
and	O 0
C9	O 0
genes	O 0
,	O 0
confirming	O 0
the	O 0
linkage	O 0
of	O 0
the	O 0
observed	O 0
C9	O 0
mutations	O 0
with	O 0
defined	O 0
haplotypes	O 0
.	O 0
.	O 0

BRCA1	O 0
mutations	O 0
in	O 0
women	O 0
attending	O 0
clinics	O 0
that	O 0
evaluate	O 0
the	O 0
risk	O 0
of	O 0
breast	B-Disease 0
cancer	I-Disease 0
.	O 0

BACKGROUND	O 0
To	O 0
define	O 0
the	O 0
incidence	O 0
of	O 0
BRCA1	O 0
mutations	O 0
among	O 0
patients	O 0
seen	O 0
in	O 0
clinics	O 0
that	O 0
evaluate	O 0
the	O 0
risk	O 0
of	O 0
breast	B-Disease 0
cancer	I-Disease 0
,	O 0
we	O 0
analyzed	O 0
DNA	O 0
samples	O 0
from	O 0
women	O 0
seen	O 0
in	O 0
this	O 0
setting	O 0
and	O 0
constructed	O 0
probability	O 0
tables	O 0
to	O 0
provide	O 0
estimates	O 0
of	O 0
the	O 0
likelihood	O 0
of	O 0
finding	O 0
a	O 0
BRCA1	O 0
mutation	O 0
in	O 0
individual	O 0
families	O 0
.	O 0

METHODS	O 0
Clinical	O 0
information	O 0
,	O 0
family	O 0
histories	O 0
,	O 0
and	O 0
blood	O 0
for	O 0
DNA	O 0
analysis	O 0
were	O 0
obtained	O 0
from	O 0
263	O 0
women	O 0
with	O 0
breast	B-Disease 0
cancer	I-Disease 0
.	O 0

Conformation	O 0
-	O 0
sensitive	O 0
gel	O 0
electrophoresis	O 0
and	O 0
DNA	O 0
sequencing	O 0
were	O 0
used	O 0
to	O 0
identify	O 0
BRCA1	O 0
mutations	O 0
.	O 0

RESULTS	O 0
BRCA1	O 0
mutations	O 0
were	O 0
identified	O 0
in	O 0
16	O 0
percent	O 0
of	O 0
women	O 0
with	O 0
a	O 0
family	O 0
history	O 0
of	O 0
breast	B-Disease 0
cancer	I-Disease 0
.	O 0

Only	O 0
7	O 0
percent	O 0
of	O 0
women	O 0
from	O 0
families	O 0
with	O 0
a	O 0
history	O 0
of	O 0
breast	B-Disease 0
cancer	I-Disease 0
but	O 0
not	O 0
ovarian	B-Disease 0
cancer	I-Disease 0
had	O 0
BRCA1	O 0
mutations	O 0
.	O 0

The	O 0
rates	O 0
were	O 0
higher	O 0
among	O 0
women	O 0
from	O 0
families	O 0
with	O 0
a	O 0
history	O 0
of	O 0
both	O 0
breast	B-Disease 0
and	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
.	O 0

Among	O 0
family	O 0
members	O 0
,	O 0
an	O 0
average	O 0
age	O 0
of	O 0
less	O 0
than	O 0
55	O 0
years	O 0
at	O 0
the	O 0
diagnosis	O 0
of	O 0
breast	B-Disease 0
cancer	I-Disease 0
,	O 0
the	O 0
presence	O 0
of	O 0
ovarian	B-Disease 0
cancer	I-Disease 0
,	O 0
the	O 0
presence	O 0
of	O 0
breast	B-Disease 0
and	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
in	O 0
the	O 0
same	O 0
woman	O 0
,	O 0
and	O 0
Ashkenazi	O 0
Jewish	O 0
ancestry	O 0
were	O 0
all	O 0
associated	O 0
with	O 0
an	O 0
increased	O 0
risk	O 0
of	O 0
detecting	O 0
a	O 0
BRCA1	O 0
mutation	O 0
.	O 0

No	O 0
association	O 0
was	O 0
found	O 0
between	O 0
the	O 0
presence	O 0
of	O 0
bilateral	O 0
breast	B-Disease 0
cancer	I-Disease 0
or	O 0
the	O 0
number	O 0
of	O 0
breast	B-Disease 0
cancers	I-Disease 0
in	O 0
a	O 0
family	O 0
and	O 0
the	O 0
detection	O 0
of	O 0
a	O 0
BRCA1	O 0
mutation	O 0
,	O 0
or	O 0
between	O 0
the	O 0
position	O 0
of	O 0
the	O 0
mutation	O 0
in	O 0
the	O 0
BRCA1	O 0
gene	O 0
and	O 0
the	O 0
presence	O 0
of	O 0
ovarian	B-Disease 0
cancer	I-Disease 0
in	O 0
a	O 0
family	O 0
.	O 0

CONCLUSIONS	O 0
Among	O 0
women	O 0
with	O 0
breast	B-Disease 0
cancer	I-Disease 0
and	O 0
a	O 0
family	O 0
history	O 0
of	O 0
the	O 0
disease	O 0
,	O 0
the	O 0
percentage	O 0
with	O 0
BRCA1	O 0
coding	O 0
-	O 0
region	O 0
mutations	O 0
is	O 0
less	O 0
than	O 0
the	O 0
45	O 0
percent	O 0
predicted	O 0
by	O 0
genetic	O 0
-	O 0
linkage	O 0
analysis	O 0
.	O 0

These	O 0
results	O 0
suggest	O 0
that	O 0
even	O 0
in	O 0
a	O 0
referral	O 0
clinic	O 0
specializing	O 0
in	O 0
screening	O 0
women	O 0
from	O 0
high	O 0
-	O 0
risk	O 0
families	O 0
,	O 0
the	O 0
majority	O 0
of	O 0
tests	O 0
for	O 0
BRCA1	O 0
mutations	O 0
will	O 0
be	O 0
negative	O 0
and	O 0
therefore	O 0
uninformative	O 0
.	O 0
.	O 0

Mutations	O 0
in	O 0
the	O 0
arginine	O 0
-	O 0
rich	O 0
protein	O 0
gene	O 0
(	O 0
ARP	O 0
)	O 0
in	O 0
pancreatic	B-Disease 0
cancer	I-Disease 0
.	O 0

The	O 0
ARP	O 0
gene	O 0
encodes	O 0
a	O 0
highly	O 0
conserved	O 0
arginine	O 0
-	O 0
rich	O 0
protein	O 0
from	O 0
chromosomal	O 0
band	O 0
3p21	O 0
.	O 0

1	O 0
1	O 0
.	O 0

At	O 0
the	O 0
cytogenetic	O 0
level	O 0
this	O 0
region	O 0
is	O 0
frequently	O 0
deleted	O 0
in	O 0
a	O 0
variety	O 0
of	O 0
different	O 0
solid	B-Disease 0
tumors	I-Disease 0
,	O 0
although	O 0
not	O 0
in	O 0
pancreatic	B-Disease 0
cancer	I-Disease 0
.	O 0

We	O 0
have	O 0
reported	O 0
the	O 0
presence	O 0
of	O 0
a	O 0
specific	O 0
mutation	O 0
(	O 0
ATG50	O 0
-	O 0
-	O 0
>	O 0
AGG	O 0
)	O 0
or	O 0
deletion	O 0
of	O 0
codon	O 0
50	O 0
of	O 0
the	O 0
ARP	O 0
gene	O 0
in	O 0
different	O 0
tumor	B-Disease 0
types	I-Disease 0
(	O 0
Shridhar	O 0
et	O 0
al	O 0
.	O 0
,	O 0
1996	O 0
,	O 0
1996a	O 0
)	O 0
.	O 0

In	O 0
the	O 0
present	O 0
study	O 0
,	O 0
we	O 0
have	O 0
observed	O 0
mutations	O 0
involving	O 0
codon	O 0
50	O 0
in	O 0
11	O 0
of	O 0
37	O 0
pancreatic	B-Disease 0
tumors	I-Disease 0
.	O 0

The	O 0
frequency	O 0
of	O 0
codon	O 0
50	O 0
mutation	O 0
is	O 0
roughly	O 0
the	O 0
same	O 0
in	O 0
pancreatic	B-Disease 0
tumors	I-Disease 0
as	O 0
in	O 0
the	O 0
other	O 0
types	O 0
of	O 0
tumors	B-Disease 0
previously	O 0
examined	O 0
.	O 0

In	O 0
addition	O 0
,	O 0
we	O 0
have	O 0
detected	O 0
mutations	O 0
at	O 0
codon	O 0
51	O 0
in	O 0
multiple	O 0
PCR	O 0
subclones	O 0
in	O 0
two	O 0
other	O 0
pancreatic	B-Disease 0
tumors	I-Disease 0
.	O 0

Mutations	O 0
in	O 0
the	O 0
ARP	O 0
gene	O 0
are	O 0
thus	O 0
commonly	O 0
observed	O 0
in	O 0
pancreatic	B-Disease 0
cancer	I-Disease 0
,	O 0
as	O 0
well	O 0
as	O 0
many	O 0
other	O 0
cancers	B-Disease 0
.	O 0

Difficulties	O 0
in	O 0
the	O 0
ascertainment	O 0
of	O 0
C9	B-Disease 0
deficiency	I-Disease 0
:	O 0
lessons	O 0
to	O 0
be	O 0
drawn	O 0
from	O 0
a	O 0
compound	O 0
heterozygote	O 0
C9	B-Disease 0
-	I-Disease 0
deficient	I-Disease 0
subject	O 0
.	O 0

A	O 0
group	O 0
of	O 0
patients	O 0
with	O 0
long	O 0
-	O 0
surviving	O 0
mismatched	O 0
kidney	O 0
allografts	O 0
were	O 0
investigated	O 0
for	O 0
complement	O 0
function	O 0
using	O 0
haemolytic	O 0
assays	O 0
in	O 0
agarose	O 0
gels	O 0
.	O 0

One	O 0
patient	O 0
was	O 0
found	O 0
to	O 0
have	O 0
no	O 0
alternative	O 0
pathway	O 0
activity	O 0
but	O 0
a	O 0
low	O 0
normal	O 0
classical	O 0
pathway	O 0
.	O 0

Surprisingly	O 0
,	O 0
investigation	O 0
revealed	O 0
that	O 0
the	O 0
patients	O 0
complement	O 0
was	O 0
normal	O 0
for	O 0
all	O 0
components	O 0
except	O 0
C9	O 0
,	O 0
which	O 0
was	O 0
functionally	O 0
absent	O 0
.	O 0

The	O 0
patient	O 0
was	O 0
shown	O 0
to	O 0
be	O 0
heterozygous	O 0
for	O 0
DNA	O 0
markers	O 0
in	O 0
the	O 0
C6	O 0
,	O 0
C7	O 0
and	O 0
C9	O 0
region	O 0
of	O 0
chromosome	O 0
5	O 0
and	O 0
therefore	O 0
appears	O 0
to	O 0
be	O 0
a	O 0
compound	O 0
heterozygote	O 0
for	O 0
two	O 0
uncharacterized	O 0
C9	B-Disease 0
deficiency	I-Disease 0
genes	O 0
.	O 0

Serological	O 0
analysis	O 0
by	O 0
ELISA	O 0
revealed	O 0
that	O 0
he	O 0
has	O 0
trace	O 0
concentrations	O 0
of	O 0
a	O 0
non	O 0
-	O 0
functional	O 0
C9	O 0
molecule	O 0
.	O 0

Western	O 0
blot	O 0
analysis	O 0
was	O 0
not	O 0
sufficiently	O 0
sensitive	O 0
to	O 0
permit	O 0
detection	O 0
of	O 0
this	O 0
molecule	O 0
.	O 0

We	O 0
hypothesize	O 0
that	O 0
the	O 0
patient	O 0
is	O 0
heterozygous	O 0
for	O 0
a	O 0
complete	B-Disease 0
deficiency	I-Disease 0
of	I-Disease 0
C9	I-Disease 0
and	O 0
for	O 0
a	O 0
gene	O 0
directing	O 0
hyposynthesis	O 0
of	O 0
a	O 0
defective	O 0
C9	O 0
.	O 0

We	O 0
also	O 0
suggest	O 0
that	O 0
C9	B-Disease 0
deficiency	I-Disease 0
may	O 0
be	O 0
more	O 0
common	O 0
among	O 0
Caucasians	O 0
than	O 0
has	O 0
been	O 0
reported	O 0
.	O 0
.	O 0

Screening	O 0
for	O 0
ESR	O 0
mutations	O 0
in	O 0
breast	B-Disease 0
and	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
patients	O 0
.	O 0

In	O 0
the	O 0
present	O 0
study	O 0
,	O 0
leukocyte	O 0
DNA	O 0
from	O 0
143	O 0
patients	O 0
with	O 0
familial	O 0
clustering	O 0
of	O 0
breast	B-Disease 0
and	I-Disease 0
/	I-Disease 0
or	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
and	O 0
tumour	B-Disease 0
DNA	O 0
from	O 0
96	O 0
breast	B-Disease 0
carcinomas	I-Disease 0
were	O 0
screened	O 0
for	O 0
base	O 0
mutations	O 0
in	O 0
the	O 0
estrogen	O 0
receptor	O 0
gene	O 0
(	O 0
ESR	O 0
)	O 0
.	O 0

Three	O 0
patients	O 0
with	O 0
a	O 0
family	O 0
history	O 0
of	O 0
cancer	B-Disease 0
were	O 0
carrying	O 0
a	O 0
Gly160Cys	O 0
germline	O 0
substitution	O 0
.	O 0

This	O 0
alteration	O 0
was	O 0
also	O 0
detected	O 0
in	O 0
eight	O 0
(	O 0
four	O 0
females	O 0
and	O 0
four	O 0
males	O 0
)	O 0
of	O 0
729	O 0
controls	O 0
(	O 0
366	O 0
female	O 0
,	O 0
363	O 0
males	O 0
)	O 0
,	O 0
indicating	O 0
that	O 0
the	O 0
substitution	O 0
probably	O 0
represents	O 0
a	O 0
polymorphism	O 0
.	O 0

However	O 0
,	O 0
in	O 0
the	O 0
229	O 0
female	O 0
controls	O 0
in	O 0
whom	O 0
family	O 0
history	O 0
of	O 0
cancer	B-Disease 0
was	O 0
known	O 0
,	O 0
one	O 0
of	O 0
two	O 0
who	O 0
had	O 0
a	O 0
sister	O 0
with	O 0
breast	B-Disease 0
cancer	I-Disease 0
was	O 0
carrying	O 0
the	O 0
variant	O 0
allele	O 0
.	O 0

Hence	O 0
,	O 0
a	O 0
possible	O 0
clinical	O 0
significance	O 0
of	O 0
the	O 0
glycine	O 0
into	O 0
cysteine	O 0
cannot	O 0
be	O 0
completely	O 0
ruled	O 0
out	O 0
and	O 0
should	O 0
be	O 0
further	O 0
investigated	O 0
.	O 0

Somatic	O 0
mutations	O 0
were	O 0
not	O 0
detected	O 0
in	O 0
any	O 0
of	O 0
the	O 0
tumours	B-Disease 0
studied	O 0
,	O 0
and	O 0
the	O 0
present	O 0
data	O 0
do	O 0
not	O 0
provide	O 0
support	O 0
for	O 0
somatic	O 0
ESR	O 0
base	O 0
mutations	O 0
as	O 0
an	O 0
important	O 0
mechanism	O 0
for	O 0
hormonal	O 0
therapy	O 0
resistance	O 0
in	O 0
estrogen	B-Disease 0
receptor	I-Disease 0
-	I-Disease 0
positive	I-Disease 0
breast	I-Disease 0
carcinomas	I-Disease 0
.	O 0
.	O 0

Molecular	O 0
bases	O 0
of	O 0
C7	B-Disease 0
deficiency	I-Disease 0
:	O 0
three	O 0
different	O 0
defects	O 0
.	O 0

The	O 0
molecular	O 0
basis	O 0
of	O 0
C7	B-Disease 0
deficiency	I-Disease 0
has	O 0
been	O 0
investigated	O 0
in	O 0
two	O 0
Irish	O 0
families	O 0
and	O 0
a	O 0
number	O 0
of	O 0
Israeli	O 0
families	O 0
of	O 0
Moroccan	O 0
Sephardic	O 0
Jewish	O 0
origin	O 0
.	O 0

Exon	O 0
PCR	O 0
and	O 0
sequencing	O 0
revealed	O 0
a	O 0
heterozygous	O 0
point	O 0
mutation	O 0
at	O 0
the	O 0
3	O 0
splice	O 0
acceptor	O 0
site	O 0
of	O 0
intron	O 0
1	O 0
in	O 0
one	O 0
Irish	O 0
family	O 0
.	O 0

In	O 0
the	O 0
other	O 0
Irish	O 0
family	O 0
,	O 0
exons	O 0
7	O 0
and	O 0
8	O 0
failed	O 0
to	O 0
amplify	O 0
and	O 0
they	O 0
were	O 0
shown	O 0
to	O 0
be	O 0
deleted	O 0
.	O 0

Marker	O 0
haplotype	O 0
studies	O 0
of	O 0
the	O 0
C6	O 0
and	O 0
C7	O 0
gene	O 0
region	O 0
and	O 0
Southern	O 0
blots	O 0
show	O 0
that	O 0
the	O 0
Irish	O 0
family	O 0
with	O 0
the	O 0
splice	O 0
defect	O 0
also	O 0
segregate	O 0
for	O 0
the	O 0
deletion	O 0
,	O 0
which	O 0
is	O 0
not	O 0
easily	O 0
detected	O 0
in	O 0
heterozygotes	O 0
.	O 0

The	O 0
Israeli	O 0
C7	B-Disease 0
-	I-Disease 0
deficient	I-Disease 0
cases	O 0
all	O 0
share	O 0
a	O 0
C7	O 0
haplotype	O 0
and	O 0
are	O 0
homozygous	O 0
for	O 0
a	O 0
mis	O 0
-	O 0
sense	O 0
mutation	O 0
in	O 0
exon	O 0
9	O 0
.	O 0

However	O 0
,	O 0
one	O 0
individual	O 0
is	O 0
heterozygous	O 0
for	O 0
markers	O 0
at	O 0
adjacent	O 0
C6	O 0
loci	O 0
,	O 0
showing	O 0
that	O 0
there	O 0
has	O 0
been	O 0
an	O 0
intergenic	O 0
recombination	O 0
and	O 0
suggesting	O 0
that	O 0
the	O 0
deficiency	O 0
mutation	O 0
is	O 0
of	O 0
appreciable	O 0
antiquity	O 0
.	O 0
.	O 0

Molecular	O 0
heterogeneity	O 0
of	O 0
classical	B-Disease 0
and	I-Disease 0
Duarte	I-Disease 0
galactosemia	I-Disease 0
:	O 0
mutation	O 0
analysis	O 0
by	O 0
denaturing	O 0
gradient	O 0
gel	O 0
electrophoresis	O 0
.	O 0

Classical	B-Disease 0
galactosemia	I-Disease 0
is	O 0
caused	O 0
by	O 0
one	O 0
common	O 0
missense	O 0
mutation	O 0
(	O 0
Q188R	O 0
)	O 0
and	O 0
by	O 0
several	O 0
rare	O 0
mutations	O 0
in	O 0
the	O 0
galactose	O 0
-	O 0
1	O 0
-	O 0
phosphate	O 0
uridyltransferase	O 0
(	O 0
GALT	O 0
)	O 0
gene	O 0
.	O 0

The	O 0
most	O 0
common	O 0
variant	O 0
of	O 0
GALT	O 0
,	O 0
the	O 0
Duarte	O 0
variant	O 0
,	O 0
occurs	O 0
as	O 0
two	O 0
types	O 0
,	O 0
Duarte	O 0
-	O 0
1	O 0
(	O 0
D	O 0
-	O 0
1	O 0
)	O 0
and	O 0
Duarte	O 0
-	O 0
2	O 0
(	O 0
D	O 0
-	O 0
2	O 0
)	O 0
,	O 0
both	O 0
of	O 0
which	O 0
carry	O 0
the	O 0
sequence	O 0
change	O 0
N314D	O 0
.	O 0

D	O 0
-	O 0
1	O 0
increases	O 0
,	O 0
whereas	O 0
D	O 0
-	O 0
2	O 0
decreases	O 0
GALT	O 0
activity	O 0
.	O 0

To	O 0
study	O 0
the	O 0
molecular	O 0
genetics	O 0
of	O 0
classical	B-Disease 0
and	I-Disease 0
Duarte	I-Disease 0
galactosemia	I-Disease 0
,	O 0
we	O 0
analyzed	O 0
the	O 0
GALT	O 0
mutations	O 0
in	O 0
30	O 0
families	O 0
with	O 0
classical	B-Disease 0
galactosemia	I-Disease 0
,	O 0
in	O 0
10	O 0
families	O 0
with	O 0
the	O 0
D	O 0
-	O 0
2	O 0
variant	O 0
and	O 0
in	O 0
3	O 0
individuals	O 0
carrying	O 0
the	O 0
D	O 0
-	O 0
1	O 0
allele	O 0
by	O 0
denaturing	O 0
gradient	O 0
gel	O 0
electrophoresis	O 0
(	O 0
DGGE	O 0
)	O 0
.	O 0

DGGE	O 0
detected	O 0
59	O 0
of	O 0
the	O 0
60	O 0
classical	O 0
galactosemia	B-Disease 0
alleles	O 0
.	O 0

Q188R	O 0
accounted	O 0
for	O 0
60	O 0
%	O 0
,	O 0
K285N	O 0
accounted	O 0
for	O 0
28	O 0
%	O 0
of	O 0
these	O 0
alleles	O 0
.	O 0

Eight	O 0
novel	O 0
candidate	O 0
galactosemia	B-Disease 0
mutations	O 0
were	O 0
found	O 0
.	O 0

On	O 0
all	O 0
D	O 0
-	O 0
2	O 0
alleles	O 0
N314D	O 0
occurred	O 0
in	O 0
cis	O 0
with	O 0
two	O 0
intronic	O 0
sequence	O 0
changes	O 0
,	O 0
on	O 0
the	O 0
D	O 0
-	O 0
1	O 0
alleles	O 0
in	O 0
cis	O 0
with	O 0
a	O 0
neutral	O 0
mutation	O 0
in	O 0
exon	O 0
7	O 0
.	O 0

We	O 0
conclude	O 0
that	O 0
the	O 0
mutations	O 0
causing	O 0
galactosemia	B-Disease 0
are	O 0
highly	O 0
heterogeneous	O 0
and	O 0
that	O 0
K285N	O 0
is	O 0
a	O 0
second	O 0
common	O 0
galactosemia	B-Disease 0
mutation	O 0
in	O 0
our	O 0
population	O 0
.	O 0
.	O 0

Isolation	O 0
of	O 0
full	O 0
-	O 0
length	O 0
ATM	O 0
cDNA	O 0
and	O 0
correction	O 0
of	O 0
the	O 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
cellular	O 0
phenotype	O 0
.	O 0

A	O 0
gene	O 0
mutated	O 0
in	O 0
the	O 0
human	O 0
genetic	B-Disease 0
disorder	I-Disease 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
(	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
)	O 0
,	O 0
ATM	O 0
,	O 0
was	O 0
recently	O 0
identified	O 0
by	O 0
positional	O 0
cloning	O 0
.	O 0

ATM	O 0
is	O 0
a	O 0
member	O 0
of	O 0
the	O 0
phosphatidylinositol	O 0
-	O 0
3	O 0
-	O 0
kinase	O 0
superfamily	O 0
,	O 0
some	O 0
of	O 0
which	O 0
are	O 0
protein	O 0
kinases	O 0
and	O 0
appear	O 0
to	O 0
have	O 0
important	O 0
roles	O 0
in	O 0
cell	O 0
cycle	O 0
control	O 0
and	O 0
radiation	O 0
signal	O 0
transduction	O 0
.	O 0

We	O 0
describe	O 0
herein	O 0
,	O 0
to	O 0
our	O 0
knowledge	O 0
,	O 0
for	O 0
the	O 0
first	O 0
time	O 0
,	O 0
the	O 0
cloning	O 0
of	O 0
a	O 0
full	O 0
-	O 0
length	O 0
cDNA	O 0
for	O 0
ATM	O 0
and	O 0
correction	O 0
of	O 0
multiple	O 0
aspects	O 0
of	O 0
the	O 0
radio	O 0
-	O 0
sensitive	O 0
phenotype	O 0
of	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
cells	O 0
by	O 0
transfection	O 0
with	O 0
this	O 0
cDNA	O 0
.	O 0

Overexpression	O 0
of	O 0
ATM	O 0
cDNA	O 0
in	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
cells	O 0
enhanced	O 0
the	O 0
survival	O 0
of	O 0
these	O 0
cells	O 0
in	O 0
response	O 0
to	O 0
radiation	O 0
exposure	O 0
,	O 0
decreased	O 0
radiation	O 0
-	O 0
induced	O 0
chromosome	O 0
aberrations	O 0
,	O 0
reduced	O 0
radio	O 0
-	O 0
resistant	O 0
DNA	O 0
synthesis	O 0
,	O 0
and	O 0
partially	O 0
corrected	O 0
defective	O 0
cell	O 0
cycle	O 0
checkpoints	O 0
and	O 0
induction	O 0
of	O 0
stress	O 0
-	O 0
activated	O 0
protein	O 0
kinase	O 0
.	O 0

This	O 0
correction	O 0
of	O 0
the	O 0
defects	O 0
in	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
cells	O 0
provides	O 0
further	O 0
evidence	O 0
of	O 0
the	O 0
multiplicity	O 0
of	O 0
effector	O 0
functions	O 0
of	O 0
the	O 0
ATM	O 0
protein	O 0
and	O 0
suggests	O 0
possible	O 0
approaches	O 0
to	O 0
gene	O 0
therapy	O 0
.	O 0
.	O 0

Fusion	O 0
genes	O 0
resulting	O 0
from	O 0
alternative	O 0
chromosomal	O 0
translocations	O 0
are	O 0
overexpressed	O 0
by	O 0
gene	O 0
-	O 0
specific	O 0
mechanisms	O 0
in	O 0
alveolar	B-Disease 0
rhabdomyosarcoma	I-Disease 0
.	O 0

Chromosomal	O 0
translocations	O 0
identified	O 0
in	O 0
hematopoietic	B-Disease 0
and	I-Disease 0
solid	I-Disease 0
tumors	I-Disease 0
result	O 0
in	O 0
deregulated	O 0
expression	O 0
of	O 0
protooncogenes	O 0
or	O 0
creation	O 0
of	O 0
chimeric	O 0
proteins	O 0
with	O 0
tumorigenic	O 0
potential	O 0
.	O 0

In	O 0
the	O 0
pediatric	O 0
solid	B-Disease 0
tumor	I-Disease 0
alveolar	B-Disease 0
rhabdomyosarcoma	I-Disease 0
,	O 0
a	O 0
consistent	O 0
t	O 0
(	O 0
2	O 0
;	O 0
13	O 0
)	O 0
(	O 0
q35	O 0
;	O 0
q14	O 0
)	O 0
or	O 0
variant	O 0
t	O 0
(	O 0
1	O 0
;	O 0
13	O 0
)	O 0
(	O 0
p36	O 0
;	O 0
q14	O 0
)	O 0
translocation	O 0
generates	O 0
PAX3	O 0
-	O 0
FKHR	O 0
or	O 0
PAX7	O 0
-	O 0
FKHR	O 0
fusion	O 0
proteins	O 0
,	O 0
respectively	O 0
.	O 0

In	O 0
this	O 0
report	O 0
,	O 0
we	O 0
demonstrate	O 0
that	O 0
in	O 0
addition	O 0
to	O 0
functional	O 0
alterations	O 0
these	O 0
translocations	O 0
are	O 0
associated	O 0
with	O 0
fusion	O 0
product	O 0
overexpression	O 0
.	O 0

Furthermore	O 0
,	O 0
PAX3	O 0
-	O 0
FKHR	O 0
and	O 0
PAX7	O 0
-	O 0
FKHR	O 0
overexpression	O 0
occurs	O 0
by	O 0
distinct	O 0
mechanisms	O 0
.	O 0

Transcription	O 0
of	O 0
PAX3	O 0
-	O 0
FKHR	O 0
is	O 0
increased	O 0
relative	O 0
to	O 0
wild	O 0
-	O 0
type	O 0
PAX3	O 0
by	O 0
a	O 0
copy	O 0
number	O 0
-	O 0
independent	O 0
process	O 0
.	O 0

In	O 0
contrast	O 0
,	O 0
PAX7	O 0
-	O 0
FKHR	O 0
overexpression	O 0
results	O 0
from	O 0
fusion	O 0
gene	O 0
amplification	O 0
.	O 0

Thus	O 0
,	O 0
gene	O 0
-	O 0
specific	O 0
mechanisms	O 0
were	O 0
selected	O 0
to	O 0
overexpress	O 0
PAX3	O 0
-	O 0
FKHR	O 0
and	O 0
PAX7	O 0
-	O 0
FKHR	O 0
in	O 0
alveolar	B-Disease 0
rhabdomyosarcoma	I-Disease 0
,	O 0
presumably	O 0
due	O 0
to	O 0
differences	O 0
in	O 0
regulation	O 0
between	O 0
the	O 0
wild	O 0
-	O 0
type	O 0
loci	O 0
.	O 0

We	O 0
postulate	O 0
that	O 0
these	O 0
overexpression	O 0
mechanisms	O 0
ensure	O 0
a	O 0
critical	O 0
level	O 0
of	O 0
gene	O 0
product	O 0
for	O 0
the	O 0
oncogenic	O 0
effects	O 0
of	O 0
these	O 0
fusions	O 0
.	O 0
.	O 0

atm	O 0
and	O 0
p53	O 0
cooperate	O 0
in	O 0
apoptosis	O 0
and	O 0
suppression	O 0
of	O 0
tumorigenesis	O 0
,	O 0
but	O 0
not	O 0
in	O 0
resistance	O 0
to	O 0
acute	B-Disease 0
radiation	I-Disease 0
toxicity	I-Disease 0
.	O 0

Mutations	O 0
in	O 0
atm	O 0
and	O 0
p53	O 0
cause	O 0
the	O 0
human	O 0
cancer	B-Disease 0
-	I-Disease 0
associated	I-Disease 0
diseases	I-Disease 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
and	O 0
Li	B-Disease 0
-	I-Disease 0
Fraumeni	I-Disease 0
syndrome	I-Disease 0
,	O 0
respectively	O 0
.	O 0

The	O 0
two	O 0
genes	O 0
are	O 0
believed	O 0
to	O 0
interact	O 0
in	O 0
a	O 0
number	O 0
of	O 0
pathways	O 0
,	O 0
including	O 0
regulation	O 0
of	O 0
DNA	O 0
damage	O 0
-	O 0
induced	O 0
cell	O 0
-	O 0
cycle	O 0
checkpoints	O 0
,	O 0
apoptosis	O 0
and	O 0
radiation	O 0
sensitivity	O 0
,	O 0
and	O 0
cellular	O 0
proliferation	O 0
.	O 0

Atm	O 0
-	O 0
null	O 0
mice	O 0
,	O 0
as	O 0
well	O 0
as	O 0
those	O 0
null	O 0
for	O 0
p53	O 0
,	O 0
develop	O 0
mainly	O 0
T	B-Disease 0
-	I-Disease 0
cell	I-Disease 0
lymphomas	I-Disease 0
,	O 0
supporting	O 0
the	O 0
view	O 0
that	O 0
these	O 0
genes	O 0
have	O 0
similar	O 0
roles	O 0
in	O 0
thymocyte	O 0
development	O 0
.	O 0

To	O 0
study	O 0
the	O 0
interactions	O 0
of	O 0
these	O 0
two	O 0
genes	O 0
on	O 0
an	O 0
organismal	O 0
level	O 0
,	O 0
we	O 0
bred	O 0
mice	O 0
heterozygous	O 0
for	O 0
null	O 0
alleles	O 0
of	O 0
both	O 0
atm	O 0
and	O 0
p53	O 0
to	O 0
produce	O 0
all	O 0
genotypic	O 0
combinations	O 0
.	O 0

Mice	O 0
doubly	O 0
null	O 0
for	O 0
atm	O 0
and	O 0
p53	O 0
exhibited	O 0
a	O 0
dramatic	O 0
acceleration	O 0
of	O 0
tumour	B-Disease 0
formation	O 0
relative	O 0
to	O 0
singly	O 0
null	O 0
mice	O 0
,	O 0
indicating	O 0
that	O 0
both	O 0
genes	O 0
collaborate	O 0
in	O 0
a	O 0
significant	O 0
manner	O 0
to	O 0
prevent	O 0
tumorigenesis	O 0
.	O 0

With	O 0
respect	O 0
to	O 0
their	O 0
roles	O 0
in	O 0
apoptosis	O 0
,	O 0
loss	O 0
of	O 0
atm	O 0
rendered	O 0
thymocytes	O 0
only	O 0
partly	O 0
resistant	O 0
to	O 0
irradiation	O 0
-	O 0
induced	O 0
apoptosis	O 0
,	O 0
whereas	O 0
additional	O 0
loss	O 0
of	O 0
p53	O 0
engendered	O 0
complete	O 0
resistance	O 0
.	O 0

This	O 0
implies	O 0
that	O 0
the	O 0
irradiation	O 0
-	O 0
induced	O 0
atm	O 0
and	O 0
p53	O 0
apoptotic	O 0
pathways	O 0
are	O 0
not	O 0
completely	O 0
congruent	O 0
.	O 0

Finally	O 0
-	O 0
and	O 0
in	O 0
contrast	O 0
to	O 0
prior	O 0
predictions	O 0
-	O 0
atm	O 0
and	O 0
p53	O 0
do	O 0
not	O 0
appear	O 0
to	O 0
interact	O 0
in	O 0
acute	B-Disease 0
radiation	I-Disease 0
toxicity	I-Disease 0
,	O 0
suggesting	O 0
a	O 0
separate	O 0
atm	O 0
effector	O 0
pathway	O 0
for	O 0
this	O 0
DNA	O 0
damage	O 0
response	O 0
and	O 0
having	O 0
implications	O 0
for	O 0
the	O 0
prognosis	O 0
and	O 0
treatment	O 0
of	O 0
human	O 0
tumours	B-Disease 0
.	O 0
.	O 0

Trinucleotide	O 0
repeat	O 0
expansion	O 0
at	O 0
the	O 0
myotonic	B-Disease 0
dystrophy	I-Disease 0
locus	O 0
reduces	O 0
expression	O 0
of	O 0
DMAHP	O 0
.	O 0

Myotonic	B-Disease 0
dystrophy	I-Disease 0
,	O 0
or	O 0
dystrophia	B-Disease 0
myotonica	I-Disease 0
(	O 0
DM	B-Disease 0
)	O 0
,	O 0
is	O 0
an	O 0
autosomal	B-Disease 0
dominant	I-Disease 0
multisystem	I-Disease 0
disorder	I-Disease 0
caused	O 0
by	O 0
the	O 0
expansion	O 0
of	O 0
a	O 0
CTG	O 0
trinucleotide	O 0
repeat	O 0
in	O 0
the	O 0
3	O 0
untranslated	O 0
region	O 0
of	O 0
the	O 0
DMPK	O 0
protein	O 0
kinase	O 0
gene	O 0
on	O 0
chromosome	O 0
19q13	O 0
.	O 0

3	O 0
(	O 0
refs	O 0
1	O 0
-	O 0
3	O 0
)	O 0
.	O 0

Although	O 0
the	O 0
DM	B-Disease 0
mutation	O 0
was	O 0
identified	O 0
more	O 0
than	O 0
five	O 0
years	O 0
ago	O 0
,	O 0
the	O 0
pathogenic	O 0
mechanisms	O 0
underlying	O 0
this	O 0
most	O 0
prevalent	O 0
form	O 0
of	O 0
hereditary	O 0
adult	O 0
neuromuscular	B-Disease 0
disease	I-Disease 0
remain	O 0
elusive	O 0
.	O 0

Previous	O 0
work	O 0
from	O 0
our	O 0
laboratory	O 0
demonstrated	O 0
that	O 0
a	O 0
DNase	O 0
l	O 0
-	O 0
hypersensitive	O 0
site	O 0
located	O 0
adjacent	O 0
to	O 0
the	O 0
repeats	O 0
on	O 0
the	O 0
wild	O 0
-	O 0
type	O 0
allele	O 0
is	O 0
eliminated	O 0
by	O 0
repeat	O 0
expansion	O 0
,	O 0
indicating	O 0
that	O 0
large	O 0
CTG	O 0
-	O 0
repeat	O 0
arrays	O 0
may	O 0
be	O 0
associated	O 0
with	O 0
a	O 0
local	O 0
chromatin	O 0
environment	O 0
that	O 0
represses	O 0
gene	O 0
expression	O 0
.	O 0

Here	O 0
we	O 0
report	O 0
that	O 0
the	O 0
hypersensitive	O 0
site	O 0
contains	O 0
an	O 0
enhancer	O 0
element	O 0
that	O 0
regulates	O 0
transcription	O 0
of	O 0
the	O 0
adjacent	O 0
DMAHP	O 0
homeobox	O 0
gene	O 0
.	O 0

Analysis	O 0
of	O 0
DMAHP	O 0
expression	O 0
in	O 0
the	O 0
cells	O 0
of	O 0
DM	B-Disease 0
patients	O 0
with	O 0
loss	O 0
of	O 0
the	O 0
hypersensitive	O 0
site	O 0
revealed	O 0
a	O 0
two	O 0
-	O 0
to	O 0
fourfold	O 0
reduction	O 0
in	O 0
steady	O 0
-	O 0
state	O 0
DMAHP	O 0
transcript	O 0
levels	O 0
relative	O 0
to	O 0
wild	O 0
-	O 0
type	O 0
controls	O 0
.	O 0

Allele	O 0
-	O 0
specific	O 0
analysis	O 0
of	O 0
DMAHP	O 0
expression	O 0
showed	O 0
that	O 0
steady	O 0
-	O 0
state	O 0
transcript	O 0
levels	O 0
from	O 0
the	O 0
expanded	O 0
allele	O 0
were	O 0
greatly	O 0
reduced	O 0
in	O 0
comparison	O 0
to	O 0
those	O 0
from	O 0
the	O 0
wild	O 0
-	O 0
type	O 0
allele	O 0
.	O 0

Together	O 0
,	O 0
these	O 0
results	O 0
demonstrate	O 0
that	O 0
CTG	O 0
-	O 0
repeat	O 0
expansions	O 0
can	O 0
suppress	O 0
local	O 0
gene	O 0
expression	O 0
and	O 0
implicate	O 0
DMAHP	O 0
in	O 0
DM	B-Disease 0
pathogenesis	O 0
.	O 0

Constitutively	O 0
methylated	O 0
CpG	O 0
dinucleotides	O 0
as	O 0
mutation	O 0
hot	O 0
spots	O 0
in	O 0
the	O 0
retinoblastoma	B-Disease 0
gene	O 0
(	O 0
RB1	O 0
)	O 0
.	O 0

A	O 0
wide	O 0
spectrum	O 0
of	O 0
mutations	O 0
,	O 0
ranging	O 0
from	O 0
point	O 0
mutations	O 0
to	O 0
large	O 0
deletions	O 0
,	O 0
have	O 0
been	O 0
described	O 0
in	O 0
the	O 0
retinoblastoma	B-Disease 0
gene	O 0
(	O 0
RB1	O 0
)	O 0
.	O 0

Mutations	O 0
have	O 0
been	O 0
found	O 0
throughout	O 0
the	O 0
gene	O 0
;	O 0
however	O 0
,	O 0
these	O 0
genetic	O 0
alterations	O 0
do	O 0
not	O 0
appear	O 0
to	O 0
be	O 0
homogeneously	O 0
distributed	O 0
.	O 0

In	O 0
particular	O 0
,	O 0
a	O 0
significant	O 0
proportion	O 0
of	O 0
disease	O 0
-	O 0
causing	O 0
mutations	O 0
results	O 0
in	O 0
the	O 0
premature	O 0
termination	O 0
of	O 0
protein	O 0
synthesis	O 0
,	O 0
and	O 0
the	O 0
majority	O 0
of	O 0
these	O 0
mutations	O 0
occur	O 0
as	O 0
C	O 0
-	O 0
-	O 0
>	O 0
T	O 0
transitions	O 0
at	O 0
CpG	O 0
dinucleotides	O 0
(	O 0
CpGs	O 0
)	O 0
.	O 0

Such	O 0
recurrent	O 0
CpG	O 0
mutations	O 0
,	O 0
including	O 0
those	O 0
found	O 0
in	O 0
RB1	O 0
,	O 0
are	O 0
likely	O 0
the	O 0
result	O 0
of	O 0
the	O 0
deamination	O 0
of	O 0
5	O 0
-	O 0
methylcytosine	O 0
within	O 0
these	O 0
CpGs	O 0
.	O 0

In	O 0
the	O 0
present	O 0
study	O 0
,	O 0
we	O 0
used	O 0
the	O 0
sodiumbisulfite	O 0
conversion	O 0
method	O 0
to	O 0
detect	O 0
cytosine	O 0
methylation	O 0
in	O 0
representative	O 0
exons	O 0
of	O 0
RB1	O 0
.	O 0

We	O 0
analyzed	O 0
DNA	O 0
from	O 0
a	O 0
variety	O 0
of	O 0
tissues	O 0
and	O 0
specifically	O 0
targeted	O 0
CGA	O 0
codons	O 0
in	O 0
RB1	O 0
,	O 0
where	O 0
recurrent	O 0
premature	O 0
termination	O 0
mutations	O 0
have	O 0
been	O 0
reported	O 0
.	O 0

We	O 0
found	O 0
that	O 0
DNA	O 0
methylation	O 0
within	O 0
RB1	O 0
exons	O 0
8	O 0
,	O 0
14	O 0
,	O 0
25	O 0
,	O 0
and	O 0
27	O 0
appeared	O 0
to	O 0
be	O 0
restricted	O 0
to	O 0
CpGs	O 0
,	O 0
including	O 0
six	O 0
CGA	O 0
codons	O 0
.	O 0

Other	O 0
codons	O 0
containing	O 0
methylated	O 0
cytosines	O 0
have	O 0
not	O 0
been	O 0
reported	O 0
to	O 0
be	O 0
mutated	O 0
.	O 0

Therefore	O 0
,	O 0
disease	O 0
-	O 0
causing	O 0
mutations	O 0
at	O 0
CpGs	O 0
in	O 0
RB1	O 0
appear	O 0
to	O 0
be	O 0
determined	O 0
by	O 0
several	O 0
factors	O 0
,	O 0
including	O 0
the	O 0
constitutive	O 0
presence	O 0
of	O 0
DNA	O 0
methylation	O 0
at	O 0
cytosines	O 0
within	O 0
CpGs	O 0
,	O 0
the	O 0
specific	O 0
codon	O 0
within	O 0
which	O 0
the	O 0
methylated	O 0
cytosine	O 0
is	O 0
located	O 0
,	O 0
and	O 0
the	O 0
particular	O 0
region	O 0
of	O 0
the	O 0
gene	O 0
within	O 0
which	O 0
that	O 0
codon	O 0
resides	O 0
.	O 0
.	O 0

The	O 0
von	B-Disease 0
Hippel	I-Disease 0
-	I-Disease 0
Lindau	I-Disease 0
tumor	I-Disease 0
suppressor	O 0
gene	O 0
product	O 0
interacts	O 0
with	O 0
Sp1	O 0
to	O 0
repress	O 0
vascular	O 0
endothelial	O 0
growth	O 0
factor	O 0
promoter	O 0
activity	O 0
.	O 0

The	O 0
von	B-Disease 0
Hippel	I-Disease 0
-	I-Disease 0
Lindau	I-Disease 0
tumor	I-Disease 0
suppressor	O 0
gene	O 0
(	O 0
VHL	O 0
)	O 0
has	O 0
a	O 0
critical	O 0
role	O 0
in	O 0
the	O 0
pathogenesis	O 0
of	O 0
clear	B-Disease 0
-	I-Disease 0
cell	I-Disease 0
renal	I-Disease 0
cell	I-Disease 0
carcinoma	I-Disease 0
(	O 0
RCC	B-Disease 0
)	O 0
,	O 0
as	O 0
VHL	O 0
mutations	O 0
have	O 0
been	O 0
found	O 0
in	O 0
both	O 0
von	B-Disease 0
Hippel	I-Disease 0
-	I-Disease 0
Lindau	I-Disease 0
disease	I-Disease 0
-	I-Disease 0
associated	I-Disease 0
and	I-Disease 0
sporadic	I-Disease 0
RCCs	I-Disease 0
.	O 0

Recent	O 0
studies	O 0
suggest	O 0
that	O 0
vascular	O 0
endothelial	O 0
growth	O 0
factor	O 0
(	O 0
VEGF	O 0
)	O 0
mRNA	O 0
is	O 0
upregulated	O 0
in	O 0
RCC	B-Disease 0
-	I-Disease 0
and	I-Disease 0
von	I-Disease 0
Hippel	I-Disease 0
-	I-Disease 0
Lindau	I-Disease 0
disease	I-Disease 0
-	I-Disease 0
associated	I-Disease 0
tumors	I-Disease 0
.	O 0

We	O 0
have	O 0
therefore	O 0
assessed	O 0
the	O 0
effect	O 0
of	O 0
the	O 0
VHL	O 0
gene	O 0
product	O 0
on	O 0
VEGF	O 0
expression	O 0
.	O 0

VEGF	O 0
promoter	O 0
-	O 0
luciferase	O 0
constructs	O 0
were	O 0
transiently	O 0
cotransfected	O 0
with	O 0
a	O 0
wild	O 0
-	O 0
type	O 0
VHL	O 0
(	O 0
wt	O 0
-	O 0
VHL	O 0
)	O 0
vector	O 0
in	O 0
several	O 0
cell	O 0
lines	O 0
,	O 0
including	O 0
293	O 0
embryonic	O 0
kidney	O 0
and	O 0
RCC	B-Disease 0
cell	O 0
lines	O 0
.	O 0

wt	O 0
-	O 0
VHL	O 0
protein	O 0
inhibited	O 0
VEGF	O 0
promoter	O 0
activity	O 0
in	O 0
a	O 0
dose	O 0
-	O 0
dependent	O 0
manner	O 0
up	O 0
to	O 0
5	O 0
-	O 0
to	O 0
10	O 0
-	O 0
fold	O 0
.	O 0

Deletion	O 0
analysis	O 0
defined	O 0
a	O 0
144	O 0
-	O 0
bp	O 0
region	O 0
of	O 0
the	O 0
VEGF	O 0
promoter	O 0
necessary	O 0
for	O 0
VHL	O 0
repression	O 0
.	O 0

This	O 0
VHL	O 0
-	O 0
responsive	O 0
element	O 0
is	O 0
GC	O 0
rich	O 0
and	O 0
specifically	O 0
binds	O 0
the	O 0
transcription	O 0
factor	O 0
Sp1	O 0
in	O 0
crude	O 0
nuclear	O 0
extracts	O 0
.	O 0

In	O 0
Drosophila	O 0
cells	O 0
,	O 0
cotransfected	O 0
VHL	O 0
represses	O 0
Sp1	O 0
-	O 0
mediated	O 0
activation	O 0
but	O 0
not	O 0
basal	O 0
activity	O 0
of	O 0
the	O 0
VEGF	O 0
promoter	O 0
.	O 0

We	O 0
next	O 0
demonstrated	O 0
in	O 0
coimmunoprecipitates	O 0
that	O 0
VHL	O 0
and	O 0
Sp1	O 0
were	O 0
part	O 0
of	O 0
the	O 0
same	O 0
complex	O 0
and	O 0
,	O 0
by	O 0
using	O 0
a	O 0
glutathione	O 0
-	O 0
S	O 0
-	O 0
transferase	O 0
-	O 0
VHL	O 0
fusion	O 0
protein	O 0
and	O 0
purified	O 0
Sp1	O 0
,	O 0
that	O 0
VHL	O 0
and	O 0
Sp1	O 0
directly	O 0
interact	O 0
.	O 0

Furthermore	O 0
,	O 0
endogenous	O 0
VEGF	O 0
mRNA	O 0
levels	O 0
were	O 0
suppressed	O 0
in	O 0
permanent	O 0
RCC	B-Disease 0
cell	O 0
lines	O 0
expressing	O 0
wt	O 0
-	O 0
VHL	O 0
,	O 0
and	O 0
nuclear	O 0
run	O 0
-	O 0
on	O 0
studies	O 0
indicated	O 0
that	O 0
VHL	O 0
regulation	O 0
of	O 0
VEGF	O 0
occurs	O 0
at	O 0
least	O 0
partly	O 0
at	O 0
the	O 0
transcriptional	O 0
level	O 0
.	O 0

These	O 0
observations	O 0
support	O 0
a	O 0
new	O 0
mechanism	O 0
for	O 0
VHL	O 0
-	O 0
mediated	O 0
transcriptional	O 0
repression	O 0
via	O 0
a	O 0
direct	O 0
inhibitory	O 0
action	O 0
on	O 0
Sp1	O 0
and	O 0
suggest	O 0
that	O 0
loss	O 0
of	O 0
Sp1	O 0
inhibition	O 0
may	O 0
be	O 0
important	O 0
in	O 0
the	O 0
pathogenesis	O 0
of	O 0
von	B-Disease 0
Hippel	I-Disease 0
-	I-Disease 0
Lindau	I-Disease 0
disease	I-Disease 0
and	O 0
RCC	B-Disease 0
.	O 0
.	O 0

Adult	B-Disease 0
onset	I-Disease 0
globoid	I-Disease 0
cell	I-Disease 0
leukodystrophy	I-Disease 0
(	O 0
Krabbe	B-Disease 0
disease	I-Disease 0
)	O 0
:	O 0
analysis	O 0
of	O 0
galactosylceramidase	O 0
cDNA	O 0
from	O 0
four	O 0
Japanese	O 0
patients	O 0
.	O 0

We	O 0
examined	O 0
galactosylceramidase	O 0
(	O 0
GALC	O 0
)	O 0
cDNA	O 0
in	O 0
four	O 0
Japanese	O 0
patients	O 0
with	O 0
adult	B-Disease 0
onset	I-Disease 0
globoid	I-Disease 0
cell	I-Disease 0
leukodystrophy	I-Disease 0
(	O 0
Krabbe	B-Disease 0
disease	I-Disease 0
;	O 0
AO	B-Disease 0
-	I-Disease 0
GLD	I-Disease 0
)	O 0
by	O 0
polymerase	O 0
chain	O 0
reaction	O 0
/	O 0
single	O 0
-	O 0
strand	O 0
conformation	O 0
polymorphism	O 0
(	O 0
PCR	O 0
-	O 0
SSCP	O 0
)	O 0
analysis	O 0
,	O 0
subsequent	O 0
sequence	O 0
determination	O 0
,	O 0
and	O 0
restriction	O 0
enzyme	O 0
digestion	O 0
of	O 0
PCR	O 0
products	O 0
,	O 0
initial	O 0
symptoms	O 0
were	O 0
the	O 0
onset	O 0
of	O 0
slowly	O 0
progressive	O 0
spastic	B-Disease 0
paraplegia	I-Disease 0
from	O 0
the	O 0
middle	O 0
of	O 0
the	O 0
second	O 0
decade	O 0
,	O 0
and	O 0
all	O 0
patients	O 0
had	O 0
diminished	B-Disease 0
GALC	I-Disease 0
activity	I-Disease 0
in	O 0
their	O 0
leukocytes	O 0
.	O 0

We	O 0
identified	O 0
three	O 0
missense	O 0
mutations	O 0
(	O 0
I66M	O 0
,	O 0
G270D	O 0
,	O 0
L618S	O 0
)	O 0
and	O 0
one	O 0
exon	O 0
-	O 0
6	O 0
skipping	O 0
(	O 0
535	O 0
-	O 0
573del	O 0
)	O 0
.	O 0

Two	O 0
of	O 0
the	O 0
patients	O 0
had	O 0
only	O 0
the	O 0
I66M	O 0
mutant	O 0
mRNA	O 0
,	O 0
and	O 0
one	O 0
only	O 0
the	O 0
G27OD	O 0
mutant	O 0
mRNA	O 0
.	O 0

The	O 0
fourth	O 0
patient	O 0
carried	O 0
a	O 0
compound	O 0
heterozygous	O 0
mutation	O 0
of	O 0
535	O 0
-	O 0
573del	O 0
and	O 0
L618S	O 0
.	O 0

To	O 0
determine	O 0
the	O 0
enzymatic	O 0
activities	O 0
produced	O 0
by	O 0
these	O 0
mutations	O 0
,	O 0
we	O 0
constructed	O 0
mutated	O 0
GALC	O 0
cDNAs	O 0
and	O 0
expressed	O 0
them	O 0
in	O 0
COS	O 0
-	O 0
1	O 0
cells	O 0
.	O 0

Three	O 0
mutations	O 0
,	O 0
viz	O 0
.	O 0
,	O 0
G270D	O 0
,	O 0
L618S	O 0
,	O 0
and	O 0
exon	O 0
-	O 0
6	O 0
skipping	O 0
(	O 0
535	O 0
-	O 0
573del	O 0
)	O 0
,	O 0
produced	O 0
diminished	B-Disease 0
GALC	I-Disease 0
activity	I-Disease 0
as	O 0
expected	O 0
.	O 0

The	O 0
I66M	O 0
mutation	O 0
in	O 0
the	O 0
wild	O 0
-	O 0
type	O 0
GALC	O 0
cDNA	O 0
(	O 0
I289	O 0
)	O 0
had	O 0
normal	O 0
activity	O 0
,	O 0
but	O 0
when	O 0
this	O 0
mutation	O 0
and	O 0
the	O 0
V289	O 0
polymorphism	O 0
were	O 0
introduced	O 0
into	O 0
the	O 0
same	O 0
allele	O 0
,	O 0
it	O 0
had	O 0
decreased	O 0
activity	O 0
.	O 0

Thus	O 0
,	O 0
the	O 0
combination	O 0
of	O 0
a	O 0
unique	O 0
mutation	O 0
and	O 0
polymorphism	O 0
causes	O 0
conformational	O 0
change	O 0
in	O 0
the	O 0
GALC	O 0
enzyme	O 0
,	O 0
resulting	O 0
in	O 0
low	O 0
enzymatic	O 0
activity	O 0
.	O 0

AO	B-Disease 0
-	I-Disease 0
GLD	I-Disease 0
mutations	O 0
,	O 0
including	O 0
those	O 0
found	O 0
here	O 0
,	O 0
are	O 0
located	O 0
in	O 0
the	O 0
N	O 0
-	O 0
terminus	O 0
(	O 0
I66M	O 0
,	O 0
G270D	O 0
,	O 0
535	O 0
-	O 0
573del	O 0
)	O 0
or	O 0
C	O 0
-	O 0
terminus	O 0
(	O 0
L618S	O 0
)	O 0
of	O 0
the	O 0
GALC	O 0
enzyme	O 0
,	O 0
whereas	O 0
the	O 0
reported	O 0
mutations	O 0
in	O 0
the	O 0
infantile	O 0
form	O 0
(	O 0
IF	B-Disease 0
-	I-Disease 0
GLD	I-Disease 0
)	O 0
are	O 0
in	O 0
the	O 0
central	O 0
domain	O 0
.	O 0

This	O 0
difference	O 0
in	O 0
mutation	O 0
sites	O 0
may	O 0
affect	O 0
the	O 0
clinical	O 0
features	O 0
of	O 0
GLD	B-Disease 0
.	O 0

